WorldWideScience

Sample records for boron neutron-capture therapy

  1. Spectromicroscopy in Boron Neutron Capture Therapy Research

    Science.gov (United States)

    Gilbert, Benjamin; Redondo, Jose; Andres, Roger; Suda, Takashi; Neumann, Michael; Steen, Steffi; Gabel, Detlef; Mercanti, Delio; Ciotti, Teresa; Perfetti, Paolo; Margaritondo, Giorgio; de Stasio, Gelsomina

    1998-03-01

    The MEPHISTO synchrotron imaging spectromicroscope can analyse ashed cells or tissue sections to reveal the microdistribution of trace elements. MEPHISTO performs core level x-ray absorption spectroscopy with synchrotron radiation, and uses an electron optics system to provide magnified photoelectron images. An application of the MEPHISTO spectromicroscope is in boron neutron capture therapy (BNCT). BNCT is a binary cancer therapy that will selectively destroy cancer cells provided that compounds containing a boron isotope are selectively accumulated in tumor tissue. Important factors for the success of BNCT include the ability to target every cancer cell, and the distribution of boron inside the cell. To investigate the boron distribution in tissue, sections of human glioblastoma containing a BNCT compound, and stained with nickel against a protein found in the nuclei of proliferating (cancer) cells, were studied with MEPHISTO.

  2. Boron neutron capture therapy: Moving toward targeted cancer therapy

    Directory of Open Access Journals (Sweden)

    Hamid Reza Mirzaei

    2016-01-01

    Full Text Available Boron neutron capture therapy (BNCT occurs when a stable isotope, boton-10, is irradiated with low-energy thermal neutrons to yield stripped down helium-4 nuclei and lithium-7 nuclei. It is a binary therapy in the treatment of cancer in which a cytotoxic event is triggered when an atom placed in a cancer cell. Here, we provide an overview on the application of BNCT in cancer therapy as well as current preclinical and clinical evidence on the efficacy of BNCT in the treatment of melanoma, brain tumors, head and neck cancer, and thyroid cancer. Several studies have shown that BNCT is effective in patients who had been treated with a full dose of conventional radiotherapy, because of its selectivity. In addition, BNCT is dependent on the normal/tumor tissue ratio of boron distribution. Increasing evidence has shown that BNCT can be combined with different drug delivery systems to enhance the delivery of boron to cancer cells. The flexibility of BNCT to be used in combination with different tumor-targeting approaches has made this strategy a promising option for cancer therapy. This review aims to provide a state-of-the-art overview of the recent advances in the use of BNCT for targeted therapy of cancer.

  3. Experience of boron neutron capture therapy in Japan

    Science.gov (United States)

    Kanda, Keiji

    1997-02-01

    In Japan the boron neutron capture therapy has been applied to more than 200 patients, mostly brain tumors and some melanomas. For brain tumors, Kyoto University, Kyoto Prefectural University of Medicine, Tsukuba University and National Kagawa Children's Hospital accept patients, and for melanomas, Kobe University and Mishima Institute of Dermatological Research accept patients so far. Recently the heavy water facility of Kyoto University Reactor has been upgraded for epithermal neutron as well as thermal neutron irradiations, and for the patient treatment during the continuous operation of the KUR.

  4. The three dimensional map of dose components in a head phantom for boron neutron capture therapy

    OpenAIRE

    Bavarnegin Elham; Sadremomtaz Alireza; Khalafi Hossein

    2013-01-01

    The in-phantom measurement of physical dose distribution and construction of a convenient phantom is very important for boron neutron capture therapy planning validation. In this study we have simulated a head phantom, suggested for construction in boron neutron capture therapy facilities, and calculated all relevant dose components inside of it using the Monte Carlo code MCNPX. A “generic” epithermal neutron beam with a broad neutron spectrum, similar to beams used for neutron capture ...

  5. Carborane derivative development for boron neutron capture therapy. Final report

    Energy Technology Data Exchange (ETDEWEB)

    Barnum, Beverly A.; Yan Hao; Moore, Roger; Hawthorne, M. Frederick; Baum, Kurt

    1999-04-01

    Boron Neutron Capture Therapy [BNCT] is a binary method of cancer therapy based on the capture of neutrons by a boron-10 atom [{sup 10}B]. Cytotoxic {sup 7}Li nuclei and {alpha}-particles are emitted, with a range in tissue of 9 and 5 {micro}m, respectively, about one cell diameter. The major obstacle to clinically viable BNCT is the selective localization of 5-30 ppm {sup 10}B in tumor cells required for effective therapy. A promising approach to BNCT is based on hydrophilic boron-rich oligomeric phosphate diesters, or ''trailers'' that have been shown to concentrate selectively in tumor tissue. Examples of these compounds were prepared previously at high cost using an automated DNA synthesizer. Direct synthesis methods are needed for the production of gram-scale quantities for further biological evaluation. The work accomplished as a result of the collaboration between Fluorochem, Inc. and UCLA demonstrates that short oligomers containing at least five carborane units with four phosphodiester linkages can be prepared in substantial quantities. This work was accomplished by the application of standard phosphoramidite coupling chemistry.

  6. Boron Neutron Capture Therapy for Malignant Brain Tumors

    Science.gov (United States)

    MIYATAKE, Shin-Ichi; KAWABATA, Shinji; HIRAMATSU, Ryo; KUROIWA, Toshihiko; SUZUKI, Minoru; KONDO, Natsuko; ONO, Koji

    2016-01-01

    Boron neutron capture therapy (BNCT) is a biochemically targeted radiotherapy based on the nuclear capture and fission reactions that occur when non-radioactive boron-10, which is a constituent of natural elemental boron, is irradiated with low energy thermal neutrons to yield high linear energy transfer alpha particles and recoiling lithium-7 nuclei. Therefore, BNCT enables the application of a high dose of particle radiation selectively to tumor cells in which boron-10 compound has been accumulated. We applied BNCT using nuclear reactors for 167 cases of malignant brain tumors, including recurrent malignant gliomas, newly diagnosed malignant gliomas, and recurrent high-grade meningiomas from January 2002 to May 2014. Here, we review the principle and history of BNCT. In addition, we introduce fluoride-18-labeled boronophenylalanine positron emission tomography and the clinical results of BNCT for the above-mentioned malignant brain tumors. Finally, we discuss the recent development of accelerators producing epithermal neutron beams. This development could provide an alternative to the current use of specially modified nuclear reactors as a neutron source, and could allow BNCT to be performed in a hospital setting. PMID:27250576

  7. Boron Neutron Capture Therapy for Malignant Brain Tumors.

    Science.gov (United States)

    Miyatake, Shin-Ichi; Kawabata, Shinji; Hiramatsu, Ryo; Kuroiwa, Toshihiko; Suzuki, Minoru; Kondo, Natsuko; Ono, Koji

    2016-07-15

    Boron neutron capture therapy (BNCT) is a biochemically targeted radiotherapy based on the nuclear capture and fission reactions that occur when non-radioactive boron-10, which is a constituent of natural elemental boron, is irradiated with low energy thermal neutrons to yield high linear energy transfer alpha particles and recoiling lithium-7 nuclei. Therefore, BNCT enables the application of a high dose of particle radiation selectively to tumor cells in which boron-10 compound has been accumulated. We applied BNCT using nuclear reactors for 167 cases of malignant brain tumors, including recurrent malignant gliomas, newly diagnosed malignant gliomas, and recurrent high-grade meningiomas from January 2002 to May 2014. Here, we review the principle and history of BNCT. In addition, we introduce fluoride-18-labeled boronophenylalanine positron emission tomography and the clinical results of BNCT for the above-mentioned malignant brain tumors. Finally, we discuss the recent development of accelerators producing epithermal neutron beams. This development could provide an alternative to the current use of specially modified nuclear reactors as a neutron source, and could allow BNCT to be performed in a hospital setting.

  8. The Swedish facility for boron neutron capture therapy

    Energy Technology Data Exchange (ETDEWEB)

    Skoeld, K.; Capala, J. [Studsvik Medical AB (Sweden); Kierkegaard, J.; Haakansson, R. [Studsvik Nuclear AB (Sweden); Gudowska, I. [Karolinska Institute (Sweden)

    2000-10-01

    A BNCT (Boron Neutron Capture Therapy) facility has been constructed at the R2-0 reactor at Studsvik, Sweden. R2-0 is a 1 MW, open core, pool reactor. The reactor core is suspended on a movable tower and can be positioned anywhere in the pool. The BNCT facility includes two adjacent, parallel filter/moderator configurations and the reactor core is positioned in front of any of them as appropriate. One of the resulting neutron beams has been optimized for clinical irradiations with a filter/moderator system that allows easy variation of the neutron spectrum from the thermal to the epithermal energy range and with an extended collimator for convenient patient positioning. The other beam has been designed for radiobiological research and is equipped with a heavy water moderator and a large irradiation cavity with a uniform field of thermal neutrons. (author)

  9. Proceedings of workshop on 'boron science and boron neutron capture therapy'

    Energy Technology Data Exchange (ETDEWEB)

    Kitaoka, Y. [ed.

    1998-12-01

    This volume contains the abstracts and programs of the 8th (1996), 9th (1997) and 10th (1998) of the workshop on 'the Boron Science and Boron Neutron Capture Therapy' and the recent progress reports especially subscribed. The 11 of the presented papers are indexed individually. (J.P.N.)

  10. Boron neutron capture therapy in cancer: past, present and future

    Energy Technology Data Exchange (ETDEWEB)

    Pisarev, Mario A.; Dagrosa, Maria Alejandra; Juvenal, Guilermo J. [National Atomic Energy Commission, Buenos Aires (Argentina). Div. of Nuclear Biochemistry; University of Buenos Aires (Argentina). School of Medicine. Dept. of Human Biochemistry

    2007-07-15

    Undifferentiated thyroid cancer (UTC) is a very aggressive tumor with no effective treatment, since it lacks iodine uptake and does not respond to radio or chemotherapy. The prognosis of these patients is bad, due to the rapid growth of the tumor and the early development of metastasis. Boron neutron capture therapy (BNCT) is based on the selective uptake of certain boron non-radioactive compounds by a tumor, and the subsequent irradiation of the area with an appropriate neutron beam. {sup 10}B is then activated to {sup 11}B, which will immediately decay releasing alpha particles and {sup 7}Li, of high linear energy transfer (LET) and limited reach. Clinical trials are being performed in patients with glioblastoma multiform and melanoma. We have explored its possible application to UTC. Our results demonstrated that a cell line of human UTC has a selective uptake of borophenylalanine (BPA) both in vitro and after transplantation to nude mice. Treatment of mice by BNCT led to a complete control of growth and cure of 100% of the animals. Moreover dogs with spontaneous UTC also have a selective uptake of BPA. At the present we are studying the biodistribution of BPA in patients with UTC before its application in humans. (author)

  11. The accelerator neutron source for boron neutron capture therapy

    Science.gov (United States)

    Kasatov, D.; Koshkarev, A.; Kuznetsov, A.; Makarov, A.; Ostreinov, Yu; Shchudlo, I.; Sorokin, I.; Sycheva, T.; Taskaev, S.; Zaidi, L.

    2016-11-01

    The accelerator based epithermal neutron source for Boron Neutron Capture Therapy (BNCT) is proposed, created and used in the Budker Institute of Nuclear Physics. In 2014, with the support of the Russian Science Foundation created the BNCT laboratory for the purpose to the end of 2016 get the neutron flux, suitable for BNCT. For getting 3 mA 2.3 MeV proton beam, was created a new type accelerator - tandem accelerator with vacuum isolation. On this moment, we have a stationary proton beam with 2.3 MeV and current 1.75 mA. Generation of neutrons is carried out by dropping proton beam on to lithium target as a result of threshold reaction 7Li(p,n)7Be. Established facility is a unique scientific installation. It provides a generating of neutron flux, including a monochromatic energy neutrons, gamma radiation, alpha-particles and positrons, and may be used by other research groups for carrying out scientific researches. The article describes an accelerator neutron source, presents and discusses the result of experiments and declares future plans.

  12. Treatment Planning for Accelerator-Based Boron Neutron Capture Therapy

    Science.gov (United States)

    Herrera, María S.; González, Sara J.; Minsky, Daniel M.; Kreiner, Andrés J.

    2010-08-01

    Glioblastoma multiforme and metastatic melanoma are frequent brain tumors in adults and presently still incurable diseases. Boron Neutron Capture Therapy (BNCT) is a promising alternative for this kind of pathologies. Accelerators have been proposed for BNCT as a way to circumvent the problem of siting reactors in hospitals and for their relative simplicity and lower cost among other advantages. Considerable effort is going into the development of accelerator-based BNCT neutron sources in Argentina. Epithermal neutron beams will be produced through appropriate proton-induced nuclear reactions and optimized beam shaping assemblies. Using these sources, computational dose distributions were evaluated in a real patient with diagnosed glioblastoma treated with BNCT. The simulated irradiation was delivered in order to optimize dose to the tumors within the normal tissue constraints. Using Monte Carlo radiation transport calculations, dose distributions were generated for brain, skin and tumor. Also, the dosimetry was studied by computing cumulative dose-volume histograms for volumes of interest. The results suggest acceptable skin average dose and a significant dose delivered to tumor with low average whole brain dose for irradiation times less than 60 minutes, indicating a good performance of an accelerator-based BNCT treatment.

  13. Power Burst Facility/Boron Neutron Capture Therapy Program for cancer treatment

    Energy Technology Data Exchange (ETDEWEB)

    Ackermann, A.L. (ed.); Dorn, R.V. III.

    1990-08-01

    This report discusses monthly progress in the Power Boron Facility/Boron Neutron Capture Therapy (PBF/BNCT) Program for Cancer Treatment. Highlights of the PBF/BNCT Program during August 1990 include progress within the areas of: Gross Boron Analysis in Tissue, Blood, and Urine, boron microscopic (subcellular) analytical development, noninvasive boron quantitative determination, analytical radiation transport and interaction modeling for BNCT, large animal model studies, neutron source and facility preparation, administration and common support and PBF operations.

  14. Isodose Curves and Treatment Planning for Boron Neutron Capture Therapy.

    Science.gov (United States)

    Liu, Hungyuan B.

    The development of Boron Neutron Capture Therapy (BNCT) has been progressing in both ^{10 }B compound development and testing and neutron beam delivery. Animal tests are now in progress with several ^{10}B compounds and once the results of these animal tests are promising, patient trials can be initiated. The objective of this study is to create a treatment planning method based on the dose calculations by a Monte Carlo code of a mixed radiation field to provide linkage between phantom dosimetry and patient irradiation. The research started with an overall review of the development of BNCT. Three epithermal neutron facilities are described, including the operating Brookhaven Medical Research Reactor (BMRR) beam, the designed Missouri University Research Reactor (MURR) beam, and a designed accelerator based neutron source. The flux and dose distributions in a head model have been calculated for irradiation by these neutron beams. Different beam parameters were inter -compared for effectiveness. Dosimetric measurements in an elliptical lucite phantom and a cylindrical water phantom were made and compared to the MCNP calculations for irradiation by the BMRR beam. Repeated measurements were made and show consistent. To improve the statistical results calculated by MCNP, a neutron source plane was designed to start neutrons at the BMRR irradiation port. The source plane was used with the phantoms for dosimetric calculations. After being verified by different phantom dosimetry and in-air flux measurements at the irradiation port, the source plane was used to calculate the flux and dose distributions in the head model. A treatment planning program was created for use on a PC which uses the MCNP calculated results as input. This program calculates the thermal neutron flux and dose distributions of each component of radiation in the central coronal section of the head model for irradiation by a neutron beam. Different combinations of head orientations and irradiation

  15. Boron nanoparticles inhibit turnour growth by boron neutron capture therapy in the murine B16-OVA model

    DEFF Research Database (Denmark)

    Petersen, Mikkel Steen; Petersen, Charlotte Christie; Agger, Ralf;

    2008-01-01

    Background: Boron neutron capture therapy usually relies on soluble, rather than particulate, boron compounds. This study evaluated the use of a novel boron nanoparticle for boron neutron capture therapy. Materials and Methods: Two hundred and fifty thousand B16-OVA tumour cells, pre......-incubated with boron nanoparticles for 12 hours, were injected subcutaneously into C57BL16J mice. The tumour sites were exposed to different doses of neutron radiation one, four, or eight days after tumour cell inoculation. Results: When the tumour site was irradiated with thermal neutrons one day after injection......, tumour growth was delayed and the treated mice survived longer than untreated controls (median survival time 20 days (N=8) compared with 10 days (N=7) for untreated mice). Conclusion: Boron nanoparticles significantly delay the growth of an aggressive B16-OVA tumour in vivo by boron neutron capture...

  16. Spectromicroscopy of boron for the optimization of boron neutron capture therapy (BNCT) for cancer

    Science.gov (United States)

    Gilbert, B.; Redondo, J.; Baudat, P.-A.; Lorusso, G. F.; Andres, R.; Van Meir, E. G.; Brunet, J.-F.; Hamou, M.-F.; Suda, T.; Mercanti, Delio; Ciotti, M. Teresa; Droubay, T. C.; Tonner, B. P.; Perfetti, P.; Margaritondo, M.; DeStasio, Gelsomina

    1998-10-01

    We used synchrotron spectromicroscopy to study the microscopic distribution of boron in rat brain tumour and healthy tissue in the field of boron neutron capture therapy (BNCT). The success of this experimental cancer therapy depends on the preferential uptake of ? in tumour cells after injection of a boron compound (in our case ?, or BSH). With the Mephisto (microscope à emission de photoélectrons par illumination synchrotronique de type onduleur) spectromicroscope, high-magnification imaging and chemical analysis was performed on brain tissue sections from a rat carrying an implanted brain tumour and the results were compared with inductively coupled plasma-atomic emission spectroscopy (ICP-AES) detection of boron in bulk tissue. Boron was found to have been taken up more favourably by regions of tumour rather than healthy tissue, but the resulting boron distribution in the tumour was inhomogeneous. The results demonstrate that Mephisto can perform microchemical analysis of tissue sections, detect and localize the presence of boron with submicron spatial resolution. The application of this technique to boron in brain tissue can therefore be used to evaluate the current efforts to optimize BNC therapy.

  17. Spectromicroscopy of boron for the optimization of boron neutron capture therapy (BNCT) for cancer

    Energy Technology Data Exchange (ETDEWEB)

    Gilbert, B.; Redondo, J.; Baudat, P-A. [Institut de Physique Appliquee, Ecole Polytechnique Federale, Lausanne (Switzerland)] [and others

    1998-10-07

    We used synchrotron spectromicroscopy to study the microscopic distribution of boron in rat brain tumour and healthy tissue in the field of boron neutron capture therapy (BNCT). The success of this experimental cancer therapy depends on the preferential uptake of {sup 10}B in tumour cells after injection of a boron compound (in our case B{sub 12}H{sub 11}SH, or BSH). With the Mephisto (microscope a emission de photoelectrons par illumination synchrotronique de type onduleur) spectromicroscope, high-magnification imaging and chemical analysis was performed on brain tissue sections from a rat carrying an implanted brain tumour and the results were compared with inductively coupled plasma-atomic emission spectroscopy (ICP-AES) detection of boron in bulk tissue. Boron was found to have been taken up more favourably by regions of tumour rather than healthy tissue, but the resulting boron distribution in the tumour was inhomogeneous. The results demonstrate that Mephisto can perform microchemical analysis of tissue sections, detect and localize the presence of boron with submicron spatial resolution. The application of this technique to boron in brain tissue can therefore be used to evaluate the current efforts to optimize BNC therapy. (author)

  18. Neutron capture therapies

    Energy Technology Data Exchange (ETDEWEB)

    Yanch, Jacquelyn C. (Cambridge, MA); Shefer, Ruth E. (Newton, MA); Klinkowstein, Robert E. (Winchester, MA)

    1999-01-01

    In one embodiment there is provided an application of the .sup.10 B(n,.alpha.).sup.7 Li nuclear reaction or other neutron capture reactions for the treatment of rheumatoid arthritis. This application, called Boron Neutron Capture Synovectomy (BNCS), requires substantially altered demands on neutron beam design than for instance treatment of deep seated tumors. Considerations for neutron beam design for the treatment of arthritic joints via BNCS are provided for, and comparisons with the design requirements for Boron Neutron Capture Therapy (BNCT) of tumors are made. In addition, exemplary moderator/reflector assemblies are provided which produce intense, high-quality neutron beams based on (p,n) accelerator-based reactions. In another embodiment there is provided the use of deuteron-based charged particle reactions to be used as sources for epithermal or thermal neutron beams for neutron capture therapies. Many d,n reactions (e.g. using deuterium, tritium or beryllium targets) are very prolific at relatively low deuteron energies.

  19. Neutron capture therapies

    Energy Technology Data Exchange (ETDEWEB)

    Yanch, J.C.; Shefer, R.E.; Klinkowstein, R.E.

    1999-11-02

    In one embodiment there is provided an application of the {sup 10}B(n,{alpha}){sup 7}Li nuclear reaction or other neutron capture reactions for the treatment of rheumatoid arthritis. This application, called Boron Neutron Capture Synovectomy (BNCS), requires substantially altered demands on neutron beam design than for instance treatment of deep seated tumors. Considerations for neutron beam design for the treatment of arthritic joints via BNCS are provided for, and comparisons with the design requirements for Boron Neutron Capture Therapy (BNCT) of tumors are made. In addition, exemplary moderator/reflector assemblies are provided which produce intense, high-quality neutron beams based on (p,n) accelerator-based reactions. In another embodiment there is provided the use of deuteron-based charged particle reactions to be used as sources for epithermal or thermal neutron beams for neutron capture therapies. Many d,n reactions (e.g. using deuterium, tritium or beryllium targets) are very prolific at relatively low deuteron energies.

  20. Beam neutron energy optimization for boron neutron capture therapy using Monte Carlo method

    OpenAIRE

    Ali Pazirandeh; Elham Shekarian

    2006-01-01

     In last two decades the optimal neutron energy for the treatment of deep seated tumors in boron neutron capture therapy in view of neutron physics and chemical compounds of boron carrier has been under thorough study. Although neutron absorption cross section of boron is high (3836b), the treatment of deep seated tumors such as gliobelastoma multiform (GBM) requires beam of neutrons of higher energy that can penetrate deeply into the brain and thermalize in the proximity of the tumor. Dosage...

  1. Implications for clinical treatment from the micrometer site dosimetric calculations in boron neutron capture therapy

    Energy Technology Data Exchange (ETDEWEB)

    Nichols, Trent L. [Department of Physics and Astronomy, University of Tennessee, Knoxville, TN 37901 (United States)], E-mail: tnichol2@utk.edu; Kabalka, George W. [Department of Chemistry, University of Tennessee, Knoxville, TN 37901 (United States); Miller, Laurence F. [Department of Nuclear and Radiological Engineering, University of Tennessee, Knoxville, TN 37901 (United States); McCormack, Michael T. [Department of Medicine, University of Tennessee Graduate School of Medicine, Knoxville, TN 37920 (United States); Johnson, Andrew [Rush University Medical Center, Chicago, IL 60612 (United States)

    2009-07-15

    Boron neutron capture therapy has now been used for several malignancies. Most clinical trials have addressed its use for the treatment of glioblastoma multiforme. A few trials have focused on the treatment of malignant melanoma with brain metastases. Trial results for the treatment of glioblastoma multiforme have been encouraging, but have not achieved the success anticipated. Results of trials for the treatment of malignant melanoma have been very promising, though with too few patients for conclusions to be drawn. Subsequent to these trials, regimens for undifferentiated thyroid carcinoma, hepatic metastases from adenocarcinoma of the colon, and head and neck malignancies have been developed. These tumors have also responded well to boron neutron capture therapy. Glioblastoma is an infiltrative tumor with distant individual tumor cells that might create a mechanism for therapeutic failure though recurrences are often local. The microdosimetry of boron neutron capture therapy can provide an explanation for this observation. Codes written to examine the micrometer scale energy deposition in boron neutron capture therapy have been used to explore the effects of near neighbor cells. Near neighbor cells can contribute a significantly increased dose depending on the geometric relationships. Different geometries demonstrate that tumors which grow by direct extension have a greater near neighbor effect, whereas infiltrative tumors lose this near neighbor dose which can be a significant decrease in dose to the cells that do not achieve optimal boron loading. This understanding helps to explain prior trial results and implies that tumors with small, closely packed cells that grow by direct extension will be the most amenable to boron neutron capture therapy.

  2. The Boron Neutron Capture Therapy (BNCT) Project at the TRIGA Reactor in Mainz, Germany

    DEFF Research Database (Denmark)

    Hampel, G.; Grunewald, C.; Schütz, C.

    2011-01-01

    The thermal column of the TRIGA reactor in Mainz is being used very effectively for medical and biological applications. The BNCT (boron neutron capture therapy) project at the University of Mainz is focussed on the treatment of liver tumours, similar to the work performed at Pavia (Italy) a few...

  3. Synthesis and evaluation of boron folates for Boron-Neutron-Capture-Therapy (BNCT)

    Energy Technology Data Exchange (ETDEWEB)

    Kettenbach, Kathrin; Schieferstein, Hanno; Grunewald, Catrin; Hampel, Gabriele; Schuetz, Christian L. [Mainz Univ. (Germany). Inst. of Nuclear Chemistry; Iffland, Dorothee; Bings, Nicolas H. [Mainz Univ. (Germany). Inst. of Inorganic Chemistry and Analytical Chemistry; Reffert, Laura M. [Hannover Medical School (Germany). Radiopharmaceutical Chemistry; Ross, Tobias L. [Mainz Univ. (Germany). Inst. of Nuclear Chemistry; Hannover Medical School (Germany). Radiopharmaceutical Chemistry

    2015-07-01

    Boron neutron capture therapy (BNCT) employs {sup 10}B-pharmaceuticals administered for the treatment of malignancies, and subsequently irradiated with thermal neutrons. So far, clinical established pharmaceuticals like boron phenylalanine (BPA) or sodium boron mercaptate (BSH) use imperfect (BPA) or passive (BSH) targeting for accumulation at target sites. Due to the need of a selective transportation of boron drugs into cancer cells and sparing healthy tissues, we combined the BNCT approach with the specific and effective folate receptor (FR) targeting concept. The FR is overexpressed on many human carcinomas and provides a selective and specific target for molecular imaging as well as for tumor therapy. We synthesized and characterized a carborane-folate as well as a BSH-folate to study their in vitro characteristics and their potential as new boron-carriers for BNCT. Uptake studies were carried out using human KB cells showing a significant increase of the boron content in cells and demonstrating the successful combination of active FR-targeting and BNCT.

  4. The three dimensional map of dose components in a head phantom for boron neutron capture therapy

    Directory of Open Access Journals (Sweden)

    Bavarnegin Elham

    2013-01-01

    Full Text Available The in-phantom measurement of physical dose distribution and construction of a convenient phantom is very important for boron neutron capture therapy planning validation. In this study we have simulated a head phantom, suggested for construction in boron neutron capture therapy facilities, and calculated all relevant dose components inside of it using the Monte Carlo code MCNPX. A “generic” epithermal neutron beam with a broad neutron spectrum, similar to beams used for neutron capture therapy clinical trials, was used. The calculated distributions of all relevant dose components in brain tissue equivalent were compared with those in water. The results show that water is a suitable dosimetry material and that the simulated head phantom is a suitable design for producing accurate three-dimensional maps of dose components at enough points inside of the phantom for boron neutron capture therapy dosimetry measurements and the use of these dose maps in beam development and benchmarking of computer-based treatment codes.

  5. Potential of using boric acid as a boron drug for boron neutron capture therapy for osteosarcoma

    Energy Technology Data Exchange (ETDEWEB)

    Hsu, C.F.; Lin, S.Y. [Institute of Nuclear Engineering and Science, National Tsing Hua University, Taiwan (China); Peir, J.J. [Nuclear Science and Technology Development Center, National Tsing Hua University, Taiwan (China); Liao, J.W. [Graduate Institute of Veterinary Pathobiology, National Chung Hsing University, Taiwan (China); Lin, Y.C. [Department of Veterinary Medicine, National Chung Hsing University, Taiwan (China); Chou, F.I., E-mail: fichou@mx.nthu.edu.tw [Institute of Nuclear Engineering and Science, National Tsing Hua University, Taiwan (China)] [Nuclear Science and Technology Development Center, National Tsing Hua University, Taiwan (China)

    2011-12-15

    Osteosarcoma is a malignant tumor commonly found in human and animals. The ability of boric acid (BA) to accumulate in osteosarcoma due to the mechanism of the bone formation of cancer cells would make boron neutron capture therapy (BNCT) an alternative therapy for osteosarcoma. This study evaluated the feasibility of using BA as the boron drug for BNCT of bone cancer. The cytotoxicity of BA to L929 cells exceeded that of UMR-106 cells. With 25 {mu}g {sup 10}B/mL medium of BA treatment, the boron concentration in UMR-106 cells was higher than that in L929 cells. The biodistribution and pharmacokinetics of BA in Sprague-Dawley (SD) rats were studied by administrating 25 mg {sup 10}B/kg body weight to SD rats. Blood boron level decreased rapidly within one hour after BA injection. Boron concentration in the long bone was 4-6 time higher than that of blood. Results of this study suggest that BA may be a potential drug for BNCT for osteosarcoma.

  6. Boron analysis for neutron capture therapy using particle-induced gamma-ray emission.

    Science.gov (United States)

    Nakai, Kei; Yamamoto, Yohei; Okamoto, Emiko; Yamamoto, Tetsuya; Yoshida, Fumiyo; Matsumura, Akira; Yamada, Naoto; Kitamura, Akane; Koka, Masashi; Satoh, Takahiro

    2015-12-01

    The neutron source of BNCT is currently changing from reactor to accelerator, but peripheral facilities such as a dose-planning system and blood boron analysis have still not been established. To evaluate the potential application of particle-induced gamma-ray emission (PIGE) for boron measurement in clinical boron neutron capture therapy, boronophenylalanine dissolved within a cell culture medium was measured using PIGE. PIGE detected 18 μgB/mL f-BPA in the culture medium, and all measurements of any given sample were taken within 20 min. Two hours of f-BPA exposure was required to create a boron distribution image. However, even though boron remained in the cells, the boron on the cell membrane could not be distinguished from the boron in the cytoplasm.

  7. Investigation of Isfahan miniature neutron source reactor (MNSR) for boron neutron capture therapy by MCNP simulation

    OpenAIRE

    S. Z. Kalantari; H Tavakoli; Nami, M.

    2015-01-01

    One of the important neutron sources for Boron Neutron Capture Therapy (BNCT) is a nuclear reactor. It needs a high flux of epithermal neutrons. The optimum conditions of the neutron spectra for BNCT are provided by the International Atomic Energy Agency (IAEA). In this paper, Miniature Neutron Source Reactor (MNSR) as a neutron source for BNCT was investigated. For this purpose, we designed a Beam Shaping Assembly (BSA) for the reactor and the neutron transport from the core of the reactor t...

  8. Nanostructured Boron Nitride With High Water Dispersibility For Boron Neutron Capture Therapy

    Science.gov (United States)

    Singh, Bikramjeet; Kaur, Gurpreet; Singh, Paviter; Singh, Kulwinder; Kumar, Baban; Vij, Ankush; Kumar, Manjeet; Bala, Rajni; Meena, Ramovatar; Singh, Ajay; Thakur, Anup; Kumar, Akshay

    2016-10-01

    Highly water dispersible boron based compounds are innovative and advanced materials which can be used in Boron Neutron Capture Therapy for cancer treatment (BNCT). Present study deals with the synthesis of highly water dispersible nanostructured Boron Nitride (BN). Unique and relatively low temperature synthesis route is the soul of present study. The morphological examinations (Scanning/transmission electron microscopy) of synthesized nanostructures showed that they are in transient phase from two dimensional hexagonal sheets to nanotubes. It is also supported by dual energy band gap of these materials calculated from UV- visible spectrum of the material. The theoretically calculated band gap also supports the same (calculated by virtual nano lab Software). X-ray diffraction (XRD) analysis shows that the synthesized material has deformed structure which is further supported by Raman spectroscopy. The structural aspect of high water disperse ability of BN is also studied. The ultra-high disperse ability which is a result of structural deformation make these nanostructures very useful in BNCT. Cytotoxicity studies on various cell lines (Hela(cervical cancer), human embryonic kidney (HEK-293) and human breast adenocarcinoma (MCF-7)) show that the synthesized nanostructures can be used for BNCT.

  9. Nuclear Physics meets Medicine and Biology: Boron Neutron Capture Therapy

    CERN Document Server

    F. Ballarini, F; S. Bortolussi, S; P. Bruschi, P; A.M. Clerici, A M; A. De Bari, A; P. Dionigi, P; C. Ferrari, C; M.A. Gadan, M A; N. Protti, N; S. Stella, S; C. Zonta, C; A. Zonta, A; S. Altieri, S

    2010-01-01

    BNCT is a tumour treatment based on thermal-neutron irradiation of tissues enriched with 10B, which according to the 10B(n, )7Li reaction produces particles with high Linear Energy Transfer and short range. Since this treatment can deliver a therapeutic tumour dose sparing normal tissues, BNCT represents an alternative for diffuse tumours and metastases, which show poor response to surgery and photontherapy. In 2001 and 2003, in Pavia BNCT was applied to an isolated liver, which was infused with boron, explanted, irradiated and re-implanted. A new project was then initiated for lung tumours, developing a protocol for Boron concentration measurements and performing organ-dose Monte Carlo calculations; in parallel, radiobiology studies are ongoing to characterize the BNCT effects down to cellular level. After a brief introduction, herein we will present the main activities ongoing in Pavia including the radiobiological ones, which are under investigation not only experimentally but also theoretically, basing on...

  10. Boron containing magnetic nanoparticles for neutron capture therapy--an innovative approach for specifically targeting tumors.

    Science.gov (United States)

    Tietze, Rainer; Unterweger, Harald; Dürr, Stephan; Lyer, Stefan; Canella, Lea; Kudejova, Petra; Wagner, Franz M; Petry, Winfried; Taccardi, Nicola; Alexiou, Christoph

    2015-12-01

    The selective delivery of (10)B into the tumor tissue remains to be further improved for successful and reliable Boron Neutron Capture Therapy applications. Magnetic Drug Targeting using intraarterially administered superparamagnetic nanoparticles and external magnetic fields already exhibited convincing results in terms of highly efficient and selective drug deposition. Using the same technique for the targeted (10)B delivery is a promising new approach. Here, systematic irradiation experiments of phantom cubes containing different concentrations of boron and nanoparticles as well as varying three-dimensional arrangements have been performed.

  11. Boron neutron capture therapy (BNCT) in Finland: technological and physical prospects after 20 years of experiences.

    Science.gov (United States)

    Savolainen, Sauli; Kortesniemi, Mika; Timonen, Marjut; Reijonen, Vappu; Kuusela, Linda; Uusi-Simola, Jouni; Salli, Eero; Koivunoro, Hanna; Seppälä, Tiina; Lönnroth, Nadja; Välimäki, Petteri; Hyvönen, Heini; Kotiluoto, Petri; Serén, Tom; Kuronen, Antti; Heikkinen, Sami; Kosunen, Antti; Auterinen, Iiro

    2013-05-01

    Boron Neutron Capture Therapy (BNCT) is a binary radiotherapy method developed to treat patients with certain malignant tumours. To date, over 300 treatments have been carried out at the Finnish BNCT facility in various on-going and past clinical trials. In this technical review, we discuss our research work in the field of medical physics to form the groundwork for the Finnish BNCT patient treatments, as well as the possibilities to further develop and optimize the method in the future. Accordingly, the following aspects are described: neutron sources, beam dosimetry, treatment planning, boron imaging and determination, and finally the possibilities to detect the efficacy and effects of BNCT on patients.

  12. The dependency of compound biological effectiveness factors on the type and the concentration of administered neutron capture agents in boron neutron capture therapy

    OpenAIRE

    Masunaga, Shin-Ichiro; Sakurai, Yoshinori; Tanaka, Hiroki; Tano, Keizo; Suzuki, Minoru; Kondo, Natsuko; Narabayashi, Masaru; Nakagawa, Yosuke; Watanabe, Tsubasa; Maruhashi, Akira; ONO, KOJI

    2014-01-01

    Purpose To examine the effect of the type and the concentration of neutron capture agents on the values of compound biological effectiveness (CBE) in boron neutron capture therapy. Methods and materials After the subcutaneous administration of a 10 B-carrier, boronophenylalanine- 10 B (BPA) or sodium mercaptododecaborate- 10 B (BSH), at 3 separate concentrations, the 10 B concentrations in tumors were measured by γ-ray spectrometry. SCC VII tumor-bearing C3H/He mice received 5-bromo-2′-deoxyu...

  13. Monte Carlo assessment of boron neutron capture therapy for the treatment of breast cancer

    Directory of Open Access Journals (Sweden)

    Mundy Daniel W.

    2005-01-01

    Full Text Available For a large number of women who are diagnosed with breast cancer every year the avail able treatment options are effective, though physically and mentally taxing. This work is a starting point of a study of the efficacy of boron neutron capture therapy as an alternative treatment for HER-2+ breast tumors. Using HER-2-specific monoclonal anti bodies coupled with a boron-rich oligomeric phosphate diester, it may be possible to deliver sufficient amounts of 10B to a tumor of the breast to al low for selective cell destruction via irradiation by thermal neutrons. A comprehensive computational model (MCNP for thermal neutron irradiation of the breast is described, as well as the results of calculations made using this model, in order to determine the optimum boron concentration within the tumor for an effective boron neutron capture therapy treatment, as compared with traditional X-ray radiotherapy. The results indicate that a boron concentration of 50-60 mg per gram of tumor tissue is optimal when considering treatment times, dose distributions and skin sparing. How ever these results are based upon best-guess assumptions that must be experimentally verified.

  14. Design of a boron neutron capture enhanced fast neutron therapy assembly

    Energy Technology Data Exchange (ETDEWEB)

    Wang, Zhonglu [Georgia Inst. of Technology, Atlanta, GA (United States)

    2006-12-01

    The use of boron neutron capture to boost tumor dose in fast neutron therapy has been investigated at several fast neutron therapy centers worldwide. This treatment is termed boron neutron capture enhanced fast neutron therapy (BNCEFNT). It is a combination of boron neutron capture therapy (BNCT) and fast neutron therapy (FNT). It is believed that BNCEFNT may be useful in the treatment of some radioresistant brain tumors, such as glioblastoma multiform (GBM). A boron neutron capture enhanced fast neutron therapy assembly has been designed for the Fermilab Neutron Therapy Facility (NTF). This assembly uses a tungsten filter and collimator near the patient's head, with a graphite reflector surrounding the head to significantly increase the dose due to boron neutron capture reactions. The assembly was designed using Monte Carlo radiation transport code MCNP version 5 for a standard 20x20 cm2 treatment beam. The calculated boron dose enhancement at 5.7-cm depth in a water-filled head phantom in the assembly with a 5x5 cm2 collimation was 21.9% per 100-ppm 10B for a 5.0-cm tungsten filter and 29.8% for a 8.5-cm tungsten filter. The corresponding dose rate for the 5.0-cm and 8.5-cm thick filters were 0.221 and 0.127 Gy/min, respectively; about 48.5% and 27.9% of the dose rate of the standard 10x10 cm2 fast neutron treatment beam. To validate the design calculations, a simplified BNCEFNT assembly was built using four lead bricks to form a 5x5 cm2 collimator. Five 1.0-cm thick 20x20 cm2 tungsten plates were used to obtain different filter thicknesses and graphite bricks/blocks were used to form a reflector. Measurements of the dose enhancement of the simplified assembly in a water-filled head phantom were performed using a pair of tissue-equivalent ion chambers. One of the ion chambers is loaded with 1000-ppm natural boron (184-ppm 10B) to measure dose due to boron neutron capture. The

  15. Boron neutron capture therapy of malignant brain tumors at the Brookhaven Medical Research Reactor

    Energy Technology Data Exchange (ETDEWEB)

    Joel, D.D.; Coderre, J.A.; Chanana, A.D. [Brookhaven National Lab., Upton, NY (United States). Medical Dept.

    1996-12-31

    Boron neutron capture therapy (BNCT) is a bimodal form of radiation therapy for cancer. The first component of this treatment is the preferential localization of the stable isotope {sup 10}B in tumor cells by targeting with boronated compounds. The tumor and surrounding tissue is then irradiated with a neutron beam resulting in thermal neutron/{sup 10}B reactions ({sup 10}B(n,{alpha}){sup 7}Li) resulting in the production of localized high LET radiation from alpha and {sup 7}Li particles. These products of the neutron capture reaction are very damaging to cells, but of short range so that the majority of the ionizing energy released is microscopically confined to the vicinity of the boron-containing compound. In principal it should be possible with BNCT to selectively destroy small nests or even single cancer cells located within normal tissue. It follows that the major improvements in this form of radiation therapy are going to come largely from the development of boron compounds with greater tumor selectivity, although there will certainly be advances made in neutron beam quality as well as the possible development of alternative sources of neutron beams, particularly accelerator-based epithermal neutron beams.

  16. Rational design of gold nanoparticles functionalized with carboranes for application in Boron Neutron Capture Therapy.

    Science.gov (United States)

    Ciani, Laura; Bortolussi, Silva; Postuma, Ian; Cansolino, Laura; Ferrari, Cinzia; Panza, Luigi; Altieri, Saverio; Ristori, Sandra

    2013-12-31

    In this paper we propose a bottom-up approach to obtain new boron carriers built with ortho-carborane functionalized gold nanoparticles (GNPs) for applications in Boron Neutron Capture Therapy. The interaction between carboranes and the gold surface was assured by one or two SH-groups directly linked to the boron atoms of the B10C2 cage. This allowed obtaining stable, nontoxic systems, though optimal biological performance was hampered by low solubility in aqueous media. To improve cell uptake, the hydrophilic character of carborane functionalized GNPs was enhanced by further coverage with an appropriately tailored diblock copolymer (PEO-b-PCL). This polymer also contained pendant carboranes to provide anchoring to the pre-functionalized GNPs. In vitro tests, carried out on osteosarcoma cells, showed that the final vectors possessed excellent biocompatibility joint to the capacity of concentrating boron atoms in the target, which is encouraging evidenced to pursue applications in vivo.

  17. Synthesis and evaluation of boron compounds for neutron capture therapy of malignant brain tumors

    Energy Technology Data Exchange (ETDEWEB)

    Soloway, A.H.; Barth, R.F.

    1990-01-01

    Boron neutron capture therapy offers the potentiality for treating brain tumors currently resistant to treatment. The success of this form of therapy is directly dependent upon the delivery of sufficient numbers of thermal-neutrons to tumor cells which possess high concentrations of B-10. The objective of this project is to develop chemical methodology to synthesize boron-containing compounds with the potential for becoming incorporated into rapidly-dividing malignant brain tumor cells and excluded from normal components of the brain and surrounding tissues, to develope biological methods for assessing the potential of the compound by use of cell culture or intratumoral injection, to develop analytical methodology for measuring boron in cells and tissue using direct current plasma atomic emission spectroscopy (DCP-AES) and alpha track autoradiography, to develop biochemical and HPLC procedures for evaluating compound uptake and tissue half-life, and to develop procedures required to assess both in vitro and vivo efficacy of BNCT with selected compounds.

  18. Boron neutron capture therapy (BNCT): implications of neutron beam and boron compound characteristics.

    Science.gov (United States)

    Wheeler, F J; Nigg, D W; Capala, J; Watkins, P R; Vroegindeweij, C; Auterinen, I; Seppälä, T; Bleuel, D

    1999-07-01

    The potential efficacy of boron neutron capture therapy (BNCT) for malignant glioma is a significant function of epithermal-neutron beam biophysical characteristics as well as boron compound biodistribution characteristics. Monte Carlo analyses were performed to evaluate the relative significance of these factors on theoretical tumor control using a standard model. The existing, well-characterized epithermal-neutron sources at the Brookhaven Medical Research Reactor (BMRR), the Petten High Flux Reactor (HFR), and the Finnish Research Reactor (FiR-1) were compared. Results for a realistic accelerator design by the E. O. Lawrence Berkeley National Laboratory (LBL) are also compared. Also the characteristics of the compound p-Boronophenylaline Fructose (BPA-F) and a hypothetical next-generation compound were used in a comparison of the BMRR and a hypothetical improved reactor. All components of dose induced by an external epithermal-neutron beam fall off quite rapidly with depth in tissue. Delivery of dose to greater depths is limited by the healthy-tissue tolerance and a reduction in the hydrogen-recoil and incident gamma dose allow for longer irradiation and greater dose at a depth. Dose at depth can also be increased with a beam that has higher neutron energy (without too high a recoil dose) and a more forward peaked angular distribution. Of the existing facilities, the FiR-1 beam has the better quality (lower hydrogen-recoil and incident gamma dose) and a penetrating neutron spectrum and was found to deliver a higher value of Tumor Control Probability (TCP) than other existing beams at shallow depth. The greater forwardness and penetration of the HFR the FiR-1 at greater depths. The hypothetical reactor and accelerator beams outperform at both shallow and greater depths. In all cases, the hypothetical compound provides a significant improvement in efficacy but it is shown that the full benefit of improved compound is not realized until the neutron beam is fully

  19. Dose estimation for internal organs during boron neutron capture therapy for body-trunk tumors.

    Science.gov (United States)

    Sakurai, Y; Tanaka, H; Suzuki, M; Masunaga, S; Kinashi, Y; Kondo, N; Ono, K; Maruhashi, A

    2014-06-01

    Radiation doses during boron neutron capture therapy for body-trunk tumors were estimated for various internal organs, using data from patients treated at Kyoto University Research Reactor Institute. Dose-volume histograms were constructed for tissues of the lung, liver, kidney, pancreas, and bowel. For pleural mesothelioma, the target total dose to the normal lung tissues on the diseased side is 5Gy-Eq in average for the whole lung. It was confirmed that the dose to the liver should be carefully considered in cases of right lung disease.

  20. Single photon image from position emission tomography with insertable collimator for boron neutron capture therapy

    Energy Technology Data Exchange (ETDEWEB)

    Jung, Joo Young; Yoo, Do Kun; Suh, Tae Suk [Dept. of Biomedical Engineering and Research Institute of Biomedical Engineering, College of Medicine, Catholic University of Korea, Seoul (Korea, Republic of); Hong, Key Jo [Molecular Imaging Program at Stanford (MIPS), Dept. of Radiology, Stanford University, Stanford (United States)

    2014-04-15

    The aim of our proposed system is to confirm the feasibility of extraction of two types of images from one positron emission tomography (PET) module with an insertable collimator for brain tumor treatment during the boron neutron capture therapy (BNCT). The BNCT theory and conceptual diagram of our proposed system are shown fig.1. Data from the PET module, neutron source, and collimator was entered in the Monte Carlon-particle extende source code. We attempted to acquire the PET and SPECT images simultaneously using only PET without an additional isotope. Single photon images were acquired using an insertable collimator on a PET detector.

  1. Potential of boron neutron capture therapy (BNCT) for malignant peripheral nerve sheath tumors (MPNST).

    Science.gov (United States)

    Fujimoto, Takuya; Andoh, Tooru; Sudo, Tamotsu; Fujita, Ikuo; Fukase, Naomasa; Takeuchi, Tamotsu; Sonobe, Hiroshi; Inoue, Masayoshi; Hirose, Tkanori; Sakuma, Toshiko; Moritake, Hiroshi; Sugimoto, Tohru; Kawamoto, Teruya; Fukumori, Yoshinobu; Yamamoto, Satomi; Atagi, Shinji; Sakurai, Yoshinori; Kurosaka, Masahiro; Ono, Koji; Ichikawa, Hideki; Suzuki, Minoru

    2015-12-01

    Malignant peripheral nerve sheath tumors (MPNST) are relatively rare neoplasms with poor prognosis. At present there is no effective treatment for MPNST other than surgical resection. Nonetheless, the anti-tumor effect of boron neutron capture therapy (BNCT) was recently demonstrated in two patients with MPNST. Subsequently, tumor-bearing nude mice subcutaneously transplanted with a human MPNST cell line were injected with p-borono-L-phenylalanine (L-BPA) and subjected to BNCT. Pathological studies then revealed that the MPNST cells were selectively destroyed by BNCT.

  2. Tetrakis(p-Carboranylthio-Tetrafluorophenyl)Chlorin (TPFC): Application for Photodynamic Therapy and Boron Neutron Capture Therapy

    Science.gov (United States)

    HIRAMATSU, RYO; KAWABATA, SHINJI; TANAKA, HIROKI; SAKURAI, YOSHINORI; SUZUKI, MINORU; ONO, KOJI; MIYATAKE, SHIN-ICHI; KUROIWA, TOSHIHIKO; HAO, ERHONG; VICENTE, M. GRAÇA H.

    2015-01-01

    Carboranyl-containing chlorins have emerged as promising dual sensitizers for use in both photodynamic therapy (PDT) and boron neutron capture therapy (BNCT), by virtue of their known tumor affinity, low cytotoxicity in dark conditions, and their strong absorptions in the red region of the optical spectrum. Tetrakis(p-carboranylthio-tetrafluorophenyl)chlorin (TPFC) is a new synthetic carboranyl-containing chlorin of high boron content (24% by weight). To evaluate TPFC’s applicability as sensitizer for both PDT and BNCT, we performed an in vitro and in vivo study using F98 rat glioma cells and F98 rat glioma-bearing brain tumor models. For the in vivo BNCT study, we used boronophenylalanine (BPA), which is currently used in clinical BNCT studies, via intravenous administration (i.v.) and/or used TPFC via convection-enhanced delivery (CED), a method for local drug infusion directly into the brain. In the in vitro PDT study, the cell surviving fraction following laser irradiation (9 J/cm2) was 0.035 whereas in the in vitro BNCT study, the cell surviving fraction following neutron irradiation (thermal neutron = 1.73 × 1012 n/cm2) was 0.04. In the in vivo BNCT study, the median survival time following concomitant administration of BPA (i.v.) and TPFC (CED) was 42 days (95% confidence interval; 37–43 days). PMID:25546823

  3. Tetrakis(p-carboranylthio-tetrafluorophenyl)chlorin (TPFC): application for photodynamic therapy and boron neutron capture therapy.

    Science.gov (United States)

    Hiramatsu, Ryo; Kawabata, Shinji; Tanaka, Hiroki; Sakurai, Yoshinori; Suzuki, Minoru; Ono, Koji; Miyatake, Shin-ichi; Kuroiwa, Toshihiko; Hao, Erhong; Vicente, M Graça H

    2015-03-01

    Carboranyl-containing chlorins have emerged as promising dual sensitizers for use in both photodynamic therapy (PDT) and boron neutron capture therapy (BNCT), by virtue of their known tumor affinity, low cytotoxicity in dark conditions, and their strong absorptions in the red region of the optical spectrum. Tetrakis(p-carboranylthio-tetrafluorophenyl)chlorin (TPFC) is a new synthetic carboranyl-containing chlorin of high boron content (24% by weight). To evaluate TPFC's applicability as sensitizer for both PDT and BNCT, we performed an in vitro and in vivo study using F98 rat glioma cells and F98 rat glioma-bearing brain tumor models. For the in vivo BNCT study, we used boronophenylalanine (BPA), which is currently used in clinical BNCT studies, via intravenous administration (i.v.) and/or used TPFC via convection-enhanced delivery (CED), a method for local drug infusion directly into the brain. In the in vitro PDT study, the cell surviving fraction following laser irradiation (9 J/cm(2) ) was 0.035 whereas in the in vitro BNCT study, the cell surviving fraction following neutron irradiation (thermal neutron = 1.73 × 10(12) n/cm(2) ) was 0.04. In the in vivo BNCT study, the median survival time following concomitant administration of BPA (i.v.) and TPFC (CED) was 42 days (95% confidence interval; 37-43 days).

  4. Boronated monoclonal antibody 225. 28S for potential use in neutron capture therapy of malignant melanoma

    Energy Technology Data Exchange (ETDEWEB)

    Tamat, S.R.; Moore, D.E.; Patwardhan, A.; Hersey, P. (Univ. of Sydney (Australia))

    1989-07-01

    The concept of conjugating boron cluster compounds to monoclonal antibodies has been examined by several groups of research workers in boron neutron capture therapy (BNCT). The procedures reported to date for boronation of monoclonal antibodies resulted in either an inadequate level of boron incorporation, the precipitation of the conjugates, or a loss of immunological activity. The present report describes the conjugation of dicesium-mercapto-undecahydrododecaborate (Cs2B12H11SH) to 225.28S monoclonal antibody directed against high molecular weight melanoma-associated antigens (HMW-MAA), using poly-L-ornithine as a bridge to increase the carrying capacity of the antibody and to minimize change in the conformational structure of antibody. The method produces a boron content of 1,300 to 1,700 B atoms per molecule 225.28S while retaining the immunoreactivity. Characterization in terms of the homogeneity of the conjugation of the boron-monoclonal antibody conjugates has been studied by gel electrophoresis and ion-exchange HPLC.

  5. Design for an accelerator-based orthogonal epithermal neutron beam for boron neutron capture therapy.

    Science.gov (United States)

    Allen, D A; Beynon, T D; Green, S

    1999-01-01

    This paper is concerned with the proposed Birmingham accelerator-based epithermal neutron beam for boron neutron capture therapy (BNCT). In particular, the option of producing a therapy beam at an orthogonal direction to the incoming protons is considered. Monte Carlo radiation transport simulations, both with and without a head phantom, have shown that an orthogonal beam geometry is not only acceptable but is indeed beneficial, in terms of a lower mean neutron energy and an enhanced therapeutic ratio for the same useful neutron fluence in the therapy beam. Typical treatment times for various beam options have been calculated, and range from 20 to 48 min with a 5 mA beam of 2.8 MeV protons, if the maximum photon-equivalent dose delivered to healthy tissue is to be 12.6 Gy Eq. The effects of proton beam diameter upon the therapy beam parameters have also been considered.

  6. Biodistribution of Amine-Amide Chlorin e6 Derivative Conjugate with a Boron Nanoparticle for Boron Neutron-Capture Therapy

    OpenAIRE

    А.B. Volovetsky; N.Y. Shilyagina; V.V. Dudenkova; S.О. Pasynkova; М.А. Grin; А.F. Mironov; А.V. Feofanov; I.V. Balalaeva; А.V. Maslennikova

    2016-01-01

    The aim of the investigation was to study the biodistribution of amino-amide chlorin e6 derivative conjugate with cobalt bis-dicarbollide as a potential boron transporter for the tasks of boron neutron-capture therapy. Materials and Methods. The experiments were carried out on Balb/c mice with induced murine colon carcinoma CT-26. Amino-amide chlorin e6 derivative conjugate with cobalt bis-dicarbollide was administered intravenously, the dose being 5 and 10 mg/kg body mass. The sampling for m...

  7. A suggestion for B-10 imaging during boron neutron capture therapy

    CERN Document Server

    Cortesi, M

    2007-01-01

    Selective accumulation of B-10 compound in tumour tissue is a fundamental condition for the achievement of BNCT (Boron Neutron Capture Therapy), since the effectiveness of therapy irradiation derives just from neutron capture reaction of B-10. Hence, the determination of the B-10 concentration ratio, between tumour and healthy tissue, and a control of this ratio, during the therapy, are essential to optimise the effectiveness of the BNCT, which it is known to be based on the selective uptake of B-10 compound. In this work, experimental methods are proposed and evaluated for the determination in vivo of B-10 compound in biological samples, in particular based on neutron radiography and gammaray spectroscopy by telescopic system. Measures and Monte Carlo calculations have been performed to investigate the possibility of executing imaging of the 10B distribution, both by radiography with thermal neutrons, using 6LiF/ZnS:Ag scintillator screen and a CCD camera, and by spectroscopy, based on the revelation of gamm...

  8. Hemorrhage in mouse tumors induced by dodecaborate cluster lipids intended for boron neutron capture therapy

    Directory of Open Access Journals (Sweden)

    Schaffran T

    2014-07-01

    Full Text Available Tanja Schaffran,1 Nan Jiang,1 Markus Bergmann,2,3 Ekkehard Küstermann,4 Regine Süss,5 Rolf Schubert,5 Franz M Wagner,6 Doaa Awad,7 Detlef Gabel1,2,8 1Department of Chemistry, University of Bremen, 2Institute of Neuropathology, Klinikum Bremen-Mitte; 3Cooperative Center Medicine, University of Bremen, 4“In-vivo-MR” AG, FB2, University of Bremen, Bremen, 5Pharmaceutical Technology, University of Freiburg, Freiburg im Breisgau, 6Forschungsneutronenquelle Heinz Maier-Leibnitz (FRM II, Technische Unversitaet Muenchen, Garching, Germany; 7Department of Biochemistry, Alexandria University, Alexandria, Egypt; 8School of Engineering and Science, Jacobs University Bremen, Bremen, Germany Abstract: The potential of boron-containing lipids with three different structures, which were intended for use in boron neutron capture therapy, was investigated. All three types of boron lipids contained the anionic dodecaborate cluster as the headgroup. Their effects on two different tumor models in mice following intravenous injection were tested; for this, liposomes with boron lipid, distearoyl phosphatidylcholine, and cholesterol as helper lipids, and containing a polyethylene glycol lipid for steric protection, were administered intravenously into tumor-bearing mice (C3H mice for SCCVII squamous cell carcinoma and BALB/c mice for CT26/WT colon carcinoma. With the exception of one lipid (B-THF-14, the lipids were well tolerated, and no other animal was lost due to systemic toxicity. The lipid which led to death was not found to be much more toxic in cell culture than the other boron lipids. All of the lipids that were well tolerated showed hemorrhage in both tumor models within a few hours after administration. The hemorrhage could be seen by in vivo magnetic resonance and histology, and was found to occur within a few hours. The degree of hemorrhage depended on the amount of boron administered and on the tumor model. The observed unwanted effect of the lipids

  9. Toward a final design for the Birmingham boron neutron capture therapy neutron beam.

    Science.gov (United States)

    Allen, D A; Beynon, T D; Green, S; James, N D

    1999-01-01

    This paper is concerned with the proposed Birmingham accelerator-based epithermal neutron beam for boron neutron capture therapy (BNCT). Details of the final moderator design, such as beam delimiter, shield, and beam exit surface shape are considered. Monte Carlo radiation transport simulations with a head and body phantom have shown that a simple flat moderator beam exit surface is preferable to the previously envisioned spherical design. Dose rates to individual body organs during treatment have been calculated using a standard MIRD phantom. We have shown that a simple polyethylene shield, doped with natural lithium, is sufficient to provide adequate protection to the rest of the body during head irradiations. The effect upon the head phantom dose distributions of the use of such a shield to delimit the therapy beam has been evaluated.

  10. Boron neutron capture therapy for malignant melanoma: first clinical case report in China

    Science.gov (United States)

    Yong, Zhong; Song, Zewen; Zhou, Yongmao; Liu, Tong; Zhang, Zizhu; Zhao, Yanzhong; Chen, Yang; Jin, Congjun; Chen, Xiang; Lu, Jianyun; Han, Rui; Li, Pengzhou; Sun, Xulong; Wang, Guohui; Shi, Guangqing; Zhu, Shaihong

    2016-01-01

    A phase I/II clinical trial for treating malignant melanoma by boron neutron capture therapy (BNCT) was designed to evaluate whether the world’s first in-hospital neutron irradiator (IHNI) was qualified for BNCT. In this clinical trial planning to enroll 30 patients, the first case was treated on August 19, 2014. We present the protocol of this clinical trial, the treating procedure, and the clinical outcome of this first case. Only grade 2 acute radiation injury was observed during the first four weeks after BNCT and the injury healed after treatment. No late radiation injury was found during the 24-month follow-up. Based on positron emission tomography-computed tomography (PET/CT) scan, pathological analysis and gross examination, the patient showed a complete response to BNCT, indicating that BNCT is a potent therapy against malignant melanoma and IHNI has the potential to enable the delivery of BNCT in hospitals. PMID:28174492

  11. Study of characteristics for heavy water photoneutron source in boron neutron capture therapy

    CERN Document Server

    Salehi, Danial; Sardari, Dariush

    2013-01-01

    Bremsstrahlung photon beams produced by medical linear accelerators are currently the most commonly used method of radiation therapy for cancerous tumors. Photons with energies greater than 8-10 MeV potentially generate neutrons through photonuclear interactions in the accelerator's treatment head, patient's body, and treatment room ambient. Electrons impinging on a heavy target generate a cascade shower of bremsstrahlung photons, the energy spectrum of which shows an end point equal to the electron beam energy. By varying the target thickness, an optimum thickness exists for which, at the given electron energy, maximum photon flux is achievable. If a source of high-energy photons i.e. bremsstrahlung, is conveniently directed to a suitable D2O target, a novel approach for production of an acceptable flux of filterable photoneturons for boron neutron capture therapy (BNCT) application is possible. This study consists of two parts. 1. Comparison and assessment of deuterium photonuclear cross section data. 2. Ev...

  12. Biodistribution of sodium borocaptate (BSH) for boron neutron capture therapy (BNCT) in an oral cancer model.

    Science.gov (United States)

    Garabalino, Marcela A; Heber, Elisa M; Monti Hughes, Andrea; González, Sara J; Molinari, Ana J; Pozzi, Emiliano C C; Nievas, Susana; Itoiz, Maria E; Aromando, Romina F; Nigg, David W; Bauer, William; Trivillin, Verónica A; Schwint, Amanda E

    2013-08-01

    Boron neutron capture therapy (BNCT) is based on selective accumulation of ¹⁰B carriers in tumor followed by neutron irradiation. We previously proved the therapeutic success of BNCT mediated by the boron compounds boronophenylalanine and sodium decahydrodecaborate (GB-10) in the hamster cheek pouch oral cancer model. Based on the clinical relevance of the boron carrier sodium borocaptate (BSH) and the knowledge that the most effective way to optimize BNCT is to improve tumor boron targeting, the specific aim of this study was to perform biodistribution studies of BSH in the hamster cheek pouch oral cancer model and evaluate the feasibility of BNCT mediated by BSH at nuclear reactor RA-3. The general aim of these studies is to contribute to the knowledge of BNCT radiobiology and optimize BNCT for head and neck cancer. Sodium borocaptate (50 mg ¹⁰B/kg) was administered to tumor-bearing hamsters. Groups of 3-5 animals were killed humanely at nine time-points, 3-12 h post-administration. Samples of blood, tumor, precancerous pouch tissue, normal pouch tissue and other clinically relevant normal tissues were processed for boron measurement by optic emission spectroscopy. Tumor boron concentration peaked to therapeutically useful boron concentration values of 24-35 ppm. The boron concentration ratio tumor/normal pouch tissue ranged from 1.1 to 1.8. Pharmacokinetic curves showed that the optimum interval between BSH administration and neutron irradiation was 7-11 h. It is concluded that BNCT mediated by BSH at nuclear reactor RA-3 would be feasible.

  13. Dose point kernel for boron-11 decay and the cellular S values in boron neutron capture therapy.

    Science.gov (United States)

    Ma, Yunzhi; Geng, JinPeng; Gao, Song; Bao, Shanglian

    2006-12-01

    The study of the radiobiology of boron neutron capture therapy is based on the cellular level dosimetry of boron-10's thermal neutron capture reaction 10B(n,alpha)7Li, in which one 1.47 MeV helium-4 ion and one 0.84 MeV lithium-7 ion are spawned. Because of the chemical preference of boron-10 carrier molecules, the dose is heterogeneously distributed in cells. In the present work, the (scaled) dose point kernel of boron-11 decay, called 11B-DPK, was calculated by GEANT4 Monte Carlo simulation code. The DPK curve drops suddenly at the radius of 4.26 microm, the continuous slowing down approximation (CSDA) range of a lithium-7 ion. Then, after a slight ascending, the curve decreases to near zero when the radius goes beyond 8.20 microm, which is the CSDA range of a 1.47 MeV helium-4 ion. With the DPK data, S values for nuclei and cells with the boron-10 on the cell surface are calculated for different combinations of cell and nucleus sizes. The S value for a cell radius of 10 microm and a nucleus radius of 5 microm is slightly larger than the value published by Tung et al. [Appl. Radiat. Isot. 61, 739-743 (2004)]. This result is potentially more accurate than the published value since it includes the contribution of a lithium-7 ion as well as the alpha particle.

  14. Functionalization and cellular uptake of boron carbide nanoparticles. The first step toward T cell-guided boron neutron capture therapy.

    Science.gov (United States)

    Mortensen, M W; Björkdahl, O; Sørensen, P G; Hansen, T; Jensen, M R; Gundersen, H J G; Bjørnholm, T

    2006-01-01

    In this paper we present surface modification strategies of boron carbide nanoparticles, which allow for bioconjugation of the transacting transcriptional activator (TAT) peptide and fluorescent dyes. Coated nanoparticles can be translocated into murine EL4 thymoma cells and B16 F10 malignant melanoma cells in amounts as high as 0.3 wt. % and 1 wt. %, respectively. Neutron irradiation of a test system consisting of untreated B16 cells mixed with B16 cells loaded with boron carbide nanoparticles were found to inhibit the proliferative capacity of untreated cells, showing that cells loaded with boron-containing nanoparticles can hinder the growth of neighboring cells upon neutron irradiation. This could provide the first step toward a T cell-guided boron neutron capture therapy.

  15. Preparation and characterization of Boron carbide nanoparticles for use as a novel agent in T cell-guided boron neutron capture therapy

    DEFF Research Database (Denmark)

    Mortensen, M. W.; Sørensen, P. G.; Björkdahl, O.;

    2006-01-01

    Boron carbide nanoparticles are proposed as a system for T cell-guided boron neutron capture therapy. Nanoparticles were produced by ball milling in various atmospheres of commercially available boron carbide. The physical and chemical properties of the particles were investigated using...

  16. The filter/moderator arrangement-optimisation for the boron-neutron capture therapy (BNCT).

    Science.gov (United States)

    Tracz, G; Dabkowski, L; Dworak, D; Pytel, K; Woźnicka, U

    2004-01-01

    The paper presents results of the numerical modelling of the fission-converter-based epithermal neutron source designed for the boron neutron capture therapy (BNCT) facility to be located at the Polish research nuclear reactor MARIA at Swierk. The unique design of the fission converter has been proposed due to a specific geometrical surrounding of the reactor. The filter/moderator arrangement has been optimised to moderate fission neutrons to epithermal energies and to remove both fast neutrons and photons from the therapeutic beam. The selected filter/moderator set-up ensures both high epithermal neutron flux and suitably low level of beam contamination. Photons originating from the reactor core are almost eliminated what is the exceptional advantage of the proposed design. It yields one order of magnitude lower gamma radiation dose than the maximum allowed dose in such a type of therapeutic facility. The MCNP code has been used for the computations.

  17. A case of radiation-induced osteosarcoma treated effectively by boron neutron capture therapy.

    Science.gov (United States)

    Futamura, Gen; Kawabata, Shinji; Siba, Hiroyuki; Kuroiwa, Toshihiko; Suzuki, Minoru; Kondo, Natsuko; Ono, Koji; Sakurai, Yoshinori; Tanaka, Minoru; Todo, Tomoki; Miyatake, Shin-Ichi

    2014-11-04

    We treated a 54-year-old Japanese female with a recurrent radiation-induced osteosarcoma arising from left occipital skull, by reactor-based boron neutron capture therapy (BNCT). Her tumor grew rapidly with subcutaneous and epidural extension. She eventually could not walk because of cerebellar ataxia. The tumor was inoperable and radioresistant. BNCT showed a marked initial therapeutic effect: the subcutaneous/epidural tumor reduced without radiation damage of the scalp except hair loss and the patient could walk again only 3 weeks after BNCT. BNCT seems to be a safe and very effective modality in the management of radiation-induced osteosarcomas that are not eligible for operation and other treatment modalities.

  18. Optimal Neutron Source and Beam Shaping Assembly for Boron Neutron Capture Therapy

    CERN Document Server

    Vujic, J L; Greenspan, E; Guess, S; Karni, Y; Kastenber, W E; Kim, L; Leung, K N; Regev, D; Verbeke, J M; Waldron, W L; Zhu, Y

    2003-01-01

    There were three objectives to this project: (1) The development of the 2-D Swan code for the optimization of the nuclear design of facilities for medical applications of radiation, radiation shields, blankets of accelerator-driven systems, fusion facilities, etc. (2) Identification of the maximum beam quality that can be obtained for Boron Neutron Capture Therapy (BNCT) from different reactor-, and accelerator-based neutron sources. The optimal beam-shaping assembly (BSA) design for each neutron source was also to e obtained. (3) Feasibility assessment of a new neutron source for NCT and other medical and industrial applications. This source consists of a state-of-the-art proton or deuteron accelerator driving and inherently safe, proliferation resistant, small subcritical fission assembly.

  19. Optimal Neutron Source & Beam Shaping Assembly for Boron Neutron Capture Therapy

    Energy Technology Data Exchange (ETDEWEB)

    J. Vujic; E. Greenspan; W.E. Kastenber; Y. Karni; D. Regev; J.M. Verbeke, K.N. Leung; D. Chivers; S. Guess; L. Kim; W. Waldron; Y. Zhu

    2003-04-30

    There were three objectives to this project: (1) The development of the 2-D Swan code for the optimization of the nuclear design of facilities for medical applications of radiation, radiation shields, blankets of accelerator-driven systems, fusion facilities, etc. (2) Identification of the maximum beam quality that can be obtained for Boron Neutron Capture Therapy (BNCT) from different reactor-, and accelerator-based neutron sources. The optimal beam-shaping assembly (BSA) design for each neutron source was also to e obtained. (3) Feasibility assessment of a new neutron source for NCT and other medical and industrial applications. This source consists of a state-of-the-art proton or deuteron accelerator driving and inherently safe, proliferation resistant, small subcritical fission assembly.

  20. Gel dosimeters as useful dose and thermal-fluence detectors in Boron Neutron Capture Therapy (BNCT)

    Energy Technology Data Exchange (ETDEWEB)

    Gambarini, G.; Valente, M. [Department of Physics of the University and INFN, Via Celoria 16, I-20133 Milan (Italy); Moss, R.L.; Daquino, G.G.; Nievaart, V.A. [Joint Research Centre, Institute for Energy, P.O. Box 2, NL-1755ZG Petten, The Netherlands (Netherlands); Mariani, M.; Vanossi, E. [Department of Nuclear Engineering of Polytechnic, CESNEF, Via Ponzio, 34/3 - I-20133 Milan (Italy); Carrara, M. [Medical Physics Department, National Cancer Institute, Via Venezian 1, I-20131, Milan (Italy)

    2006-07-01

    The dosimetry method based on Fricke-Xylenol-Orange-infused gels in form of layers has shown noticeable potentiality for in-phantom or in-free-beam dose and thermal flux profiling and imaging in the high fluxes of thermal or epithermal neutrons utilised for boron neutron capture therapy (BNCT). Gel-dosimeters in form of layers give the possibility not only of obtaining spatial dose distributions but also of achieving measurements of each dose contribution in neutron fields. The discrimination of the various dose components is achieved by means of pixel-to-pixel manipulations of pairs of images obtained with gel-dosimeters having different isotopic composition. It is possible to place large dosimeters, detecting in such a way large dose images, because the layer geometry of dosimeters avoids sensitive variation of neutron transport due to the gel isotopic composition. Some results obtained after the last improvements of the method are reported. (Author)

  1. The Boron Neutron Capture Therapy (BNCT) Project at the TRIGA Reactor in Mainz, Germany

    Energy Technology Data Exchange (ETDEWEB)

    Hampel, G.; Grunewald, C.; Schutz, C.; Schmitz, T.; Kratz, J.V. [Nuclear Chemistry, University of Mainz, D-55099 Mainz (Germany); Brochhausen, C.; Kirkpatrick, J. [Department of Pathology, University of Mainz, D-55099 Mainz (Germany); Bortulussi, S.; Altieri, S. [Department of Nuclear and Theoretical Physics University of Pavia, Pavia (Italy); National Institute of Nuclear Physics (INFN) Pavia Section, Pavia (Italy); Kudejova, P. [Forschungs-Neutronenquelle Heinz Maier-Leibnitz (FRM II), Technische Universitaet Muenchen, D-85748 Garching (Germany); Appelman, K.; Moss, R. [Joint Research Centre (JRC) of the European Commission, NL-1755 ZG Petten (Netherlands); Bassler, N. [University of Aarhus, Norde Ringade, DK-8000, Aarhus C (Denmark); Blaickner, M.; Ziegner, M. [Molecular Medicine, Health and Environment Department, AIT Austrian Institute of Technology GmbH (Austria); Sharpe, P.; Palmans, H. [National Physical Laboratory, Teddington TW11 0LW, Middlesex (United Kingdom); Otto, G. [Department of Hepatobiliary, Pancreatic and Transplantation Surgery, University of Mainz, D-55099 Mainz (Germany)

    2011-07-01

    The thermal column of the TRIGA reactor in Mainz is being used very effectively for medical and biological applications. The BNCT (boron neutron capture therapy) project at the University of Mainz is focussed on the treatment of liver tumours, similar to the work performed in Pavia (Italy) a few years ago, where patients with liver metastases were treated by combining BNCT with auto-transplantation of the organ. Here, in Mainz, a preclinical trial has been started on patients suffering from liver metastases of colorectal carcinoma. In vitro experiments and the first animal tests have also been initiated to investigate radiobiological effects of radiation generated during BNCT. For both experiments and the treatment, a reliable dosimetry system is necessary. From work elsewhere, the use of alanine detectors appears to be an appropriate dosimetry technique. (author)

  2. Boron microquantification in oral mucosa and skin following administration of a neutron capture therapy agent

    Energy Technology Data Exchange (ETDEWEB)

    Kiger, S.W. III; Micca, P.L.; Morris, G.M.; Coderre, J.A

    2002-07-01

    Clinical trials of boron neutron capture therapy (BNCT) for intracranial tumours using boronphenylalanine-fructose undertaken at Harvard-MIT and Brookhaven National Laboratory have observed acute normal tissue reactions in the skin and oral mucosa. Because the range of the {sup 10}B(n,a){sup 7}Li reaction products is very short, 10-14 {mu}m combined, knowledge of the 10B microdistribution in tissue is critical for understanding the microdosimetry and radiobiology of BNCT. This paper reports measurements of the microdistribution of {sup 10}B in an animal model, rat skin and tongue, using high resolution quantitative autoradiography (HRQAR), a neutron-induced track etch autoradiographic technique. The steep spatial gradient and high absolute value relative to blood of the {sup 10}B concentration observed in some strata of the rat tongue epithelium and skin are important for properly evaluating the radiobiology and the biological effectiveness factors for normal tissue reactions such as oral mucositis, which are generally assessed using the blood boron concentration rather than the tissue boron concentration. (author)

  3. Beam neutron energy optimization for boron neutron capture therapy using Monte Carlo method

    Directory of Open Access Journals (Sweden)

    Ali Pazirandeh

    2006-06-01

    Full Text Available  In last two decades the optimal neutron energy for the treatment of deep seated tumors in boron neutron capture therapy in view of neutron physics and chemical compounds of boron carrier has been under thorough study. Although neutron absorption cross section of boron is high (3836b, the treatment of deep seated tumors such as gliobelastoma multiform (GBM requires beam of neutrons of higher energy that can penetrate deeply into the brain and thermalize in the proximity of the tumor. Dosage from recoil proton associated with fast neutrons however poses some constraints on maximum neutron energy that can be used in the treatment. For this reason neutrons in the epithermal energy range of 10eV-10keV are generally to be the most appropriate. The simulation carried out by Monte Carlo methods using MCBNCT and MCNP4C codes along with the cross section library in 290 groups extracted from ENDF/B6 main library. The optimal neutron energy for deep seated tumors depends on the size and depth of tumor. Our estimated optimized energy for the tumor of 5cm wide and 1-2cm thick stands at 5cm depth is in the range of 3-5keV

  4. Inborn errors in metabolism and 4-boronophenylalanine-fructose-based boron neutron capture therapy.

    Science.gov (United States)

    Laakso, Juha; Ruokonen, Inkeri; Lapatto, Risto; Kallio, Merja

    2003-11-01

    Infusions of boronophenylalanine-fructose complex (BPA-F), at doses up to 900 mg/kg of BPA and 860 mg/kg of fructose, have been used to deliver boron to cancer tissue for boron neutron capture therapy (BNCT). In patients with phenylketonuria (PKU), phenylalanine accumulates, which is harmful in the long run. PKU has been an exclusion criterion for BPA-F-mediated BNCT. Fructose is harmful to individuals with hereditary fructose intolerance (HFI) in amounts currently used in BNCT. The harmful effects are mediated through induction of hypoglycemia and acidosis, which may lead to irreversible organ damage or even death. Consequently, HFI should be added as an exclusion criterion for BNCT if fructose-containing solutions are used in boron carriers. Non-HFI subjects may also develop symptoms, such as gastrointestinal pain, if the fructose infusion rate is high. We therefore recommend monitoring of glucose levels and correcting possible hypoglycemia promptly. Except for some populations with extremely low PKU prevalence, HFI and PKU prevalences are similar, approximately 1 or 2 per 20,000.

  5. Boron-Containing Compounds for Liposome-Mediated Tumor Localization and Application to Neutron Capture Therapy

    Energy Technology Data Exchange (ETDEWEB)

    Hawthorne, M. Frederick [Univ. of California, Los Angeles, CA (United States)

    2005-04-07

    Medical application of boron neutron capture therapy (BNCT) has been significantly hindered by the slow development of boron drug-targeting methodologies for the selective delivery of high boron concentration sto malignant cells. We have successfully sought to fill this need by creating liposomes suitable as in vivo boron delivery vehicles for BNCT. Delivery of therapeutic quantities of boron to tumors in murine models has been achieved with small unilamellar boron-rich liposomes. Subsequently, attempts have been made to improve delivery efficiency of liposomes encapsulating boron-containing water-soluble species into their hollow core by incorporating lipophilic boron compounds as addenda to the liposome bilayer, incorporating boron compounds as structural components of the bilayer (which however, poses the risk of sacrificing some stability), and combinations thereof. Regardless of the method, approximately 90% of the total liposome mass remains therapeutically inactive and comprised of the vehicle's construction materials, while less than 5% is boron for neutron targeting. Following this laboratory's intensive study, the observed tumor specificity of certain liposomes has been attributed to their diminutive size of these liposomes (30-150 nm), which enables these small vesicles to pass through the porous, immature vasculature of rapidly growing tumor tissue. We surmised that any amphiphilic nanoparticle of suitable size could possess some tumor selectivity. Consequently, the discovery of a very boron-rich nanoparticle delivery agent with biodistribution performance similar to unilamellar liposomes became one of our goals. Closomers, a new class of polyhedral borane derivatives, attracted us as an alternative BNCT drug-delivery system. We specifically envisioned dodeca (nido-carboranyl)-substituted closomers as possibly having a great potential role in BNCT drug delivery. They could function as extraordinarily boron-rich BNCT drugs since they are

  6. Can epithermal boron neutron capture therapy treat primary and metastatic liver cancer?

    Energy Technology Data Exchange (ETDEWEB)

    Wallace, S.A. [Austin Repatriation Medical Centre, Heidelberg (Australia); Carolan, M.C. [Illawarra Cancer Care Centre, Wollongong (Australia); Allen, B.J. [St George Cancer Care Centre, Kogarah (Australia)

    1996-12-31

    Full text: The poor prognosis of metastatic cancer to the liver calls for the investigation of alternative treatment modalities. This paper analyses the possible use of epithermal boron neutron capture therapy for the palliative treatment of these cancers. We examine possible treatment planning scenarios for selected tumour to liver boron ratios, and specifically for the epithermal beam at the HFR, Petten. It is required that a therapeutic ratio> 1 be achieved over the entire organ. Monte Carlo calculations were performed using the radiation transport code MCNP. The geometrical model used a `variable voxel` technique to reconstruct an anthropomorphic phantom from CT scans. Regions of interest such as the liver were modelled to a resolution of a few millimetres, whereas surrounding regions were modelled with lesser detail thereby facilitating faster computation time. Three dimensional dose distributions were calculated for a frontal beam directed at the liver, and found to be in satisfactory agreement with measurements using bare and cadmium covered gold foils, PIN and MOSFET dosimeters for fast neutron and gamma measurements respectively. Dose distributions were calculated for orthogonal epithermal neutron beams to the front and side, using the parameters of the epithermal beam at Petten, and assumed tumour and normal tissue boron-10 concentrations of 30 ppm and 7.5 ppm boron-10 respectively. The therapeutic ratio (i e the dose to the tumour relative to the maximum dose to normal tissue) was found to be about 1.8, reducing to unity for the limiting condition of a tumour in the posterior liver. This result opens up the possibility of palliative therapy for the management of primary and metastatic liver cancer.

  7. Application of generalized perturbation theory to sensitivity analysis in boron neutron capture therapy

    Energy Technology Data Exchange (ETDEWEB)

    Garcia, Vanessa S. [Universidade Federal Fluminense (EEIMVR/UFF-RJ), Volta Redonda, RJ (Brazil). Escola de Engenharia Industrial e Metalurgica. Programa de Pos-Graduacao em Modelagem Computacional em Ciencia e Tecnologia; Silva, Fernando C.; Silva, Ademir X., E-mail: fernando@con.ufrj.b, E-mail: ademir@con.ufrj.b [Coordenacao dos Programas de Pos-Graduacao de Engenharia (PEN/COPPE/UFRJ), Rio de Janeiro, RJ (Brazil). Programa de Engenharia Nuclear; Alvarez, Gustavo B. [Universidade Federal Fluminense (EEIMVR/UFF-RJ), Volta Redonda, RJ (Brazil). Escola de Engenharia Industrial e Metalurgica. Dept. de Ciencias Exatas

    2011-07-01

    Boron neutron capture therapy - BNCT - is a binary cancer treatment used in brain tumors. The tumor is loaded with a boron compound and subsequently irradiated by thermal neutrons. The therapy is based on the {sup 10}B (n, {alpha}) {sup 7}Li nuclear reaction, which emits two types of high-energy particles, {alpha} particle and the {sup 7}Li nuclei. The total kinetic energy released in this nuclear reaction, when deposited in the tumor region, destroys the cancer cells. Since the success of the BNCT is linked to the different selectivity between the tumor and healthy tissue, it is necessary to carry out a sensitivity analysis to determinate the boron concentration. Computational simulations are very important in this context because they help in the treatment planning by calculating the lowest effective absorbed dose rate to reduce the damage to healthy tissue. The objective of this paper is to present a deterministic method based on generalized perturbation theory (GPT) to perform sensitivity analysis with respect to the {sup 10}B concentration and to estimate the absorbed dose rate by patients undergoing this therapy. The advantage of the method is a significant reduction in computational time required to perform these calculations. To simulate the neutron flux in all brain regions, the method relies on a two-dimensional neutron transport equation whose spatial, angular and energy variables are discretized by the diamond difference method, the discrete ordinate method and multigroup formulation, respectively. The results obtained through GPT are consistent with those obtained using other methods, demonstrating the efficacy of the proposed method. (author)

  8. Thermal neutron irradiation field design for boron neutron capture therapy of human explanted liver.

    Science.gov (United States)

    Bortolussi, S; Altieri, S

    2007-12-01

    The selective uptake of boron by tumors compared to that by healthy tissue makes boron neutron capture therapy (BNCT) an extremely advantageous technique for the treatment of tumors that affect a whole vital organ. An example is represented by colon adenocarcinoma metastases invading the liver, often resulting in a fatal outcome, even if surgical resection of the primary tumor is successful. BNCT can be performed by irradiating the explanted organ in a suitable neutron field. In the thermal column of the Triga Mark II reactor at Pavia University, a facility was created for this purpose and used for the irradiation of explanted human livers. The neutron field distribution inside the organ was studied both experimentally and by means of the Monte Carlo N-particle transport code (MCNP). The liver was modeled as a spherical segment in MCNP and a hepatic-equivalent solution was used as an experimental phantom. In the as-built facility, the ratio between maximum and minimum flux values inside the phantom ((phi(max)/phi(min)) was 3.8; this value can be lowered to 2.3 by rotating the liver during the irradiation. In this study, the authors proposed a new facility configuration to achieve a uniform thermal neutron flux distribution in the liver. They showed that a phi(max)/phi(min) ratio of 1.4 could be obtained without the need for organ rotation. Flux distributions and dose volume histograms were reported for different graphite configurations.

  9. Boron neutron capture therapy outcomes for advanced or recurrent head and neck cancer

    Science.gov (United States)

    Suzuki, Minoru; Kato, Ituro; Aihara, Teruhito; Hiratsuka, Junichi; Yoshimura, Kenichi; Niimi, Miyuki; Kimura, Yoshihiro; Ariyoshi, Yasunori; Haginomori, Shin-ichi; Sakurai, Yoshinori; Kinashi, Yuko; Masunaga, Shin-ichiro; Fukushima, Masanori; Ono, Koji; Maruhashi, Akira

    2014-01-01

    We retrospectively review outcomes of applying boron neutron capture therapy (BNCT) to unresectable advanced or recurrent head and neck cancers. Patients who were treated with BNCT for either local recurrent or newly diagnosed unresectable head or neck cancers between December 2001 and September 2007 were included. Clinicopathological characteristics and clinical outcomes were retrieved from hospital records. Either a combination of borocaptate sodium and boronophenylalanine (BPA) or BPA alone were used as boron compounds. In all the treatment cases, the dose constraint was set to deliver a dose <10–12 Gy-eq to the skin or oral mucosa. There was a patient cohort of 62, with a median follow-up of 18.7 months (range, 0.7–40.8). A total of 87 BNCT procedures were performed. The overall response rate was 58% within 6 months after BNCT. The median survival time was 10.1 months from the time of BNCT. The 1- and 2-year overall survival (OS) rates were 43.1% and 24.2%, respectively. The major acute Grade 3 or 4 toxicities were hyperamylasemia (38.6%), fatigue (6.5%), mucositis/stomatitis (9.7%) and pain (9.7%), all of which were manageable. Three patients died of treatment-related toxicity. Three patients experienced carotid artery hemorrhage, two of whom had coexistent infection of the carotid artery. This study confirmed the feasibility of our dose-estimation method and that controlled trials are warranted. PMID:23955053

  10. An accelerator-based epithermal photoneutron source for boron neutron capture therapy

    Energy Technology Data Exchange (ETDEWEB)

    Mitchell, H.E.

    1996-04-01

    Boron neutron capture therapy is an experimental binary cancer radiotherapy modality in which a boronated pharmaceutical that preferentially accumulates in malignant tissue is first administered, followed by exposing the tissue in the treatment volume to a thermal neutron field. Current usable beams are reactor-based but a viable alternative is the production of an epithermal neutron beam from an accelerator. Current literature cites various proposed accelerator-based designs, most of which are based on proton beams with beryllium or lithium targets. This dissertation examines the efficacy of a novel approach to BNCT treatments that incorporates an electron linear accelerator in the production of a photoneutron source. This source may help to resolve some of the present concerns associated with accelerator sources, including that of target cooling. The photoneutron production process is discussed as a possible alternate source of neutrons for eventual BNCT treatments for cancer. A conceptual design to produce epithermal photoneutrons by high photons (due to bremsstrahlung) impinging on deuterium targets is presented along with computational and experimental neutron production data. A clinically acceptable filtered epithermal neutron flux on the order of 10{sup 7} neutrons per second per milliampere of electron current is shown to be obtainable. Additionally, the neutron beam is modified and characterized for BNCT applications by employing two unique moderating materials (an Al/AlF{sub 3} composite and a stacked Al/Teflon design) at various incident electron energies.

  11. Basic and clinical study of boron neutron capture therapy for malignant brain tumor

    Energy Technology Data Exchange (ETDEWEB)

    Nose, Tadao; Matsumura, Akira; Nakai, Kei; Nakagawa, Kunio; Yoshii, Yoshihiko [Tsukuba Univ., Ibaraki (Japan). Inst. of Clinical Medicine; Shibata, Yasushi; Yamamoto, Tetsuya; Hayakawa, Yoshinori; Yamada, Takashi

    1998-01-01

    Rat malignant cells (9L glioma cell) were exposed to neutron radiation after culturing with boron compounds; BSH and STA-BX909, and cell growing ability after the exposure was determined by colony forming assay. The effects of in vivo radiation were examined by measuring neutron flux levels in rat brain and skin aiming to use neutron radiation in clinical study. STA-BX909 was found to show a dose-dependent cell toxicity, which was higher than that of BSH. The radiation induced G2/M block in 9L-glioma cells and their cell cycles recovered thereafter in low-dose radiated cells, but high-dose radiated cells became aneuploidy. Furthermore, boron neutron capture therapy (BNCT) was applied in two patients, 41-year old woman with glioma grade 3 recurred and 45-year old man with glioblastoma multiforme. The former died from systemic deterioration due to ileus, but BNCT was made only one time although conventional radiotherapy is carried out for a relatively long period. Therefore, BNCT was thought to be beneficial from an aspect of `quality of life` and the effects to repress a recurrence of cancer also seemed larger than the conventional one. (M.N.)

  12. GPU-based prompt gamma ray imaging from boron neutron capture therapy

    Energy Technology Data Exchange (ETDEWEB)

    Yoon, Do-Kun; Jung, Joo-Young; Suk Suh, Tae, E-mail: suhsanta@catholic.ac.kr [Department of Biomedical Engineering and Research Institute of Biomedical Engineering, College of Medicine, Catholic University of Korea, Seoul 505 137-701 (Korea, Republic of); Jo Hong, Key [Molecular Imaging Program at Stanford (MIPS), Department of Radiology, Stanford University, 300 Pasteur Drive, Stanford, California 94305 (United States); Sil Lee, Keum [Department of Radiation Oncology, Stanford University School of Medicine, 875 Blake Wilbur Drive, Stanford, California 94305-5847 (United States)

    2015-01-15

    Purpose: The purpose of this research is to perform the fast reconstruction of a prompt gamma ray image using a graphics processing unit (GPU) computation from boron neutron capture therapy (BNCT) simulations. Methods: To evaluate the accuracy of the reconstructed image, a phantom including four boron uptake regions (BURs) was used in the simulation. After the Monte Carlo simulation of the BNCT, the modified ordered subset expectation maximization reconstruction algorithm using the GPU computation was used to reconstruct the images with fewer projections. The computation times for image reconstruction were compared between the GPU and the central processing unit (CPU). Also, the accuracy of the reconstructed image was evaluated by a receiver operating characteristic (ROC) curve analysis. Results: The image reconstruction time using the GPU was 196 times faster than the conventional reconstruction time using the CPU. For the four BURs, the area under curve values from the ROC curve were 0.6726 (A-region), 0.6890 (B-region), 0.7384 (C-region), and 0.8009 (D-region). Conclusions: The tomographic image using the prompt gamma ray event from the BNCT simulation was acquired using the GPU computation in order to perform a fast reconstruction during treatment. The authors verified the feasibility of the prompt gamma ray image reconstruction using the GPU computation for BNCT simulations.

  13. An accelerator-based epithermal photoneutron source for boron neutron capture therapy

    Energy Technology Data Exchange (ETDEWEB)

    Mitchell, Hannah E. [Georgia Inst. of Technology, Atlanta, GA (United States)

    1996-04-01

    Boron neutron capture therapy is an experimental binary cancer radiotherapy modality in which a boronated pharmaceutical that preferentially accumulates in malignant tissue is first administered, followed by exposing the tissue in the treatment volume to a thermal neutron field. Current usable beams are reactor-based but a viable alternative is the production of an epithermal neutron beam from an accelerator. Current literature cites various proposed accelerator-based designs, most of which are based on proton beams with beryllium or lithium targets. This dissertation examines the efficacy of a novel approach to BNCT treatments that incorporates an electron linear accelerator in the production of a photoneutron source. This source may help to resolve some of the present concerns associated with accelerator sources, including that of target cooling. The photoneutron production process is discussed as a possible alternate source of neutrons for eventual BNCT treatments for cancer. A conceptual design to produce epithermal photoneutrons by high photons (due to bremsstrahlung) impinging on deuterium targets is presented along with computational and experimental neutron production data. A clinically acceptable filtered epithermal neutron flux on the order of 107 neutrons per second per milliampere of electron current is shown to be obtainable. Additionally, the neutron beam is modified and characterized for BNCT applications by employing two unique moderating materials (an Al/AlF3 composite and a stacked Al/Teflon design) at various incident electron energies.

  14. Selective uptake of p-boronophenylalanine by osteosarcoma cells for boron neutron capture therapy

    Energy Technology Data Exchange (ETDEWEB)

    Ferrari, C. [Department of Surgery, Experimental Surgery Laboratory, University of Pavia, Piazza Botta, Pavia (Italy)], E-mail: ferraric@unipv.it; Zonta, C.; Cansolino, L.; Clerici, A.M.; Gaspari, A. [Department of Surgery, Experimental Surgery Laboratory, University of Pavia, Piazza Botta, Pavia (Italy); Altieri, S.; Bortolussi, S.; Stella, S. [Department of Nuclear and Theoretical Physics of University, Via Bassi, 6, Pavia (Italy); National Institute of Nuclear Physics (INFN) Section of Pavia, Via Bassi, 6, Pavia (Italy); Bruschi, P. [Department of Nuclear and Theoretical Physics of University, Via Bassi, 6, Pavia (Italy); Dionigi, P.; Zonta, A. [Department of Surgery, Experimental Surgery Laboratory, University of Pavia, Piazza Botta, Pavia (Italy)

    2009-07-15

    Osteosarcoma is the most common non-hematologic primary cancer type that develops in bone. Current osteosarcoma treatments combine multiagent chemotherapy with extensive surgical resection, which in some cases makes necessary the amputation of the entire limb. Nevertheless its infiltrative growth leads to a high incidence of local and distant recurrences that reduce the percentage of cured patients to less than 60%. These poor data required to set up a new therapeutic approach aimed to restrict the surgical removal meanwhile performing a radical treatment. Boron neutron capture therapy (BNCT), a particular radiotherapy based on the nuclear capture and fission reactions by atoms of {sup 10}B, when irradiated with thermal neutrons, could be a valid alternative or integrative option in case of osteosarcoma management, thanks to its peculiarity in selectively destroying neoplastic cells without damaging normal tissues. Aim of the present work is to investigate the feasibility of employing BNCT to treat the limb osteosarcoma. Boronophenylalanine (BPA) is used to carry {sup 10}B inside the neoplastic cells. As a first step the endocellular BPA uptake is tested in vitro on the UMR-106 osteosarcoma cell line. The results show an adequate accumulation capability. For the in vivo experiments, an animal tumor model is developed in Sprague-Dawley rats by means of an intrafemoral injection of UMR-106 cells at the condyle site. The absolute amounts of boron loading and the tumor to normal tissue {sup 10}B ratio are evaluated 2 h after the i.v. administration of BPA. The boron uptake by the neoplastic tissue is almost twice the normal one. However, higher values of boron concentration in tumor are requested before upholding BNCT as a valid therapeutic option in the treatment of osteosarcoma.

  15. Epithermal neutron beam adoption for liver cancer treatment by boron and gadolinium neutron capture therapy

    Energy Technology Data Exchange (ETDEWEB)

    Matsumoto, Tetsuo [Musashi Inst. of Tech., Kawasaki, Kanagawa (Japan). Atomic Energy Research Lab

    2001-06-01

    Comparative evaluation was made on depth-dose distribution in boron neutron capture therapy (B-NCT) and gadolinium one (Gd-NCT) for the treatments of liver cancers. At present, epithermal neutron beam is expected to be applicable to the treatment of deep and widespread tumors. ICRU computational model of ADAM and EVA was used as a liver phantom loading a tumor at depth of 6 cm in its central region. Epithermal neutron beam of Musashi reactor was used as the primary neutron beam for the depth-dose calculation. Calculation was conducted using the three-dimensional continuous-energy Monte Carlo code MCNP4A. The doses observed in both NCTs were bumped over the tumor region but the dose for Gd-NCT was not so tumor-specific compared with that for BNCT because radiation in Gd-NCT was due to {gamma}-ray. The mean physical dose was 4 Gy/h for boron 30 ppm and 5 Gy/h for Gd 1000 ppm when exposed to an epithermal neutron flux of 5x10{sup 8} n/cm{sup -2}/sec and the dose ratio of tumor-to normal tissue was 2.7 for boron and 2.5 for Gd. The lethal dose of 50 Gy for the liver can be accomplished under conditions where the dose has not reached 25 Gy, the tolerance dose of the normal tissue. This seems very encouraging and indicating that both B-NCT and Gd-NCT are applicable for the treatment for liver cancer. However, if normal tissue contain 1/4 of the tumor concentration of boron or Gd, the BNCT would still possible when considering a large RBE value for {sup 10}B(n, {alpha}) reaction but the Gd-NCT would impossible for deep liver treatment. (M.N.)

  16. Development of JCDS, a computational dosimetry system at JAEA for boron neutron capture therapy

    Science.gov (United States)

    Kumada, H.; Yamamoto, K.; Matsumura, A.; Yamamoto, T.; Nakagawa, Y.

    2007-06-01

    Clinical trials of boron neutron capture therapy (BNCT) are being carried out using several research reactors throughout the world. In Japan, many medical groups perform clinical trials of BNCT using Japan Research Reactor No.4 (JRR-4) in Japan Atomic Energy Agency (JAEA). JAEA has developed a treatment planning system, JCDS, in order to evaluate radiation dose given to a patient in the BNCT. JCDS employs a voxel calculation method to compute the radiation dose given to a patient. An initial version of JCDS created a voxel model, dividing a space into 1 × 1 × 1 cm3voxel cells. JCDS was improved to create a detailed voxel model consisting of minute voxel cells such as 2 × 2 × 2 mm3voxel cells. Verification of accuracy of calculations with the detailed voxel mode demonstrated that the detailed voxel model enables JCDS to evaluate more accurately the radiation doses to a patient undergoing BNCT. Furthermore, the calculation code of JCDS is being incorporated into the PHITS system as a Monte-Carlo transport code. By employing the PHITS system in the dose evaluation, total doses given to a patient by combined modality therapy such as BNCT and X-ray therapy can be estimated accurately. Here, an outline and the performances of the latest version of JCDS are presented, and a future system integrated with JCDS is introduced.

  17. A Project of Boron Neutron Capture Therapy System based on a Proton Linac Neutron Source

    Science.gov (United States)

    Kiyanagi, Yoshikai; Asano, Kenji; Arakawa, Akihiro; Fukuchi, Shin; Hiraga, Fujio; Kimura, Kenju; Kobayashi, Hitoshi; Kubota, Michio; Kumada, Hiroaki; Matsumoto, Hiroshi; Matsumoto, Akira; Sakae, Takeji; Saitoh, Kimiaki; Shibata, Tokushi; Yoshioka, Masakazu

    At present, the clinical trials of Boron Neutron Capture Therapy (BNCT) are being performed at research reactor facilities. However, an accelerator based BNCT has a merit that it can be built in a hospital. So, we just launched a development project for the BNCT based on an accelerator in order to establish and to spread the BNCT as an effective therapy in the near future. In the project, a compact proton linac installed in a hospital will be applied as a neutron source, and energy of the proton beam is planned to be less than about 10 MeV to reduce the radioactivity. The BNCT requires epithermal neutron beam with an intensity of around 1x109 (n/cm2/sec) to deliver the therapeutic dose to a deeper region in a body and to complete the irradiation within an hour. From this condition, the current of the proton beam required is estimated to be a few mA on average. Enormous heat deposition in the target is a big issue. We are aiming at total optimization of the accelerator based BNCT from the linac to the irradiation position. Here, the outline of the project is introduced and the moderator design is presented.

  18. Characteristics of a heavy water photoneutron source in boron neutron capture therapy

    Institute of Scientific and Technical Information of China (English)

    Danial Salehi; Dariush Sardari; M.Salehi Jozani

    2013-01-01

    Bremsstrahlung photon beams produced by medical linear accelerators are currently the most commonly used method of radiation therapy for cancerous tumors.Photons with energies greater than 8-10 MeV potentially generate neutrons through photonuclear interactions in the accelerator's treatment head,patient's body,and treatment room ambient.Electrons impinging on a heavy target generate a cascade shower of bremsstrahlung photons,the energy spectrum of which shows an end point equal to the electron beam energy.By varying the target thickness,an optimum thickness exists for which,at the given electron energy,maximum photon flux is achievable.If a source of high-energy photons i.e.bremsstrahlung,is conveniently directed to a suitable D2O target,a novel approach for production of an acceptable flux of filterable photoneturons for boron neutron capture therapy (BNCT) application is possible.This study consists of two parts.1.Comparison and assessment of deuterium photonuclear cross section data.2.Evaluation of the heavy water photonuclear source.

  19. Boron neutron capture therapy of brain tumors: an emerging therapeutic modality.

    Science.gov (United States)

    Barth, R F; Soloway, A H; Goodman, J H; Gahbauer, R A; Gupta, N; Blue, T E; Yang, W; Tjarks, W

    1999-03-01

    Boron neutron capture therapy (BNCT) is based on the nuclear reaction that occurs when boron-10, a stable isotope, is irradiated with low-energy thermal neutrons to yield alpha particles and recoiling lithium-7 nuclei. For BNCT to be successful, a large number of 10B atoms must be localized on or preferably within neoplastic cells, and a sufficient number of thermal neutrons must be absorbed by the 10B atoms to sustain a lethal 10B (n, alpha) lithium-7 reaction. There is a growing interest in using BNCT in combination with surgery to treat patients with high-grade gliomas and possibly metastatic brain tumors. The present review covers the biological and radiobiological considerations on which BNCT is based, boron-containing low- and high-molecular weight delivery agents, neutron sources, clinical studies, and future areas of research. Two boron compounds currently are being used clinically, sodium borocaptate and boronophenylalanine, and a number of new delivery agents are under investigation, including boronated porphyrins, nucleosides, amino acids, polyamines, monoclonal and bispecific antibodies, liposomes, and epidermal growth factor. These are discussed, as is optimization of their delivery. Nuclear reactors currently are the only source of neutrons for BNCT, and the fission reaction within the core produces a mixture of lower energy thermal and epithermal neutrons, fast or high-energy neutrons, and gamma-rays. Although thermal neutron beams have been used clinically in Japan to treat patients with brain tumors and cutaneous melanomas, epithermal neutron beams now are being used in the United States and Europe because of their superior tissue-penetrating properties. Currently, there are clinical trials in progress in the United States, Europe, and Japan using a combination of debulking surgery and then BNCT to treat patients with glioblastomas. The American and European studies are Phase I trials using boronophenylalanine and sodium borocaptate, respectively

  20. The Anti-Proliferative Effect of Boron Neutron Capture Therapy in a Prostate Cancer Xenograft Model.

    Directory of Open Access Journals (Sweden)

    Kiyoshi Takahara

    Full Text Available Boron neutron capture therapy (BNCT is a selective radiation treatment for tumors that preferentially accumulate drugs carrying the stable boron isotope, 10B. BNCT has been evaluated clinically as an alternative to conventional radiation therapy for the treatment of brain tumors, and more recently, recurrent advanced head and neck cancer. Here we investigated the effect of BNCT on prostate cancer (PCa using an in vivo mouse xenograft model that we have developed.Mice bearing the xenotransplanted androgen-independent human PCa cell line, PC3, were divided into four groups: Group 1: untreated controls; Group 2: Boronophenylalanine (BPA; Group 3: neutron; Group 4: BPA-mediated BNCT. We compared xenograft growth among these groups, and the body weight and any motility disturbance were recorded. Immunohistochemical (IHC studies of the proliferation marker, Ki-67, and TUNEL staining were performed 9 weeks after treatment.The in vivo studies demonstrated that BPA-mediated BNCT significantly delayed tumor growth in comparison with the other groups, without any severe adverse events. There was a significant difference in the rate of freedom from gait abnormalities between the BPA-mediated BNCT group and the other groups. The IHC studies revealed that BNCT treatment significantly reduced the number of Ki-67-positive cells in comparison with the controls (mean ± SD 6.9 ± 1.5 vs 12.7 ± 4.0, p<0.05, while there was no difference in the number of apoptotic cells, suggesting that BPA-mediated BNCT reduced PCa progression without affecting apoptosis at 9 weeks post-treatment.This study has provided the first preclinical proof-of-principle data to indicate that BPA-mediated BNCT reduces the in vivo growth of PCa. Although further studies will be necessary, BNCT might be a novel potential treatment for PCa.

  1. DNA damage induced by boron neutron capture therapy is partially repaired by DNA ligase IV.

    Science.gov (United States)

    Kondo, Natsuko; Sakurai, Yoshinori; Hirota, Yuki; Tanaka, Hiroki; Watanabe, Tsubasa; Nakagawa, Yosuke; Narabayashi, Masaru; Kinashi, Yuko; Miyatake, Shin-ichi; Hasegawa, Masatoshi; Suzuki, Minoru; Masunaga, Shin-ichiro; Ohnishi, Takeo; Ono, Koji

    2016-03-01

    Boron neutron capture therapy (BNCT) is a particle radiation therapy that involves the use of a thermal or epithermal neutron beam in combination with a boron ((10)B)-containing compound that specifically accumulates in tumor. (10)B captures neutrons and the resultant fission reaction produces an alpha ((4)He) particle and a recoiled lithium nucleus ((7)Li). These particles have the characteristics of high linear energy transfer (LET) radiation and therefore have marked biological effects. High-LET radiation is a potent inducer of DNA damage, specifically of DNA double-strand breaks (DSBs). The aim of the present study was to clarify the role of DNA ligase IV, a key player in the non-homologous end-joining repair pathway, in the repair of BNCT-induced DSBs. We analyzed the cellular sensitivity of the mouse embryonic fibroblast cell lines Lig4-/- p53-/- and Lig4+/+ p53-/- to irradiation using a thermal neutron beam in the presence or absence of (10)B-para-boronophenylalanine (BPA). The Lig4-/- p53-/- cell line had a higher sensitivity than the Lig4+/+ p53-/-cell line to irradiation with the beam alone or the beam in combination with BPA. In BNCT (with BPA), both cell lines exhibited a reduction of the 50 % survival dose (D 50) by a factor of 1.4 compared with gamma-ray and neutron mixed beam (without BPA). Although it was found that (10)B uptake was higher in the Lig4+/+ p53-/- than in the Lig4-/- p53-/- cell line, the latter showed higher sensitivity than the former, even when compared at an equivalent (10)B concentration. These results indicate that BNCT-induced DNA damage is partially repaired using DNA ligase IV.

  2. Boron Neutron Capture Therapy (BCNT) for the Treatment of Liver Metastases: Biodistribution Studies of Boron Compounds in an Experimental Model

    Energy Technology Data Exchange (ETDEWEB)

    Marcela A. Garabalino; Andrea Monti Hughes; Ana J. Molinari; Elisa M. Heber; Emiliano C. C. Pozzi; Maria E. Itoiz; Veronica A. Trivillin; Amanda E. Schwint; Jorge E. Cardoso; Lucas L. Colombo; Susana Nievas; David W. Nigg; Romina F. Aromando

    2011-03-01

    Abstract We previously demonstrated the therapeutic efficacy of different boron neutron capture therapy (BNCT) protocols in an experimental model of oral cancer. BNCT is based on the selective accumulation of 10B carriers in a tumor followed by neutron irradiation. Within the context of exploring the potential therapeutic efficacy of BNCT for the treatment of liver metastases, the aim of the present study was to perform boron biodistribution studies in an experimental model of liver metastases in rats. Different boron compounds and administration conditions were assayed to determine which administration protocols would potentially be therapeutically useful in in vivo BNCT studies at the RA-3 nuclear reactor. A total of 70 BDIX rats were inoculated in the liver with syngeneic colon cancer cells DHD/K12/TRb to induce the development of subcapsular tumor nodules. Fourteen days post-inoculation, the animals were used for biodistribution studies. We evaluated a total of 11 administration protocols for the boron compounds boronophenylalanine (BPA) and GB-10 (Na210B10H10), alone or combined at different dose levels and employing different administration routes. Tumor, normal tissue, and blood samples were processed for boron measurement by atomic emission spectroscopy. Six protocols proved potentially useful for BNCT studies in terms of absolute boron concentration in tumor and preferential uptake of boron by tumor tissue. Boron concentration values in tumor and normal tissues in the liver metastases model show it would be feasible to reach therapeutic BNCT doses in tumor without exceeding radiotolerance in normal tissue at the thermal neutron facility at RA-3.

  3. Lithium Nitride Synthesized by in situ Lithium Deposition and Ion Implantation for Boron Neutron Capture Therapy

    Science.gov (United States)

    Ishitama, Shintaro; Baba, Yuji; Fujii, Ryo; Nakamura, Masaru; Imahori, Yoshio

    Li3N synthesis on Li deposition layer was conducted without H2O and O2 by in situ lithium deposition in high vacuum chamber of 10-6 Pa and ion implantation techniques and the thermo-chemical stability of the Li3N/Li/Cu tri-layered target for Boron Neutron Capture Therapy (BNCT) under laser heating and air exposure was characterized by X-ray photoelectron spectroscopy (XPS). Following conclusions were derived; (1) Li3N/Li/Cu tri-layered target with very low oxide and carbon contamination was synthesized by in situ lithium vacuum deposition and N2+ ion implantation without H2O and O2 additions, (2) The starting temperature of evaporation of Li3N/Li/Cu tri-layered target increased by 120K compared to that of the Li/Cu target and (3) Remarkable oxidation and carbon contamination were observed on the surface of Li3N/Li/Cu after air exposure and these contaminated compositions was not removed by Ar+ heavy sputtering.

  4. High-power liquid-lithium target prototype for accelerator-based boron neutron capture therapy.

    Science.gov (United States)

    Halfon, S; Paul, M; Arenshtam, A; Berkovits, D; Bisyakoev, M; Eliyahu, I; Feinberg, G; Hazenshprung, N; Kijel, D; Nagler, A; Silverman, I

    2011-12-01

    A prototype of a compact Liquid-Lithium Target (LiLiT), which will possibly constitute an accelerator-based intense neutron source for Boron Neutron Capture Therapy (BNCT) in hospitals, was built. The LiLiT setup is presently being commissioned at Soreq Nuclear Research Center (SNRC). The liquid-lithium target will produce neutrons through the (7)Li(p,n)(7)Be reaction and it will overcome the major problem of removing the thermal power generated using a high-intensity proton beam (>10 kW), necessary for sufficient neutron flux. In off-line circulation tests, the liquid-lithium loop generated a stable lithium jet at high velocity, on a concave supporting wall; the concept will first be tested using a high-power electron beam impinging on the lithium jet. High intensity proton beam irradiation (1.91-2.5 MeV, 2-4 mA) will take place at Soreq Applied Research Accelerator Facility (SARAF) superconducting linear accelerator currently in construction at SNRC. Radiological risks due to the (7)Be produced in the reaction were studied and will be handled through a proper design, including a cold trap and appropriate shielding. A moderator/reflector assembly is planned according to a Monte Carlo simulation, to create a neutron spectrum and intensity maximally effective to the treatment and to reduce prompt gamma radiation dose risks.

  5. Monte Carlo simulation of depth dose distribution in several organic models for boron neutron capture therapy

    Science.gov (United States)

    Matsumoto, T.

    2007-09-01

    Monte Carlo simulations are performed to evaluate depth-dose distributions for possible treatment of cancers by boron neutron capture therapy (BNCT). The ICRU computational model of ADAM & EVA was used as a phantom to simulate tumors at a depth of 5 cm in central regions of the lungs, liver and pancreas. Tumors of the prostate and osteosarcoma were also centered at the depth of 4.5 and 2.5 cm in the phantom models. The epithermal neutron beam from a research reactor was the primary neutron source for the MCNP calculation of the depth-dose distributions in those cancer models. For brain tumor irradiations, the whole-body dose was also evaluated. The MCNP simulations suggested that a lethal dose of 50 Gy to the tumors can be achieved without reaching the tolerance dose of 25 Gy to normal tissue. The whole-body phantom calculations also showed that the BNCT could be applied for brain tumors without significant damage to whole-body organs.

  6. Dose monitoring for boron neutron capture therapy using a reactor-based epithermal neutron beam

    Science.gov (United States)

    Raaijmakers, C. P. J.; Nottelman, E. L.; Konijnenberg, M. W.; Mijnheer, B. J.

    1996-12-01

    The aims of this study were (i) to determine the variation with time of the relevant beam parameters of a clinical reactor-based epithermal neutron beam for boron neutron capture therapy (BNCT) and (ii) to test a monitoring system for its applicability to monitor the dose delivered to the dose specification point in a patient treated with BNCT. For this purpose two fission chambers covered with Cd and two GM counters were positioned in the beam-shaping collimator assembly of the epithermal neutron beam. The monitor count rates were compared with in-phantom reference measurements of the thermal neutron fluence rate, the gamma-ray dose rate and the fast neutron dose rate, at a constant reactor power, over a period of 2 years. Differences in beam output, defined as the thermal neutron fluence rate at 2 cm depth in a phantom, of up to 15% were observed between various reactor cycles. A decrease in beam output of about 5% was observed in each reactor cycle. An unacceptable decrease of 50% in beam output due to malfunctioning of the beam filter assembly was detected. For safe and accurate treatment of patients, on-line monitoring of the beam is essential. Using the calibrated monitor system, the standard uncertainty in the total dose at depth due to variations with time of the beam output parameters has been reduced to a clinically acceptable value of 1% (one standard deviation).

  7. Verification of the computational dosimetry system in JAERI (JCDS) for boron neutron capture therapy

    Science.gov (United States)

    Kumada, H.; Yamamoto, K.; Matsumura, A.; Yamamoto, T.; Nakagawa, Y.; Nakai, K.; Kageji, T.

    2004-08-01

    Clinical trials for boron neutron capture therapy (BNCT) by using the medical irradiation facility installed in Japan Research Reactor No. 4 (JRR-4) at Japan Atomic Energy Research Institute (JAERI) have been performed since 1999. To carry out the BNCT procedure based on proper treatment planning and its precise implementation, the JAERI computational dosimetry system (JCDS) which is applicable to dose planning has been developed in JAERI. The aim of this study was to verify the performance of JCDS. The experimental data with a cylindrical water phantom were compared with the calculation results using JCDS. Data of measurements obtained from IOBNCT cases at JRR-4 were also compared with retrospective evaluation data with JCDS. In comparison with phantom experiments, the calculations and the measurements for thermal neutron flux and gamma-ray dose were in a good agreement, except at the surface of the phantom. Against the measurements of clinical cases, the discrepancy of JCDS's calculations was approximately 10%. These basic and clinical verifications demonstrated that JCDS has enough performance for the BNCT dosimetry. Further investigations are recommended for precise dose distribution and faster calculation environment.

  8. Induced radioactivity in the blood of cancer patients following Boron Neutron Capture Therapy.

    Science.gov (United States)

    Fujiwara, Keiko; Kinashi, Yuko; Takahashi, Tomoyuki; Yashima, Hiroshi; Kurihara, Kouta; Sakurai, Yoshinori; Tanaka, Hiroki; Ono, Koji; Takahashi, Sentaro

    2013-07-01

    Since 1990, Boron Neutron Capture Therapy (BNCT) has been used for over 400 cancer patients at the Kyoto University Research Reactor Institute (KURRI). After BNCT, the patients are radioactive and their (24)Na and (38)Cl levels can be detected via a Na-I scintillation counter. This activity is predominantly due to (24)Na, which has a half-life of 14.96 h and thus remains in the body for extended time periods. Radioactive (24)Na is mainly generated from (23)Na in the target tissue that is exposed to the neutron beam in BNCT. The purpose of this study is to evaluate the relationship between the radioactivity of blood (24)Na following BNCT and the absorbed gamma ray dose in the irradiated field. To assess blood (24)Na, 1 ml of peripheral blood was collected from 30 patients immediately after the exposure, and the radioactivity of blood (24)Na was determined using a germanium counter. The activity of (24)Na in the blood correlated with the absorbed gamma ray doses in the irradiated field. For the same absorbed gamma ray dose in the irradiated field, the activity of blood (24)Na was higher in patients with neck or lung tumors than in patients with brain or skin tumors. The reasons for these findings are not readily apparent, but the difference in the blood volume and the ratio of bone to soft tissue in the irradiated field, as well as the dose that leaked through the clinical collimator, may be responsible.

  9. Improvement of dose distribution by central beam shielding in boron neutron capture therapy

    Science.gov (United States)

    Sakurai, Yoshinori; Ono, Koji

    2007-12-01

    Since boron neutron capture therapy (BNCT) with epithermal neutron beams started at the Kyoto University Reactor (KUR) in June 2002, nearly 200 BNCT treatments have been carried out. The epithermal neutron irradiation significantly improves the dose distribution, compared with the previous irradiation mainly using thermal neutrons. However, the treatable depth limit still remains. One effective technique to improve the limit is the central shield method. Simulations were performed for the incident neutron energies and the annular components of the neutron source. It was clear that thermal neutron flux distribution could be improved by decreasing the lower energy neutron component and the inner annular component of the incident beam. It was found that a central shield of 4-6 cm diameter and 10 mm thickness is effective for the 12 cm diameter irradiation field. In BNCT at KUR, the depth dose distribution can be much improved by the central shield method, resulting in a relative increase of the dose at 8 cm depth by about 30%. In addition to the depth dose distribution, the depth dose profile is also improved. As the dose rate in the central area is reduced by the additional shielding, the necessary irradiation time, however, increases by about 30% compared to normal treatment.

  10. Gyrotron-driven high current ECR ion source for boron-neutron capture therapy neutron generator

    Science.gov (United States)

    Skalyga, V.; Izotov, I.; Golubev, S.; Razin, S.; Sidorov, A.; Maslennikova, A.; Volovecky, A.; Kalvas, T.; Koivisto, H.; Tarvainen, O.

    2014-12-01

    Boron-neutron capture therapy (BNCT) is a perspective treatment method for radiation resistant tumors. Unfortunately its development is strongly held back by a several physical and medical problems. Neutron sources for BNCT currently are limited to nuclear reactors and accelerators. For wide spread of BNCT investigations more compact and cheap neutron source would be much more preferable. In present paper an approach for compact D-D neutron generator creation based on a high current ECR ion source is suggested. Results on dense proton beams production are presented. A possibility of ion beams formation with current density up to 600 mA/cm2 is demonstrated. Estimations based on obtained experimental results show that neutron target bombarded by such deuteron beams would theoretically yield a neutron flux density up to 6·1010 cm-2/s. Thus, neutron generator based on a high-current deuteron ECR source with a powerful plasma heating by gyrotron radiation could fulfill the BNCT requirements significantly lower price, smaller size and ease of operation in comparison with existing reactors and accelerators.

  11. Dosimetric effects of beam size and collimation of epithermal neutrons for boron neutron capture therapy.

    Science.gov (United States)

    Yanch, J C; Harling, O K

    1993-08-01

    A series of studies of "ideal" beams has been carried out using Monte Carlo simulation with the goal of providing guidance for the design of epithermal beams for boron neutron capture therapy (BNCT). An "ideal" beam is defined as a monoenergetic, photon-free source of neutrons with user-specified size, shape and angular dependence of neutron current. The dosimetric behavior of monoenergetic neutron beams in an elliptical phantom composed of brain-equivalent material has been assessed as a function of beam diameter and neutron emission angle (beam angle), and the results are reported here. The simulation study indicates that substantial differences exist in the dosimetric behavior of small and large neutron beams (with respect to the phantom) as a function of the extent of beam collimation. With a small beam, dose uniformity increases as the beam becomes more isotropic (less collimated); the opposite is seen with large beams. The penetration of thermal neutrons is enhanced as the neutron emission angle is increased with a small beam; again the opposite trend is seen with large beams. When beam size is small, the dose delivered per neutron is very dependent on the extent of beam collimation; this does not appear to be the case with a larger beam. These trends in dose behavior are presented graphically and discussed in terms of their effect on several figures of merit, the advantage depth, the advantage ratio, and the advantage depth-dose rate. Tables giving quick summaries of these results are provided.

  12. Designing accelerator-based epithermal neutron beams for boron neutron capture therapy.

    Science.gov (United States)

    Bleuel, D L; Donahue, R J; Ludewigt, B A; Vujic, J

    1998-09-01

    The 7Li(p,n)7Be reaction has been investigated as an accelerator-driven neutron source for proton energies between 2.1 and 2.6 MeV. Epithermal neutron beams shaped by three moderator materials, Al/AlF3, 7LiF, and D2O, have been analyzed and their usefulness for boron neutron capture therapy (BNCT) treatments evaluated. Radiation transport through the moderator assembly has been simulated with the Monte Carlo N-particle code (MCNP). Fluence and dose distributions in a head phantom were calculated using BNCT treatment planning software. Depth-dose distributions and treatment times were studied as a function of proton beam energy and moderator thickness. It was found that an accelerator-based neutron source with Al/AlF3 or 7LiF as moderator material can produce depth-dose distributions superior to those calculated for a previously published neutron beam design for the Brookhaven Medical Research Reactor, achieving up to approximately 50% higher doses near the midline of the brain. For a single beam treatment, a proton beam current of 20 mA, and a 7LiF moderator, the treatment time was estimated to be about 40 min. The tumor dose deposited at a depth of 8 cm was calculated to be about 21 Gy-Eq.

  13. Gyrotron-driven high current ECR ion source for boron-neutron capture therapy neutron generator

    Energy Technology Data Exchange (ETDEWEB)

    Skalyga, V., E-mail: skalyga.vadim@gmail.com [Institute of Applied Physics, RAS, 46 Ul’yanova st., 603950 Nizhny Novgorod (Russian Federation); Lobachevsky State University of Nizhny Novgorod (UNN), 23 Gagarina st., 603950 Nizhny Novgorod (Russian Federation); Izotov, I.; Golubev, S.; Razin, S. [Institute of Applied Physics, RAS, 46 Ul’yanova st., 603950 Nizhny Novgorod (Russian Federation); Sidorov, A. [Institute of Applied Physics, RAS, 46 Ul’yanova st., 603950 Nizhny Novgorod (Russian Federation); Lobachevsky State University of Nizhny Novgorod (UNN), 23 Gagarina st., 603950 Nizhny Novgorod (Russian Federation); Maslennikova, A. [Lobachevsky State University of Nizhny Novgorod (UNN), 23 Gagarina st., 603950 Nizhny Novgorod (Russian Federation); Nizhny Novgorod State Medical Academy, 10/1 Minina Sq., 603005 Nizhny Novgorod (Russian Federation); Volovecky, A. [Lobachevsky State University of Nizhny Novgorod (UNN), 23 Gagarina st., 603950 Nizhny Novgorod (Russian Federation); Kalvas, T.; Koivisto, H.; Tarvainen, O. [University of Jyvaskyla, Department of Physics, PO Box 35 (YFL), 40500 Jyväskylä (Finland)

    2014-12-21

    Boron-neutron capture therapy (BNCT) is a perspective treatment method for radiation resistant tumors. Unfortunately its development is strongly held back by a several physical and medical problems. Neutron sources for BNCT currently are limited to nuclear reactors and accelerators. For wide spread of BNCT investigations more compact and cheap neutron source would be much more preferable. In present paper an approach for compact D–D neutron generator creation based on a high current ECR ion source is suggested. Results on dense proton beams production are presented. A possibility of ion beams formation with current density up to 600 mA/cm{sup 2} is demonstrated. Estimations based on obtained experimental results show that neutron target bombarded by such deuteron beams would theoretically yield a neutron flux density up to 6·10{sup 10} cm{sup −2}/s. Thus, neutron generator based on a high-current deuteron ECR source with a powerful plasma heating by gyrotron radiation could fulfill the BNCT requirements significantly lower price, smaller size and ease of operation in comparison with existing reactors and accelerators.

  14. Boron neutron capture therapy (BNCT) for liver metastasis: therapeutic efficacy in an experimental model

    Energy Technology Data Exchange (ETDEWEB)

    David W. Nigg

    2012-08-01

    Boron neutron capture therapy (BNCT) was proposed for untreatable colorectal liver metastases. The present study evaluates tumor control and potential radiotoxicity of BNCT in an experimental model of liver metastasis. BDIX rats were inoculated with syngeneic colon cancer cells DHD/K12/TRb. Tumor-bearing animals were divided into three groups: BPA–BNCT, boronophenylalanine (BPA) ? neutron irradiation; Beam only, neutron irradiation; Sham, matched manipulation. The total absorbed dose administered with BPA–BNCT was 13 ± 3 Gy in tumor and 9 ± 2 Gy in healthy liver. Three weeks posttreatment, the tumor surface area post-treatment/pre-treatment ratio was 0.46 ± 0.20 for BPA–BNCT, 2.7 ± 1.8 for Beam only and 4.5 ± 3.1 for Sham. The pre-treatment tumor nodule mass of 48 ± 19 mgfell significantly to 19 ± 16 mg for BPA–BNCT, but rose significantly to 140 ± 106 mg for Beam only and to 346 ± 302 mg for Sham. For both end points, the differences between the BPA–BNCT group and each of the other groups were statistically significant (ANOVA). No clinical, macroscopic or histological normal liver radiotoxicity was observed. It is concluded that BPA– BNCT induced a significant remission of experimental colorectal tumor nodules in liver with no contributory liver toxicity.

  15. Design and Simulation of Photoneutron Source by MCNPX Monte Carlo Code for Boron Neutron Capture Therapy

    Directory of Open Access Journals (Sweden)

    Mona Zolfaghari

    2015-07-01

    Full Text Available Introduction Electron linear accelerator (LINAC can be used for neutron production in Boron Neutron Capture Therapy (BNCT. BNCT is an external radiotherapeutic method for the treatment of some cancers. In this study, Varian 2300 C/D LINAC was simulated as an electron accelerator-based photoneutron source to provide a suitable neutron flux for BNCT. Materials and Methods Photoneutron sources were simulated, using MCNPX Monte Carlo code. In this study, a 20 MeV LINAC was utilized for electron-photon reactions. After the evaluation of cross-sections and threshold energies, lead (Pb, uranium (U and beryllium deuteride (BeD2were selected as photoneutron sources. Results According to the simulation results, optimized photoneutron sources with a compact volume and photoneutron yields of 107, 108 and 109 (n.cm-2.s-1 were obtained for Pb, U and BeD2 composites. Also, photoneutrons increased by using enriched U (10-60% as an electron accelerator-based photoneutron source. Conclusion Optimized photoneutron sources were obtained with compact sizes of 107, 108 and 109 (n.cm-2.s-1, respectively. These fluxs can be applied for BNCT by decelerating fast neutrons and using a suitable beam-shaping assembly, surrounding electron-photon and photoneutron sources.

  16. Investigation of Isfahan miniature neutron source reactor (MNSR for boron neutron capture therapy by MCNP simulation

    Directory of Open Access Journals (Sweden)

    S.Z Kalantari

    2015-01-01

    Full Text Available One of the important neutron sources for Boron Neutron Capture Therapy (BNCT is a nuclear reactor. It needs a high flux of epithermal neutrons. The optimum conditions of the neutron spectra for BNCT are provided by the International Atomic Energy Agency (IAEA. In this paper, Miniature Neutron Source Reactor (MNSR as a neutron source for BNCT was investigated. For this purpose, we designed a Beam Shaping Assembly (BSA for the reactor and the neutron transport from the core of the reactor to the output windows of BSA was simulated by MCNPX code. To optimize the BSA performance, two sets of parameters should be evaluated, in-air and in-phantom parameters. For evaluating in-phantom parameters, a Snyder head phantom was used and biological dose rate and dose-depth curve were calculated in brain normal and tumor tissues. Our calculations showed that the neutron flux of the MNSR reactor can be used for BNCT, and the designed BSA in optimum conditions had a good therapeutic characteristic for BNCT.

  17. Dynamic infrared imaging for biological and medical applications in Boron neutron capture therapy

    Science.gov (United States)

    Santa Cruz, Gustavo A.; González, Sara J.; Dagrosa, Alejandra; Schwint, Amanda E.; Carpano, Marina; Trivillin, Verónica A.; Boggio, Esteban F.; Bertotti, José; Marín, Julio; Monti Hughes, Andrea; Molinari, Ana J.; Albero, Miguel

    2011-05-01

    Boron Neutron Capture Therapy (BNCT) is a treatment modality, currently focused on the treatment of cancer, which involves a tumor selective 10B compound and a specially tuned neutron beam to produce a lethal nuclear reaction. BNCT kills target cells with microscopic selectivity while sparing normal tissues from potentially lethal doses of radiation. In the context of the Argentine clinical and research BNCT projects at the National Atomic Energy Commission and in a strong collaboration with INVAP SE, we successfully implemented Dynamic Infrared Imaging (DIRI) in the clinical setting for the observation of cutaneous melanoma patients and included DIRI as a non invasive methodology in several research protocols involving small animals. We were able to characterize melanoma lesions in terms of temperature and temperature rate-of-recovery after applying a mild cold thermal stress, distinguishing melanoma from other skin pigmented lesions. We observed a spatial and temporal correlation between skin acute reactions after irradiation, the temperature pattern and the dose distribution. We studied temperature distribution as a function of tumor growth in mouse xenografts, observing a significant correlation between tumor temperature and drug uptake; we investigated temperature evolution in the limbs of Wistar rats for a protocol of induced rheumatoid arthritis (RA), DIRI being especially sensitive to RA induction even before the development of clinical signs and studied surface characteristics of tumors, precancerous and normal tissues in a model of oral cancer in the hamster cheek pouch.

  18. Effectiveness of boron neutron capture therapy for recurrent head and neck malignancies

    Energy Technology Data Exchange (ETDEWEB)

    Kato, Itsuro [Department of Oral and Maxillofacial Surgery, II Osaka University, Graduate School of Dentistry, Osaka (Japan)], E-mail: katoitsu@dent.osaka-u.ac.jp; Fujita, Yusei [Department of Oral and Maxillofacial Surgery, II Osaka University, Graduate School of Dentistry, Osaka (Japan); Maruhashi, Akira [Radiation Oncology Research Laboratory, Research Reactor Institut, Kyoto University, Osaka (Japan); Kumada, Hiroaki [Japan Atomic Energy Agency, Tokai Research and Development Center, Ibaraki (Japan); Ohmae, Masatoshi [Department of Oral and Maxillofacial Surgery, Izimisano Municipal Hospital, Rinku General Hospital, Izumisano, Osaka (Japan); Kirihata, Mitsunori [Graduate School of Environment and Life Science, Osaka prefectural University, Osaka (Japan); Imahori, Yoshio [Department of Neurosurgery, Kyoto Prefectural University, Kyoto (Japan); CEO of Cancer Intelligence Care Systems, Inc., Tokyo (Japan); Suzuki, Minoru [Radiation Oncology Research Laboratory, Research Reactor Institut, Kyoto University, Osaka (Japan); Sakrai, Yoshinori [Graduate School of Medicine, Sapporo Medical University of Medicine, Hokkaido (Japan); Sumi, Tetsuro; Iwai, Soichi; Nakazawa, Mitsuhiro [Department of Oral and Maxillofacial Surgery, II Osaka University, Graduate School of Dentistry, Osaka (Japan); Murata, Isao; Miyamaru, Hiroyuki [Division of Electrical, Electronic and Information Engineering, Graduate School of Engineering, Osaka University (Japan); Ono, Koji [Radiation Oncology Research Laboratory, Research Reactor Institut, Kyoto University, Osaka (Japan)

    2009-07-15

    It is necessary to explore new treatments for recurrent head and neck malignancies (HNM) to avoid severe impairment of oro-facial structures and functions. Boron neutron capture therapy (BNCT) is tumor-cell targeted radiotherapy that has significant superiority over conventional radiotherapies in principle. We have treated with BNCT 42 times for 26 patients (19 squamous cell carcinomas (SCC), 4 salivary gland carcinomas and 3 sarcomas) with a recurrent and far advanced HNM since 2001. Results of (1) {sup 10}B concentration of tumor/normal tissue ratios (T/N ratio) of FBPA-PET studies were SCC: 1.8-5.7, sarcoma: 2.5-4.0, parotid tumor: 2.5-3.7. (2) Therapeutic effects were CR: 12 cases, PR: 10 cases, PD: 3 cases NE (not evaluated): 1 case. Response rate was 85%. (3) Improvement of QOL such as a relief of severe pain, bleeding, and exudates at the local lesion, improvement of PS, disappearance of ulceration, covered with normal skin and preserved oral and maxillofacial functions and tissues. (4) Survival periods after BNCT were 1-72 months (mean: 13.6 months). Six-year survival rate was 24% by Kaplan-Meier analysis. (5) Adverse-events were transient mucositis and alopecia in most of the cases; three osteomyelitis and one brain necrosis were recognized. These results indicate that BNCT represents a new and promising treatment approach for advanced HNM.

  19. Epithermal neutron formation for boron neutron capture therapy by adiabatic resonance crossing concept

    Science.gov (United States)

    Khorshidi, A.; Ghafoori-Fard, H.; Sadeghi, M.

    2014-05-01

    Low-energy protons from the cyclotron in the range of 15-30 MeV and low current have been simulated on beryllium (Be) target with a lead moderator around the target. This research was accomplished to design an epithermal neutron beam for Boron Neutron Capture Therapy (BNCT) using the moderated neutron on the average produced from 9Be target via (p, xn) reaction in Adiabatic Resonance Crossing (ARC) concept. Generation of neutron to proton ratio, energy distribution, flux and dose components in head phantom have been simulated by MCNP5 code. The reflector and collimator were designed in prevention and collimation of derivation neutrons from proton bombarding. The scalp-skull-brain phantom consisting of bone and brain equivalent material has been simulated in order to evaluate the dosimetric effect on the brain. Results of this analysis demonstrated while the proton energy decreased, the dose factor altered according to filters thickness. The maximum epithermal flux revealed using fluental, Fe and bismuth (Bi) filters with thicknesses of 9.4, 3 and 2 cm, respectively and also the epithermal to thermal neutron flux ratio was 103.85. The potential of the ARC method to replace or complement the current reactor-based supply sources of BNCT purposes.

  20. Development of the JAERI computational dosimetry system (JCDS) for boron neutron capture therapy. Cooperative research

    CERN Document Server

    Kumada, H; Matsumura, A; Nakagawa, Y; Nose, T; Torii, Y; Uchiyama, J; Yamamoto, K; Yamamoto, T

    2003-01-01

    The Neutron Beam Facility at JRR-4 enables us to carry out boron neutron capture therapy with epithermal neutron beam. In order to make treatment plans for performing the epithermal neutron beam BNCT, it is necessary to estimate radiation doses in a patient's head in advance. The JAERI Computational Dosimetry System (JCDS), which can estimate distributions of radiation doses in a patient's head by simulating in order to support the treatment planning for epithermal neutron beam BNCT, was developed. JCDS is a software that creates a 3-dimentional head model of a patient by using CT and MRI images, and that generates a input data file automatically for calculation of neutron flux and gamma-ray dose distributions in the brain with the Monte Carlo code MCNP, and that displays these dose distributions on the head model for dosimetry by using the MCNP calculation results. JCDS has any advantages as follows; By using CT data and MRI data which are medical images, a detail three-dimensional model of patient's head is...

  1. Boron neutron capture therapy of brain tumors: past history, current status, and future potential.

    Science.gov (United States)

    Barth, R F; Soloway, A H; Brugger, R M

    1996-01-01

    Boron neutron capture therapy (BNCT) is based on the nuclear reaction that occurs when boron-10 is irradiated with low-energy thermal neutrons to yield alpha particles and recoiling lithium-7 nuclei. High-grade astrocytomas, glioblastoma multiforme, and metastatic brain tumors constitute a major group of neoplasms for which there is no effective treatment. There is growing interest in using BNCT in combination with surgery to treat patients with primary, and possibly metastatic brain tumors. For BNCT to be successful, a large number of 10B atoms must be localized on or preferably within neoplastic cells, and a sufficient number of thermal neutrons must reach and be absorbed by the 10B atoms to sustain a lethal 10B(n, alpha)7 Li reaction. Two major questions will be addressed in this review. First, how can a large number of 10B atoms be delivered selectively to cancer cells? Second, how can a high fluence of neutrons be delivered to the tumor? Two boron compounds currently are being used clinically, sodium borocaptate (BSH) and boronophenylalanine (BPA), and a number of new delivery agents are under investigation, including boronated porphyrins, nucleosides, amino acids, polyamines, monoclonal and bispecific antibodies, liposomes, and epidermal growth factor. These will be discussed, and potential problems associated with their use as boron delivery agents will be considered. Nuclear reactors, currently, are the only source of neutrons for BNCT, and the fission process within the core produces a mixture of lower-energy thermal and epithermal neutrons, fast or high (> 10,000 eV) energy neutrons, and gamma rays. Although thermal neutron beams have been used clinically in Japan to treat patients with brain tumors and cutaneous melanomas, epithermal neutron beams should be more useful because of their superior tissue-penetrating properties. Beam sources and characteristics will be discussed in the context of current and future BNCT trials. Finally, the past and present

  2. Early clinical experience utilizing scintillator with optical fiber (SOF) detector in clinical boron neutron capture therapy: its issues and solutions

    OpenAIRE

    Ishikawa, Masayori; Yamamoto, Tetsuya; Matsumura, Akira; Hiratsuka, Junichi; Miyatake, Shin-Ichi; Kato, Itsuro; Sakurai, Yoshinori; Kumada, Hiroaki; Shrestha, Shubhechha J.; ONO, KOJI

    2016-01-01

    Background Real-time measurement of thermal neutrons in the tumor region is essential for proper evaluation of the absorbed dose in boron neutron capture therapy (BNCT) treatment. The gold wire activation method has been routinely used to measure the neutron flux distribution in BNCT irradiation, but a real-time measurement using gold wire is not possible. To overcome this issue, the scintillator with optical fiber (SOF) detector has been developed. The purpose of this study is to demonstrate...

  3. Measurement of in-phantom neutron flux and gamma dose in Tehran research reactor boron neutron capture therapy beam line

    OpenAIRE

    Elham Bavarnegin; Alireza Sadremomtaz; Hossein Khalafi; Yaser Kasesaz

    2016-01-01

    Aim: Determination of in-phantom quality factors of Tehran research reactor (TRR) boron neutron capture therapy (BNCT) beam. Materials and Methods: The doses from thermal neutron reactions with 14N and 10B are calculated by kinetic energy released per unit mass approach, after measuring thermal neutron flux using neutron activation technique. Gamma dose is measured using TLD-700 dosimeter. Results: Different dose components have been measured in a head phantom which has been designed an...

  4. Boron neutron capture therapy design calculation of a 3H(p,n) reaction based BSA for brain cancer setup

    OpenAIRE

    Bassem Elshahat; Akhtar Naqvi; Nabil Maalej

    2015-01-01

    Purpose: Boron neutron capture therapy (BNCT) is a promising technique for the treatment of malignant disease targeting organs of the human body. Monte Carlo simulations were carried out to calculate optimum design parameters of an accelerator based beam shaping assembly (BSA) for BNCT of brain cancer setup.Methods: Epithermal beam of neutrons were obtained through moderation of fast neutrons from 3H(p,n) reaction in a high density polyethylene moderator and a graphite reflector. The dimensio...

  5. Optimization of the geometry and composition of a neutron system for treatment by Boron Neutron Capture Therapy

    OpenAIRE

    2015-01-01

    Background: In the field of the treatment by Boron Neutron Capture Therapy (BNCT), an optimized neutron system was proposed. This study (simulation) was conducted to optimize the geometry and composition of neutron system and increase the epithermal neutron flux for the treatment of deep tumors is performed. Materials and Methods: A neutron system for BNCT was proposed. The system included 252Cf neutron source, neutron moderator/reflector arrangement, filter and concrete. To capture fast ...

  6. Characterization of neutron beams for boron neutron capture therapy: in-air radiobiological dosimetry.

    Science.gov (United States)

    Yamamoto, Tetsuya; Matsumura, Akira; Yamamoto, Kazuyoshi; Kumada, Hiroaki; Hori, Naohiko; Torii, Yoshiya; Shibata, Yasushi; Nose, Tadao

    2003-07-01

    The survival curves and the RBE for the dose components generated in boron neutron capture therapy (BNCT) were determined separately in neutron beams at Japan Research Reactor No. 4. The surviving fractions of V79 Chinese hamster cells with or without 10B were obtained using an epithermal neutron beam (ENB), a mixed thermal-epithermal neutron beam (TNB-1), and a thermal (TNB-2) neutron beam; these beams were used or are planned for use in BNCT clinical trials. The cell killing effect of the neutron beam in the presence or absence of 10B was highly dependent on the neutron beam used and depended on the epithermal and fast-neutron content of the beam. The RBEs of the boron capture reaction for ENB, TNB-1 and TNB-2 were 4.07 +/- 0.22, 2.98 +/- 0.16 and 1.42 +/- 0.07, respectively. The RBEs of the high-LET dose components based on the hydrogen recoils and the nitrogen capture reaction were 2.50 +/- 0.32, 2.34 +/- 0.30 and 2.17 +/- 0.28 for ENB, TNB-1 and TNB-2, respectively. The RBEs of the neutron and photon components were 1.22 +/- 0.16, 1.23 +/- 0.16, and 1.21 +/- 0.16 for ENB, TNB-1 and TNB-2, respectively. The approach to the experimental determination of RBEs outlined in this paper allows the RBE-weighted dose calculation for each dose component of the neutron beams and contributes to an accurate inter-beam comparison of the neutron beams at the different facilities employed in ongoing and planned BNCT clinical trials.

  7. Molecular Medicine: Synthesis and In Vivo Detection of Agents for use in Boron Neutron Capture Therapy. Final Report

    Energy Technology Data Exchange (ETDEWEB)

    Kabalka, G. W.

    2005-06-28

    The primary objective of the project was the development of in vivo methods for the detection and evaluation of tumors in humans. The project was focused on utilizing positron emission tomography (PET) to monitor the distribution and pharamacokinetics of a current boron neutron capture therapy (BNCT) agent, p-boronophenylalanine (BPA) by labeling it with a fluorine-18, a positron emitting isotope. The PET data was then used to develop enhanced treatment planning protocols. The study also involved the synthesis of new tumor selective BNCTagents that could be labeled with radioactive nuclides for the in vivo detection of boron.

  8. Effect of diameter of nanoparticles and capture cross-section library on macroscopic dose enhancement in boron neutron capture therapy

    Science.gov (United States)

    Farhood, Bagher

    2014-01-01

    Purpose The aim of this study is evaluation of the effect of diameter of 10B nanoparticles and various neutron capture cross-section libraries on macroscopic dose enhancement in boron neutron capture therapy (BNCT). Material and methods MCNPX Monte Carlo code was used for simulation of a 252Cf source, a soft tissue phantom and a tumor containing 10B nanoparticles. Using 252Cf as a neutron source, macroscopic dose enhancement factor (MDEF) and total dose rate in tumor in the presence of 100, 200, and 500 ppm of 10B nanoparticles with 25 nm, 50 nm, and 100 nm diameters were calculated. Additionally, the effect of ENDF, JEFF, JENDL, and CENDL neutron capture cross-section libraries on MDEF was evaluated. Results There is not a linear relationship between the average MDEF value and nanoparticles’ diameter but the average MDEF grows with increased concentration of 10B nanoparticles. There is an increasing trend for average MDEF with the tumor distance. The average MDEF values were obtained the same for various neutron capture cross-section libraries. The maximum and minimum doses that effect on the total dose in tumor were neutron and secondary photon doses, respectively. Furthermore, the boron capture related dose component reduced in some extent with increase of diameter of 10B nanoparticles. Conclusions Based on the results of this study, it can be concluded that from physical point of view, various nanoparticle diameters have no dominant effect on average MDEF value in tumor. Furthermore, it is concluded that various neutron capture cross-section libraries are resulted to the same macroscopic dose enhancements. However, it is predicted that taking into account the biological effects for various nanoparticle diameters will result in different dose enhancements. PMID:25834582

  9. Workshop on neutron capture therapy

    Energy Technology Data Exchange (ETDEWEB)

    Fairchild, R.G.; Bond, V.P. (eds.)

    1986-01-01

    Potentially optimal conditions for Neutron Capture Therapy (NCT) may soon be in hand due to the anticipated development of band-pass filtered beams relatively free of fast neutron contaminations, and of broadly applicable biomolecules for boron transport such as porphyrins and monoclonal antibodies. Consequently, a number of groups in the US are now devoting their efforts to exploring NCT for clinical application. The purpose of this Workshop was to bring these groups together to exchange views on significant problems of mutual interest, and to assure a unified and effective approach to the solutions. Several areas of preclinical investigation were deemed to be necessary before it would be possible to initiate clinical studies. As neither the monomer nor the dimer of sulfhydryl boron hydride is unequivocally preferable at this time, studies on both compounds should be continued until one is proven superior.

  10. Feasibility study on epithermal neutron field for cyclotron-based boron neutron capture therapy.

    Science.gov (United States)

    Yonai, Shunsuke; Aoki, Takao; Nakamura, Takashi; Yashima, Hiroshi; Baba, Mamoru; Yokobori, Hitoshi; Tahara, Yoshihisa

    2003-08-01

    To realize the accelerator-based boron neutron capture therapy (BNCT) at the Cyclotron and Radioisotope Center of Tohoku University, the feasibility of a cyclotron-based BNCT was evaluated. This study focuses on optimizing the epithermal neutron field with an energy spectrum and intensity suitable for BNCT for various combinations of neutron-producing reactions and moderator materials. Neutrons emitted at 90 degrees from a thick (stopping-length) Ta target, bombarded by 50 MeV protons of 300 microA beam current, were selected as a neutron source, based on the measurement of angular distributions and neutron energy spectra. As assembly composed of iron, AlF3/Al/6LiF, and lead was chosen as moderators, based on the simulation trials using the MCNPX code. The depth dose distributions in a cylindrical phantom, calculated with the MCNPX code, showed that, within 1 h of therapeutic time, the best moderator assembly, which is 30-cm-thick iron, 39-cm-thick AlF3/Al/6LiF, and 1-cm-thick lead, provides an epithermal neutron flux of 0.7 x 10(9) [n cm(-2) s(-1)]. This results in a tumor dose of 20.9 Gy-eq at a depth of 8 cm in the phantom, which is 6.4 Gy-eq higher than that of the Brookhaven Medical Research Reactor at the equivalent condition of maximum normal tissue tolerance. The beam power of the cyclotron is 15 kW, which is much lower than other accelerator-based BNCT proposals.

  11. First application of dynamic infrared imaging in boron neutron capture therapy for cutaneous malignant melanoma

    Energy Technology Data Exchange (ETDEWEB)

    Santa Cruz, G. A.; Gonzalez, S. J.; Bertotti, J.; Marin, J. [Departamento de Instrumentacion y Control, Comision Nacional de Energia Atomica, Avenida del Libertador 8250, 1429 Buenos Aires (Argentina); Departamento de Instrumentacion y Control, Comision Nacional de Energia Atomica, Avenida del Libertador 8250, 1429 Buenos Aires (Argentina) and CONICET, Avenida Rivadavia 1917, 1033 Buenos Aires (Argentina); Universidad Favaloro, Solis 453, 1078 Buenos Aires (Argentina)

    2009-10-15

    Purpose: The purpose of this study is to assess the potential of dynamic infrared imaging (DIRI) as a functional, noninvasive technique for evaluating the skin acute toxicity and tumor control within the framework of the Argentine boron neutron capture therapy (BNCT) program for cutaneous malignant melanoma. Methods: Two patients enrolled in the Argentine phase I/II BNCT clinical trial for cutaneous malignant melanoma were studied with DIRI. An uncooled infrared camera, providing a video output signal, was employed to register the temperature evolution of the normal skin and tumor regions in patients subjected to a mild local cooling (cold stimulus). In order to study the spatial correlation between dose and acute skin reactions, three-dimensional representations of the superficial dose delivered to skin were constructed and cameralike projections of the dose distribution were coregistered with visible and infrared images. Results: The main erythematous reaction was observed clinically between the second and fifth week post-BNCT. Concurrently, with its clinical onset, a reactive increase above the basal skin temperature was observed with DIRI in the third week post-BNCT within regions that received therapeutic doses. Melanoma nodules appeared as highly localized hyperthermic regions. 2 min after stimulus, these regions reached a temperature plateau and increased in size. Temperature differences with respect to normal skin up to 10 deg. C were observed in the larger nodules. Conclusions: Preliminary results suggest that DIRI, enhanced by the application of cold stimuli, may provide useful functional information associated with the metabolism and vasculature of tumors and inflammatory processes related to radiation-induced changes in the skin as well. These capabilities are aimed at complementing the clinical observations and standard imaging techniques, such as CT and Doppler ultrasound.

  12. Development of the JAERI computational dosimetry system (JCDS) for boron neutron capture therapy. Cooperative research

    Energy Technology Data Exchange (ETDEWEB)

    Kumada, Hiroaki; Yamamoto, Kazuyoshi; Torii, Yoshiya; Uchiyama, Junzo [Japan Atomic Energy Research Inst., Tokai, Ibaraki (Japan). Tokai Research Establishment; Matsumura, Akira; Yamamoto, Tetsuya; Nose, Tadao [Tsukuba Univ., Tsukuba, Ibaraki (Japan); Nakagawa, Yoshinobu [National Sanatorium Kagawa-Children' s Hospital, Kagawa (Japan); Kageji, Teruyoshi [Tokushima Univ., Tokushima (Japan)

    2003-03-01

    The Neutron Beam Facility at JRR-4 enables us to carry out boron neutron capture therapy with epithermal neutron beam. In order to make treatment plans for performing the epithermal neutron beam BNCT, it is necessary to estimate radiation doses in a patient's head in advance. The JAERI Computational Dosimetry System (JCDS), which can estimate distributions of radiation doses in a patient's head by simulating in order to support the treatment planning for epithermal neutron beam BNCT, was developed. JCDS is a software that creates a 3-dimentional head model of a patient by using CT and MRI images, and that generates a input data file automatically for calculation of neutron flux and gamma-ray dose distributions in the brain with the Monte Carlo code MCNP, and that displays these dose distributions on the head model for dosimetry by using the MCNP calculation results. JCDS has any advantages as follows; By using CT data and MRI data which are medical images, a detail three-dimensional model of patient's head is able to be made easily. The three-dimensional head image is editable to simulate the state of a head after its surgical processes such as skin flap opening and bone removal in the BNCT with craniotomy that are being performed in Japan. JCDS can provide information for the Patient Setting System which can support to set the patient to an actual irradiation position swiftly and accurately. This report describes basic design of JCDS and functions in several processing, calculation methods, characteristics and performance of JCDS. (author)

  13. General Electric PETtrace cyclotron as a neutron source for boron neutron capture therapy

    Science.gov (United States)

    Bosko, Andrey

    This research investigates the use of a PETtrace cyclotron produced by General Electric (GE) as a neutron source for boron neutron capture therapy (BNCT). The GE PETtrace was chosen for this investigation because this type of cyclotron is popular among nuclear pharmacies and clinics in many countries; it is compact and reliable; it produces protons with energies high enough to produce neutrons with appropriate energy and fluence rate for BNCT and it does not require significant changes in design to provide neutrons. In particular, the standard PETtrace 18O target is considered. The cyclotron efficiency may be significantly increased if unused neutrons produced during radioisotopes production could be utilized for other medical modalities such as BNCT at the same time. The resulting dose from the radiation emitted from the target is evaluated using the Monte Carlo radiation transport code MCNP at several depths in a brain phantom for different scattering geometries. Four different moderating materials of various thicknesses were considered: light water, carbon, heavy water, arid Fluental(TM). The fluence rate tally was used to calculate photon and neutron dose, by applying fluence rate-to-dose conversion factors. Fifteen different geometries were considered and a 30-cm thick heavy water moderator was chosen as the most suitable for BNCT with the GE PETtrace cyclotron. According to the Brookhaven Medical Research Reactor (BMRR) protocol, the maximum dose to the normal brain is set to 12.5 RBEGy, which for the conditions of using a heavy water moderator, assuming a 60 muA beam current, would be reached with a treatment time of 258 min. Results showed that using a PETtrace cyclotron in this configuration provides a therapeutic ratio of about 2.4 for depths up to 4 cm inside a brain phantom. Further increase of beam current proposed by GE should significantly improve the beam quality or the treatment time and allow treating tumors at greater depths.

  14. A benchmark analysis of radiation flux distribution for Boron Neutron Capture Therapy of canine brain tumors

    Energy Technology Data Exchange (ETDEWEB)

    Moran, J.M.

    1992-02-01

    Calculations of radiation flux and dose distributions for Boron Neutron Capture Therapy (BNCT) of brain tumors are typically performed using sophisticated three-dimensional analytical models based on either a homogeneous approximation or a simplified few-region approximation to the actual highly-heterogeneous geometry of the irradiation volume. Such models should be validated by comparison with calculations using detailed models in which all significant macroscopic tissue heterogeneities and geometric structures are explicitly represented as faithfully as possible. This work describes a validation exercise for BNCT of canine brain tumors. Geometric measurements of the canine anatomical structures of interest for this work were performed by dissecting and examining two essentially identical Labrador Retriever heads. Chemical analyses of various tissue samples taken during the dissections were conducted to obtain measurements of elemental compositions for tissues of interest. The resulting geometry and tissue composition data were then used to construct a detailed heterogeneous calculational model of the Labrador Retriever head. Calculations of three-dimensional radiation flux distributions pertinent to BNCT were performed for the model using the TORT discrete-ordinates radiation transport code. The calculations were repeated for a corresponding volume-weighted homogeneous tissue model. Comparison of the results showed that the peak neutron and photon flux magnitudes were quite similar for the two models (within 5%), but that the spatial flux profiles were shifted in the heterogeneous model such that the fluxes in some locations away from the peak differed from the corresponding fluxes in the homogeneous model by as much as 10-20%. Differences of this magnitude can be therapeutically significant, emphasizing the need for proper validation of simplified treatment planning models.

  15. Monte Carlo based treatment planning systems for Boron Neutron Capture Therapy in Petten, The Netherlands

    Science.gov (United States)

    Nievaart, V. A.; Daquino, G. G.; Moss, R. L.

    2007-06-01

    Boron Neutron Capture Therapy (BNCT) is a bimodal form of radiotherapy for the treatment of tumour lesions. Since the cancer cells in the treatment volume are targeted with 10B, a higher dose is given to these cancer cells due to the 10B(n,α)7Li reaction, in comparison with the surrounding healthy cells. In Petten (The Netherlands), at the High Flux Reactor, a specially tailored neutron beam has been designed and installed. Over 30 patients have been treated with BNCT in 2 clinical protocols: a phase I study for the treatment of glioblastoma multiforme and a phase II study on the treatment of malignant melanoma. Furthermore, activities concerning the extra-corporal treatment of metastasis in the liver (from colorectal cancer) are in progress. The irradiation beam at the HFR contains both neutrons and gammas that, together with the complex geometries of both patient and beam set-up, demands for very detailed treatment planning calculations. A well designed Treatment Planning System (TPS) should obey the following general scheme: (1) a pre-processing phase (CT and/or MRI scans to create the geometric solid model, cross-section files for neutrons and/or gammas); (2) calculations (3D radiation transport, estimation of neutron and gamma fluences, macroscopic and microscopic dose); (3) post-processing phase (displaying of the results, iso-doses and -fluences). Treatment planning in BNCT is performed making use of Monte Carlo codes incorporated in a framework, which includes also the pre- and post-processing phases. In particular, the glioblastoma multiforme protocol used BNCT_rtpe, while the melanoma metastases protocol uses NCTPlan. In addition, an ad hoc Positron Emission Tomography (PET) based treatment planning system (BDTPS) has been implemented in order to integrate the real macroscopic boron distribution obtained from PET scanning. BDTPS is patented and uses MCNP as the calculation engine. The precision obtained by the Monte Carlo based TPSs exploited at Petten

  16. Accelerator-based epithermal neutron sources for boron neutron capture therapy of brain tumors.

    Science.gov (United States)

    Blue, Thomas E; Yanch, Jacquelyn C

    2003-01-01

    This paper reviews the development of low-energy light ion accelerator-based neutron sources (ABNSs) for the treatment of brain tumors through an intact scalp and skull using boron neutron capture therapy (BNCT). A major advantage of an ABNS for BNCT over reactor-based neutron sources is the potential for siting within a hospital. Consequently, light-ion accelerators that are injectors to larger machines in high-energy physics facilities are not considered. An ABNS for BNCT is composed of: (1) the accelerator hardware for producing a high current charged particle beam, (2) an appropriate neutron-producing target and target heat removal system (HRS), and (3) a moderator/reflector assembly to render the flux energy spectrum of neutrons produced in the target suitable for patient irradiation. As a consequence of the efforts of researchers throughout the world, progress has been made on the design, manufacture, and testing of these three major components. Although an ABNS facility has not yet been built that has optimally assembled these three components, the feasibility of clinically useful ABNSs has been clearly established. Both electrostatic and radio frequency linear accelerators of reasonable cost (approximately 1.5 M dollars) appear to be capable of producing charged particle beams, with combinations of accelerated particle energy (a few MeV) and beam currents (approximately 10 mA) that are suitable for a hospital-based ABNS for BNCT. The specific accelerator performance requirements depend upon the charged particle reaction by which neutrons are produced in the target and the clinical requirements for neutron field quality and intensity. The accelerator performance requirements are more demanding for beryllium than for lithium as a target. However, beryllium targets are more easily cooled. The accelerator performance requirements are also more demanding for greater neutron field quality and intensity. Target HRSs that are based on submerged-jet impingement and

  17. The radiobiological principles of boron neutron capture therapy: A critical review

    Energy Technology Data Exchange (ETDEWEB)

    Hopewell, J.W., E-mail: john.hopewell@gtc.ox.ac.uk [Green Templeton College and Particle Therapy Cancer Research Institute, University of Oxford, Oxford (United Kingdom); Morris, G.M. [Medical Department, Brookhaven National Laboratory, Upton, NY (United States); Schwint, A. [Department of Radiobiology, Constituyentes Atomic Center, National Atomic Energy Commission, San Martin, Buenos Aires (Argentina); Coderre, J.A. [Ora Inc, 300 Brickstone Square, Andover, MA (United States)

    2011-12-15

    The radiobiology of the dose components in a BNCT exposure is examined. The effect of exposure time in determining the biological effectiveness of {gamma}-rays, due to the repair of sublethal damage, has been largely overlooked in the application of BNCT. Recoil protons from fast neutrons vary in their relative biological effectiveness (RBE) as a function of energy and tissue endpoint. Thus the energy spectrum of a beam will influence the RBE of this dose component. Protons from the neutron capture reaction in nitrogen have not been studied but in practice protons from nitrogen capture have been combined with the recoil proton contribution into a total proton dose. The relative biological effectiveness of the products of the neutron capture reaction in boron is derived from two factors, the RBE of the short range particles and the bio-distribution of boron, referred to collectively as the compound biological effectiveness factor. Caution is needed in the application of these factors for different normal tissues and tumors. - Highlights: Black-Right-Pointing-Pointer Radiobiological properties of different dose components in BNCT are considered. Black-Right-Pointing-Pointer Effectiveness of {gamma}-ray dose depends strongly on exposure time due to sublethal damage repair. Black-Right-Pointing-Pointer Effectiveness of fast neutron dose depends on neutron energy spectrum. Black-Right-Pointing-Pointer {gamma}-ray and fast neutron characteristics vary between beams and thus weighting factors will differ. Black-Right-Pointing-Pointer Weighing factors for boron dose depend on the carrier, the tissue and its mode of administration.

  18. Boron neutron capture therapy induces apoptosis of glioma cells through Bcl-2/Bax

    Directory of Open Access Journals (Sweden)

    Mao Xinggang

    2010-12-01

    Full Text Available Abstract Background Boron neutron capture therapy (BNCT is an alternative treatment modality for patients with glioma. The aim of this study was to determine whether induction of apoptosis contributes to the main therapeutic efficacy of BNCT and to compare the relative biological effect (RBE of BNCT, γ-ray and reactor neutron irradiation. Methods The neutron beam was obtained from the Xi'an Pulsed Reactor (XAPR and γ-rays were obtained from [60Co] γ source of the Fourth Military Medical University (FMMU in China. Human glioma cells (the U87, U251, and SHG44 cell lines were irradiated by neutron beams at the XAPR or [60Co] γ-rays at the FMMU with different protocols: Group A included control nonirradiated cells; Group B included cells treated with 4 Gy of [60Co] γ-rays; Group C included cells treated with 8 Gy of [60Co] γ-rays; Group D included cells treated with 4 Gy BPA (p-borono-phenylalanine-BNCT; Group E included cells treated with 8 Gy BPA-BNCT; Group F included cells irradiated in the reactor for the same treatment period as used for Group D; Group G included cells irradiated in the reactor for the same treatment period as used for Group E; Group H included cells irradiated with 4 Gy in the reactor; and Group I included cells irradiated with 8 Gy in the reactor. Cell survival was determined using the 3-(4,5-dimethylthiazol-2-yl-2,5-diphenyltetrazolium (MTT cytotoxicity assay. The morphology of cells was detected by Hoechst33342 staining and transmission electron microscope (TEM. The apoptosis rate was detected by flow cytometer (FCM. The level of Bcl-2 and Bax protein was measured by western blot analysis. Results Proliferation of U87, U251, and SHG44 cells was much more strongly inhibited by BPA-BNCT than by irradiation with [60Co] γ-rays (P 60Co] γ-rays (P P Conclusions Compared with ��-ray and reactor neutron irradiation, a higher RBE can be achieved upon treatment of glioma cells with BNCT. Glioma cell apoptosis induced by

  19. Determination and production of an optimal neutron energy spectrum for boron neutron capture therapy

    Science.gov (United States)

    Bleuel, Darren Leo

    An accelerator-based neutron irradiation facility employing an electrostatic quadrupole (ESQ) accelerator for Boron Neutron Capture Therapy (BNCT) has been proposed at Lawrence Berkeley National Laboratory. In this dissertation, the properties of an ideal neutron beam for delivering a maximized dose to a glioblastoma multiforme tumor in a reasonable time while minimizing the dose to healthy tissue is examined. A variety of materials, beam shaping assemblies, and neutron sources were considered to deliver a neutron spectrum as close to the calculated idealized spectrum as possible. Several optimization studies were performed to determine the best proton energy and moderator material to maximize the efficacy of an accelerator-based BNCT facility utilizing the 7Li(p,n)7Be reaction as a neutron source. A new, faster method of performing such an optimization was developed, known as the "Ubertally" method, in which data from a single Monte Carlo simulation is reweighted to produce results for any neutron spatial, energy and angular source distribution. Results were confirmed experimentally at Lawrence Berkeley National Laboratory's 88″ cyclotron. Thermal fluxes in this experiment were found to be approximately 30% lower than expected, but the depth-dose profile was confirmed to within 8% maximum deviation. A final beam shaping assembly is then recommended. Utilizing a material known as Fluental as a moderating material, deep-seated tumor doses 50% higher than that delivered by clinical trials at the Brookhaven Medical Research Reactor (BMRR) are predicted. The final recommended design should contain a 37 cm thickness of Fluental(TM) moderator, a 1--2 cm gamma shield, an Al2O3 reflector, a V-shaped aluminum-backed or copper-backed source with heavy water cooling, and a 13 cm lithiated polyethylene delimiter. This design would be operated at 2.4 MeV proton energy at 20 mA to conduct treatments in less than an hour and a half. However, this design may be easily altered

  20. Boronophenylalanine, a boron delivery agent for boron neutron capture therapy, is transported by ATB0,+, LAT1 and LAT2.

    Science.gov (United States)

    Wongthai, Printip; Hagiwara, Kohei; Miyoshi, Yurika; Wiriyasermkul, Pattama; Wei, Ling; Ohgaki, Ryuichi; Kato, Itsuro; Hamase, Kenji; Nagamori, Shushi; Kanai, Yoshikatsu

    2015-03-01

    The efficacy of boron neutron capture therapy relies on the selective delivery of boron carriers to malignant cells. p-Boronophenylalanine (BPA), a boron delivery agent, has been proposed to be localized to cells through transporter-mediated mechanisms. In this study, we screened aromatic amino acid transporters to identify BPA transporters. Human aromatic amino acid transporters were functionally expressed in Xenopus oocytes and examined for BPA uptake and kinetic parameters. The roles of the transporters in BPA uptake were characterized in cancer cell lines. For the quantitative assessment of BPA uptake, HPLC was used throughout the study. Among aromatic amino acid transporters, ATB(0,+), LAT1 and LAT2 were found to transport BPA with Km values of 137.4 ± 11.7, 20.3 ± 0.8 and 88.3 ± 5.6 μM, respectively. Uptake experiments in cancer cell lines revealed that the LAT1 protein amount was the major determinant of BPA uptake at 100 μM, whereas the contribution of ATB(0,+) became significant at 1000 μM, accounting for 20-25% of the total BPA uptake in MCF-7 breast cancer cells. ATB(0,+), LAT1 and LAT2 transport BPA at affinities comparable with their endogenous substrates, suggesting that they could mediate effective BPA uptake in vivo. The high and low affinities of LAT1 and ATB(0,+), respectively, differentiate their roles in BPA uptake. ATB(0,+), as well as LAT1, could contribute significantly to the tumor accumulation of BPA at clinical dose.

  1. Conceptual design of an RFQ accelerator-based neutron source for boron neutron-capture therapy

    Energy Technology Data Exchange (ETDEWEB)

    Wangler, T.P.; Stovall, J.E.; Bhatia, T.S.; Wang, C.K.; Blue, T.E.; Gahbauer, R.A.

    1989-01-01

    We present a conceptual design of a low-energy neutron generator for treatment of brain tumors by boron neutron capture theory (BNCT). The concept is based on a 2.5-MeV proton beam from a radio-frequency quadrupole (RFQ) linac, and the neutrons are produced by the /sup 7/Li(p,n)/sup 7/Be reaction. A liquid lithium target and modulator assembly are designed to provide a high flux of epithermal neutrons. The patient is administered a tumor-specific /sup 10/Be-enriched compound and is irradiated by the neutrons to create a highly localized dose from the reaction /sup 10/B(n,..cap alpha..)/sup 7/Li. An RFQ accelerator-based neutron source for BNCT is compact, which makes it practical to site the facility within a hospital. 11 refs., 5 figs., 1 tab.

  2. MAGIC polymer gel for dosimetric verification in boron neutron capture therapy.

    Science.gov (United States)

    Uusi-Simola, Jouni; Heikkinen, Sami; Kotiluoto, Petri; Serén, Tom; Seppälä, Tiina; Auterinen, Iiro; Savolainen, Sauli

    2007-04-30

    Radiation sensitive polymer gels are among the most promising three-dimensional dose verification tools developed to date. Polymer gel dosimeter known by the acronym MAGIC has been tested for evaluation of its use in boron neutron capture (BNCT) dosimetry. We irradiated a large (diameter 10 cm, length 20 cm) cylindrical gel phantom in the epithermal neutron beam of the Finnish BNCT facility at the FiR 1 nuclear reactor. Neutron irradiation was simulated with a Monte Carlo radiation transport code MCNP. Gel samples from the same production batch were also irradiated with 6 MV photons from a medical linear accelerator to compare dose response in the two different types of beams. Irradiated gel phantoms were imaged using MRI to determine their relaxation rate R2 maps. The measured and normalized dose distribution in the epithermal neutron beam was compared to the dose distribution calculated by computer simulation. The results support the feasibility MAGIC gel in BNCT dosimetry.

  3. PEMODELAN KOLIMATOR DI RADIAL BEAM PORT REAKTOR KARTINI UNTUK BORON NEUTRON CAPTURE THERAPY

    Directory of Open Access Journals (Sweden)

    Bemby Yulio Vallenry

    2015-03-01

    Full Text Available Salah satu metode terapi kanker adalah Boron Neutron Capture Therapy (BNCT. BNCT memanfaatkan tangkapan neutron oleh 10B yang terendapkan pada sel kanker. Keunggulan BNCT dibandingkan dengan terapi radiasi lainnya adalah tingkat selektivitas yang tinggi karena tingkatannya adalah sel. Pada penelitian ini dilakukan pemodelan kolimator di radial beamport reaktor Kartini sebagai dasar pemilihan material dan manufature kolimator sebagai sumber neutron untuk BNCT. Pemodelan ini dilakukan dengan simulasi menggunakan perangkat lunak Monte Carlo N-Particle versi 5 (MCNP 5. MCNP 5 adalah suatu paket program untuk memodelkan sekaligus menghitung masalah transpor partikel dengan mengikuti sejarah hidup neutron semenjak lahir, bertranspor pada bahan hingga akhirnya hilang karena mengalami reaksi penyerapan atau keluar dari sistem. Pemodelan ini menggunakan variasi material dan ukurannya agar menghasilkan nilai dari tiap parameter-parameter yang sesuai dengan rekomendasi I International Atomic Energy Agency (IAEA untuk BNCT, yaitu fluks neutron epitermal (Фepi > 9 n.cm-2.s-1, rasio antara laju dosis neutron cepat dan fluks neutron epitermal (Ḋf/Фepi 0,7. Berdasarkan hasil optimasi dari pemodelan ini, material dan ukuran penyusun kolimator yang didapatkan yaitu 0,75 cm Ni sebagai dinding kolimator, 22 cm Al sebagai moderator dan 4,5 cm Bi sebagai perisai gamma. Keluaran berkas radiasi yang dihasilkan dari pemodelan kolimator radial beamport yaitu Фepi = 5,25 x 106 n.cm-2s-1, Ḋf/Фepi =1,17 x 10-13 Gy.cm2.n-1, Ḋγ/Фepi = 1,70 x 10-12 Gy.cm2.n-1, Фth/Фepi = 1,51 dan J/Фepi = 0,731. Berdasarkan penelitian ini, hasil optimasi 5 parameter sebagai persyaratan kolimator untuk BNCT yang keluar dari radial beam port tidak sepenuhnya memenuhi kriteria yang direkomendasikan oleh IAEA sehingga perlu dilakukan penelitian lebih lanjut agar tercapainya persyaratan IAEA. Kata kunci: BNCT, radial beamport, MCNP 5, kolimator   One of the cancer therapy methods is

  4. Boron neutron capture therapy (BNCT) for glioblastoma multiforme using the epithermal neutron beam at the Brookhaven Medical Research Reactor

    Energy Technology Data Exchange (ETDEWEB)

    Capala, J. [Brookhaven National Lab., Upton, NY (United States); Diaz, A.Z.; Chadha, M. [Univ. Hospital, State Univ. of New York, NY (United States)] [and others

    1997-12-31

    The abstract describes evaluation of boron neutron capture therapy (BNCT) for two groups of glioblastoma multiforme patients. From September 1994 to February 1996 15 patients have been treated. In September 1997 another 34 patients were examined. Authors determined a safe starting dose for BNCT using epithermal neutrons and BPA-F. They have also evaluated adverse effects of BNCT at this starting dose. Therapeutic effectiveness of this starting dose has been evaluated. No significant side effects from BPA-F infusion or BNCT treatment were observed in normal brains.

  5. Iodine neutron capture therapy

    Science.gov (United States)

    Ahmed, Kazi Fariduddin

    A new technique, Iodine Neutron Capture Therapy (INCT) is proposed to treat hyperthyroidism in people. Present thyroid therapies, surgical removal and 131I treatment, result in hypothyroidism and, for 131I, involve protracted treatment times and excessive whole-body radiation doses. The new technique involves using a low energy neutron beam to convert a fraction of the natural iodine stored in the thyroid to radioactive 128I, which has a 24-minute half-life and decays by emitting 2.12-MeV beta particles. The beta particles are absorbed in and damage some thyroid tissue cells and consequently reduce the production and release of thyroid hormones to the blood stream. Treatment times and whole-body radiation doses are thus reduced substantially. This dissertation addresses the first of the several steps needed to obtain medical profession acceptance and regulatory approval to implement this therapy. As with other such programs, initial feasibility is established by performing experiments on suitable small mammals. Laboratory rats were used and their thyroids were exposed to the beta particles coming from small encapsulated amounts of 128I. Masses of 89.0 mg reagent-grade elemental iodine crystals have been activated in the ISU AGN-201 reactor to provide 0.033 mBq of 128I. This activity delivers 0.2 Gy to the thyroid gland of 300-g male rats having fresh thyroid tissue masses of ˜20 mg. Larger iodine masses are used to provide greater doses. The activated iodine is encapsulated to form a thin (0.16 cm 2/mg) patch that is then applied directly to the surgically exposed thyroid of an anesthetized rat. Direct neutron irradiation of a rat's thyroid was not possible due to its small size. Direct in-vivo exposure of the thyroid of the rat to the emitted radiation from 128I is allowed to continue for 2.5 hours (6 half-lives). Pre- and post-exposure blood samples are taken to quantify thyroid hormone levels. The serum T4 concentration is measured by radioimmunoassay at

  6. Preparation and characterization of Boron carbide nanoparticles for use as a novel agent in T cell-guided boron neutron capture therapy.

    Science.gov (United States)

    Mortensen, M W; Sørensen, P G; Björkdahl, O; Jensen, M R; Gundersen, H J G; Bjørnholm, T

    2006-03-01

    Boron carbide nanoparticles are proposed as a system for T cell-guided boron neutron capture therapy. Nanoparticles were produced by ball milling in various atmospheres of commercially available boron carbide. The physical and chemical properties of the particles were investigated using transmission electron microscopy, photon correlation spectroscopy, X-ray photoelectron spectroscopy, X-ray diffraction, vibrational spectroscopy, gel electrophoresis and chemical assays and reveal profound changes in surface chemistry and structural characteristics. In vitro thermal neutron irradiation of B16 melanoma cells incubated with sub-100 nm nanoparticles (381.5 microg/g (10)B) induces complete cell death. The nanoparticles alone induce no toxicity.

  7. Investigation of current status in Europe and USA on boron neutron capture therapy

    Energy Technology Data Exchange (ETDEWEB)

    NONE

    2000-11-01

    This report describes on the spot investigation results of current status of medical irradiation in Europe and USA at Feb. 1999. In HFR (Netherlands), the phase 1 study with the Joint Research Centre (JRC) of the EU had been already finished in those days, at the same time, an improvement of medical irradiation field of VTT(Finland) had been finishing and then clinical trial research had been about to start. On the other hand, phase 1 studies by two groups of BNL (Brook heaven National Laboratory) and MIT (Nuclear Engineering of Massachusetts Institute of Technology) in US were now in almost final stage, and they would start on phase 2 study. Either reactors of MIT and BNL were in modification to increase neutron flux, especially that employing fission converter into the irradiation facility and installation of irradiation room were carrying out in the former. In Europe and USA, the accelerator-based BNCT planes are now in progress vigorously, and will have reality. A reform of dynamitron accelerator at University of Birmingham was progressed, and the clinical treatment would be started from September 2000. The accelerator group at MIT has a small type of tandem accelerator, and they were performing basic experiment for BNCS (Boron Neutron Capture Synovectomy) with this accelerator. The concept design for an accelerator and a moderator had been finished at Lawrence Berkeley National Laboratory and University of Berkeley. (author)

  8. Research in boron neutron capture synovectomy

    Science.gov (United States)

    Binello, E.; Shortkroff, S.; Jones, A.; Viveiros, C.; Ly, A.; Sledge, C. B.; Davison, A.; Shefer, Ruth E.; Yanch, Jacquelyn C.

    1997-02-01

    Boron Neutron Capture Synovectomy (BNCS) is a novel application of the 10B(n, (alpha) )7Li reaction for the treatment of Rheumatoid Arthritis. This potential treatment modality is in its developmental stages; in this paper results of research in two aspects of BNCS are presented. First, quantification of 10B-uptake in samples of human arthritic tissue by Prompt Gamma Neutron Activation Analysis is presented. 10B concentrations from 1625 to 2726 ppm are readily achieved. Second, ideal neutron beam studies have been undertaken and indicate that neutrons from thermal energies to 1 keV are useful for BNCS. This information is of use in designing practical therapy beams should this treatment modality be realized.

  9. Feasibility study on the utilization of boron neutron capture therapy (BNCT) in a rat model of diffuse lung metastases

    Energy Technology Data Exchange (ETDEWEB)

    Bakeine, G.J. [Department of Clinical Medicine and Neurology, Cattinara Hospital, University of Trieste (Italy)], E-mail: jamesbakeine1@yahoo.com; Di Salvo, M. [Department of Nuclear and Theoretical Physics, University of Pavia, Via Bassi 6, Pavia (Italy); Bortolussi, S.; Stella, S. [Department of Nuclear and Theoretical Physics, University of Pavia, Via Bassi 6, Pavia (Italy); National Institute of Nuclear Physics (INFN) Section of Pavia, Via Bassi 6, Pavia (Italy); Bruschi, P. [Department of Nuclear and Theoretical Physics, University of Pavia, Via Bassi 6, Pavia (Italy); Bertolotti, A.; Nano, R. [Department of Animal Biology University of Pavia, Piazza Botta, Pavia (Italy); Clerici, A.; Ferrari, C.; Zonta, C. [Department of Surgery University of Pavia, Piazza Botta, Pavia (Italy); Marchetti, A. [Scientific Research Office, Fondazione San Matteo University Policlinic, Pavia (Italy); Altieri, S. [Department of Nuclear and Theoretical Physics, University of Pavia, Via Bassi 6, Pavia (Italy); National Institute of Nuclear Physics (INFN) Section of Pavia, Via Bassi 6, Pavia (Italy)

    2009-07-15

    In order for boron neutron capture therapy (BNCT) to be eligible for application in lung tumour disease, three fundamental criteria must be fulfilled: there must be selective uptake of boron in the tumour cells with respect to surrounding healthy tissue, biological effectiveness of the radiation therapy and minimal damage or collateral effects of the irradiation on the surrounding tissues. In this study, we evaluated the biological effectiveness of BNCT by in vitro irradiation of rat colon-carcinoma cells previously incubated in boron-enriched medium. One part of these cells was re-cultured in vitro while the other was inoculated via the inferior vena cava to induce pulmonary metastases in a rat model. We observed a post-irradiation in vitro cell viability of 0.05% after 8 days of cell culture. At 4 months follow-up, all animal subjects in the treatment group that received irradiated boron-containing cells were alive. No animal survived beyond 1 month in the control group that received non-treated cells (p<0.001 Kaplan-Meier). These preliminary findings strongly suggest that BNCT has a significant lethal effect on tumour cells and post irradiation surviving cells lose their malignant capabilities in vivo. This radio-therapeutic potential warrants the investigation of in vivo BNCT for lung tumour metastases.

  10. Advances in boron neutron capture therapy (BNCT) at kyoto university - From reactor-based BNCT to accelerator-based BNCT

    Science.gov (United States)

    Sakurai, Yoshinori; Tanaka, Hiroki; Takata, Takushi; Fujimoto, Nozomi; Suzuki, Minoru; Masunaga, Shinichiro; Kinashi, Yuko; Kondo, Natsuko; Narabayashi, Masaru; Nakagawa, Yosuke; Watanabe, Tsubasa; Ono, Koji; Maruhashi, Akira

    2015-07-01

    At the Kyoto University Research Reactor Institute (KURRI), a clinical study of boron neutron capture therapy (BNCT) using a neutron irradiation facility installed at the research nuclear reactor has been regularly performed since February 1990. As of November 2014, 510 clinical irradiations were carried out using the reactor-based system. The world's first accelerator-based neutron irradiation system for BNCT clinical irradiation was completed at this institute in early 2009, and the clinical trial using this system was started in 2012. A shift of BCNT from special particle therapy to a general one is now in progress. To promote and support this shift, improvements to the irradiation system, as well as its preparation, and improvements in the physical engineering and the medical physics processes, such as dosimetry systems and quality assurance programs, must be considered. The recent advances in BNCT at KURRI are reported here with a focus on physical engineering and medical physics topics.

  11. Synthesis and biological evaluation of new boron-containing chlorin derivatives as agents for both photodynamic therapy and boron neutron capture therapy of cancer.

    Science.gov (United States)

    Asano, Ryuji; Nagami, Amon; Fukumoto, Yuki; Miura, Kaori; Yazama, Futoshi; Ito, Hideyuki; Sakata, Isao; Tai, Akihiro

    2014-03-01

    New boron-containing chlorin derivatives 9 and 13 as agents for both photodynamic therapy (PDT) and boron neutron capture therapy (BNCT) of cancer were synthesized from photoprotoporphyrin IX dimethyl ester (2) and L-4-boronophenylalanine-related compounds. The in vivo biodistribution and clearance of 9 and 13 were investigated in tumor-bearing mice. The time to maximum accumulation of compound 13 in tumor tissue was one-fourth of that of compound 9, and compound 13 showed rapid clearance from normal tissues within 24h after injection. The in vivo therapeutic efficacy of PDT using 13 was evaluated by measuring tumor growth rates in tumor-bearing mice with 660 nm light-emitting diode irradiation at 3h after injection of 13. Tumor growth was significantly inhibited by PDT using 13. These results suggested that 13 might be a good candidate for both PDT and BNCT of cancer.

  12. Progress towards boron neutron capture therapy at the High Flux Reactor Petten.

    Science.gov (United States)

    Moss, R L

    1990-01-01

    During 1988 the first positive steps were taken to proceed with the design and construction of a neutron capture therapy facility on the High Flux Reactor (HFR) at Petten. The immediate aim is to realise within a short time (summer 1989), an epithermal neutron beam for radiobiological and filter optimisation studies on one of the 10 small aperture horizontal beam tubes. The following summer, a much larger neutron beam, i.e., in cross section and neutron fluence rate, will be constructed on one of the two large beam tubes that replaced the old thermal column in 1984. This latter beam tube faces one whole side of the reactor vessel, extending from a 50 x 40 cm input aperture to a 35 x 35 cm exit hole. The radiotherapeutic facility will be housed here, with the intention to start clinical trials at the beginning of 1991. This paper describes the present status of the project and includes: a general description of the pertinent characteristics with respect to NCT of the HFR; results of the recently completed preliminary neutron metrology and computer modeling at the input end of the candidate beam tube; the structure and planning of the proposed Work Programme; and the respective direct and indirect participation and collaboration with the Netherlands Cancer Institute and the European Collaboration Group on BNCT.

  13. Optimization of the Epithermal Neutron Beam for Boron Neutron Capture Therapy at the Brookhaven Medical Research Reactor

    Science.gov (United States)

    Hu, Jih-Perng; Rorer, David C.; Reciniello, Richard N.; Holden, Norman E.

    2003-06-01

    Clinical trials of Boron Neutron Capture Therapy for patients with malignant brain tumor had been carried out for half a decade, using an epithermal neutron beam at the Brookhaven Medical Reactor. The decision to permanently close this reactor in 2000 cut short the efforts to implement a new conceptual design to optimize this beam in preparation for use with possible new protocols. Details of the conceptual design to produce a higher intensity, more forward-directed neutron beam with less contamination from gamma rays, fast and thermal neutrons are presented here for their potential applicability to other reactor facilities. Monte Carlo calculations were used to predict the flux and absorbed dose produced by the proposed design. The results were benchmarked by the dose rate and flux measurements taken at the facility then in use.

  14. Optimization of the epithermal neutron beam for Boron Neutron Capture Therapy at the Brookhaven Medical Research Reactor.

    Science.gov (United States)

    Hu, Jih-Perng; Reciniello, Richard N; Holden, Norman E

    2004-05-01

    The use of epithermal neutron beam in clinical trials of Boron Neutron Capture Therapy for patients with malignant brain tumors had been carried out for half a decade at the Brookhaven's Medical Reactor. The decision to permanently close this reactor in 2000 cut short the efforts to implement a new conceptual design to optimize this beam in preparation for use with possible new BNCT protocols. Details of the conceptual design to produce a highly intensified and focused neutron beam with less gamma and neutron contamination in tissues are presented here for their potential applicability to other reactor facilities. Neutron-photon coupled Monte Carlo calculations were used to predict the flux, current, heating, and absorbed dose produced by the proposed design. The results were benchmarked by the dose rate and flux measurements taken at the facility then in use.

  15. Investigation of Dose Distribution in Mixed Neutron-Gamma Field of Boron Neutron Capture Therapy using N-Isopropylacrylamide Gel

    Directory of Open Access Journals (Sweden)

    Elham Bavarnegin

    2017-02-01

    Full Text Available Gel dosimeters have unique advantages in comparison with other dosimeters. Until now, these gels have been used in different radiotherapy techniques as a reliable dosimetric tool. Because dose distribution measurement is an important factor for appropriate treatment planning in different radiotherapy techniques, in this study, we evaluated the ability of the N-isopropylacrylamide (NIPAM polymer gel to record the dose distribution resulting from the mixed neutron-gamma field of boron neutron capture therapy (BNCT. In this regard, a head phantom containing NIPAM gel was irradiated using the Tehran Research Reactor BNCT beam line, and then by a magnetic resonance scanner. Eventually, the R2 maps were obtained in different slices of the phantom by analyzing T2-weighted images. The results show that NIPAM gel has a suitable potential for recording three-dimensional dose distribution in mixed neutron-gamma field dosimetry.

  16. Application of adjoint Monte Carlo to accelerate simulations of mono-directional beams in treatment planning for Boron Neutron Capture Therapy

    NARCIS (Netherlands)

    Nievaart, V.A.; Legrady, D.; Moss, R.L.; Kloosterman, J.L.; Van der Hagen, T.H.; Van Dam, H.

    2007-01-01

    This paper deals with the application of the adjoint transport theory in order to optimize Monte Carlo based radiotherapy treatment planning. The technique is applied to Boron Neutron Capture Therapy where most often mixed beams of neutrons and gammas are involved. In normal forward Monte Carlo simu

  17. Electrostatic design and beam transport for a folded tandem electrostatic quadrupole accelerator facility for accelerator-based boron neutron capture therapy

    Energy Technology Data Exchange (ETDEWEB)

    Thatar Vento, V., E-mail: Vladimir.ThatarVento@gmail.com [Gerencia de Investigacion y Aplicaciones, CNEA, Av. Gral. Paz 1499 (1650), San Martin, Buenos Aires (Argentina)] [CONICET, Av. Rivadavia 1917 (1033), Ciudad Autonoma de Buenos Aires (Argentina); Bergueiro, J.; Cartelli, D. [Gerencia de Investigacion y Aplicaciones, CNEA, Av. Gral. Paz 1499 (1650), San Martin, Buenos Aires (Argentina)] [CONICET, Av. Rivadavia 1917 (1033), Ciudad Autonoma de Buenos Aires (Argentina); Valda, A.A. [Gerencia de Investigacion y Aplicaciones, CNEA, Av. Gral. Paz 1499 (1650), San Martin, Buenos Aires (Argentina)] [Escuela de Ciencia y Tecnologia, UNSAM, M. Irigoyen 3100 (1650), San Martin, Buenos Aires (Argentina); Kreiner, A.J. [Gerencia de Investigacion y Aplicaciones, CNEA, Av. Gral. Paz 1499 (1650), San Martin, Buenos Aires (Argentina)] [CONICET, Av. Rivadavia 1917 (1033), Ciudad Autonoma de Buenos Aires (Argentina)] [Escuela de Ciencia y Tecnologia, UNSAM, M. Irigoyen 3100 (1650), San Martin, Buenos Aires (Argentina)

    2011-12-15

    Within the frame of an ongoing project to develop a folded Tandem-Electrostatic-Quadrupole (TESQ) accelerator facility for Accelerator-Based Boron Neutron Capture Therapy (AB-BNCT), we discuss here the electrostatic design of the machine, including the accelerator tubes with electrostatic quadrupoles and the simulations for the transport and acceleration of a high intensity beam.

  18. Considerations for boron neutron capture therapy studies; Consideracoes sobre o estudo da BNCT (terapia de captura neutronica por boro)

    Energy Technology Data Exchange (ETDEWEB)

    Faria Gaspar, P. de

    1994-12-31

    Radiotherapy is indispensable as a mean to eradicate deeply or infiltrating tumor tissue that can not be removed surgically. Therefore, it is not selective and may also kill the surrounding health tissue. The principle of BNCT (Boron Neutron Capture Therapy) consist in targeting a tumor selectively with a boron-10 compound. This nuclide has a large capture cross section for thermal neutrons and the nuclear reaction and the delivered energy in locus will selective the tumor. Since its initial proposal in 1963 BNCT has made much progress, however it is not used in a routine treatment. In this work it was approached some complex procedures, as the obtention of selective boron compounds, the adequate set up of neutron beams, the biodistribution, the in vivo and in vitro studies, and also human patients treatments. This work provide fundamentals about BNCT to professional of different areas of knowledge since it comprises multidisciplinary study. It includes appendixes for the ones not related to the field for a better comprehension of the many aspects involved. It is also presented a glossary containing technical and basic aspects involved. It is also presented a glossary containing technical and basic terms referred in the work. (author). 174 refs, 1 fig, 12 apps.

  19. From radiation-induced chromosome damage to cell death: modelling basic mechanisms and applications to boron neutron capture therapy.

    Science.gov (United States)

    Ballarini, F; Bortolussi, S; Clerici, A M; Ferrari, C; Protti, N; Altieri, S

    2011-02-01

    Cell death is a crucial endpoint in radiation-induced biological damage: on one side, cell death is a reference endpoint to characterise the action of radiation in biological targets; on the other side, any cancer therapy aims to kill tumour cells. Starting from Lea's target theory, many models have been proposed to interpret radiation-induced cell killing; after briefly discussing some of these models, in this paper, a mechanistic approach based on an experimentally observed link between chromosome aberrations and cell death was presented. More specifically, a model and a Monte Carlo code originally developed for chromosome aberrations were extended to simulate radiation-induced cell death applying an experimentally observed one-to-one relationship between the average number of 'lethal aberrations' (dicentrics, rings and deletions) per cell and -ln S, S being the fraction of surviving cells. Although such observation was related to X rays, in the present work, the approach was also applied to protons and alpha particles. A good agreement between simulation outcomes and literature data provided a model validation for different radiation types. The same approach was then successfully applied to simulate the survival of cells enriched with boron and irradiated with thermal neutrons at the Triga Mark II reactor in Pavia, to mimic a typical treatment for boron neutron capture therapy.

  20. GPU-based prompt gamma ray imaging from boron neutron capture therapy

    Energy Technology Data Exchange (ETDEWEB)

    Yoon, Do-Kun; Jung, Joo-Young; Suh, Tae Suk [College of Medicine, Catholic University of Korea, Seoul (Korea, Republic of)

    2015-05-15

    This reaction can be applied to the therapy and diagnosis about the tumor simultaneously. After the compound labeled with the boron is accumulated at the tumor site, the alpha particle induced by the reaction between the thermal neutron and the boron induces tumor cell death. Also, the 478 keV prompt gamma ray is emitted from the same reaction point. If this single prompt photon is detected by single photon emission computed tomography (SPECT), the tomographic image of the therapy region can be monitored during the radiation treatment. However, in order to confirm the therapy region using the image during the treatment, the image needs to be provided promptly. Due to a relatively long acquisition time required to get SPECT images, both reduced number of projections and the fast image reconstruction schemes are needed to provide the images during radiation treatment. The computation time for image reconstruction using the GPU with the modified OSEM algorithm was measured and compared with the computation time using CPU. Through the results, we confirmed the feasibility of the image reconstruction for prompt gamma ray image using GPU for the BNCT. In the further study, the development of the algorithm for faster reconstruction of the prompt gamma ray image during the BNCT using the GPU computation will be conducted. Also, the analysis of the target to background level about the reconstructed image will be performed using the extracted image profile.

  1. Studies for the application of boron neutron capture therapy to the treatment of differentiated thyroid cancer

    Energy Technology Data Exchange (ETDEWEB)

    Dagrosa, A., E-mail: dagrosa@cnea.gov.ar [Department of Radiobiology, National Atomic Energy Commission (CNEA), Av General Paz 1499, San Martin (1560) (Argentina)] [National Research Council of Argentina (CONICET), Rivadavia 1917, (1033) Buenos Aires (Argentina); Carpano, M. [Department of Radiobiology, National Atomic Energy Commission (CNEA), Av General Paz 1499, San Martin (1560) (Argentina); Perona, M. [Department of Radiobiology, National Atomic Energy Commission (CNEA), Av General Paz 1499, San Martin (1560) (Argentina)] [National Research Council of Argentina (CONICET), Rivadavia 1917, (1033) Buenos Aires (Argentina); Thomasz, L. [Department of Radiobiology, National Atomic Energy Commission (CNEA), Av General Paz 1499, San Martin (1560) (Argentina); Nievas, S. [Department of Chemistry, National Atomic Energy Commission (CNEA), Av General Paz 1499, San Martin (1560) (Argentina); Cabrini, R. [Department of Radiobiology, National Atomic Energy Commission (CNEA), Av General Paz 1499, San Martin (1560) (Argentina); Juvenal, G. [Department of Radiobiology, National Atomic Energy Commission (CNEA), Av General Paz 1499, San Martin (1560) (Argentina)] [National Research Council of Argentina (CONICET), Rivadavia 1917, (1033) Buenos Aires (Argentina); Pisarev, M. [Department of Radiobiology, National Atomic Energy Commission (CNEA), Av General Paz 1499, San Martin (1560) (Argentina)] [National Research Council of Argentina (CONICET), Rivadavia 1917, (1033) Buenos Aires (Argentina)] [Department of Biochemistry, UBA School of Medicine (Argentina)

    2011-12-15

    The aim of these studies was to evaluate the possibility of treating differentiated thyroid cancer by BNCT. These carcinomas are well controlled with surgery followed by therapy with {sup 131}I; however, some patients do not respond to this treatment. BPA uptake was analyzed both in vitro and in nude mice implanted with cell lines of differentiated thyroid carcinoma. The boron intracellular concentration in the different cell lines and the biodistribution studies showed the selectivity of the BPA uptake by this kind of tumor.

  2. In Vivo Boron Uptake Determination for Boron Neutron Capture Synovectomy

    Energy Technology Data Exchange (ETDEWEB)

    Binello, Emanuela; Shortkroff, Sonya; Yanch, Jacquelyn C.

    1999-06-06

    Boron neutron capture synovectomy (BNCS) has been proposed as a new application of the boron neutron capture reaction for the treatment of rheumatoid arthritis. In BNCS, a boron compound is injected into the joint space, where it is taken up by the synovium. The joint is then irradiated with neutrons of a desired energy range, inducing the boron neutron capture reaction in boron-loaded cells. Boron uptake by the synovium is an important parameter in the assessment of the potential of BNCS and in the determination of whether to proceed to animal irradiations for the testing of therapeutic efficacy. We present results from an investigation of boron uptake in vivo by the synovium.

  3. Synthesis, characterization and biological evaluation of carboranylmethylbenzo[b]acridones as novel agents for boron neutron capture therapy.

    Science.gov (United States)

    da Silva, A Filipa F; Seixas, Raquel S G R; Silva, Artur M S; Coimbra, Joana; Fernandes, Ana C; Santos, Joana P; Matos, António; Rino, José; Santos, Isabel; Marques, Fernanda

    2014-07-28

    Herein we present the synthesis and characterization of benzo[b]acridin-12(7H)-ones bearing carboranyl moieties and test their biological effectiveness as boron neutron capture therapy (BNCT) agents in cancer treatment. The cellular uptake of these novel compounds into the U87 human glioblastoma cells was evaluated by boron analysis (ICP-MS) and by fluorescence imaging (confocal microscopy). The compounds enter the U87 cells exhibiting a similar profile, i.e., preferential accumulation in the cytoskeleton and membranes and a low cytotoxic activity (IC50 values higher than 200 μM). The cytotoxic activity and cellular morphological alterations after neutron irradiation in the Portuguese Research Reactor (6.6 × 10(7) neutrons cm(-2) s(-1), 1 MW) were evaluated by the MTT assay and by electron microscopy (TEM). Post-neutron irradiation revealed that BNCT has a higher cytotoxic effect on the cells. Accumulation of membranous whorls in the cytoplasm of cells treated with one of the compounds correlates well with the cytotoxic effect induced by radiation. Results provide a strong rationale for considering one of these compounds as a lead candidate for a new generation of BNCT agents.

  4. Current status of boron neutron capture therapy of high grade gliomas and recurrent head and neck cancer

    Science.gov (United States)

    2012-01-01

    Boron neutron capture therapy (BNCT) is a biochemically targeted radiotherapy based on the nuclear capture and fission reactions that occur when non-radioactive boron-10, which is a constituent of natural elemental boron, is irradiated with low energy thermal neutrons to yield high linear energy transfer alpha particles and recoiling lithium-7 nuclei. Clinical interest in BNCT has focused primarily on the treatment of high grade gliomas, recurrent cancers of the head and neck region and either primary or metastatic melanoma. Neutron sources for BNCT currently have been limited to specially modified nuclear reactors, which are or until the recent Japanese natural disaster, were available in Japan, the United States, Finland and several other European countries, Argentina and Taiwan. Accelerators producing epithermal neutron beams also could be used for BNCT and these are being developed in several countries. It is anticipated that the first Japanese accelerator will be available for therapeutic use in 2013. The major hurdle for the design and synthesis of boron delivery agents has been the requirement for selective tumor targeting to achieve boron concentrations in the range of 20 μg/g. This would be sufficient to deliver therapeutic doses of radiation with minimal normal tissue toxicity. Two boron drugs have been used clinically, a dihydroxyboryl derivative of phenylalanine, referred to as boronophenylalanine or “BPA”, and sodium borocaptate or “BSH” (Na2B12H11SH). In this report we will provide an overview of other boron delivery agents that currently are under evaluation, neutron sources in use or under development for BNCT, clinical dosimetry, treatment planning, and finally a summary of previous and on-going clinical studies for high grade gliomas and recurrent tumors of the head and neck region. Promising results have been obtained with both groups of patients but these outcomes must be more rigorously evaluated in larger, possibly randomized

  5. Current status of boron neutron capture therapy of high grade gliomas and recurrent head and neck cancer.

    Science.gov (United States)

    Barth, Rolf F; Vicente, M Graca H; Harling, Otto K; Kiger, W S; Riley, Kent J; Binns, Peter J; Wagner, Franz M; Suzuki, Minoru; Aihara, Teruhito; Kato, Itsuro; Kawabata, Shinji

    2012-08-29

    Boron neutron capture therapy (BNCT) is a biochemically targeted radiotherapy based on the nuclear capture and fission reactions that occur when non-radioactive boron-10, which is a constituent of natural elemental boron, is irradiated with low energy thermal neutrons to yield high linear energy transfer alpha particles and recoiling lithium-7 nuclei. Clinical interest in BNCT has focused primarily on the treatment of high grade gliomas, recurrent cancers of the head and neck region and either primary or metastatic melanoma. Neutron sources for BNCT currently have been limited to specially modified nuclear reactors, which are or until the recent Japanese natural disaster, were available in Japan, United States, Finland and several other European countries, Argentina and Taiwan. Accelerators producing epithermal neutron beams also could be used for BNCT and these are being developed in several countries. It is anticipated that the first Japanese accelerator will be available for therapeutic use in 2013. The major hurdle for the design and synthesis of boron delivery agents has been the requirement for selective tumor targeting to achieve boron concentrations in the range of 20 μg/g. This would be sufficient to deliver therapeutic doses of radiation with minimal normal tissue toxicity. Two boron drugs have been used clinically, a dihydroxyboryl derivative of phenylalanine, referred to as boronophenylalanine or "BPA", and sodium borocaptate or "BSH" (Na2B12H11SH). In this report we will provide an overview of other boron delivery agents that currently are under evaluation, neutron sources in use or under development for BNCT, clinical dosimetry, treatment planning, and finally a summary of previous and on-going clinical studies for high grade gliomas and recurrent tumors of the head and neck region. Promising results have been obtained with both groups of patients but these outcomes must be more rigorously evaluated in larger, possibly randomized clinical trials

  6. Current status of boron neutron capture therapy of high grade gliomas and recurrent head and neck cancer

    Directory of Open Access Journals (Sweden)

    Barth Rolf F

    2012-08-01

    Full Text Available Abstract Boron neutron capture therapy (BNCT is a biochemically targeted radiotherapy based on the nuclear capture and fission reactions that occur when non-radioactive boron-10, which is a constituent of natural elemental boron, is irradiated with low energy thermal neutrons to yield high linear energy transfer alpha particles and recoiling lithium-7 nuclei. Clinical interest in BNCT has focused primarily on the treatment of high grade gliomas, recurrent cancers of the head and neck region and either primary or metastatic melanoma. Neutron sources for BNCT currently have been limited to specially modified nuclear reactors, which are or until the recent Japanese natural disaster, were available in Japan, United States, Finland and several other European countries, Argentina and Taiwan. Accelerators producing epithermal neutron beams also could be used for BNCT and these are being developed in several countries. It is anticipated that the first Japanese accelerator will be available for therapeutic use in 2013. The major hurdle for the design and synthesis of boron delivery agents has been the requirement for selective tumor targeting to achieve boron concentrations in the range of 20 μg/g. This would be sufficient to deliver therapeutic doses of radiation with minimal normal tissue toxicity. Two boron drugs have been used clinically, a dihydroxyboryl derivative of phenylalanine, referred to as boronophenylalanine or “BPA”, and sodium borocaptate or “BSH” (Na2B12H11SH. In this report we will provide an overview of other boron delivery agents that currently are under evaluation, neutron sources in use or under development for BNCT, clinical dosimetry, treatment planning, and finally a summary of previous and on-going clinical studies for high grade gliomas and recurrent tumors of the head and neck region. Promising results have been obtained with both groups of patients but these outcomes must be more rigorously evaluated in larger

  7. Neutron spectrum for neutron capture therapy in boron; Espectro de neutrones para terapia por captura de neutrones en boro

    Energy Technology Data Exchange (ETDEWEB)

    Medina C, D.; Soto B, T. G. [Universidad Autonoma de Zacatecas, Unidad Academica de Estudios Nucleares, Programa de Doctorado en Ciencias Basicas, 98068 Zacatecas, Zac. (Mexico); Baltazar R, A. [Universidad Autonoma de Zacatecas, Unidad Academica de Ingenieria Electrica, Programa de Doctorado en Ingenieria y Tecnologia Aplicada, 98068 Zacatecas, Zac. (Mexico); Vega C, H. R., E-mail: dmedina_c@hotmail.com [Universidad Autonoma de Zacatecas, Unidad Academica de Estudios Nucleares, Cipres No. 10, Fracc. La Penuela, 98068 Zacatecas, Zac. (Mexico)

    2016-10-15

    Glioblastoma multiforme is the most common and aggressive of brain tumors and is difficult to treat by surgery, chemotherapy or conventional radiation therapy. One treatment alternative is the Neutron Capture Therapy in Boron, which requires a beam modulated in neutron energy and a drug with {sup 10}B able to be fixed in the tumor. When the patients head is exposed to the neutron beam, they are captured by the {sup 10}B and produce a nucleus of {sup 7}Li and an alpha particle whose energy is deposited in the cancer cells causing it to be destroyed without damaging the normal tissue. One of the problems associated with this therapy is to have an epithermal neutrons flux of the order of 10{sup 9} n/cm{sup 2}-sec, whereby irradiation channels of a nuclear research reactor are used. In this work using Monte Carlo methods, the neutron spectra obtained in the radial irradiation channel of the TRIGA Mark III reactor are calculated when inserting filters whose position and thickness have been modified. From the arrangements studied, we found that the Fe-Cd-Al-Cd polyethylene filter yielded a ratio between thermal and epithermal neutron fluxes of 0.006 that exceeded the recommended value (<0.05), and the dose due to the capture gamma rays is lower than the dose obtained with the other arrangements studied. (Author)

  8. Boronated unnatural cyclic amino acids as potential delivery agents for neutron capture therapy

    Energy Technology Data Exchange (ETDEWEB)

    Kabalka, George W.; Shaikh, Aarif L. [Departments of Radiology and Chemistry, University of Tennessee, Knoxville, TN (United States); Barth, Rolf F.; Huo Tianyao; Yang Weilian [Department of Pathology, Ohio State University, Columbus, OH (United States); Gordnier, Pamela M. [Department of Biomedical Engineering and Cornell SIMS Laboratory, Cornell University, Ithaca, NY (United States); Chandra, Subhash, E-mail: sc40@cornell.edu [Department of Biomedical Engineering and Cornell SIMS Laboratory, Cornell University, Ithaca, NY (United States)

    2011-12-15

    Boron delivery characteristics of cis and trans isomers of a boronated unnatural amino acid, 1-amino-3-boronocyclopentanecarboxylic acid (ABCPC) were tested in the B16 mouse model for human melanoma. Both ABCPC isomers delivered comparable boron to B16 melanoma tumor cells as L-p-boronophenylalanine (BPA). Secondary ion mass spectrometry (SIMS) analysis revealed the presence of boron throughout the tumor from these compounds, and a near homogeneous distribution between the nucleus and cytoplasm of B16 cells grown in vitro. These encouraging observations support further studies of these new boron carriers in BNCT.

  9. Optimization of the geometry and composition of a neutron system for treatment by Boron Neutron Capture Therapy

    Directory of Open Access Journals (Sweden)

    Rohollah Gheisari

    2015-01-01

    Full Text Available Background: In the field of the treatment by Boron Neutron Capture Therapy (BNCT, an optimized neutron system was proposed. This study (simulation was conducted to optimize the geometry and composition of neutron system and increase the epithermal neutron flux for the treatment of deep tumors is performed. Materials and Methods: A neutron system for BNCT was proposed. The system included 252Cf neutron source, neutron moderator/reflector arrangement, filter and concrete. To capture fast neutrons, different neutron filters Fe, Pb, Ni and PbF2 with various thicknesses were simulated and studied. Li (with 1 mm thick was used for filtering of thermal neutrons. Bi with thickness of 1 cm was used to minimize the intensity of gamma rays. Monte Carlo simulation code MCNPX 2.4.0 was used for design of the neutron system and calculation of the neutron components at the output port of the system. Results: For different thicknesses of the filters, the fast neutron flux, the epithermal and thermal flux were calculated at the output port of the system. The spatial distribution of the fast neutron flux, the epithermal flux and gamma flux in human head phantom with the presence of 40 ppm of 10B were obtained. The present calculations showed that Pb filter (about 1 cm at the output port is suitable for fast neutron capture. The thickness of Li filter was determined due to its high absorption cross-section in thermal region. Bi was used as a gamma filter by the reason of it is good for shielding gamma rays, while having high transmission epithermal neutrons. Conclusion: The epithermal neutron flux has enhanced about 38 percent at the output port of the present system, compared with recent system proposed by Ghassoun et al. At 2 cm depth inside the head phantom, the neutron flux reaches a maximum value about . At this depth, the ratio of the thermal neutron flux to the epithermal flux is about three times, that suggests such a neutron system to treat tumors in the

  10. Folate receptor-mediated boron-10 containing carbon nanoparticles as potential delivery vehicles for boron neutron capture therapy of nonfunctional pituitary adenomas.

    Science.gov (United States)

    Dai, Congxin; Cai, Feng; Hwang, Kuo Chu; Zhou, Yongmao; Zhang, Zizhu; Liu, Xiaohai; Ma, Sihai; Yang, Yakun; Yao, Yong; Feng, Ming; Bao, Xinjie; Li, Guilin; Wei, Junji; Jiao, Yonghui; Wei, Zhenqing; Ma, Wenbin; Wang, Renzhi

    2013-02-01

    Invasive nonfunctional pituitary adenomas (NFPAs) are difficult to completely resect and often develop tumor recurrence after initial surgery. Currently, no medications are clinically effective in the control of NFPA. Although radiation therapy and radiosurgery are useful to prevent tumor regrowth, they are frequently withheld because of severe complications. Boron neutron capture therapy (BNCT) is a binary radiotherapy that selectively and maximally damages tumor cells without harming the surrounding normal tissue. Folate receptor (FR)-targeted boron-10 containing carbon nanoparticles is a novel boron delivery agent that can be selectively taken up by FR-expressing cells via FR-mediated endocytosis. In this study, FR-targeted boron-10 containing carbon nanoparticles were selectively taken up by NFPAs cells expressing FR but not other types of non-FR expressing pituitary adenomas. After incubation with boron-10 containing carbon nanoparticles and following irradiation with thermal neutrons, the cell viability of NFPAs was significantly decreased, while apoptotic cells were simultaneously increased. However, cells administered the same dose of FR-targeted boron-10 containing carbon nanoparticles without neutron irradiation or received the same neutron irradiation alone did not show significant decrease in cell viability or increase in apoptotic cells. The expression of Bcl-2 was down-regulated and the expression of Bax was up-regulated in NFPAs after treatment with FR-mediated BNCT. In conclusion, FR-targeted boron-10 containing carbon nanoparticles may be an ideal delivery system of boron to NFPAs cells for BNCT. Furthermore, our study also provides a novel insight into therapeutic strategies for invasive NFPA refractory to conventional therapy, while exploring these new applications of BNCT for tumors, especially benign tumors.

  11. Designing an epithermal neutron beam for boron neutron capture therapy for a DIDO type reactor using MCNP

    Science.gov (United States)

    Ross, D.; Constantine, G.; Weaver, D. R.; Beynon, T. D.

    1993-10-01

    This paper describes work undertaken to design an epithermal neutron beam for a DIDO type reactor for use in boron neutron capture therapy, a form of cancer treatment. It involved extensive use of MCNP, a Monte Carlo computer code. Initially, calculations were made with MCNP to simulate earlier experiments with an epithermal beam on the DIDO reactor. This comparison made it possible both to validate the Monte Carlo modelling of the reactor and to gain an insight into the important features of the simulation. Following this, MCNP was used to design a filtered epithermal neutron beam facility for DIDO's largest beam tube, a 13.7 cm radius horizontal tube which extends radially away from the core. First a selection was made of the optimum filter components for the beam. Then the research concentrated on combining these filter elements to construct a practical epithermal beam design. The results suggest that the optimum method of generating the epithermal neutron source is to employ a filter combination consisting principally of liquid argon with the addition of cadmium, aluminium, titanium and possibly tin. The calculations also show that the resultant neutron beam would have a flux greater than 1.0 × 10 9 n cm -2 s -1 and have sufficiently low fast-neutron and gamma-ray contamination.

  12. In-phantom two-dimensional thermal neutron distribution for intraoperative boron neutron capture therapy of brain tumours

    Science.gov (United States)

    Yamamoto, T.; Matsumura, A.; Yamamoto, K.; Kumada, H.; Shibata, Y.; Nose, T.

    2002-07-01

    The aim of this study was to determine the in-phantom thermal neutron distribution derived from neutron beams for intraoperative boron neutron capture therapy (IOBNCT). Gold activation wires arranged in a cylindrical water phantom with (void-in-phantom) or without (standard phantom) a cylinder styrene form placed inside were irradiated by using the epithermal beam (ENB) and the mixed thermal-epithermal beam (TNB-1) at the Japan Research Reactor No 4. With ENB, we observed a flattened distribution of thermal neutron flux and a significantly enhanced thermal flux delivery at a depth compared with the results of using TNB-1. The thermal neutron distribution derived from both the ENB and TNB-1 was significantly improved in the void-in-phantom, and a double high dose area was formed lateral to the void. The flattened distribution in the circumference of the void was observed with the combination of ENB and the void-in-phantom. The measurement data suggest that the ENB may provide a clinical advantage in the form of an enhanced and flattened dose delivery to the marginal tissue of a post-operative cavity in which a residual and/or microscopically infiltrating tumour often occurs. The combination of the epithermal neutron beam and IOBNCT will improve the clinical results of BNCT for brain tumours.

  13. Boron neutron capture therapy design calculation of a 3H(p,n reaction based BSA for brain cancer setup

    Directory of Open Access Journals (Sweden)

    Bassem Elshahat

    2015-09-01

    Full Text Available Purpose: Boron neutron capture therapy (BNCT is a promising technique for the treatment of malignant disease targeting organs of the human body. Monte Carlo simulations were carried out to calculate optimum design parameters of an accelerator based beam shaping assembly (BSA for BNCT of brain cancer setup.Methods: Epithermal beam of neutrons were obtained through moderation of fast neutrons from 3H(p,n reaction in a high density polyethylene moderator and a graphite reflector. The dimensions of the moderator and the reflector were optimized through optimization of epithermal / fast neutron intensity ratio as a function of geometric parameters of the setup. Results: The results of our calculation showed the capability of our setup to treat the tumor within 4 cm of the head surface. The calculated peak therapeutic ratio for the setup was found to be 2.15. Conclusion: With further improvement in the polyethylene moderator design and brain phantom irradiation arrangement, the setup capabilities can be improved to reach further deep-seated tumor.

  14. User's manual of a supporting system for treatment planning in boron neutron capture therapy. JAERI computational dosimetry system

    CERN Document Server

    Kumada, H

    2002-01-01

    A boron neutron capture therapy (BNCT) with epithermal neutron beam is expected to treat effectively for malignant tumor that is located deeply in the brain. It is indispensable to estimate preliminarily the irradiation dose in the brain of a patient in order to perform the epithermal neutron beam BNCT. Thus, the JAERI Computational Dosimetry System (JCDS), which can calculate the dose distributions in the brain, has been developed. JCDS is a software that creates a 3-dimensional head model of a patient by using CT and MRI images and that generates a input data file automatically for calculation neutron flux and gamma-ray dose distribution in the brain by the Monte Carlo code: MCNP, and that displays the dose distribution on the head model for dosimetry by using the MCNP calculation results. JCDS has any advantages as follows; By treating CT data and MRI data which are medical images, a detail three-dimensional model of patient's head is able to be made easily. The three-dimensional head image is editable to ...

  15. Boronated monoclonal antibodies for potential neutron capture therapy of malignant melanoma and leukaemia

    Energy Technology Data Exchange (ETDEWEB)

    Tamat, S.R.; Patwardhan, A.; Moore, D.E.; Kabral, A.; Bradstock, K.; Hersey, P.; Allen, B.J.

    The authors report a preparation and characterisation of boronated melanoma and leukaemia antibodies and the separation from native antibody by anion exchange liquid chromatography. Two types of biodistribution experiments were performed with the boronated melanoma antibody 225.28S using Balb/c derived nude mice in which melanoma tumours had been raised in the thigh by subcutaneous injection of a human malignant melanoma cell line, designated CMC. From these experiments, one may conclude that the boronated antibody has the ability to localise in the melanoma following systemic injection, but more efficient use of the preparation is achieved with perilesional administration.

  16. Experimental evaluation of boron neutron capture therapy of human breast carcinoma implanted on nude mice

    Science.gov (United States)

    Bose, Satya Ranjan

    2000-06-01

    An in-pool small animal irradiation neutron tube (SAINT) facility was designed, constructed and installed at the University of Virginia Nuclear Research Reactor (UVAR). Thermal neutron flux profiles were measured by foil activation analysis (gold) and verified with DORT and MCNP computer code models. The gamma-ray absorbed dose in the neutron-gamma mixed field was determined from TLD measurements. The SAINT thermal neutron flux was used to investigate the well characterized human breast cancer cell line MCF-7B on both in-vitro samples and in- vivo animal subjects. Boronophenylalanine (BPA enriched in 95% 10B) was used as a neutron capturing agent. The in-vitro response of MCF-7B human breast carcinoma cells to BPA in a mixed field of neutron-gamma radiation or pure 60Co gamma radiation was investigated. The best result (lowest surviving fraction) was observed in cell cultures pre-incubated with BPA and given the neutron irradiation. The least effective treatment consisted of 60Co irradiation only. Immunologically deficient nude mice were inoculated subcutaneously with human breast cancer MCF-7B cells and estradiol pellets (to support tumor growth). The tumor volume in the mouse control group increased over time, as expected. The group of mice exposed only to neutron treatment exhibited initial tumor volume reduction lasting until 35 days following the treatment, followed by renewed tumor growth. Both groups given BPA plus neutron treatment showed continuous reduction in tumor volume over the 55-day observation period. The group given the higher BPA concentration showed the best tumor reduction response. The results on both in-vitro and in-vivo studies showed increased cell killing with BPA, substantiating the incorporation of BPA into the tumor or cell line. Therefore, BNCT may be a possible choice for the treatment of human breast carcinoma. However, prior to the initiation of any clinical studies, it is necessary to determine the therapeutic efficacy in a large

  17. Synthesis and evaluation of boron compounds for neutron capture therapy of malignant brain tumors

    Energy Technology Data Exchange (ETDEWEB)

    Soloway, A.H.

    1991-01-01

    Current progress on this research includes the synthesis of chemical structures for malignant brain tumors. These structures include boron-containing derivatives of lipophilic anticonvulsants and CNS depressants; carboranyl precursors of nucleic acids and related structures; and carboranyl amino acids. Cellular uptake and persistence studies have also been carried out with F98 rat glioma cells. 1 fig., 1 tab.

  18. Preliminary study of MAGAT polymer gel dosimetry for boron-neutron capture therapy

    Science.gov (United States)

    Hayashi, Shin-ichiro; Sakurai, Yoshinori; Uchida, Ryohei; Suzuki, Minoru; Usui, Shuji; Tominaga, Takahiro

    2015-01-01

    MAGAT gel dosimeter with boron is irradiated in Heavy Water Neutron Irradiation Facility (HWNIF) of Kyoto University Research Reactor (KUR). The cylindrical gel phantoms are exposed to neutron beams of three different energy spectra (thermal neutron rich, epithermal and fast neutron rich and the mixed modes) in air. Preliminary results corresponding to depth-dose responses are obtained as the transverse relaxation rate (R2=1/T2) from magnetic resonance imaging data. As the results MAGAT gel dosimeter has the higher sensitivity on thermal neutron than on epi-thermal and fast neutron, and the gel with boron showed an enhancement and a change in the depth-R2 response explicitly. From these results, it is suggested that MAGAT gel dosimeter can be an effective tool in BNCT dosimetry.

  19. Boron neutron capture therapy for glioblastoma multiforme using p-boronophenylalanine and epithermal neutrons: trial design and early clinical results.

    Science.gov (United States)

    Coderre, J A; Elowitz, E H; Chadha, M; Bergland, R; Capala, J; Joel, D D; Liu, H B; Slatkin, D N; Chanana, A D

    1997-05-01

    A Phase I/II clinical trial of boron neutron capture therapy (BNCT) for glioblastoma multiforme is underway using the amino acid analog p-boronophenylalanine (BPA) and the epithermal neutron beam at the Brook-haven Medical Research Reactor. Biodistribution studies were carried out in 18 patients at the time of craniotomy using an i.v. infusion of BPA, solubilized as a fructose complex (BPA-F). There were no toxic effects related to the BPA-F administration at doses of 130, 170, 210, or 250 mg BPA/kg body weight. The tumor/ blood, brain/blood and scalp/blood boron concentration ratios were approximately 3.5:1, 1:1 and 1.5:1, respectively. Ten patients have received BNCT following 2-hr infusions of 250 mg BPA/kg body weight. The average boron concentration in the blood during the irradiation was 13.0 +/- 1.5 micrograms 10B/g. The prescribed maximum dose to normal brain (1 cm3 volume) was 10.5 photon-equivalent Gy (Gy-Eq). Estimated maximum and minimum doses (mean +/- sd, n = 10) to the tumor volume were 52.6 +/- 4.9 Gy-Eq (range: 64.4-47.6) and 25.2 +/- 4.2 Gy-Eq (range: 32.3-20.0), respectively). The estimated minimum dose to the target volume (tumor +2 cm margin) was 12.3 +/- 2.7 Gy-Eq (range: 16.2-7.8). There were no adverse effects on normal brain. The scalp showed mild erythema, followed by epilation in the 8 cm diameter field. Four patients developed recurrent tumor, apparently in the lower dose (deeper) regions of the target volume, at post-BNCT intervals of 7,5,3.5 and 3 months, respectively. The remaining patients have had less than 4 months of post-BNCT follow-up. BNCT, at this starting dose level, appears safe. Plans are underway to begin the dose escalation phase of this protocol.

  20. Boron neutron capture therapy (BNCT) for the treatment of spontaneous nasal planum squamous cell carcinoma in felines.

    Science.gov (United States)

    Trivillin, Verónica A; Heber, Elisa M; Rao, Monica; Cantarelli, María A; Itoiz, Maria E; Nigg, David W; Calzetta, Osvaldo; Blaumann, Herman; Longhino, Juan; Schwint, Amanda E

    2008-02-01

    Recently, Boron neutron capture therapy (BNCT) was successfully applied to treat experimental squamous cell carcinomas (SCC) of the hamster cheek pouch mucosa, with no damage to normal tissue. It was also shown that treating spontaneous nasal planum SCC in terminal feline patients with low dose BNCT is safe and feasible. In an extension of this work, the present study aimed at evaluation of the response of tumor and dose-limiting normal tissues to potentially therapeutic BNCT doses. Biodistribution studies with (10)B-boronophenylalanine (BPA enriched in (10)B) as a (10)B carrier were performed on three felines that showed advanced nasal planum SCC without any standard therapeutic option. Following the biodistribution studies, BNCT mediated by (10)BPA was done using the thermalized epithermal neutron beam at the RA-6 Nuclear Reactor. Follow-up included clinical evaluation, assessment of macroscopic tumor and normal tissue response and biopsies for histopathological analysis. The treated animals did not show any apparent radiation-induced toxicity. All three animals exhibited partial tumor control and an improvement in clinical condition. Enhanced therapeutic efficacy was associated with a high (10)B content of the tumor and a small tumor size. BNCT is therefore believed to be potentially effective in the treatment of spontaneous SCC. However, improvement in targeting (10)B into all tumor cells and delivering a sufficient dose at a greater depth are still required for the treatment of deep-seated, large tumors. Future studies are needed to evaluate the potential efficacy of the dual mode cellular (e.g. BPA-BNCT) and vascular (e.g. GB-10-BNCT) targeting protocol in a preclinical scenario, employing combinations of (10)B compounds with different properties and complementary uptake mechanisms.

  1. Characteristics comparison between a cyclotron-based neutron source and KUR-HWNIF for boron neutron capture therapy

    Science.gov (United States)

    Tanaka, H.; Sakurai, Y.; Suzuki, M.; Masunaga, S.; Kinashi, Y.; Kashino, G.; Liu, Y.; Mitsumoto, T.; Yajima, S.; Tsutsui, H.; Maruhashi, A.; Ono, K.

    2009-06-01

    At Kyoto University Research Reactor Institute (KURRI), 275 clinical trials of boron neutron capture therapy (BNCT) have been performed as of March 2006, and the effectiveness of BNCT has been revealed. In order to further develop BNCT, it is desirable to supply accelerator-based epithermal-neutron sources that can be installed near the hospital. We proposed the method of filtering and moderating fast neutrons, which are emitted from the reaction between a beryllium target and 30-MeV protons accelerated by a cyclotron accelerator, using an optimum moderator system composed of iron, lead, aluminum and calcium fluoride. At present, an epithermal-neutron source is under construction from June 2008. This system consists of a cyclotron accelerator, beam transport system, neutron-yielding target, filter, moderator and irradiation bed. In this article, an overview of this system and the properties of the treatment neutron beam optimized by the MCNPX Monte Carlo neutron transport code are presented. The distribution of biological effect weighted dose in a head phantom compared with that of Kyoto University Research Reactor (KUR) is shown. It is confirmed that for the accelerator, the biological effect weighted dose for a deeply situated tumor in the phantom is 18% larger than that for KUR, when the limit dose of the normal brain is 10 Gy-eq. The therapeutic time of the cyclotron-based neutron sources are nearly one-quarter of that of KUR. The cyclotron-based epithermal-neutron source is a promising alternative to reactor-based neutron sources for treatments by BNCT.

  2. Role of p53 mutation in the effect of boron neutron capture therapy on oral squamous cell carcinoma

    Directory of Open Access Journals (Sweden)

    Ohnishi Ken

    2009-12-01

    Full Text Available Abstract Background Boron neutron capture therapy (BNCT is a selective radiotherapy, being effective for the treatment of even advanced malignancies in head and neck regions as well as brain tumors and skin melanomas. To clarify the role of p53 gene, the effect of BNCT on oral squamous cell carcinoma (SCC cells showing either wild- (SAS/neo or mutant-type (SAS/mp53 p53 was examined. Methods Cells were exposed to neutron beams in the presence of boronophenylalanine (BPA at Kyoto University Research Reactor. Treated cells were monitored for modulations in colony formation, proliferation, cell cycle, and expression of cell cycle-associated proteins. Results When SAS/neo and SAS/mp53 cells were subjected to BNCT, more suppressive effects on colony formation and cell viability were observed in SAS/neo compared with SAS/mp53 cells. Cell cycle arrest at the G1 checkpoint was observed in SAS/neo, but not in SAS/mp53. Apoptotic cells increased from 6 h after BNCT in SAS/neo and 48 h in SAS/mp53 cells. The expression of p21 was induced in SAS/neo only, but G2 arrest-associated proteins including Wee1, cdc2, and cyclin B1 were altered in both cell lines. Conclusion These results indicate that oral SCC cells with mutant-type are more resistant to BNCT than those with wild-type p53, and that the lack of G1 arrest and related apoptosis may contribute to the resistance. At a physical dose affecting the cell cycle, BNCT inhibits oral SCC cells in p53-dependent and -independent manners.

  3. NOTE: Computational study of the required dimensions for standard sized phantoms in boron neutron capture therapy dosimetry

    Science.gov (United States)

    Koivunoro, H.; Auterinen, I.; Kosunen, A.; Kotiluoto, P.; Seppälä, T.; Savolainen, S.

    2003-11-01

    The minimum size of a water phantom used for calibration of an epithermal neutron beam of the boron neutron capture therapy (BNCT) facility at the VTT FiR 1 research reactor is studied by Monte Carlo simulations. The criteria for the size of the phantom were established relative to the neutron and photon radiation fields present at the thermal neutron fluence maximum in the central beam axis (considered as the reference point). At the reference point, for the most commonly used beam aperture size at FiR 1 (14 cm diameter), less than 1% disturbance of the neutron and gamma radiation fields in a phantom were achieved with a minimum a 30 cm × 30 cm cross section of the phantom. For the largest 20 cm diameter beam aperture size, a minimum 40 cm × 40 cm cross-section of the phantom and depth of 20 cm was required to achieve undisturbed radiation field. This size can be considered as the minimum requirement for a reference phantom for dosimetry at FiR 1. The secondary objective was to determine the phantom dimensions for full characterization of the FiR 1 beam in a rectangular water phantom. In the water scanning phantom, isodoses down to the 5% level are measured for the verifications of the beam model in the dosimetric and treatment planning calculations. The dose distribution results without effects caused by the limited phantom size were achieved for the maximum aperture diameter (20 cm) with a 56 cm × 56 cm × 28 cm rectangular phantom. A similar approach to study the required minimum dimensions of the reference and water scanning phantoms can be used for epithermal neutron beams at the other BNCT facilities.

  4. Boron Neutron Capture Therapy at the TRIGA Mark II of Pavia, Italy - The BNCT of the diffuse tumours

    Energy Technology Data Exchange (ETDEWEB)

    Altieri, S.; Bortolussi, S.; Stella, S.; Bruschi, P.; Gadan, M.A. [University of Pavia (Italy); INFN - National Institute for Nuclear Physics, of Pavia (Italy)

    2008-10-29

    The selectivity based on the B distribution rather than on the irradiation field makes Boron neutron Capture Therapy (BNCT) a valid option for the treatment of the disseminated tumours. As the range of the high LET particles is shorter than a cell diameter, the normal cells around the tumour are not damaged by the reactions occurring in the tumoral cells. PAVIA 2001: first treatment of multiple hepatic metastases from colon ca by BNCT and auto-transplantation technique: TAOrMINA project. The liver was extracted after BPA infusion, irradiated in the Thermal Column of the Pavia TRIGA Mark II reactor, and re-implanted in the patient. Two patients were treated, demonstrating the feasibility of the therapy and the efficacy in destroying the tumoral nodules sparing the healthy tissues. In the last years, the possibility of applying BNCT to the lung tumours using epithermal collimated neutron beams and without explanting the organ, is being explored. The principal obtained results of the BNCT research are presented, with particular emphasis on the following aspects: a) the project of a new thermal column configuration to make the thermal neutron flux more uniform inside the explanted liver, b) the Monte Carlo study by means of the MCNP code of the thermal neutron flux distribution inside a patient's thorax irradiated with epithermal neutrons, and c) the measurement of the boron concentration in tissues by (n,{alpha}) spectroscopy and neutron autoradiography. The dose distribution in the thorax are simulated using MCNP and the anthropomorphic model ADAM. To have a good thermal flux distribution inside the lung epithermal neutrons must be used, which thermalize crossing the first tissue layers. Thermal neutrons do not penetrate and the obtained uniformity is poor. In the future, the construction of a PGNAA facility using a horizontal channel of the TRIGA Mark II is planned. With this method the B concentration can be measured also in liquid samples (blood, urine) and

  5. Design of multidirectional neutron beams for boron neutron capture synovectomy

    Energy Technology Data Exchange (ETDEWEB)

    Gierga, D.P.; Yanch, J.C. [Massachusetts Institute of Technology, Cambridge, MA (United States); Shefer, R.E. [Newton Scientific, Inc., Cambridge, MA (United States)

    1997-12-01

    Boron neutron capture synovectomy (BNCS) is a potential application of the {sup 10}B(n, a) {sup 7}Li reaction for the treatment of rheumatoid arthritis. The target of therapy is the synovial membrane. Rheumatoid synovium is greatly inflamed and is the source of the discomfort and disability associated with the disease. The BNCS proposes to destroy the synovium by first injecting a boron-labeled compound into the joint space and then irradiating the joint with a neutron beam. This study discusses the design of a multidirectional neutron beam for BNCS.

  6. Radiation injury of boron neutron capture therapy using mixed epithermal- and thermal neutron beams in patients with malignant glioma

    Energy Technology Data Exchange (ETDEWEB)

    Kageji, T. E-mail: kageji@clin.med.tokushima-u.ac.jp; Nagahiro, S.; Mizobuchi, Y.; Toi, H.; Nakagawa, Y.; Kumada, H

    2004-11-01

    The purpose of this study was to clarify the radiation injury in acute or delayed stage after boron neutron capture therapy (BNCT) using mixed epithermal- and thermal neutron beams in patients with malignant glioma. Eighteen patients with malignant glioma underwent mixed epithermal- and thermal neutron beam and sodium borocaptate between 1998 and 2004. The radiation dose (i.e. physical dose of boron n-alpha reaction) in the protocol used between 1998 and 2000 (Protocol A, n=8) prescribed a maximum tumor volume dose of 15 Gy. In 2001, a new dose-escalated protocol was introduced (Protocol B, n=4); it prescribes a minimum tumor volume dose of 18 Gy or, alternatively, a minimum target volume dose of 15 Gy. Since 2002, the radiation dose was reduced to 80-90% dose of Protocol B because of acute radiation injury. A new Protocol was applied to 6 glioblastoma patients (Protocol C, n=6). The average values of the maximum vascular dose of brain surface in Protocol A, B and C were 11.4{+-}4.2 Gy, 15.7{+-}1.2 and 13.9{+-}3.6 Gy, respectively. Acute radiation injury such as a generalized convulsion within 1 week after BNCT was recognized in three patients of Protocol B. Delayed radiation injury such as a neurological deterioration appeared 3-6 months after BNCT, and it was recognized in 1 patient in Protocol A, 5 patients in Protocol B. According to acute radiation injury, the maximum vascular dose was 15.8{+-}1.3 Gy in positive and was 12.6{+-}4.3 Gy in negative. There was no significant difference between them. According to the delayed radiation injury, the maximum vascular dose was 13.8{+-}3.8 Gy in positive and was 13.6{+-}4.9 Gy in negative. There was no significant difference between them. The dose escalation is limited because most patients in Protocol B suffered from acute radiation injury. We conclude that the maximum vascular dose does not exceed over 12 Gy to avoid the delayed radiation injury, especially, it should be limited under 10 Gy in the case that tumor

  7. Boron neutron capture therapy at the Institute of Medical Radiobiology (IMR) and Paul Scherrer Institute (PSI)

    Science.gov (United States)

    Argentini, M.; Arkuszewski, J.; Crawford, John F.; Larsson, B.; Stepanek, Jiri; Teichmann, Sarah; Weinreich, R.

    1997-02-01

    Although all of the over 200 patients treated with NCT have been irradiated by reactor-produced neutrons, in the present climate of public opinion one cannot expect the routine use of nuclear reactors in hospitals or clinics to be tolerated. While there are several other methods of producing neutrons in the necessary quantities, the Paul Scherrer Institute (PSI) is very well placed to develop techniques base don spallation, in which a beam of protons hits a production target of some convenient material such as tungsten. Because spallation produces neutrons of very similar energies to reactors, the problem of moderating them to keV energies is rather similar. However, there is an additional component of high-energy neutrons, whose intensity depends on the energy of the initial beam, which has to be taken into account in any practical design. Simulations using the well-known codes LAHET, MCNP and GEANT show that a 100 (mu) A beam of 72 MeV protons, well within the capabilities of PSI, could produce enough keV neutrons for therapy.

  8. Synthesis and evaluation of boron compounds for neutron capture therapy of malignant brain tumors. Technical progress report No. 1, May 1, 1990--January 31, 1991

    Energy Technology Data Exchange (ETDEWEB)

    Soloway, A.H.; Barth, R.F.

    1990-12-31

    Boron neutron capture therapy offers the potentiality for treating brain tumors currently resistant to treatment. The success of this form of therapy is directly dependent upon the delivery of sufficient numbers of thermal-neutrons to tumor cells which possess high concentrations of B-10. The objective of this project is to develop chemical methodology to synthesize boron-containing compounds with the potential for becoming incorporated into rapidly-dividing malignant brain tumor cells and excluded from normal components of the brain and surrounding tissues, to develope biological methods for assessing the potential of the compound by use of cell culture or intratumoral injection, to develop analytical methodology for measuring boron in cells and tissue using direct current plasma atomic emission spectroscopy (DCP-AES) and alpha track autoradiography, to develop biochemical and HPLC procedures for evaluating compound uptake and tissue half-life, and to develop procedures required to assess both in vitro and vivo efficacy of BNCT with selected compounds.

  9. Conceptual study of a compact accelerator-driven neutron source for radioisotope production, boron neutron capture therapy and fast neutron therapy

    CERN Document Server

    Angelone, M; Rollet, S

    2002-01-01

    The feasibility of a compact accelerator-driven device for the generation of neutron spectra suitable for isotope production by neutron capture, boron neutron capture therapy and fast neutron therapy, is analyzed by Monte Carlo simulations. The device is essentially an extension of the activator proposed by Rubbia left bracket CERN/LHC/97-04(EET) right bracket , in which fast neutrons are diffused and moderated within a properly sized lead block. It is shown that by suitable design of the lead block, as well as of additional elements of moderating and shielding materials, one can generate and exploit neutron fluxes with the spectral features required for the above applications. The linear dimensions of the diffusing-moderating device can be limited to about 1 m. A full-scale device for all the above applications would require a fast neutron source of about 10**1**4 s**-**1, which could be produced by a 1 mA, 30 MeV proton beam impinging on a Be target. The concept could be tested at the Frascati Neutron Gener...

  10. Optimum design and criticality safety of a beam-shaping assembly with an accelerator-driven subcritical neutron multiplier for boron neutron capture therapies.

    Science.gov (United States)

    Hiraga, F

    2015-12-01

    The beam-shaping assembly for boron neutron capture therapies with a compact accelerator-driven subcritical neutron multiplier was designed so that an epithermal neutron flux of 1.9×10(9) cm(-2) s(-1) at the treatment position was generated by 5 MeV protons in a beam current of 2 mA. Changes in the atomic density of (135)Xe in the nuclear fuel due to the operation of the beam-shaping assembly were estimated. The criticality safety of the beam-shaping assembly in terms of Xe poisoning is discussed.

  11. A CONCEPTUAL DESIGN OF NEUTRON COLLIMATOR IN THE THERMAL COLUMN OF KARTINI RESEARCH REACTOR FOR IN VITRO AND IN VIVO TEST OF BORON NEUTRON CAPTURE THERAPY

    OpenAIRE

    Nina Fauziah; Andang Widiharto; Yohannes Sardjono

    2015-01-01

    Studies were carried out to design a collimator which results in epithermal neutron beam for IN VITRO and IN VIVO of Boron Neutron Capture Therapy (BNCT) at the Kartini research reactor by means of Monte Carlo N-Particle (MCNP) codes. Reactor within 100 kW of thermal power was used as the neutron source. The design criteria were based on recommendation from the International Atomic Energy Agency (IAEA). All materials used were varied in size, according to the value of mean free path for each ...

  12. Development of high intensity ion sources for a Tandem-Electrostatic-Quadrupole facility for Accelerator-Based Boron Neutron Capture Therapy

    Energy Technology Data Exchange (ETDEWEB)

    Bergueiro, J. [Gerencia de Investigacion y Aplicaciones, Comision Nacional de Energia Atomica (Argentina)] [CONICET, Buenos Aires (Argentina); Igarzabal, M.; Suarez Sandin, J.C. [Gerencia de Investigacion y Aplicaciones, Comision Nacional de Energia Atomica (Argentina); Somacal, H.R. [Gerencia de Investigacion y Aplicaciones, Comision Nacional de Energia Atomica (Argentina)] [Escuela de Ciencia y Tecnologia, Universidad Nacional de San Martin (Argentina); Thatar Vento, V. [Gerencia de Investigacion y Aplicaciones, Comision Nacional de Energia Atomica (Argentina)] [CONICET, Buenos Aires (Argentina); Huck, H.; Valda, A.A. [Gerencia de Investigacion y Aplicaciones, Comision Nacional de Energia Atomica (Argentina)] [Escuela de Ciencia y Tecnologia, Universidad Nacional de San Martin (Argentina); Repetto, M. [Gerencia de Investigacion y Aplicaciones, Comision Nacional de Energia Atomica (Argentina)

    2011-12-15

    Several ion sources have been developed and an ion source test stand has been mounted for the first stage of a Tandem-Electrostatic-Quadrupole facility For Accelerator-Based Boron Neutron Capture Therapy. A first source, designed, fabricated and tested is a dual chamber, filament driven and magnetically compressed volume plasma proton ion source. A 4 mA beam has been accelerated and transported into the suppressed Faraday cup. Extensive simulations of the sources have been performed using both 2D and 3D self-consistent codes.

  13. Boron neutron capture therapy for clear cell sarcoma (CCS): Biodistribution study of p-borono-L-phenylalanine in CCS-bearing animal models

    Energy Technology Data Exchange (ETDEWEB)

    Andoh, T. [Laboratory of Pharmaceutical Technology, Faculty of Pharmaceutical Sciences and Cooperative Research Center of Life Sciences, Kobe Gakuin University, Kobe 650-8586 (Japan); Fujimoto, T. [Department of Orthopaedic Surgery, Hyogo Cancer Center, Akashi 673-0021 (Japan); Sudo, T. [Section of Translational Research, Hyogo Cancer Center, Akashi 673-0021 (Japan); Fujita, I.; Imabori, M. [Department of Orthopaedic Surgery, Hyogo Cancer Center, Akashi 673-0021 (Japan); Moritake, H. [Department of Pediatrics, Miyazaki University, Kiyotake 889-1692 (Japan); Sugimoto, T. [Department of Pediatrics, Saiseikai Shigaken Hospital, Ritto 520-3046 (Japan); Sakuma, Y. [Department of Pathology, Hyogo Cancer Center, Akashi 673-0021 (Japan); Takeuchi, T. [Department of Pathology, Kochi University, Nangoku 783-8505 (Japan); Kawabata, S. [Department of Neurosurgery, Osaka Medical College, Osaka 569-8686 (Japan); Kirihata, M. [Graduate School of Life and Environmental Sciences, Osaka Prefecture University, Sakai 599-8531 (Japan); Akisue, T. [Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, Kobe 650-0017 (Japan); Yayama, K. [Laboratory of Cardiovascular Pharmacology, Faculty of Pharmaceutical Sciences and Cooperative Research Center of Life Sciences, Kobe Gakuin University, Kobe 650-8586 (Japan); Kurosaka, M. [Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, Kobe 650-0017 (Japan); Miyatake, S. [Department of Neurosurgery, Osaka Medical College, Osaka 569-8686 (Japan); Fukumori, Y. [Laboratory of Pharmaceutical Technology, Faculty of Pharmaceutical Sciences and Cooperative Research Center of Life Sciences, Kobe Gakuin University, Kobe 650-8586 (Japan); Ichikawa, H., E-mail: ichikawa@pharm.kobegakuin.ac.jp [Laboratory of Pharmaceutical Technology, Faculty of Pharmaceutical Sciences and Cooperative Research Center of Life Sciences, Kobe Gakuin University, Kobe 650-8586 (Japan)

    2011-12-15

    Clear cell sarcoma (CCS) is a rare melanocytic malignant tumor with a poor prognosis. Our previous study demonstrated that in vitro cultured CCS cells have the ability to highly uptake L-BPA and thus boron neutron capture therapy could be a new option for CCS treatment. This paper proved that a remarkably high accumulation of {sup 10}B (45-74 ppm) in tumor was obtained even in a CCS-bearing animal with a well-controlled biodistribution followed by intravenous administration of L-BPA-fructose complex (500 mg BPA/kg).

  14. PGNAA of human arthritic synovium for boron neutron capture synovectomy

    Energy Technology Data Exchange (ETDEWEB)

    Binello, E.; Yanch, J.C. [Massashucetts Institute of Technology, Cambridge, MA (United States); Shortkroff, S. [Brigham and Women`s Hospital, Boston, MA (United States)

    1997-12-01

    Boron neutron capture synovectomy (BNCS), is a proposed new therapy modality for the treatment of rheumatoid arthritis, an autoimmune disease afflicting the joints. The synovium, which is the membrane lining the joint, becomes inflamed and represents the target tissue for therapy. When a joint is unresponsive to drug treatment, physical removal of the synovium, termed synovectomy, becomes necessary. Existing options include surgery and radiation synovectomy. BNCS has advantages over these options in that it is noninvasive and does not require the administration of radioactive substances. Previous studies have shown that the uptake of {sup 10}B by human arthritic synovium ex vivo is high, ranging from 194 to 545 ppm with an unenriched boron compound. While tissue samples remain viable up to 1 week, ex vivo conditions do not accurately reflect those in vivo. This paper presents results from experiments assessing the washout of boron from the tissue and examines the implications for in vivo studies.

  15. Monitoring the distribution of prompt gamma rays in boron neutron capture therapy using a multiple-scattering Compton camera: A Monte Carlo simulation study

    Energy Technology Data Exchange (ETDEWEB)

    Lee, Taewoong; Lee, Hyounggun; Lee, Wonho, E-mail: wonhol@korea.ac.kr

    2015-10-21

    This study evaluated the use of Compton imaging technology to monitor prompt gamma rays emitted by {sup 10}B in boron neutron capture therapy (BNCT) applied to a computerized human phantom. The Monte Carlo method, including particle-tracking techniques, was used for simulation. The distribution of prompt gamma rays emitted by the phantom during irradiation with neutron beams is closely associated with the distribution of the boron in the phantom. Maximum likelihood expectation maximization (MLEM) method was applied to the information obtained from the detected prompt gamma rays to reconstruct the distribution of the tumor including the boron uptake regions (BURs). The reconstructed Compton images of the prompt gamma rays were combined with the cross-sectional images of the human phantom. Quantitative analysis of the intensity curves showed that all combined images matched the predetermined conditions of the simulation. The tumors including the BURs were distinguishable if they were more than 2 cm apart.

  16. Therapeutic efficacy of boron neutron capture therapy mediated by boron-rich liposomes for oral cancer in the hamster cheek pouch model.

    Science.gov (United States)

    Heber, Elisa M; Hawthorne, M Frederick; Kueffer, Peter J; Garabalino, Marcela A; Thorp, Silvia I; Pozzi, Emiliano C C; Monti Hughes, Andrea; Maitz, Charles A; Jalisatgi, Satish S; Nigg, David W; Curotto, Paula; Trivillin, Verónica A; Schwint, Amanda E

    2014-11-11

    The application of boron neutron capture therapy (BNCT) mediated by liposomes containing (10)B-enriched polyhedral borane and carborane derivatives for the treatment of head and neck cancer in the hamster cheek pouch oral cancer model is presented. These liposomes are composed of an equimolar ratio of cholesterol and 1,2-distearoyl-sn-glycero-3-phosphocholine, incorporating K[nido-7-CH3(CH2)15-7,8-C2B9H11] (MAC) in the bilayer membrane while encapsulating the hydrophilic species Na3[ae-B20H17NH3] (TAC) in the aqueous core. Unilamellar liposomes with a mean diameter of 83 nm were administered i.v. in hamsters. After 48 h, the boron concentration in tumors was 67 ± 16 ppm whereas the precancerous tissue contained 11 ± 6 ppm, and the tumor/normal pouch tissue boron concentration ratio was 10:1. Neutron irradiation giving a 5-Gy dose to precancerous tissue (corresponding to 21 Gy in tumor) resulted in an overall tumor response (OR) of 70% after a 4-wk posttreatment period. In contrast, the beam-only protocol gave an OR rate of only 28%. Once-repeated BNCT treatment with readministration of liposomes at an interval of 4, 6, or 8 wk resulted in OR rates of 70-88%, of which the complete response ranged from 37% to 52%. Because of the good therapeutic outcome, it was possible to extend the follow-up of BNCT treatment groups to 16 wk after the first treatment. No radiotoxicity to normal tissue was observed. A salient advantage of these liposomes was that only mild mucositis was observed in dose-limiting precancerous tissue with a sustained tumor response of 70-88%.

  17. Proceedings of the first international symposium on neutron capture therapy

    Energy Technology Data Exchange (ETDEWEB)

    Fairchild, R.G.; Brownell, G.L. (eds.)

    1982-01-01

    This meeting was arranged jointly by MIT and BNL in order to illuminate progress in the synthesis and targeting of boron compounds and to evaluate and document progress in radiobiological and dosimetric aspects of neutron capture therapy. It is hoped that this meeting will facilitate transfer of information between groups working in these fields, and encourage synergistic collaboration.

  18. Characterisation of neutron and gamma-ray emission from thick target Be(p,n) reaction for boron neutron capture therapy

    Energy Technology Data Exchange (ETDEWEB)

    Guzek, J.; Mateva, T.; Tapper, U.A.S. [De Beers Diamond Res. Lab., Southdale (South Africa); McMurray, W.R. [National Accelerator Centre, Van de Graaff Group, P.O. Box 72, Faure 7131 (South Africa); Franklyn, C.B. [Atomic Energy Corporation of South Africa, P.O. Box 582, Pretoria (South Africa)

    1998-04-01

    Low energy accelerator-based neutron sources have promising potential for use in a clinical treatment of cancer with boron neutron capture therapy (BNCT) and boron neutron capture synovectomy (BNCS). Such sources often utilise a thick target Be(p,n) reaction using incident proton energies from several hundred keV to 1-2 MeV above the reaction threshold of 2.06 MeV. The resulting neutron and gamma-ray beams require considerable moderation and filtration in order to obtain thermal and epithermal neutron fluxes for therapy. The detailed knowledge of neutron and gamma-ray spectra, yield and angular distribution are necessary in order to design effective moderators and filters to be used for the treatment. Thick and thin beryllium target neutron and gamma spectra have been investigated in detail using the time-of-flight (TOF) technique, for incident proton energies from above threshold to 4 MeV. The results show characteristics of neutron and gamma-ray production of importance for the application of this neutron source for BNCT and BNCS. (orig.) 6 refs.

  19. Development of a dual phantom technique for measuring the fast neutron component of dose in boron neutron capture therapy

    Energy Technology Data Exchange (ETDEWEB)

    Sakurai, Yoshinori, E-mail: yosakura@rri.kyoto-u.ac.jp; Tanaka, Hiroki; Kondo, Natsuko; Kinashi, Yuko; Suzuki, Minoru; Masunaga, Shinichiro; Ono, Koji; Maruhashi, Akira [Kyoto University Research Reactor Institute, Asashironishi 2-1010, Kumatori-cho, Sennan-gun, Osaka 590-0494 (Japan)

    2015-11-15

    Purpose: Research and development of various accelerator-based irradiation systems for boron neutron capture therapy (BNCT) is underway throughout the world. Many of these systems are nearing or have started clinical trials. Before the start of treatment with BNCT, the relative biological effectiveness (RBE) for the fast neutrons (over 10 keV) incident to the irradiation field must be estimated. Measurements of RBE are typically performed by biological experiments with a phantom. Although the dose deposition due to secondary gamma rays is dominant, the relative contributions of thermal neutrons (below 0.5 eV) and fast neutrons are virtually equivalent under typical irradiation conditions in a water and/or acrylic phantom. Uniform contributions to the dose deposited from thermal and fast neutrons are based in part on relatively inaccurate dose information for fast neutrons. This study sought to improve the accuracy in the dose estimation for fast neutrons by using two phantoms made of different materials in which the dose components can be separated according to differences in the interaction cross sections. The development of a “dual phantom technique” for measuring the fast neutron component of dose is reported. Methods: One phantom was filled with pure water. The other phantom was filled with a water solution of lithium hydroxide (LiOH) capitalizing on the absorbing characteristics of lithium-6 (Li-6) for thermal neutrons. Monte Carlo simulations were used to determine the ideal mixing ratio of Li-6 in LiOH solution. Changes in the depth dose distributions for each respective dose component along the central beam axis were used to assess the LiOH concentration at the 0, 0.001, 0.01, 0.1, 1, and 10 wt. % levels. Simulations were also performed with the phantom filled with 10 wt. % {sup 6}LiOH solution for 95%-enriched Li-6. A phantom was constructed containing 10 wt. % {sup 6}LiOH solution based on the simulation results. Experimental characterization of the

  20. Quantitative bioimaging of p-boronophenylalanine in thin liver tissue sections as a tool for treatment planning in boron neutron capture therapy.

    Science.gov (United States)

    Reifschneider, Olga; Schütz, Christian L; Brochhausen, Christoph; Hampel, Gabriele; Ross, Tobias; Sperling, Michael; Karst, Uwe

    2015-03-01

    An analytical method using laser ablation-inductively coupled plasma-mass spectrometry (LA-ICP-MS) was developed and applied to assess enrichment of 10B-containing p-boronophenylalanine-fructose (BPA-f) and its pharmacokinetic distribution in human tissues after application for boron neutron capture therapy (BNCT). High spatial resolution (50 μm) and limits of detection in the low parts-per-billion range were achieved using a Nd:YAG laser of 213 nm wavelength. External calibration by means of 10B-enriched standards based on whole blood proved to yield precise quantification results. Using this calibration method, quantification of 10B in cancerous and healthy tissue was carried out. Additionally, the distribution of 11B was investigated, providing 10B enrichment in the investigated tissues. Quantitative imaging of 10B by means of LA-ICP-MS was demonstrated as a new option to characterise the efficacy of boron compounds for BNCT.

  1. Boron nitride nanotubes for boron neutron capture therapy as contrast agents in magnetic resonance imaging at 3 T

    Energy Technology Data Exchange (ETDEWEB)

    Menichetti, L., E-mail: luca.menichetti@ifc.cnr.it [CNR-National Research Council of Italy, Institute of Clinical Physiology, via G. Moruzzi 1, 56124 Pisa (Italy); De Marchi, D. [Fondazione Toscana Gabriele Monasterio per la Ricerca Medica e la Sanita Pubblica, CNR-Regione Toscana, via Trieste 41, 56126 Pisa (Italy); Calucci, L. [CNR-National Research Council of Italy, ICCOM-Institute of OrganoMetallic Chemistry, via G. Moruzzi 1, 56124 Pisa (Italy); Ciofani, G.; Menciassi, A. [Italian Institute of Technology c/o Scuola Superiore Sant' Anna, viale R. Piaggio 34, 56025 Pontedera (Italy); Forte, C. [CNR-National Research Council of Italy, ICCOM-Institute of OrganoMetallic Chemistry, via G. Moruzzi 1, 56124 Pisa (Italy)

    2011-12-15

    The applicability of boron nitride nanotubes (BNNTs) containing Fe paramagnetic impurities as contrast agents in magnetic resonance imaging (MRI) was investigated. The measurement of longitudinal and transverse relaxation times of water protons in homogeneous aqueous dispersions of BNNTs wrapped with poly(L-lysine) at different concentrations allowed longitudinal (r{sub 1}) and transverse (r{sub 2}) relaxivities to be determined at 3 T. The r{sub 2} value was comparable to those of commercial superparamagnetic iron oxide nanoparticles, indicating that Fe-containing BNNTs have the potential to be used as T{sub 2} contrast-enhancement agents in MRI at 3 T.

  2. Research needs for neutron capture therapy

    Energy Technology Data Exchange (ETDEWEB)

    NONE

    1995-12-01

    Key issues and questions addressed by the workshop related to optimization of Boron Neutron Capture Therapy (BNCT), in general, and to the possibility of success of the present BNCT trials at Brookhaven National Laboratory (BNL) and Massachusetts Institute of Technology (MIT), in particular. Both trials use nuclear fission reactors as neutron sources for BNCT of glioblastoma multiforme (BNL) and of deep seated melanoma (MIT). Presentations and discussions focussed on optimal boron-labeled compounds, mainly for brain tumors such as glioblastoma multiforme, and the best mode of compound delivery to the tumor. Also, optimizing neutron irradiation with dose delivery to the tumor cells and the issues of dosimetry of BNCT especially in the brain were discussed. Planning of treatment and of follow-up of patients, coordination of BNCT at various treatment sites, and the potential of delivering BNCT to various types of cancer with an appropriately tailored protocol were additional issues. The need for multicentric interdisciplinary cooperation among the different medical specialties was highlighted.

  3. Development of an optical fiber type detector using a Eu:LiCaAlF{sub 6} scintillator for neutron monitoring in boron neutron capture therapy

    Energy Technology Data Exchange (ETDEWEB)

    Watanabe, Kenichi, E-mail: k-watanabe@nucl.nagoya-u.ac.jp [Nagoya University, Furo-cho, Chikusa-ku, Nagoya, 464-8603 (Japan); Kawabata, Yuya; Yamazaki, Atsushi; Uritani, Akira; Iguchi, Tetsuo [Nagoya University, Furo-cho, Chikusa-ku, Nagoya, 464-8603 (Japan); Fukuda, Kentaro [Tokuyama Corp., 1-1 Mikage-cho, Shunan-shi, Yamaguchi, 745-8648 (Japan); Yanagida, Takayuki [Nara Institute of Science and Technology, 8916-5 Takayama, Ikoma, Nara, 630-0192 (Japan)

    2015-12-01

    We have developed a small neutron detector probe as a thermal neutron flux monitor for boron neutron capture therapy. The detector consists of an optical fiber and a small Eu:LiCaAlF{sub 6} scintillator. In order to improve neutron-gamma ray discrimination capability, we use the small-size scintillator, whose size is controlled to be smaller than fast electron range produced by gamma-rays and larger than the range of charged particles induced by {sup 6}Li(n,t) reactions. We confirmed the improved neutron-gamma ray discrimination capability by comparing the detector responses between a small-size scintillator and a slab one. We also evaluated the neutron sensitivity of the fabricated optical fiber type neutron detector to be 2×10{sup −4} cm{sup 2}.

  4. A conceptual design of a beam-shaping assembly for boron neutron capture therapy based on deuterium-tritium neutron generators.

    Science.gov (United States)

    Martín, Guido; Abrahantes, Arian

    2004-05-01

    A conceptual design of a beam-shaping assembly for boron neutron capture therapy using deuterium-tritium accelerator based neutrons source is developed. Calculations based on a simple geometry model for the radiation transport are initially performed to estimate the assembly materials and their linear dimensions. Afterward, the assembly geometry is produced, optimized and verified. In order to perform these calculations the general-purpose MCNP code is used. Irradiation time and therapeutic gain are utilized as beam assessment parameters. Metallic uranium and manganese are successfully tested for fast-to-epithermal neutron moderation. In the present beam-shaping assembly proposal, the therapeutic gain is improved by 23% and the accelerator current required for a fixed irradiation period is reduced by six times compared to previous proposals based on the same D-T reaction.

  5. Boron neutron capture synovectomy (BNCS) as a potential therapy for rheumatoid arthritis: boron biodistribution study in a model of antigen-induced arthritis in rabbits.

    Science.gov (United States)

    Trivillin, Verónica A; Abramson, David B; Bumaguin, Gaston E; Bruno, Leandro J; Garabalino, Marcela A; Monti Hughes, Andrea; Heber, Elisa M; Feldman, Sara; Schwint, Amanda E

    2014-11-01

    Boron neutron capture synovectomy (BNCS) is explored for the treatment of rheumatoid arthritis (RA). The aim of the present study was to perform boron biodistribution studies in a model of antigen-induced arthritis (AIA) in female New Zealand rabbits, with the boron carriers boronophenylalanine (BPA) and sodium decahydrodecaborate (GB-10) to assess the potential feasibility of BNCS for RA. Rabbits in chronic phase of AIA were used for biodistribution studies employing the following protocols: intra-articular (ia) (a) BPA-f 0.14 M (0.7 mg (10)B), (b) GB-10 (5 mg (10)B), (c) GB-10 (50 mg (10)B) and intravenous (iv), (d) BPA-f 0.14 M (15.5 mg (10)B/kg), (e) GB-10 (50 mg (10)B/kg), and (f) BPA-f (15.5 mg (10)B/kg) + GB-10 (50 mg (10)B/kg). At different post-administration times (13-85 min for ia and 3 h for iv), samples of blood, pathological synovium (target tissue), cartilage, tendon, muscle, and skin were taken for boron measurement by inductively coupled plasma mass spectrometry. The intra-articular administration protocols at boron concentrations (>20 ppm) in the pathological synovium. Dosimetric estimations suggest that BNCS would be able to achieve a therapeutically useful dose in pathological synovium without exceeding the radiotolerance of normal tissues in the treatment volume, employing boron carriers approved for use in humans. Radiobiological in vivo studies will be necessary to determine the actual therapeutic efficacy of BNCS to treat RA in an experimental model.

  6. Design of a rotating facility for extracorporal treatment of an explanted liver with disseminated metastases by boron neutron capture therapy with an epithermal neutron beam.

    Science.gov (United States)

    Nievaart, V A; Moss, R L; Kloosterman, J L; van der Hagen, T H J J; van Dam, H; Wittig, A; Malago, M; Sauerwein, W

    2006-07-01

    In 2001, at the TRIGA reactor of the University of Pavia (Italy), a patient suffering from diffuse liver metastases from an adenocarcinoma of the sigmoid was successfully treated by boron neutron capture therapy (BNCT). The procedure involved boron infusion prior to hepatectomy, irradiation of the explanted liver at the thermal column of the reactor, and subsequent reimplantation. A complete response was observed. This encouraging outcome stimulated the Essen/Petten BNCT group to investigate whether such an extracorporal irradiation could be performed at the BNCT irradiation facility at the HFR Petten (The Netherlands), which has very different irradiation characteristics than the Pavia facility. A computational study has been carried out. A rotating PMMA container with a liver, surrounded by PMMA and graphite, is simulated using the Monte Carlo code MCNP. Due to the rotation and neutron moderation of the PMMA container, the initial epithermal neutron beam provides a nearly homogeneous thermal neutron field in the liver. The main conditions for treatment as reported from the Pavia experiment, i.e. a thermal neutron fluence of 4 x 10(12) +/- 20% cm(-2), can be closely met at the HFR in an acceptable time, which, depending on the defined conditions, is between 140 and 180 min.

  7. Improvement of the boron neutron capture therapy (BNCT) by the previous administration of the histone deacetylase inhibitor sodium butyrate for the treatment of thyroid carcinoma.

    Science.gov (United States)

    Perona, M; Rodríguez, C; Carpano, M; Thomasz, L; Nievas, S; Olivera, M; Thorp, S; Curotto, P; Pozzi, E; Kahl, S; Pisarev, M; Juvenal, G; Dagrosa, A

    2013-08-01

    We have shown that boron neutron capture therapy (BNCT) could be an alternative for the treatment of poorly differentiated thyroid carcinoma (PDTC). Histone deacetylase inhibitors (HDACI) like sodium butyrate (NaB) cause hyperacetylation of histone proteins and show capacity to increase the gamma irradiation effect. The purpose of these studies was to investigate the use of the NaB as a radiosensitizer of the BNCT for PDTC. Follicular thyroid carcinoma cells (WRO) and rat thyroid epithelial cells (FRTL-5) were incubated with 1 mM NaB and then treated with boronophenylalanine ¹⁰BPA (10 μg ¹⁰B ml⁻¹) + neutrons, or with 2, 4-bis (α,β-dihydroxyethyl)-deutero-porphyrin IX ¹⁰BOPP (10 μg ¹⁰B ml⁻¹) + neutrons, or with a neutron beam alone. The cells were irradiated in the thermal column facility of the RA-3 reactor (flux = (1.0 ± 0.1) × 10¹⁰ n cm⁻² s⁻¹). Cell survival decreased as a function of the physical absorbed dose in both cell lines. Moreover, the addition of NaB decreased cell survival (p < 0.05) in WRO cells incubated with both boron compounds. NaB increased the percentage of necrotic and apoptotic cells in both BNCT groups (p < 0.05). An accumulation of cells in G2/M phase at 24 h was observed for all the irradiated groups and the addition of NaB increased this percentage. Biodistribution studies of BPA (350 mg kg⁻¹ body weight) 24 h after NaB injection were performed. The in vivo studies showed that NaB treatment increases the amount of boron in the tumor at 2-h post-BPA injection (p < 0.01). We conclude that NaB could be used as a radiosensitizer for the treatment of thyroid carcinoma by BNCT.

  8. Quantitative evaluation of boron neutron capture therapy (BNCT) drugs for boron delivery and retention at subcellular-scale resolution in human glioblastoma cells with imaging secondary ion mass spectrometry (SIMS).

    Science.gov (United States)

    Chandra, S; Ahmad, T; Barth, R F; Kabalka, G W

    2014-06-01

    Boron neutron capture therapy (BNCT) of cancer depends on the selective delivery of a sufficient number of boron-10 ((10)B) atoms to individual tumour cells. Cell killing results from the (10)B (n, α)(7) Li neutron capture and fission reactions that occur if a sufficient number of (10)B atoms are localized in the tumour cells. Intranuclear (10)B localization enhances the efficiency of cell killing via damage to the DNA. The net cellular content of (10)B atoms reflects both bound and free pools of boron in individual tumour cells. The assessment of these pools, delivered by a boron delivery agent, currently cannot be made at subcellular-scale resolution by clinically applicable techniques such as positron emission tomography and magnetic resonance imaging. In this study, a secondary ion mass spectrometry based imaging instrument, a CAMECA IMS 3f ion microscope, capable of 500 nm spatial resolution was employed. Cryogenically prepared cultured human T98G glioblastoma cells were evaluated for boron uptake and retention of two delivery agents. The first, L-p-boronophenylalanine (BPA), has been used clinically for BNCT of high-grade gliomas, recurrent tumours of the head and neck region and melanomas. The second, a boron analogue of an unnatural amino acid, 1-amino-3-borono-cyclopentanecarboxylic acid (cis-ABCPC), has been studied in rodent glioma and melanoma models by quantification of boron in the nucleus and cytoplasm of individual tumour cells. The bound and free pools of boron were assessed by exposure of cells to boron-free nutrient medium. Both BPA and cis-ABCPC delivered almost 70% of the pool of boron in the free or loosely bound form to the nucleus and cytoplasm of human glioblastoma cells. This free pool of boron could be easily mobilized out of the cell and was in some sort of equilibrium with extracellular boron. In the case of BPA, the intracellular free pool of boron also was affected by the presence of phenylalanine in the nutrient medium. This

  9. Toward a clinical application of ex situ boron neutron capture therapy for lung tumors at the RA-3 reactor in Argentina

    Energy Technology Data Exchange (ETDEWEB)

    Farías, R. O.; Trivillin, V. A.; Portu, A. M.; Schwint, A. E.; González, S. J., E-mail: srgonzal@cnea.gov.ar [Comisión Nacional de Energía Atómica (CNEA), San Martín 1650, Argentina and Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires 1033 (Argentina); Garabalino, M. A.; Monti Hughes, A.; Pozzi, E. C. C.; Thorp, S. I.; Curotto, P.; Miller, M. E.; Santa Cruz, G. A.; Saint Martin, G. [Comisión Nacional de Energía Atómica (CNEA), San Martín 1650 (Argentina); Ferraris, S.; Santa María, J.; Rovati, O.; Lange, F. [CIDME, Universidad Maimónides, Buenos Aires 1405 (Argentina); Bortolussi, S. [Istituto Nazionale di Fisica Nucleare, Sezione di Pavia 27100 (Italy); Altieri, S. [Istituto Nazionale di Fisica Nucleare, Sezione di Pavia 27100, Italy and Dipartimento di Fisica, Università di Pavia, Pavia 27100 (Italy)

    2015-07-15

    Purpose: Many types of lung tumors have a very poor prognosis due to their spread in the whole organ volume. The fact that boron neutron capture therapy (BNCT) would allow for selective targeting of all the nodules regardless of their position, prompted a preclinical feasibility study of ex situ BNCT at the thermal neutron facility of RA-3 reactor in the province of Buenos Aires, Argentina. (L)-4p-dihydroxy-borylphenylalanine fructose complex (BPA-F) biodistribution studies in an adult sheep model and computational dosimetry for a human explanted lung were performed to evaluate the feasibility and the therapeutic potential of ex situ BNCT. Methods: Two kinds of boron biodistribution studies were carried out in the healthy sheep: a set of pharmacokinetic studies without lung excision, and a set that consisted of evaluation of boron concentration in the explanted and perfused lung. In order to assess the feasibility of the clinical application of ex situ BNCT at RA-3, a case of multiple lung metastases was analyzed. A detailed computational representation of the geometry of the lung was built based on a real collapsed human lung. Dosimetric calculations and dose limiting considerations were based on the experimental results from the adult sheep, and on the most suitable information published in the literature. In addition, a workable treatment plan was considered to assess the clinical application in a realistic scenario. Results: Concentration-time profiles for the normal sheep showed that the boron kinetics in blood, lung, and skin would adequately represent the boron behavior and absolute uptake expected in human tissues. Results strongly suggest that the distribution of the boron compound is spatially homogeneous in the lung. A constant lung-to-blood ratio of 1.3 ± 0.1 was observed from 80 min after the end of BPA-F infusion. The fact that this ratio remains constant during time would allow the blood boron concentration to be used as a surrogate and indirect

  10. Development and characteristics of the HANARO ex-core neutron irradiation facility for applications in the boron neutron capture therapy field

    CERN Document Server

    Kim, M S; Jun, B J; Kim, H; Lee, B C; Hwang, Sung-Yul; Jun, Byung-Jin; Kim, Heonil; Kim, Myong-Seop; Lee, Byung-Chul

    2006-01-01

    The HANARO ex-core neutron irradiation facility was developed for various applications in the boron neutron capture therapy (BNCT) field, and its characteristics have been investigated. In order to obtain a sufficient thermal neutron flux with a low level contamination of fast neutrons and gamma-rays, a radiation filtering method is adopted. The radiation filter has been designed by using a silicon single crystal cooled by liquid nitrogen and a bismuth crystal. The installation of the main components of the irradiation facility and the irradiation room are finished. Experimental measurements of the neutron beam characteristics have been performed by using bare and cadmium covered gold foils and wires. The in-phantom neutron flux distribution was measured for a flux mapping inside the phantom. The gamma-ray dose was determined by using TLD-700 thermoluminescence dosimeters. The thermal and fast neutron fluxes and the gamma-ray dose were calculated by using the MCNP code, and they were compared with experimenta...

  11. Demonstration of a high-intensity neutron source based on a liquid-lithium target for Accelerator based Boron Neutron Capture Therapy.

    Science.gov (United States)

    Halfon, S; Arenshtam, A; Kijel, D; Paul, M; Weissman, L; Berkovits, D; Eliyahu, I; Feinberg, G; Kreisel, A; Mardor, I; Shimel, G; Shor, A; Silverman, I; Tessler, M

    2015-12-01

    A free surface liquid-lithium jet target is operating routinely at Soreq Applied Research Accelerator Facility (SARAF), bombarded with a ~1.91 MeV, ~1.2 mA continuous-wave narrow proton beam. The experiments demonstrate the liquid lithium target (LiLiT) capability to constitute an intense source of epithermal neutrons, for Accelerator based Boron Neutron Capture Therapy (BNCT). The target dissipates extremely high ion beam power densities (>3 kW/cm(2), >0.5 MW/cm(3)) for long periods of time, while maintaining stable conditions and localized residual activity. LiLiT generates ~3×10(10) n/s, which is more than one order of magnitude larger than conventional (7)Li(p,n)-based near threshold neutron sources. A shield and moderator assembly for BNCT, with LiLiT irradiated with protons at 1.91 MeV, was designed based on Monte Carlo (MCNP) simulations of BNCT-doses produced in a phantom. According to these simulations it was found that a ~15 mA near threshold proton current will apply the therapeutic doses in ~1h treatment duration. According to our present results, such high current beams can be dissipated in a liquid-lithium target, hence the target design is readily applicable for accelerator-based BNCT.

  12. Design calculations of an epithermal neutron beam and development of a treatment planning system for the renovation of thor for boron neutron capture therapy

    Energy Technology Data Exchange (ETDEWEB)

    Liu, Y-W H.; Teng, Y.H.; Liao, M.Z. [National Tsing Hua Univ., Department of Engineering and System Science, Taiwan (China)

    2000-10-01

    Tsing Hua University was recently granted by National Science Council a five-year project to renovate its Open-Pool reactor (THOR) for boron neutron capture therapy. With this support, the whole graphite blocks in the original thermal column region can be removed for redesigning and constructing a better epithermal neutron beam. THOR is a 1 MW research reactor. The cross section area of the core facing the thermal column is 60 cm x 50 cm. By using 60 cm FLUENTAL plus 10 cm Pb, with cross section area of 70 cm x 60 cm and surrounded by 6 cm thick PbF{sub 2} reflector, the epithermal neutron flux at the filter/moderator exit can reach {approx}8.5 x 10{sup 9} n/cm{sup 2}/s. When the collimator is added, the epithermal neutron beam intensity at the beam exit is reduced to 3 x 10{sup 9} n/cm{sup 2}/sec, but is still six times higher than the previous beam. Facing the clinical trials scheduled 3 and half years from now, a preliminary version of treatment planning system is developed. It includes a pre-processor to read CT scan and post-processors to display dose distributions. (author)

  13. Basic research of boron neutron-capture therapy for treatment of pancreatic cancer. Application of neutron radiography for visualization of boron compound on BNCT

    Energy Technology Data Exchange (ETDEWEB)

    Yanagie, Hironobu [Tokyo Univ. (Japan). Inst. of Medical Science

    1997-02-01

    The cytotoxic effects of locally injected {sup 10}B-immunoliposomes (anti-CEA) on human pancreatic carcinoma xenografts in nude mice were evaluated with thermal neutron irradiation. After thermal neutron irradiation of mice injected with {sup 10}B-immunoliposomes, AsPC-1 tumour growth was suppressed relative to controls. Histopathologically, hyalinization and necrosis were found in {sup 10}B-treated tumours, while tumour tissue injected with saline or saline-containing immunoliposomes showed neither destruction nor necrosis. These results suggest that intratumoral injection of boronated immunoliposomes can increase the retention of {sup 10}B atoms by tumour cells, causing tumour growth suppression in vivo upon thermal neutron irradiation. We prepared boronated PEG-binding bovine serum albumin ({sup 10}B-PEG-BSA). {sup 10}B concentrations in AsPC-1, human pancreatic cancer cells (2 x 10{sup 5} /well) obtained 24 hrs after incubation with {sup 10}B-PEG-BSA was 13.01 {+-} 1.74 ppm. The number of {sup 10}B atoms delivered to the tumor cells was calculated to be 7.83 x 10{sup 11} at 24 hrs after incubation with {sup 10}B-PEG-BSA. These data indicated that the {sup 10}B-PEG-BSA could deliver a sufficient amount of {sup 10}B atoms (more than 10{sup 9} atoms/cell) to the tumor cells to induce cytotoxic effects after incubation upon thermal neutron irradiation. Neutron capture autoradiography by using an Imaging Plate (IP-NCR) was performed on AsPC-1 tumor-bearing mouse that had been given an intratumoral injection of {sup 10}B-PEG BSA or {sup 10}B-cationic liposome. We had demonstrated the {sup 10}B-PEG BSA or {sup 10}B-cationic liposome is taken up by AsPC-1 tumor tissue to a much greater extent than by normal tissues. (J.P.N.)

  14. Design of low-energy neutron beams for boron neutron capture synovectomy

    Science.gov (United States)

    Yanch, Jacquelyn C.; Shefer, Ruth E.; Binello, E.

    1997-02-01

    A novel application of the 10B(n, (alpha) )7Li nuclear reaction for the treatment of rheumatoid arthritis is under development. this application, called Boron Neutron Capture Synovectomy (BNCS), is briefly described here and the differences between BNCS and Boron Neutron Capture Therapy (BNCT) are discussed in detail. These differences lead to substantially altered demands on neutron beam design for each therapy application. In this paper the considerations for neutron beam design for the treatment of arthritic joints via BNCS are discussed, and comparisons with the design requirements for BNCT are made. This is followed by a description of potential moderator/reflector assemblies that are calculated to produce intense, high- quality neutron beams based on the 7Li(p,n) accelerator- based reactions. Total therapy time and therapeutic ratios are given as a function of both moderator length and boron concentration. Finally, a means of carrying out multi- directional irradiations of arthritic joints is proposed.

  15. Experimental Studies of Boronophenylalanine ({sup 10}BPA) Biodistribution for the Individual Application of Boron Neutron Capture Therapy (BNCT) for Malignant Melanoma Treatment

    Energy Technology Data Exchange (ETDEWEB)

    Carpano, Marina; Perona, Marina; Rodriguez, Carla [Department of Radiobiology, National Atomic Energy Commission, San Martín (Argentina); Nievas, Susana; Olivera, Maria; Santa Cruz, Gustavo A. [Department of Boron Neutron Capture Therapy, National Atomic Energy Commission, San Martín (Argentina); Brandizzi, Daniel; Cabrini, Romulo [Department of Radiobiology, National Atomic Energy Commission, San Martín (Argentina); School of Dentistry, University of Buenos Aires, Buenos Aires (Argentina); Pisarev, Mario [Department of Radiobiology, National Atomic Energy Commission, San Martín (Argentina); National Research Council of Argentina, Buenos Aires (Argentina); Department of Human Biochemistry, School of Medicine, University of Buenos Aires, Buenos Aires (Argentina); Juvenal, Guillermo Juan [Department of Radiobiology, National Atomic Energy Commission, San Martín (Argentina); National Research Council of Argentina, Buenos Aires (Argentina); Dagrosa, Maria Alejandra, E-mail: dagrosa@cnea.gov.ar [Department of Radiobiology, National Atomic Energy Commission, San Martín (Argentina); National Research Council of Argentina, Buenos Aires (Argentina)

    2015-10-01

    Purpose: Patients with the same histopathologic diagnosis of cutaneous melanoma treated with identical protocols of boron neutron capture therapy (BNCT) have shown different clinical outcomes. The objective of the present studies was to evaluate the biodistribution of boronophenilalanina ({sup 10}BPA) for the potential application of BNCT for the treatment of melanoma on an individual basis. Methods and Materials: The boronophenilalanine (BPA) uptake was evaluated in 3 human melanoma cell lines: MEL-J, A375, and M8. NIH nude mice were implanted with 4 10{sup 6} MEL-J cells, and biodistribution studies of BPA (350 mg/kg intraperitoneally) were performed. Static infrared imaging using a specially modified infrared camera adapted to measure the body infrared radiance of small animals was used. Proliferation marker, Ki-67, and endothelial marker, CD31, were analyzed in tumor samples. Results: The in vitro studies demonstrated different patterns of BPA uptake for each analyzed cell line (P<.001 for MEL-J and A375 vs M8 cells). The in vivo studies showed a maximum average boron concentration of 25.9 ± 2.6 μg/g in tumor, with individual values ranging between 11.7 and 52.0 μg/g of {sup 10}B 2 hours after the injection of BPA. Tumor temperature always decreased as the tumors increased in size, with values ranging between 37°C and 23°C. A significant correlation between tumor temperature and tumor-to-blood boron concentration ratio was found (R{sup 2} = 0.7, rational function fit). The immunohistochemical studies revealed, in tumors with extensive areas of viability, a high number of positive cells for Ki-67, blood vessels of large diameter evidenced by the marker CD31, and a direct logistic correlation between proliferative status and boron concentration difference between tumor and blood (R{sup 2} = 0.81, logistic function fit). Conclusion: We propose that these methods could be suitable for designing new screening protocols applied before melanoma BNCT

  16. A CONCEPTUAL DESIGN OF NEUTRON COLLIMATOR IN THE THERMAL COLUMN OF KARTINI RESEARCH REACTOR FOR IN VITRO AND IN VIVO TEST OF BORON NEUTRON CAPTURE THERAPY

    Directory of Open Access Journals (Sweden)

    Nina Fauziah

    2015-03-01

    Full Text Available Studies were carried out to design a collimator which results in epithermal neutron beam for IN VITRO and IN VIVO of Boron Neutron Capture Therapy (BNCT at the Kartini research reactor by means of Monte Carlo N-Particle (MCNP codes. Reactor within 100 kW of thermal power was used as the neutron source. The design criteria were based on recommendation from the International Atomic Energy Agency (IAEA. All materials used were varied in size, according to the value of mean free path for each material. MCNP simulations indicated that by using 5 cm thick of Ni as collimator wall, 60 cm thick of Al as moderator, 15 cm thick of 60Ni as filter, 2 cm thick of Bi as γ-ray shielding, 3 cm thick of 6Li2CO3-polyethylene as beam delimiter, with 1 to 5 cm varied aperture size, epithermal neutron beam with maximum flux of 7.65 x 108 n.cm-2.s-1 could be produced. The beam has minimum fast neutron and γ-ray components of, respectively, 1.76 x 10-13 Gy.cm2.n-1 and 1.32 x 10-13 Gy.cm2.n-1, minimum thermal neutron per epithermal neutron ratio of 0.008, and maximum directionality of 0.73. It did not fully pass the IAEA’s criteria, since the epithermal neutron flux was below the recommended value, 1.0 x 109 n.cm-2.s-1. Nonetheless, it was still usable with epithermal neutron flux exceeding 5.0 x 108 n.cm-2.s-1. When it was assumed that the graphite inside the thermal column was not discharged but only the part which was going to be replaced by the collimator, the performance of the collimator became better within the positive effect from the surrounding graphite that the beam resulted passed all criteria with epithermal neutron flux up to 1.68 x 109 n.cm-2.s-1. Keywords: design, collimator, epithermal neutron beam, BNCT, MCNP, criteria   Telah dilakukan penelitian tentang desain kolimator yang menghasilkan radiasi netron epitermal untuk uji in vitro dan in vivo pada Boron Neutron Capture Therapy (BNCT di Reaktor Riset Kartini dengan menggunakan program Monte

  17. Irradiation facility for boron neutron capture therapy application based on a rf-driven D-T neutron source and a new beam shaping assembly (abstract)

    Science.gov (United States)

    Cerullo, N.; Esposito, J.; Leung, K. N.

    2002-02-01

    Selecting the best neutron source for boron neutron capture therapy (BNCT) requires optimizing neutron beam parameters. This involves solving many complex problems. Safety issues related to the use of nuclear reactor in hospital environments, as well as lower costs have led to interest in the development of accelerator-driven neutron sources. The BNCT research programs at the Nuclear Departments of Pisa and Genova Universities (DIMNP and DITEC) focus on studies of new concepts for accelerator-based DT neutron sources. Simple and compact accelerator designs using relatively low deuteron beam energy, ˜100 keV, have been developed which, in turn, can generate high neutron yields. New studies have been started for optimization of moderator materials for the 14.1 MeV DT neutrons. Our aim is to obtain an epithermal neutron beam for therapeutic application at the exit end, with minimal beam intensity losses, the specific goal is to achieve an epithermal neutron flux of at least of 1×109 n/cm2 s at the beam port, with low gamma and fast neutron dose contamination. According to the most recent neutron BNCT beam parameters some moderating and spectrum shifter materials and geometrical configurations have thus far been tested, and neutron and gamma beam data at beam port have been computed. A possible beam shaping assembly model has been designed. This research demonstrates that a DT neutron source could be successfully implemented for BNCT application, with performance surpassing the minimum requirements stated above, using DT neutron sources with yields in the range 1013-1014 n/s. The latest Monte Carlo simulation results of an accelerator based facility which relies on a rf-driven DT fusion neutron generator will be presented.

  18. Dosimetry and radiobiology at the new RA-3 reactor boron neutron capture therapy (BNCT) facility: application to the treatment of experimental oral cancer.

    Science.gov (United States)

    Pozzi, E; Nigg, D W; Miller, M; Thorp, S I; Heber, E M; Zarza, L; Estryk, G; Monti Hughes, A; Molinari, A J; Garabalino, M; Itoiz, M E; Aromando, R F; Quintana, J; Trivillin, V A; Schwint, A E

    2009-07-01

    The National Atomic Energy Commission of Argentina (CNEA) constructed a novel thermal neutron source for use in boron neutron capture therapy (BNCT) applications at the RA-3 research reactor facility located in Buenos Aires. The aim of the present study was to perform a dosimetric characterization of the facility and undertake radiobiological studies of BNCT in an experimental model of oral cancer in the hamster cheek pouch. The free-field thermal flux was 7.1 x 10(9) n cm(-2)s(-1) and the fast neutron flux was 2.5 x 10(6) n cm(-2)s(-1), indicating a very well-thermalized neutron field with negligible fast neutron dose. For radiobiological studies it was necessary to shield the body of the hamster from the neutron flux while exposing the everted cheek pouch bearing the tumors. To that end we developed a lithium (enriched to 95% in (6)Li) carbonate enclosure. Groups of tumor-bearing hamsters were submitted to BPA-BNCT, GB-10-BNCT, (GB-10+BPA)-BNCT or beam only treatments. Normal (non-cancerized) hamsters were treated similarly to evaluate normal tissue radiotoxicity. The total physical dose delivered to tumor with the BNCT treatments ranged from 6 to 8.5 Gy. Tumor control at 30 days ranged from 73% to 85%, with no normal tissue radiotoxicity. Significant but reversible mucositis in precancerous tissue surrounding tumors was associated to BPA-BNCT. The therapeutic success of different BNCT protocols in treating experimental oral cancer at this novel facility was unequivocally demonstrated.

  19. Effects of employing a 10B-carrier and manipulating intratumour hypoxia on local tumour response and lung metastatic potential in boron neutron capture therapy

    Science.gov (United States)

    Masunaga, S; Sakurai, Y; Tanaka, H; Suzuki, M; Liu, Y; Kondo, N; Maruhashi, A; Kinashi, Y; Ono, K

    2012-01-01

    Objectives To evaluate the effects of employing a 10B-carrier and manipulating intratumour hypoxia on local tumour response and lung metastatic potential in boron neutron capture therapy (BNCT) by measuring the response of intratumour quiescent (Q) cells. Methods B16-BL6 melanoma tumour-bearing C57BL/6 mice were continuously given 5-bromo-2′-deoxyuridine (BrdU) to label all proliferating (P) cells. The tumours received reactor thermal neutron beam irradiation following the administration of a 10B-carrier [L-para-boronophenylalanine-10B (BPA) or sodium mercaptoundecahydrododecaborate-10B (BSH)] in combination with an acute hypoxia-releasing agent (nicotinamide) or mild temperature hyperthermia (MTH). Immediately after the irradiation, cells from some tumours were isolated and incubated with a cytokinesis blocker. The responses of the Q and total (P+Q) cell populations were assessed based on the frequency of micronuclei using immunofluorescence staining for BrdU. In other tumour-bearing mice, macroscopic lung metastases were enumerated 17 days after irradiation. Results BPA-BNCT increased the sensitivity of the total tumour cell population more than BSH-BNCT. However, the sensitivity of Q cells treated with BPA was lower than that of BSH-treated Q cells. With or without a 10B–carrier, MTH enhanced the sensitivity of the Q cell population. Without irradiation, nicotinamide treatment decreased the number of lung metastases. With irradiation, BPA-BNCT, especially in combination with nicotinamide treatment, showed the potential to reduce the number of metastases more than BSH-BNCT. Conclusion BSH-BNCT in combination with MTH improves local tumour control, while BPA-BNCT in combination with nicotinamide may reduce the number of lung metastases. PMID:22391496

  20. Sensitivity studies of beam directionality, beam size, and neutron spectrum for a fission converter-based epithermal neutron beam for boron neutron capture therapy.

    Science.gov (United States)

    Sakamoto, S; Kiger, W S; Harling, O K

    1999-09-01

    Sensitivity studies of epithermal neutron beam performance in boron neutron capture therapy are presented for realistic neutron beams with varying filter/moderator and collimator/delimiter designs to examine the relative importance of neutron beam spectrum, directionality, and size. Figures of merit for in-air and in-phantom beam performance are calculated via the Monte Carlo technique for different well-optimized designs of a fission converter-based epithermal neutron beam with head phantoms as the irradiation target. It is shown that increasing J/phi, a measure of beam directionality, does not always lead to corresponding monotonic improvements in beam performance. Due to the relatively low significance, for most configurations, of its effect on in-phantom performance and the large intensity losses required to produce beams with very high J/phi, beam directionality should not be considered an important figure of merit in epithermal neutron beam design except in terms of its consequences on patient positioning and collateral dose. Hardening the epithermal beam spectrum, while maintaining the specific fast neutron dose well below the inherent hydrogen capture dose, improves beam penetration and advantage depth and, as a desirable by-product, significantly increases beam intensity. Beam figures of merit are shown to be strongly dependent on beam size relative to target size. Beam designs with J/phi approximately 0.65-0.7, specific fast neutron doses of 2-2.6x10(-13) Gy cm2/n and beam sizes equal to or larger than the size of the head target produced the deepest useful penetration, highest therapeutic ratios, and highest intensities.

  1. Phase II clinical study of boron neutron capture therapy combined with X-ray radiotherapy/temozolomide in patients with newly diagnosed glioblastoma multiforme-Study design and current status report

    Energy Technology Data Exchange (ETDEWEB)

    Kawabata, Shinji, E-mail: neu046@poh.osaka-med.ac.jp [Department of Neurosurgery, Osaka Medical College, 2-7 Daigaku-Machi, Takatsuki, Osaka 569-8686 (Japan); Miyatake, Shin-Ichi; Hiramatsu, Ryo; Hirota, Yuki; Miyata, Shiro; Takekita, Yoko; Kuroiwa, Toshihiko [Department of Neurosurgery, Osaka Medical College, 2-7 Daigaku-Machi, Takatsuki, Osaka 569-8686 (Japan); Kirihata, Mitsunori [Graduate School of Life and Environmental Sciences, Osaka Prefecture University, 1-1 Gakuen-cho, Naka-ku, Sakai, Osaka 599-8931 (Japan); Sakurai, Yoshinori; Maruhashi, Akira; Ono, Koji [Kyoto University Research Reactor Institute, 2 Asashiro-Nishi, Kumatori-cho, Sennan-gun, Osaka 590-0494 (Japan)

    2011-12-15

    Recently, we reported our clinical experiences of boron neutron capture therapy (BNCT) for the newly diagnosed glioblastoma. The major differences of our protocol from the other past studies were simultaneous use of both sodium borocapate and boronophenylalanine, and combination with fractionated X-ray irradiation. These results showed the efficacy of combination therapy with external beam X-ray irradiation and BNCT. For our future study, we planned the multi-centric phase II clinical study for newly diagnosed glioblastoma patients in Japan (OSAKA-TRIBRAIN0902, NCT00974987).

  2. Optimal moderator materials at various proton energies considering photon dose rate after irradiation for an accelerator-driven ⁹Be(p, n) boron neutron capture therapy neutron source.

    Science.gov (United States)

    Hashimoto, Y; Hiraga, F; Kiyanagi, Y

    2015-12-01

    We evaluated the accelerator beam power and the neutron-induced radioactivity of (9)Be(p, n) boron neutron capture therapy (BNCT) neutron sources having a MgF2, CaF2, or AlF3 moderator and driven by protons with energy from 8 MeV to 30 MeV. The optimal moderator materials were found to be MgF2 for proton energies less than 10 MeV because of lower required accelerator beam power and CaF2 for higher proton energies because of lower photon dose rate at the treatment position after neutron irradiation.

  3. Biodistribution of boron after intravenous 4-dihydroxyborylphenylalanine-fructose (BPA-F) infusion in meningioma and schwannoma patients: A feasibility study for boron neutron capture therapy.

    Science.gov (United States)

    Kulvik, Martti; Kallio, Merja; Laakso, Juha; Vähätalo, Jyrki; Hermans, Raine; Järviluoma, Eija; Paetau, Anders; Rasilainen, Merja; Ruokonen, Inkeri; Seppälä, Matti; Jääskeläinen, Juha

    2015-12-01

    We studied the uptake of boron after 100 mg/kg BPA infusion in three meningioma and five schwannoma patients as a pre-BNCT feasibility study. With average tumour-to-whole blood boron concentrations of 2.5, we discuss why BNCT could, and probably should, be developed to treat severe forms of the studied tumours. However, analysing 72 tumour and 250 blood samples yielded another finding: the plasma-to-whole blood boron concentrations varied with time, suggesting that the assumed constant boron ratio of 1:1 between normal brain tissue and whole blood deserves re-assessment.

  4. Biodistribution of the boron carriers boronophenylalanine (BPA) and/or decahydrodecaborate (GB-10) for Boron Neutron Capture Therapy (BNCT) in an experimental model of lung metastases

    Energy Technology Data Exchange (ETDEWEB)

    D.W. Nigg; Various Others

    2014-06-01

    BNCT was proposed for the treatment of diffuse, non-resectable tumors in the lung. We performed boron biodistribution studies with 5 administration protocols employing the boron carriers BPA and/or GB-10 in an experimental model of disseminated lung metastases in rats. All 5 protocols were non-toxic and showed preferential tumor boron uptake versus lung. Absolute tumor boron concentration values were therapeutically useful (25–76 ppm) for 3 protocols. Dosimetric calculations indicate that BNCT at RA-3 would be potentially therapeutic without exceeding radiotolerance in the lung.

  5. Neutron capture therapy: Years of experimentation---Years of reflection

    Energy Technology Data Exchange (ETDEWEB)

    Farr, L.E.

    1991-12-16

    This report describes early research on neutron capture therapy over a number of years, beginning in 1950, speaking briefly of patient treatments but dwelling mostly on interpretations of our animal experiments. This work carried out over eighteen years, beginning over forty years ago. Yet, it is only fitting to start by relating how neutron capture therapy became part of Brookhaven`s Medical Research Center program.

  6. Neutron capture therapy: Years of experimentation---Years of reflection

    Energy Technology Data Exchange (ETDEWEB)

    Farr, L.E.

    1991-12-16

    This report describes early research on neutron capture therapy over a number of years, beginning in 1950, speaking briefly of patient treatments but dwelling mostly on interpretations of our animal experiments. This work carried out over eighteen years, beginning over forty years ago. Yet, it is only fitting to start by relating how neutron capture therapy became part of Brookhaven's Medical Research Center program.

  7. L-Phenylalanine preloading reduces the (10)B(n, α)(7)Li dose to the normal brain by inhibiting the uptake of boronophenylalanine in boron neutron capture therapy for brain tumours.

    Science.gov (United States)

    Watanabe, Tsubasa; Tanaka, Hiroki; Fukutani, Satoshi; Suzuki, Minoru; Hiraoka, Masahiro; Ono, Koji

    2016-01-01

    Boron neutron capture therapy (BNCT) is a cellular-level particle radiation therapy that combines the selective delivery of boron compounds to tumour tissue with neutron irradiation. Previously, high doses of one of the boron compounds used for BNCT, L-BPA, were found to reduce the boron-derived irradiation dose to the central nervous system. However, injection with a high dose of L-BPA is not feasible in clinical settings. We aimed to find an alternative method to improve the therapeutic efficacy of this therapy. We examined the effects of oral preloading with various analogues of L-BPA in a xenograft tumour model and found that high-dose L-phenylalanine reduced the accumulation of L-BPA in the normal brain relative to tumour tissue. As a result, the maximum irradiation dose in the normal brain was 19.2% lower in the L-phenylalanine group relative to the control group. This study provides a simple strategy to improve the therapeutic efficacy of conventional boron compounds for BNCT for brain tumours and the possibility to widen the indication of BNCT to various kinds of other tumours.

  8. Monte Carlo based dosimetry for neutron capture therapy of brain tumors

    Science.gov (United States)

    Zaidi, Lilia; Belgaid, Mohamed; Khelifi, Rachid

    2016-11-01

    Boron Neutron Capture Therapy (BNCT) is a biologically targeted, radiation therapy for cancer which combines neutron irradiation with a tumor targeting agent labeled with a boron10 having a high thermal neutron capture cross section. The tumor area is subjected to the neutron irradiation. After a thermal neutron capture, the excited 11B nucleus fissions into an alpha particle and lithium recoil nucleus. The high Linear Energy Transfer (LET) emitted particles deposit their energy in a range of about 10μm, which is of the same order of cell diameter [1], at the same time other reactions due to neutron activation with body component are produced. In-phantom measurement of physical dose distribution is very important for BNCT planning validation. Determination of total absorbed dose requires complex calculations which were carried out using the Monte Carlo MCNP code [2].

  9. Improved methods for the generation of 24.5 keV neutron beams with possible application to boron neutron capture therapy

    Science.gov (United States)

    Constantine, G.; Baker, L. J.; Taylor, N. P.

    1986-09-01

    The production of epithermal neutron beams, filtered to provide a spectrum in which a small energy range predominates, is of importance for radiobiological research and in the development and calibration of instruments for monitoring intermediate energy neutrons. The penetration characteristics of intermediate energy neutrons in tissue lead to the possibility of application in the field of neutron capture therapy if beams of sufficient intensity and adequate spectral properties can be generated. In this paper methods of utilising the 24.5 keV antiresonance in the iron neutron cross section are described, and the DENIS (depth enhanced neutron intense source) principle by which beam intensities may be optimised is explained. Calculations and experimental measurements in an in-core facility in the DIDO reactor at Harwell have indicated that a DENIS scatterer can achieve a 6-fold improvement in 24.5 keV beam intensity compared with a conventional titanium disc scatterer.

  10. Boron neutron capture therapy of EGFR or EGFRvIII positive gliomas using either boronated monoclonal antibodies or epidermal growth factor as molecular targeting agents

    Energy Technology Data Exchange (ETDEWEB)

    Yang, W. [Department of Pathology, Ohio State University, 165 Hamilton Hall, 1645 Neil Avenue, Columbus, OH 43210 (United States); Barth, R.F. [Department of Pathology, Ohio State University, 165 Hamilton Hall, 1645 Neil Avenue, Columbus, OH 43210 (United States)], E-mail: rolf.barth@osumc.edu; Wu, G. [Department of Pathology, Ohio State University, 165 Hamilton Hall, 1645 Neil Avenue, Columbus, OH 43210 (United States); Tjarks, W. [College of Pharmacy, Ohio State University, Columbus, OH 43210 (United States); Binns, P.; Riley, K. [Nuclear Reactor Laboratory and Department of Nuclear Engineering, Massachusetts Institute of Technology, Cambridge, MA 02215 (United States)

    2009-07-15

    In the present report we have summarized studies carried out over the past five years on molecular targeting of the epidermal growth factor receptor (EGFR) and its mutant isoform, EFGRvIII, for BNCT of genetically engineered F98 rat gliomas, expressing either wildtype (F98{sub EGFR}) or mutant receptors (F98{sub npEGFRvIII}). EGF or the monoclonal antibodies (mAbs), cetuximab (IMC-C225) and L8A4, which recognize wildtype EGFR and EGFRvIII, respectively, were heavily boronated using polyamidoamine (PAMAM) dendrimers (BD) linked to the targeting vehicles by means of heterobifunctional reagents. Boronated EGF or mAbs, alone or in combination with i.v. boronophenylalanine (BPA), were administered intracerebrally (i.c.) by either intratumoral (i.t.) injection or convection enhanced delivery (CED) to rats bearing F98 gliomas following which BNCT was initiated. The best survival data were obtained in rats bearing F98{sub npEGFRvIII} gliomas that had received CED of BD-L8A4 either alone or in combination with i.v. boronophenylalanine (BPA). Studies carried out in rats bearing composite tumors (F98{sub EGFR}/F98{sub npEGFRvIII}) demonstrated that it was essential to target both tumor cell populations in order to obtain an optimal therapeutic effect. Based on these observations, we have concluded that EGFR targeting vehicles are useful, but not stand-alone boron delivery agents due to the heterogeneity of receptor expression in brain tumors. They could, however, be quite useful in combination with the two drugs that currently are being used clinically, BPA and sodium borocaptate (BSH) for BNCT of either brain tumors or head and neck cancers.

  11. Therapeutic efficacy of boron neutron capture therapy mediated by boron-rich liposomes for oral cancer in the hamster cheek pouch model

    Energy Technology Data Exchange (ETDEWEB)

    Heber, Elisa M. [Comision Nacional de Energia Atomica (CNEA), Buenos Aires (Argentina); Hawthorne, M. Frederick [Univ. of Missouri, Columbia, MO (United States). International Inst. of Nano and Molecular Medicine; Kueffer, Peter J. [Univ. of Missouri, Columbia, MO (United States). International Inst. of Nano and Molecular Medicine; Garabalino, Marcela A. [Comision Nacional de Energia Atomica (CNEA), Buenos Aires (Argentina); Thorp, Silvia I. [Comision Nacional de Energia Atomica (CNEA), Buenos Aires (Argentina); Pozzi, Emiliano C. C. [Comision Nacional de Energia Atomica (CNEA), Buenos Aires (Argentina); Hughes, Andrea Monti [Comision Nacional de Energia Atomica (CNEA), Buenos Aires (Argentina); Maitz, Charles A. [Univ. of Missouri, Columbia, MO (United States). International Inst. of Nano and Molecular Medicine; Jalisatgi, Satish S. [Univ. of Missouri, Columbia, MO (United States). International Inst. of Nano and Molecular Medicine; Nigg, David W. [Idaho National Lab. (INL), Idaho Falls, ID (United States); Curotto, Paula [Comision Nacional de Energia Atomica (CNEA), Buenos Aires (Argentina); Trivillin, Verónica A. [Comision Nacional de Energia Atomica (CNEA), Buenos Aires (Argentina); Schwint, Amanda E. [Comision Nacional de Energia Atomica (CNEA), Buenos Aires (Argentina)

    2014-11-11

    Unilamellar liposomes formulated with an equimolar mixture of cholesterol and 1,2-distearoyl-sn-glycero-3-phosphocholine, incorporating K[nido-7-CH3(CH2)15-7,8-C2B9H11] in the lipid bilayer, and encapsulating Na3[1-(2’-B10-H9)-2-NH3B10H8] were prepared by probe sonication and investigated in vivo. Microwave assisted digestion followed by inductively coupled plasma-optical emission spectroscopy was utilized to determine the biodistribution of boron in various tissues following either a single tail vein injection or two identical injections (separated by 24 hours) of the liposomal suspension in BALB/c mice bearing EMT6 mammary adenocarcinomas in their right flank. Double-injection protocols resulted in a boron content in the tumor exceeding 50 µg of boron per gram of tissue for 48 to 72 hours subsequent to the initial injection while tumor:blood boron ratios were more ideal from 54 hours (1.9:1) to 96 hours (5.7:1) subsequent to the initial injection. Tumor bearing mice were given a double-injection of liposomes containing the 10B-enriched analogs of the aforementioned agents and subjected to a 30 minute irradiation by thermal neutrons with a flux of 8.8 x 108 (±7%) neutrons/cm2 s integrated over the energy range of 0.0 – 0.414 eV. Significant tumor response for a single BNCT treatment was demonstrated by growth curves versus a control group. Vastly diminished tumor growth was witnessed at 14 days (186% increase versus 1551% in controls) in mice that were given a second injection/radiation treatment 7 days after the first. Mice given a one hour neutron irradiation following the double-injection of liposomes had a similar response (169% increase at 14 days) suggesting that neutron fluence is the limiting factor towards BNCT efficacy in this study.

  12. Neutron-photon mixed field dosimetry by TLD-700 glow curve analysis and its implementation in dose monitoring for Boron Neutron Capture Therapy (BNCT) treatments

    Energy Technology Data Exchange (ETDEWEB)

    Boggio, E. F.; Longhino, J. M. [Centro Atomico Bariloche, Departamento de Fisica de Reactores y Radiaciones / CNEA, Av. E. Bustillo Km 9.5, R8402AGP San Carlos de Bariloche (Argentina); Andres, P. A., E-mail: efboggio@cab.cnea.gov.ar [Centro Atomico Bariloche, Division Proteccion Radiologica / CNEA, Av. E. Bustillo Km 9.5, R8402AGP San Carlos de Bariloche (Argentina)

    2015-10-15

    BNCT is a cancerous cells selective, non-conventional radiotherapy modality to treat malignant tumors such as glioblastoma, melanoma and recurrent head and neck cancer. It consists of a two-step procedure: first, the patient is injected with a tumor localizing drug containing a non-radioactive isotope (Boron-10) with high slow neutron capture cross-section. In a second step, the patient is irradiated with neutrons, which are absorbed by the Boron-10 agent with the subsequently nuclear reaction B- 10(n,a)Li-7, thereby resulting in dose at cellular level due to the high-Let particles. The neutron fields suitable for BNCT are characterized by high neutron fluxes and low gamma dose. Determination of each component is not an easy task, especially when the volume of measurement is quite small or inaccessible for a miniature ionization chamber, for example. A method of measuring the photon and slow neutron dose(mainly by N-14 and B-10) from the glow curve (GC) analysis of a single {sup 7}LiF thermoluminescence detector is evaluated. This method was suggested by the group headed by Dr. Grazia Gambarini. The dosemeters used were TLD-600 ({sup 6}LiF:Mg,Ti with 95.6% {sup 6}Li) and TLD-700 ({sup 7}LiF:Mg,Ti with 99.9% {sup 7}LiF) from Harshaw. Photon dose measurement using the GC analysis method with TLD-700 in mixed fields requires the relation of the two main peaks of a TLD-600 GC shape obtained from an exposition to the same neutron field, and a photon calibrated GC with TLD-700. The requirements for slow neutron dose measurements are similar. In order to properly apply the GC analysis method at the Ra-6 Research Reactor BNCT facility, measurements were carried out in a standard water phantom, fully characterized on the BNCT beam by conventional techniques (activation detectors and paired ionization chambers technique). Next, the method was implemented in whole body dose monitoring of a patient undergoing a BNCT treatment, using a Bo MAb (Bottle Manikin Absorption) phantom

  13. Feasibility evaluation of neutron capture therapy for hepatocellular carcinoma using selective enhancement of boron accumulation in tumour with intra-arterial administration of boron-entrapped water-in-oil-in-water emulsion

    Energy Technology Data Exchange (ETDEWEB)

    Yanagie, Hironobu, E-mail: yanagie@n.t.u-tokyo.ac.jp [Dept of Nuclear Engineering and Management, Graduate School of Engineering, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8656 (Japan)] [Cooperative Unit of Medicine and Engineering, University of Tokyo Hospital, Tokyo (Japan); Kumada, Hiroaki [Proton Medical Research Center, University of Tsukuba, Ibaraki (Japan); Nakamura, Takemi [Japan Atomic Energy Research Institute, Ibaraki (Japan); Higashi, Syushi [Dept of Surgery, Ebihara Memorial Hospital, Miyazaki (Japan)] [Kyushu Industrial Sources Foundation, Miyazaki (Japan); Ikushima, Ichiro [Dept of Radiology, Miyakonojyo Metropolitan Hospital, Miyazaki (Japan); Morishita, Yasuyuki [Dept of Human and Molecular Pathology, Graduate School of Medicine, University of Tokyo, Tokyo (Japan); Shinohara, Atsuko [Dept of Humanities, Graduate School of Seisen University, Tokyo (Japan); Fijihara, Mitsuteru [SPG Techno Ltd. Co., Miyazaki (Japan); Suzuki, Minoru; Sakurai, Yoshinori [Research Reactor Institute, Kyoto University, Osaka (Japan); Sugiyama, Hirotaka [Cooperative Unit of Medicine and Engineering, University of Tokyo Hospital, Tokyo (Japan); Kajiyama, Tetsuya [Kyushu Industrial Sources Foundation, Miyazaki (Japan); Nishimura, Ryohei [Dept of Veternary Surgery, University of Tokyo Veternary Hospital, Tokyo (Japan); Ono, Koji [Research Reactor Institute, Kyoto University, Osaka (Japan); Nakajima, Jun; Ono, Minoru [Dept of Cardiothracic Surgery, University of Tokyo Hospital, Tokyo (Japan); Eriguchi, Masazumi [Cooperative Unit of Medicine and Engineering, University of Tokyo Hospital, Tokyo (Japan)] [Department of Surgery, Shin-Yamanote Hospital, Saitama (Japan); Takahashi, Hiroyuki [Dept of Nuclear Engineering and Management, Graduate School of Engineering, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8656 (Japan)] [Cooperative Unit of Medicine and Engineering, University of Tokyo Hospital, Tokyo (Japan)

    2011-12-15

    Introduction: Hepatocellular carcinoma (HCC) is one of the most difficult to cure with surgery, chemotherapy, or other combinational therapies. In the treatment of HCC, only 30% patients can be operated due to complication of liver cirrhosis or multiple intrahepatic tumours. Tumour cell destruction in boron neutron-capture therapy (BNCT) is due to the nuclear reaction between {sup 10}B atoms and thermal neutrons, so it is necessary to accumulate a sufficient quantity of {sup 10}B atoms in tumour cells for effective tumour cell destruction by BNCT. Water-in-oil-in-water (WOW) emulsion has been used as the carrier of anti-cancer agents on intra-arterial injections in clinical. In this study, we prepared {sup 10}BSH entrapped WOW emulsion by double emulsifying technique using iodized poppy-seed oil (IPSO), {sup 10}BSH and surfactant, for selective intra-arterial infusion to HCC, and performed simulations of the irradiation in order to calculate the dose delivered to the patients. Materials and methods: WOW emulsion was administrated with intra-arterial injections via proper hepatic artery on VX-2 rabbit hepatic tumour models. We simulated the irradiation of epithermal neutron and calculated the dose delivered to the tissues with JAEA computational dosimetry system (JCDS) at JRR4 reactor of Japan Atomic Research Institute, using the CT scans of a HCC patient. Results and discussions: The {sup 10}B concentrations in VX-2 tumour obtained by delivery with WOW emulsion were superior to those by conventional IPSO mix emulsion. According to the rabbit model, the boron concentrations (ppm) in tumour, normal liver tissue, and blood are 61.7, 4.3, and 0.1, respectively. The results of the simulations show that normal liver biologically weighted dose is restricted to 4.9 Gy-Eq (CBE; liver tumour: 2.5, normal liver: 0.94); the maximum, minimum, and mean tumour weighted dose are 43.1, 7.3, and 21.8 Gy-Eq, respectively, in 40 min irradiation. In this study, we show that {sup 10}B

  14. In-phantom dose mapping in neutron capture therapy by means of solid state detectors

    Science.gov (United States)

    Baccaro, S.; Cemmi, A.; Colombi, C.; Fiocca, M.; Gambarini, G.; Lietti, B.; Rosi, G.

    2004-01-01

    A method has been developed, based on thermoluminescent dosimeters and alanine, aimed at measuring the absorbed dose in tissue-equivalent phantoms exposed to an epithermal neutron beam suitable for neutron capture therapy (NCT), separating the contributions due to the various secondary radiations generated by neutrons. Exposures have been made at the TAPIRO nuclear reactor (ENEA, Italy), in the epithermal column properly designed and set up for experiments on boron NCT.

  15. {sup 33}S for Neutron Capture Therapy: Nuclear Data for Monte Carlo Calculations

    Energy Technology Data Exchange (ETDEWEB)

    Porras, I., E-mail: porras@ugr.es [Departamento de Física Atómica, Molecular y Nuclear, Facultad de Ciencias, Universidad de Granada, E-18071 Granada (Spain); Sabaté-Gilarte, M.; Praena, J.; Quesada, J.M. [Departamento de Física Atómica, Molecular y Nuclear, Facultad de Física, Universidad de Sevilla, E-41012 Sevilla (Spain); Esquinas, P.L. [Departament of Physics and Astronomy, University of British Columbia, Vancouver, BC (Canada)

    2014-06-15

    A study of the nuclear data required for the Monte Carlo simulation of boron neutron capture therapy including the {sup 33}S isotope as an enhancer of the dose at small depths has been performed. In particular, the controversy on the available data for the {sup 33}S(n, α) cross section will be shown, which motivates new measurements. In addition to this, kerma factors for the main components of tissue are calculated with the use of fitting functions. Finally, we have applied these data to a potential neutron capture treatment with boron and sulfur addition to tissue in which part of the hydrogen atoms are replaced by deuterium, which improves the procedure.

  16. Molecular medicine: Synthesis and in-vivo detection of agents for use in boron neutron capture therapy. Final report, May 1, 1993--April 30, 1996

    Energy Technology Data Exchange (ETDEWEB)

    Kabalka, G.W.

    1997-08-01

    During the early stages of this project, the author developed the first whole-body boron MRI technique. They found that, for the first time, information concerning both the location and the quantity of boron present in living tissues could be obtained through the use of magnetic resonance imaging (MRI) and magnetic resonance spectroscopy (MRS) respectively. However, it was also discovered that boron MRI was not without problems. Both naturally occurring isotopes of boron (boron-10 and boron-11) possess magnetic moments, making them amenable to MR detection. The author found that there are difficulties in obtaining boron MRI images which are a consequence of the inherently poor magnetic resonance characteristics of the boron nucleus. The magnetogyric ratios of both boron-10 and boron-11 are smaller than those of hydrogen, which makes boron much less sensitive to magnetic resonance detection. In addition, both isotopes of boron posses nuclear electric quadrupole moments which serve to shorten their magnetization relaxation times; this causes the MR signal to broaden and decay rapidly, often before the receiver coils can collect the MR information. The rapid rate of signal decay is enhanced in biological systems which leads to further signal loss and a decrease in the signal to noise ratio (SNR).

  17. Theoretical and experimental physical methods of neutron-capture therapy

    Science.gov (United States)

    Borisov, G. I.

    2011-09-01

    This review is based to a substantial degree on our priority developments and research at the IR-8 reactor of the Russian Research Centre Kurchatov Institute. New theoretical and experimental methods of neutron-capture therapy are developed and applied in practice; these are: A general analytical and semi-empiric theory of neutron-capture therapy (NCT) based on classical neutron physics and its main sections (elementary theories of moderation, diffuse, reflection, and absorption of neutrons) rather than on methods of mathematical simulation. The theory is, first of all, intended for practical application by physicists, engineers, biologists, and physicians. This theory can be mastered by anyone with a higher education of almost any kind and minimal experience in operating a personal computer.

  18. Blood-brain barrier (BBB) toxicity and permeability assessment after L-(4-¹⁰Boronophenyl)alanine, a conventional B-containing drug for boron neutron capture therapy, using an in vitro BBB model.

    Science.gov (United States)

    Roda, E; Nion, S; Bernocchi, G; Coccini, T

    2014-10-01

    Since brain tumours are the primary candidates for treatment by Boron Neutron Capture Therapy, one major challenge in the selective drug delivery to CNS is the crossing of the blood-brain barrier (BBB). The present pilot study investigated (i) the transport of a conventional B-containing product (i.e., L-(4-(10)Boronophenyl)alanine, L-(10)BPA), already used in medicine but still not fully characterized regarding its CNS interactions, as well as (ii) the effects of the L-(10)BPA on the BBB integrity using an in vitro model, consisting of brain capillary endothelial cells co-cultured with glial cells, closely mimicking the in vivo conditions. The multi-step experimental strategy (i.e. Integrity test, Filter study, Transport assay) checked L-(10)BPA toxicity at 80 µg Boron equivalent/ml, and its ability to cross the BBB, additionally by characterizing the cytoskeletal and TJ's proteins by immunocytochemistry and immunoblotting. In conclusion, a lack of toxic effects of L-(10)BPA was demonstrated, nevertheless accompanied by cellular stress phenomena (e.g. vimentin expression modification), paralleled by a low permeability coefficient (0.39 ± 0.01 × 10(-3)cm min(-1)), corroborating the scarce probability that L-(10)BPA would reach therapeutically effective cerebral concentration. These findings emphasized the need for novel strategies aimed at optimizing boron delivery to brain tumours, trying to ameliorate the compound uptake or developing new targeted products suitable to safely and effectively treat head cancer. Thus, the use of in vitro BBB model for screening studies may provide a useful early safety assessment for new effective compounds.

  19. Improvement effect on the depth-dose distribution by CSF drainage and air infusion of a tumour-removed cavity in boron neutron capture therapy for malignant brain tumours

    Science.gov (United States)

    Sakurai, Yoshinori; Ono, Koji; Miyatake, Shin-ichi; Maruhashi, Akira

    2006-03-01

    Boron neutron capture therapy (BNCT) without craniotomy for malignant brain tumours was started using an epi-thermal neutron beam at the Kyoto University Reactor in June 2002. We have tried some techniques to overcome the treatable-depth limit in BNCT. One of the effective techniques is void formation utilizing a tumour-removed cavity. The tumorous part is removed by craniotomy about 1 week before a BNCT treatment in our protocol. Just before the BNCT irradiation, the cerebro-spinal fluid (CSF) in the tumour-removed cavity is drained out, air is infused to the cavity and then the void is made. This void improves the neutron penetration, and the thermal neutron flux at depth increases. The phantom experiments and survey simulations modelling the CSF drainage and air infusion of the tumour-removed cavity were performed for the size and shape of the void. The advantage of the CSF drainage and air infusion is confirmed for the improvement in the depth-dose distribution. From the parametric surveys, it was confirmed that the cavity volume had good correlation with the improvement effect, and the larger effect was expected as the cavity volume was larger.

  20. Boron neutron capture therapy (BNCT) for liver metastasis in an experimental model: dose–response at five-week follow-up based on retrospective dose assessment in individual rats

    Energy Technology Data Exchange (ETDEWEB)

    Emiliano C. C. Pozzi; Veronica A. Trivilin; Lucas L. Colombo; Andrea Monti Hughes; Silvia I. Thorp; Jorge E. Cardoso; Marcel A. Garabalino; Ana J. Molinari; Elisa M. Heber; Paula Curotto; Marcelo Miller; Maria E. Itoiz; Romina F. Aromando; David W. Nigg; Amanda E. Schwint

    2013-11-01

    Boron neutron capture therapy (BNCT) was proposed for untreatable colorectal liver metastases. Employing an experimental model of liver metastases in rats, we recently demonstrated that BNCT mediated by boronophenylalanine (BPA-BNCT) at 13 Gy prescribed to tumor is therapeutically useful at 3-week follow-up. The aim of the present study was to evaluate dose–response at 5-week follow-up, based on retrospective dose assessment in individual rats. BDIX rats were inoculated with syngeneic colon cancer cells DHD/K12/TRb. Tumor-bearing animals were divided into three groups: BPA-BNCT (n = 19), Beam only (n = 8) and Sham (n = 7) (matched manipulation, no treatment). For each rat, neutron flux was measured in situ and boron content was measured in a pre-irradiation blood sample for retrospective individual dose assessment. For statistical analysis (ANOVA), individual data for the BPA-BNCT group were pooled according to absorbed tumor dose, BPA-BNCT I: 4.5–8.9 Gy and BPA-BNCT II: 9.2–16 Gy. At 5 weeks post-irradiation, the tumor surface area post-treatment/pre-treatment ratio was 12.2 +/- 6.6 for Sham, 7.8 +/- 4.1 for Beam only, 4.4 +/- 5.6 for BPA-BNCT I and 0.45 +/- 0.20 for BPA-BNCT II; tumor nodule weight was 750 +/- 480 mg for Sham, 960 +/- 620 mg for Beam only, 380 +/- 720 mg for BPA-BNCT I and 7.3 +/- 5.9 mg for BPA-BNCT II. The BPA-BNCT II group exhibited statistically significant tumor control with no contributory liver toxicity. Potential threshold doses for tumor response and significant tumor control were established at 6.1 and 9.2 Gy, respectively.

  1. High-power electron beam tests of a liquid-lithium target and characterization study of (7)Li(p,n) near-threshold neutrons for accelerator-based boron neutron capture therapy.

    Science.gov (United States)

    Halfon, S; Paul, M; Arenshtam, A; Berkovits, D; Cohen, D; Eliyahu, I; Kijel, D; Mardor, I; Silverman, I

    2014-06-01

    A compact Liquid-Lithium Target (LiLiT) was built and tested with a high-power electron gun at Soreq Nuclear Research Center (SNRC). The target is intended to demonstrate liquid-lithium target capabilities to constitute an accelerator-based intense neutron source for Boron Neutron Capture Therapy (BNCT) in hospitals. The lithium target will produce neutrons through the (7)Li(p,n)(7)Be reaction and it will overcome the major problem of removing the thermal power >5kW generated by high-intensity proton beams, necessary for sufficient therapeutic neutron flux. In preliminary experiments liquid lithium was flown through the target loop and generated a stable jet on the concave supporting wall. Electron beam irradiation demonstrated that the liquid-lithium target can dissipate electron power densities of more than 4kW/cm(2) and volumetric power density around 2MW/cm(3) at a lithium flow of ~4m/s, while maintaining stable temperature and vacuum conditions. These power densities correspond to a narrow (σ=~2mm) 1.91MeV, 3mA proton beam. A high-intensity proton beam irradiation (1.91-2.5MeV, 2mA) is being commissioned at the SARAF (Soreq Applied Research Accelerator Facility) superconducting linear accelerator. In order to determine the conditions of LiLiT proton irradiation for BNCT and to tailor the neutron energy spectrum, a characterization of near threshold (~1.91MeV) (7)Li(p,n) neutrons is in progress based on Monte-Carlo (MCNP and Geant4) simulation and on low-intensity experiments with solid LiF targets. In-phantom dosimetry measurements are performed using special designed dosimeters based on CR-39 track detectors.

  2. Computational assessment of deep-seated tumor treatment capability of the 9Be(d,n)10B reaction for accelerator-based boron neutron capture therapy (AB-BNCT).

    Science.gov (United States)

    Capoulat, M E; Minsky, D M; Kreiner, A J

    2014-03-01

    The 9Be(d,n)10B reaction was studied as an epithermal neutron source for brain tumor treatment through Boron Neutron Capture Therapy (BNCT). In BNCT, neutrons are classified according to their energies as thermal (epithermal (from 0.5 eV to 10 keV) or fast (>10 keV). For deep-seated tumors epithermal neutrons are needed. Since a fraction of the neutrons produced by this reaction are quite fast (up to 5-6 MeV, even for low-bombarding energies), an efficient beam shaping design is required. This task was carried out (1) by selecting the combinations of bombarding energy and target thickness that minimize the highest-energy neutron production; and (2) by the appropriate choice of the Beam Shaping Assembly (BSA) geometry, for each of the combinations found in (1). The BSA geometry was determined as the configuration that maximized the dose deliverable to the tumor in a 1 h treatment, within the constraints imposed by the healthy tissue dose adopted tolerance. Doses were calculated through the MCNP code. The highest dose deliverable to the tumor was found for an 8 μm target and a deuteron beam of 1.45 MeV. Tumor weighted doses ≥40 Gy can be delivered up to about 5 cm in depth, with a maximum value of 51 Gy at a depth of about 2 cm. This dose performance can be improved by relaxing the treatment time constraint and splitting the treatment into two 1-h sessions. These good treatment capabilities strengthen the prospects for a potential use of this reaction in BNCT.

  3. Tratamiento del cáncer por captura neutrónica de boro: Su aplicación al carcinoma indiferenciado de tiroides Boron neutron capture therapy applied to undifferentiated thyroid carcinoma

    Directory of Open Access Journals (Sweden)

    Mario A. Pisarev

    2006-12-01

    Full Text Available El cáncer indiferenciado de tiroides es un tumor muy agresivo, de muy mal pronóstico y sin tratamiento efectivo. La terapia por captura neutrónica de boro (BNCT podría ser una alternativa para el tratamiento de esta enfermedad. Se basa en la captación selectiva de boro por el tumor y su activación por un haz de neutrones. El boro activado libera un núcleo de litio-7 y una partícula alfa, las cuales tienen una alta transmisión linear de energía (linear energy transfer, LET y un alcance de 5-9 µm, destruyendo el tumor. En estudios previos hemos mostrado que la línea celular humana de cáncer indiferenciado de tiroides (ARO tiene una captación selectiva de borofenilalanina (10BPA tanto in vitro como después de ser implantada en ratones NIH nude. También demostramos en estos animales inyectados con BPA e irradiados con un haz de neutrones térmicos, un 100% de control sobre el crecimiento tumoral y un 50% de cura histológica. En trabajos posteriores mostramos que la porfirina 10BOPP tetrakis-carborane carboxylate ester de 2,4-bis-(a,b-dihydroxyethyl-deutero-porphyrin IX cuando es inyectada 5-7 días antes que el BPA se obtiene una concentración tumoral de boro de aproximadamente el doble que el BPA solo (45-38 ppm vs. 20 ppm. La posterior irradiación con neutrones mostró un 100% de remisión completa en animales con tumores cuyo volumen pre-tratamiento era de 50 mm³ o menor. Los perros padecen CIT espontáneo, con un comportamiento biológico similar al humano, y una captación selectiva de BPA, abriendo la posibilidad de su tratamiento por BNCT.Undifferentiated thyroid carcinoma (UTC is an aggressive tumor with a poor prognosis due to the lack of an effective treatment. Boron neutron capture therapy (BNCT is based on the selective uptake of boron by the tumor and its activation by a neutron beam, releasing lithium-7 and an alpha particle that will kill the tumor cells by their high linear energy transfer (LET. In previous

  4. Dosimetry methods in boron neutron capture therapy

    Energy Technology Data Exchange (ETDEWEB)

    Gambarini, G.; Artuso, E.; Felisi, M.; Regazzoni, V.; Giove, D. [Universita degli Studi di Milano, Department of Physics, Via Festa del Patrono 7, 20122 Milano (Italy); Agosteo, S.; Barcaglioni, L. [Istituto Nazionale di Fisica Nucleare, Milano (Italy); Campi, F.; Garlati, L. [Politecnico di Milano, Energy Department, Piazza Leonardo Da Vinci 32, 20133 Milano (Italy); De Errico, F. [Universita degli Studi di Pisa, Department of Civil and Industrial Engineering, Lungamo Pacinotti 43, 56126 Pisa (Italy); Borroni, M.; Carrara, M. [Fondazione IRCCS Istituto Nazionale Tumori, Medical Physics Unit, Via Venezian 1, 20133 Milano (Italy); Burian, J.; Klupak, V.; Viererbl, L.; Marek, M. [Research Centre Rez, Department of Neutron Physics, 250-68 Husinec-Rez (Czech Republic)

    2014-08-15

    Dosimetry studies have been carried out at thermal and epithermal columns of Lvr-15 research reactor for investigating the spatial distribution of gamma dose, fast neutron dose and thermal neutron fluence. Two different dosimetry methods, both based on solid state detectors, have been studied and applied and the accuracy and consistency of the results have been inspected. One method is based on Fricke gel dosimeters that are dilute water solutions and have good tissue equivalence for neutrons and also for all the secondary radiations produced by neutron interactions in tissue or water phantoms. Fricke gel dosimeters give the possibility of separating the various dose contributions, i.e. the gamma dose, the fast neutron dose and the dose due to charged particles generated during thermal neutron reactions by isotopes having high cross section, like 10-B. From this last dose, thermal neutron fluence can be obtained by means of the kerma factor. The second method is based on thermoluminescence dosimeters. In particular, the developed method draw advantage from the different heights of the peaks of the glow curve of such phosphors when irradiated with photons or with thermal neutrons. The results show that satisfactory results can be obtained with simple methods, in spite of the complexity of the subject. However, the more suitable dosimeters and principally their utilization and analysis modalities are different for the various neutron beams, mainly depending on the relative intensities of the three components of the neutron field, in particular are different for thermal and epithermal columns. (Author)

  5. Development and construction of a neutron beam line for accelerator-based boron neutron capture synovectomy.

    Science.gov (United States)

    Gierga, D P; Yanch, J C; Shefer, R E

    2000-01-01

    A potential application of the 10B(n, alpha)7Li nuclear reaction for the treatment of rheumatoid arthritis, termed Boron Neutron Capture Synovectomy (BNCS), is under investigation. In an arthritic joint, the synovial lining becomes inflamed and is a source of great pain and discomfort for the afflicted patient. The goal of BNCS is to ablate the synovium, thereby eliminating the symptoms of the arthritis. A BNCS treatment would consist of an intra-articular injection of boron followed by neutron irradiation of the joint. Monte Carlo radiation transport calculations have been used to develop an accelerator-based epithermal neutron beam line for BNCS treatments. The model includes a moderator/reflector assembly, neutron producing target, target cooling system, and arthritic joint phantom. Single and parallel opposed beam irradiations have been modeled for the human knee, human finger, and rabbit knee joints. Additional reflectors, placed to the side and back of the joint, have been added to the model and have been shown to improve treatment times and skin doses by about a factor of 2. Several neutron-producing charged particle reactions have been examined for BNCS, including the 9Be(p,n) reaction at proton energies of 4 and 3.7 MeV, the 9Be(d,n) reaction at deuteron energies of 1.5 and 2.6 MeV, and the 7Li(p,n) reaction at a proton energy of 2.5 MeV. For an accelerator beam current of 1 mA and synovial boron uptake of 1000 ppm, the time to deliver a therapy dose of 10,000 RBEcGy ranges from 3 to 48 min, depending on the treated joint and the neutron producing charged particle reaction. The whole-body effective dose that a human would incur during a knee treatment has been estimated to be 3.6 rem or 0.75 rem, for 1000 ppm or 19,000 ppm synovial boron uptake, respectively, although the shielding configuration has not yet been optimized. The Monte Carlo design process culminated in the construction, installation, and testing of a dedicated BNCS beam line on the high

  6. 用于硼中子俘获治疗的超热中子束理论设计%Theoretical design of an epithermal neutron beam for boron neutron capture therapy

    Institute of Scientific and Technical Information of China (English)

    张晓敏; 潘洁; 宁静; 谢向东; 杨国山

    2010-01-01

    Objective To design a scheme of epithermal neutron beam used for boron neutron capture therapy (BNCT).Methods Based on Tsinghua University experimental reactor and its No.1 passage,five schemes comprised of moderate materials,absorbing materials of thermal neutron and γ shielding materials were designed according to different locations of materials placed in No.1 passage.To select a proper scheme from five schemes,the neutron fluence rate,the neutron dose rate and γ dose rate at exit of beam in each scheme were calculated with Monte Carlo simulating methods and then contrasted with BNCT technique criterion.Results The scheme of epithermal neutron beam meeting technical requirements of BNCT was obtained,in which the thickness of moderate material,absorbing materials of thermal neutron and γ shielding materials are 53.5 cm,2 mm and 9 cm,respectively.Conclusions The theoretical scheme could provide some reference to realize BNCT on reactor.%目的 设计用于硼中子俘获治疗(BNCT)的超热中子束理论方案.方法 基于清华大学试验核反应堆,以其1号孔道为材料布放孔道,设计了由慢化材料、热中子吸收材料、γ屏蔽材料组成,但材料布放位置具有差异的5种理论方案;利用蒙特卡罗(MC)模拟方法,分别计算5种方案束出口处的中子注量率、剂量率及γ剂量率值,通过与BNCT技术指标对比,从5种方案中选择一种合适的方案.结果 得到了一个符合BNCT各项技术指标的超热中子束理论方案,其慢化材料厚度为53.5 cm、热中子吸收材料厚度为2 mm、γ屏蔽材料厚度为9 cm.结论 本研究给出的超热中子束理论方案为基于反应堆实现BNCT提供一定的理论参考.

  7. The design, construction and performance of a variable collimator for epithermal neutron capture therapy beams

    Science.gov (United States)

    Riley, K. J.; Binns, P. J.; Ali, S. J.; Harling, O. K.

    2004-05-01

    A patient collimator for the fission converter based epithermal neutron beam (FCB) at the Massachusetts Institute of Technology Research Reactor (MITR-II) was built for clinical trials of boron neutron capture therapy (BNCT). A design was optimized by Monte Carlo simulations of the entire beam line and incorporates a modular construction for easy modifications in the future. The device was formed in-house by casting a mixture of lead spheres (7.6 mm diameter) in epoxy resin loaded with either 140 mg cm-3 of boron carbide or 210 mg cm-3 of lithium fluoride (95% enriched in 6Li). The cone shaped collimator allows easy field placement anywhere on the patient and is equipped with a laser indicator of central axis, beam's eye view optics and circular apertures of 80, 100, 120 and 160 mm diameter. Beam profiles and the collateral dose in a half-body phantom were measured for the 160 mm field using fission counters, activation foils as well as tissue equivalent (A-150) and graphite walled ionization chambers. Leakage radiation through the collimator contributes less than 10% to the total collateral dose up to 0.15 m beyond the edge of the aperture and becomes relatively more prominent with lateral displacement. The measured whole body dose equivalent of 24 ± 2 mSv per Gy of therapeutic dose is comparable to doses received during conventional therapy and is due principally (60-80%) to thermal neutron capture reactions with boron. These findings, together with the dose distributions for the primary beam, demonstrate the suitability of this patient collimator for BNCT.

  8. The design, construction and performance of a variable collimator for epithermal neutron capture therapy beams.

    Science.gov (United States)

    Riley, K J; Binns, P J; Ali, S J; Harling, O K

    2004-05-21

    A patient collimator for the fission converter based epithermal neutron beam (FCB) at the Massachusetts Institute of Technology Research Reactor (MITR-II) was built for clinical trials of boron neutron capture therapy (BNCT). A design was optimized by Monte Carlo simulations of the entire beam line and incorporates a modular construction for easy modifications in the future. The device was formed in-house by casting a mixture of lead spheres (7.6 mm diameter) in epoxy resin loaded with either 140 mg cm(-3) of boron carbide or 210 mg cm(-3) of lithium fluoride (95% enriched in 6Li). The cone shaped collimator allows easy field placement anywhere on the patient and is equipped with a laser indicator of central axis, beam's eye view optics and circular apertures of 80, 100, 120 and 160 mm diameter. Beam profiles and the collateral dose in a half-body phantom were measured for the 160 mm field using fission counters, activation foils as well as tissue equivalent (A-150) and graphite walled ionization chambers. Leakage radiation through the collimator contributes less than 10% to the total collateral dose up to 0.15 m beyond the edge of the aperture and becomes relatively more prominent with lateral displacement. The measured whole body dose equivalent of 24 +/- 2 mSv per Gy of therapeutic dose is comparable to doses received during conventional therapy and is due principally (60-80%) to thermal neutron capture reactions with boron. These findings, together with the dose distributions for the primary beam, demonstrate the suitability of this patient collimator for BNCT.

  9. 硼中子俘获疗法诱导U87胶质瘤细胞凋亡%Boron neutron capture therapy inducing apoptosis in U87 glioblastoma cells

    Institute of Scientific and Technical Information of China (English)

    王鹏; 章翔; 江新标; 程光; 赵英; 曹锐峰; 刘红; 王剑博

    2009-01-01

    目的 探讨硼中子俘获疗法(BNCT)对人脑胶质瘤细胞株U87的增殖抑制和诱导凋亡的作用及可能机制.方法 实验分为未照射组(0 Gy)、γ射线对照组(4、8 Gy)、反应堆组(3.5 Gy)、BNCT组(4、8 Gy).采用形态观察、流式细胞仪Annexin V/PI荧光染色、四甲基偶氮唑蓝(MTT)法等方法观察BNCT对U87细胞的增殖抑制和诱导凋亡的作用,以免疫组织化学技术检测P53蛋白的表达,应用western blot检测BCL-2、BAX蛋白表达的变化.结果 硼中子照射后细胞出现典型的凋亡形态改变.BNCT 4、8 Gy组处理后48 h细胞的凋亡率分别为65.1%、85.9%.BNCT 4、8 Gy组细胞生长抑制作用显著高于同等剂量的γ射线照射组(P<0.01).未照射的U87细胞P53蛋白表达阴性,BNCT4、8 Gy照射后P53蛋白表达阳性.BNCT4、8 Gy照射后BCL-2蛋白表达下降,BAX蛋白上升.结论 BNCT对U87细胞具有显著的增殖抑制作用,并有剂量、时间依赖性特点.%Objective To explore the effect of boron neutron capture therapy(BNCT)on human brain glioma U87 cell line and its mechanisms.Method U87 cells in exponential phase were divided into 6 groups:untreated control,60Co γ 4 Gy,60Co γ 8 Gy,nuclear reactor exposure without boronophenylalanine (BPA)3.5 Gy,BNCT 4 Gy and BNCT 8 Gy.The anti-tumor effects were analyzed through cell morphology,the Annexin V/PI assay by flow cytometer(FCM),and methyl thiazolyl tetrazolium(MTT)assay.The expression of P53 protein was studied by immunocytochemistry and the expression of BCL-2 protein and BAX protein were measured by western blot.Results Typical morphological changes were observed after BNCT irradiation.The apoptotic rates were observed 48 h after irradiation with 65.1%and 85.9%for BNCT 4 Gy and 8 Gy.BNCT showed higher apoptotic rates than those of γ-ray control irradiation (P<0.01).The expression level of P53 protein was negative in U87,while positive expression of P53 protein was observed in BNCT 4 Gy and 8 Gy groups

  10. Studies on preparation of folate-targeted boron liposomes as potential delivery agents for neutron capture therapy%叶酸靶向含硼脂质体的制备及其包封率的测定

    Institute of Scientific and Technical Information of China (English)

    王志会; 钱林学; 刘冬

    2012-01-01

    To prepare folate-targeted liposomes with high encapsulation efficiency is an effective targeted drug delivery agent for boron neutron capture therapy (BNCT). The double emulsion method is used to prepare liposomes. The combination of thin film hydration and ultrasonic dispersion method is used to prepare liposomes loaded with HBA,TBA or BBA. The content and the encapsulation efficiency of HBA,TBA or BBA liposomes are evaluated by high performance liquid chromatography ( HPLC). As the basis of the encapsulation efficiency, the optimal conditions for preparing liposomes were explored by the single factor method. The optimal chromatographic conditions of the three drugs were filtered out. They had a good linear relation in a range of 1 ~ 100 μg/mL. The encapsulation efficiency of HBA, TBA and BBA liposomes were 25. 7 % , 38. 9 % and 94. 8 % at the optimal preparation and condition. The optimal conditions for preparing BBA liposomes are as follows; the mass ratio of cholesterol and phospholipid is 1: 1, the ratio of drug and lipid is 1: 50 and the optimal pH value is 7. 4. The entrapment efficiency for BBA liposomes in the optimal groups reached 94. 8 % . The technique of preparing folate-tar-geted liposomes is feasible and the method of quality control is simple and high accuracy. The liposomes appeare to be round, and well separated with high entrapment efficiency.%制备具有良好靶向性及包封率高的硼脂质体,为硼中子俘获治疗方法的研究与应用建立了一个有效的靶向给药途径.采用复乳法及薄膜—超声分散法制备叶酸靶向硼脂质体,利用高效液相色谱法检测4—羟基苯硼酸4—Hydroxyphenylboronicacid (HBA)脂质体、2—噻吩硼酸2—thiophenylboric acid(TBA)脂质体、4—叔丁基苯硼酸4—tert-Butylphenylboronic Acid(BBA)脂质体的含量及包封率,以包封率为评价指标,采用单因素法优化脂质体的制备处方和工艺条件.筛选出HBA、TBA、BBA最优的色谱条件,分

  11. Monte-Carlo simulation of primary stochastic effects induced at the cellular level in boron neutron capture therapy; Simulation Monte-Carlo des effets stochastiques primaires induits au niveau cellulaire lors de la therapie par capture de neutrons sur le {sup 10}B

    Energy Technology Data Exchange (ETDEWEB)

    Cirioni, L.; Patau, J.P.; Nepveu, F. [Universite Paul Sabatier, 31 - Toulouse (France)

    1998-04-01

    A Monte Carlo code is developed to study the action of particles in Boron Neutron Capture Therapy (BNCT). Our aim is to calculate the probability of dissipating a lethal dose in cell nuclei. Cytoplasmic and nuclear membranes are considered as non-concentric ellipsoids. All geometrical parameters may be adjusted to fit actual configurations. The reactions {sup 10}B(n,{gamma} {alpha}){sup 7}Li and {sup 14}N(n,p) {sup 14}C create heavy ions which slow clown losing their energy. Their trajectories can be simulated taking into account path length straggling. The contribution of each reaction to the deposited dose in different cellular compartments can be studied and analysed for any distribution of {sup 10}B. (authors)

  12. Dosimetric evaluation of neutron capture therapy for local advanced breast cancer

    Energy Technology Data Exchange (ETDEWEB)

    Yanagie, H. [Department of Nuclear Engineering and Management, Graduate School of Engineering, University of Tokyo, Tokyo (Japan); Cooperative Unit of Medicine and Engineering, University of Tokyo Hospital, Tokyo (Japan)], E-mail: yanagie@n.t.u-tokyo.ac.jp; Kumada, H. [Japan Atomic Research Institute, Ibaraki (Japan); Sakurai, Y. [Research Reactor Institute, Kyoto University, Osaka (Japan); Nakamura, T. [Japan Atomic Research Institute, Ibaraki (Japan); Department of Nuclear Physics, Ibaraki University, Ibaraki (Japan); Furuya, Y. [Department of Surgery, Satukidai Hospital, Chiba (Japan); Sugiyama, H. [Cooperative Unit of Medicine and Engineering, University of Tokyo Hospital, Tokyo (Japan); Ono, K. [Research Reactor Institute, Kyoto University, Osaka (Japan); Takamoto, S. [Cooperative Unit of Medicine and Engineering, University of Tokyo Hospital, Tokyo (Japan); Department of Cardiac Surgery, University of Tokyo Hospital, Tokyo (Japan); Eriguchi, M. [Cooperative Unit of Medicine and Engineering, University of Tokyo Hospital, Tokyo (Japan); Department of Microbiology, Syowa University School of Pharmaceutical Sciences, Tokyo (Japan); Takahashi, H. [Department of Nuclear Engineering and Management, Graduate School of Engineering, University of Tokyo, Tokyo (Japan); Cooperative Unit of Medicine and Engineering, University of Tokyo Hospital, Tokyo (Japan)

    2009-07-15

    Local recurrence breast cancer is one of the most difficult conditions to cure and there is a need for new therapy. If sufficient boron compound can be targeted to the tumor, boron neutron capture therapy (BNCT) can be applied to local recurrent breast cancer. In this study, we performed a preliminary dosimetry with a phantom model of the mammary gland at Kyoto University Research Reactor (KUR), and a feasibility dosimetry with JAERI Computational Dosimetry System (JCDS) at JRR4 reactor of Japan Atomic Research Institute. We performed preliminary dosimetry of a phantom model of the mammary gland with thermal neutron irradiation (OO-0011 mode) on LiF collimation at KUR. The thermal neutron flux was 5.16 E+08 cm{sup -2} s{sup -1} at the surface of phantom. The blood boron concentration is estimated to be 30 ppm; tumor boron concentration is also estimated to be 90 ppm according to tumor/blood ratio 3 and skin/blood ratio 1.2. Tumor RBE dose is estimated to be 47 Gy/h, and skin RBE dose is 12.4 Gy/h. In case of advanced breast cancer, we performed the feasibility estimation of 3D construction of tumor according to the MRI imaging of a patient with epithermal neutron mode at JRR4. The blood boron concentration (ppm) and tumor/normal tissue ratio are estimated to be 24 and 3.5, respectively. Skin RBE dose is restricted to 10 Gy/h, the maximum tumor RBE dose, minimum tumor RBE dose, and mean tumor RBE dose are 42.2, 11.3, and 28.9 Gy-Eq, respectively, in half hour irradiation. In this study, we showed the possibility to apply BNCT to local recurrent breast cancer. We can irradiate tumors selectively and as safely as possible, reducing the effects on neighboring healthy tissues.

  13. Relative biological effectiveness of the boron neutron-capture beam for the inactivation of biological macromolecules

    Energy Technology Data Exchange (ETDEWEB)

    Saito, Masahiro (Kyoto Univ., Kumatori, Osaka (Japan). Research Reactor Inst.)

    1993-12-01

    The r.b.e. values of the boron neutron-capture beam (BNCB) for inactivation of yeast alcohol dehydrogenase (YADH) and the coenzyme NADH were determined in aqueous and air-saturated state. The r.b.e. value for YADH was 0.24 at a protein concentration of 0.2 mg/ml and that for NADH at the same concentration was 0.4. These r.b.e. values are less than unity in contrast to the r.b.e. values of BNCB for cell killing and mutagenesis which usually exceed 2. The small r.b.e. values for biological macromolecules is mainly explained from a relatively low yield of the radical species OH and H produced by high LET radiations compared to low LET radiations. Dithiothreitol protected YADH efficiently against inactivation by BNCB. It was suggested that radical repair process is the major cause of the observed radioprotective effect. (author).

  14. Synovectomy by neutron capture in boron; Sinovectomia por captura de neutrones en boro

    Energy Technology Data Exchange (ETDEWEB)

    Vega C, H.R. [Unidades Academicas de Estudios Nucleares, Ingenieria Electrica y Matematicas, Universidad Autonoma de Zacatecas, A.P. 336, C.P. 98000 Zacatecas (Mexico)

    2002-07-01

    The rheumatoid arthritis is an illness which affect approximately at 3% of the World population. This illness is characterized by the inflammation of the joints which reduces the quality of life and the productivity of the patients. Since, it is an autoimmune illness, the inflammation is due to the overproduction of synovial liquid by the increase in the quantity of synoviocytes. The rheumatoid arthritis does not have a definitive recovery and the patients have three options of treatment: the use of drugs, the surgery and the radio synovectomy. The synovectomy by neutron capture in Boron is a novel proposal of treatment of the rheumatoid arthritis that consists in using a charged compound with Boron 10 that is preferently incorporated in the synoviocytes and to a less extent in the rest of surrounding tissues of the joint. Then, the joint is exposed to a thermal neutron field that induces the reaction (n, {alpha}) in the {sup 10} B. the products of this reaction place their energy inside synoviocytes producing their reduction and therefore the reduction of the joint inflammation. Since it is a novel procedure, the synovectomy by neutron capture in boron has two problems: the source design and the design of the adequate drug. In this work it has been realized a Monte Carlo study with the purpose to design a moderating medium that with a {sup 239} Pu Be source in its center, produces a thermal neutron field. With the produced neutron spectra, the neutrons spectra and neutron doses were calculated in different sites inside a model of knee joint. In Monte Carlo studies it is necessary to know the elemental composition of all the joint components, for the case of synovia and the synovial liquid this information does not exist in such way that it is supposed that its composition is equal than the water. In this work also it has been calculated the kerma factors by neutrons of synovia and the synovial liquid supposing that their elemental composition are similar to the

  15. A state-of-the-art epithermal neutron irradiation facility for neutron capture therapy

    Science.gov (United States)

    Riley, K. J.; Binns, P. J.; Harling, O. K.

    2004-08-01

    At the Massachusetts Institute of Technology (MIT) the first fission converter-based epithermal neutron beam (FCB) has proven suitable for use in clinical trials of boron neutron capture therapy (BNCT). The modern facility provides a high intensity beam together with low levels of contamination that is ideally suited for use with future, more selective boron delivery agents. Prescriptions for normal tissue tolerance doses consist of 2 or 3 fields lasting less than 10 min each with the currently available beam intensity, that are administered with an automated beam monitoring and control system to help ensure safety of the patient and staff alike. A quality assurance program ensures proper functioning of all instrumentation and safety interlocks as well as constancy of beam output relative to routine calibrations. Beam line shutters and the medical room walls provide sufficient shielding to enable access and use of the facility without affecting other experiments or normal operation of the multipurpose research reactor at MIT. Medical expertise and a large population in the greater Boston area are situated conveniently close to the university, which operates the research reactor 24 h a day for approximately 300 days per year. The operational characteristics of the facility closely match those established for conventional radiotherapy, which together with a near optimum beam performance ensure that the FCB is capable of determining whether the radiobiological promise of NCT can be realized in routine practice.

  16. On-line beam monitoring for neutron capture therapy at the MIT Research Reactor

    Science.gov (United States)

    Harling, Otto K.; Moulin, Damien J.; Chabeuf, Jean-Michel; Solares, Guido R.

    1995-08-01

    Neutron capture therapy sets new requirements on the measurement and monitoring of the radiation fields used in this new form of therapy. Beams used for neutron capture therapy are comprised of mixed radiation fields which include slow, epithermal, and fast neutrons, as well as gamma rays. A computer-based beam monitoring system for epithermal or thermal neutron capture therapy is described. This system provides accurate, sensitive, and rapid on-line readout and recording of the various beam components. Readout of fluxes, fluences, and corresponding doses in the target are provided in color coded graphic analog as well as numerical form on the computer monitors. Variations in neutron spectrum or spatial distribution of the beam can be rapidly diagnosed with the aid of the monitor readout. Redundancy of fluence measurement is provided by an independent system using scalers and timers and by utilizing reactor power measuring instruments.

  17. Neutron capture therapy of ocular melanoma: dosimetry and microdosimetry approaches; Therapie par capture de neutrons des melanomes oculaires: approches dosimetrique et microdosimetrique

    Energy Technology Data Exchange (ETDEWEB)

    Pignol, J.P.; Methlin, G. [Centre Paul Strauss, 67 - Strasbourg (France); Abbe, J.C. [Strasbourg-1 Univ., 67 (France). Centre de Recherches Nucleaires; Stampfler, A. [Strasbourg-1 Univ., 67 (France); Lefebvre, O. [Faculte de Medecine, 67 - Strasbourg (France); Sahel, J. [Centre Hospitalier Universitaire, 67 - Strasbourg (France)

    1994-06-01

    Neutron capture therapy (NCT) aims at destroying cancerous cells with the {alpha} and {sup 7}Li particles produced by the neutron capture reaction on {sup 10}B. This note reports on the study of the boron distribution in tissues on an animal model (nude mice) xenografted with a human ocular melanoma after an i.p.injection of 2g/kg of {sup 10}B-BPA and in cells cultured in the presence of 530 {mu}mol/l of {sup 10}B-BPA. A concentration of 64 ppm of {sup 10}B in the active part of the tumour with a ratio of concentrations versus the skin of 3.7 are observed. Investigations on cells reveal the presence of boron in the cytoplasm. The biological, dosimetric and microdosimetric consequences of these findings are discussed. (authors). 15 refs., 2 tabs., 2 figs.

  18. Design of a californium-based epithermal neutron beam for neutron capture therapy.

    Science.gov (United States)

    Yanch, J C; Kim, J K; Wilson, M J

    1993-08-01

    The potential of the spontaneously fissioning isotope, 252Cf, to provide epithermal neutrons for use in boron neutron capture therapy (BNCT) has been investigated using Monte Carlo simulation. The Monte Carlo code MCNP was used to design an assembly composed of a 26 cm long, 11 cm radius cylindrical D2O moderator followed by a 64 cm long Al filter. Lithium filters are placed between the moderator and the filter and between the Al and the patient. A reflector surrounding the moderator/filter assembly is required in order to maintain adequate therapy flux at the patient position. An ellipsoidal phantom composed of skull- and brain-equivalent material was used to determine the dosimetric effect of this beam. It was found that both advantage depths and advantage ratios compare very favourably with reactor and accelerator epithermal neutron sources. The dose rate obtainable, on the other hand, is 4.1 RBE cGy min-1, based on a very large (1.0 g) source of 252Cf. This dose rate is two to five times lower than those provided by existing reactor beams and can be viewed as a drawback of using 252Cf as a neutron source. Radioisotope sources, however, do offer the advantage of in-hospital installation.

  19. Tumor growth suppression by gadolinium-neutron capture therapy using gadolinium-entrapped liposome as gadolinium delivery agent.

    Science.gov (United States)

    Dewi, Novriana; Yanagie, Hironobu; Zhu, Haito; Demachi, Kazuyuki; Shinohara, Atsuko; Yokoyama, Kazuhito; Sekino, Masaki; Sakurai, Yuriko; Morishita, Yasuyuki; Iyomoto, Naoko; Nagasaki, Takeshi; Horiguchi, Yukichi; Nagasaki, Yukio; Nakajima, Jun; Ono, Minoru; Kakimi, Kazuhiro; Takahashi, Hiroyuki

    2013-07-01

    Neutron capture therapy (NCT) is a promising non-invasive cancer therapy approach and some recent NCT research has focused on using compounds containing gadolinium as an alternative to currently used boron-10 considering several advantages that gadolinium offers compared to those of boron. In this study, we evaluated gadolinium-entrapped liposome compound as neutron capture therapy agent by in vivo experiment on colon-26 tumor-bearing mice. Gadolinium compound were injected intravenously via tail vein and allowed to accumulate into tumor site. Tumor samples were taken for quantitative analysis by ICP-MS at 2, 12, and 24 h after gadolinium compound injection. Highest gadolinium concentration was observed at about 2 h after gadolinium compound injection with an average of 40.3 μg/g of wet tumor tissue. We performed neutron irradiation at JRR-4 reactor facility of Japan Atomic Energy Research Institute in Tokaimura with average neutron fluence of 2×10¹² n/cm². The experimental results showed that the tumor growth suppression of gadolinium-injected irradiated group was revealed until about four times higher compared to the control group, and no significant weight loss were observed after treatment suggesting low systemic toxicity of this compound. The gadolinium-entrapped liposome will become one of the candidates for Gd delivery system on NCT.

  20. Convection enhanced delivery of carboranylporphyrins for neutron capture therapy of brain tumors.

    Science.gov (United States)

    Kawabata, Shinji; Yang, Weilian; Barth, Rolf F; Wu, Gong; Huo, Tianyao; Binns, Peter J; Riley, Kent J; Ongayi, Owendi; Gottumukkala, Vijay; Vicente, M Graça H

    2011-06-01

    Boron neutron capture therapy (BNCT) is based on the nuclear capture and fission reactions that occur when non-radioactive 10B is irradiated with low energy thermal neutrons to produce α-particles (10B[n,α] Li). Carboranylporphyrins are a class of substituted porphyrins containing multiple carborane clusters. Three of these compounds, designated H2TBP, H2TCP, and H2DCP, have been evaluated in the present study. The goals were two-fold. First, to determine their biodistribution following intracerebral (i.c.) administration by short term (30 min) convection enhanced delivery (CED) or sustained delivery over 24 h by Alzet™ osmotic pumps to F98 glioma bearing rats. Second, to determine the efficacy of H2TCP and H2TBP as boron delivery agents for BNCT in F98 glioma bearing rats. Tumor boron concentrations immediately after i.c. pump delivery were high and they remained so at 24 h. The corresponding normal brain concentrations were low and the blood and liver concentrations were undetectable. Based on these data, therapy studies were initiated at the Massachusetts Institute of Technology (MIT) Research Reactor (MITR) with H2TCP and H2TBP 24 h after CED or pump delivery. Mean survival times (MST) ± standard deviations of animals that had received H2TCP or H2TBP, followed by BNCT, were of 35 ± 4 and 44 ± 10 days, compared to 23 ± 3 and 27 ± 3 days, respectively, for untreated and irradiated controls. However, since the tumor boron concentrations of the carboranylporphyrins were 3-5× higher than intravenous (i.v.) boronophenylalanine (BPA), we had expected that the MSTs would have been greater. Histopathologic examination of brains of BNCT treated rats revealed that there were large numbers of porphyrin-laden macrophages, as well as extracellular accumulations of porphyrins, indicating that the seemingly high tumor boron concentrations did not represent the true tumor cellular uptake. Nevertheless, our data are the first to show that carboranyl porphyrins can be

  1. Gadolinium as an element for neutron capture therapy

    Energy Technology Data Exchange (ETDEWEB)

    Brugger, R.M.; Liu, H.B.; Laster, B.H.; Gordon, C.R.; Greenberg, D.D.; Warkentien, L.S.

    1992-01-01

    At BNL, preparations are being made to test in vitro compounds containing Gd and compare their response to the response of GD-DTPA to determine if one or several compounds can be located that enter the cells and enhance the Auger effect. Two similar rotators with positions for cell vials that have been constructed for these tests. The first rotator is made of only paraffin which simulates healthy tissue and provides control curves. The second rotator has 135 ppM of Gd-157 in the paraffin to simulate a Gd loaded tumor. Cells are irradiated in vials in the paraffin rotator and in the Gd-paraffin rotator at the epithermal beam of the Brookhaven Medical Research Reactor (BMRR). This produces an irradiation similar to what a patient would receive In an actual treatment. A combination of irradiations are made with both rotators; with no Gd compound or IdUrd In the cell media, with only Gd compound in the cell media and with both Gd compound and IdUrd in the cell media. The first set shows the effects of gamma rays from the H(n,gamma) reaction and the prompt gamma rays from capture of neutrons by Gd. The second set shows if there is any effect of Gd being in the cell media or inside the cells, i.e., an Auger effect. The third set shows the effect of enhancement by the IdUrd produced by the gamma rays from neutrons captured by either H or Gd. The fourth set combines all of the reactions and enhancements. Preliminary calculations and physical measurements of the doses that the cells will receive In these rotators have been made.

  2. Gadolinium as an element for neutron capture therapy

    Energy Technology Data Exchange (ETDEWEB)

    Brugger, R.M.; Liu, H.B.; Laster, B.H.; Gordon, C.R.; Greenberg, D.D.; Warkentien, L.S.

    1992-12-31

    At BNL, preparations are being made to test in vitro compounds containing Gd and compare their response to the response of GD-DTPA to determine if one or several compounds can be located that enter the cells and enhance the Auger effect. Two similar rotators with positions for cell vials that have been constructed for these tests. The first rotator is made of only paraffin which simulates healthy tissue and provides control curves. The second rotator has 135 ppM of Gd-157 in the paraffin to simulate a Gd loaded tumor. Cells are irradiated in vials in the paraffin rotator and in the Gd-paraffin rotator at the epithermal beam of the Brookhaven Medical Research Reactor (BMRR). This produces an irradiation similar to what a patient would receive In an actual treatment. A combination of irradiations are made with both rotators; with no Gd compound or IdUrd In the cell media, with only Gd compound in the cell media and with both Gd compound and IdUrd in the cell media. The first set shows the effects of gamma rays from the H(n,gamma) reaction and the prompt gamma rays from capture of neutrons by Gd. The second set shows if there is any effect of Gd being in the cell media or inside the cells, i.e., an Auger effect. The third set shows the effect of enhancement by the IdUrd produced by the gamma rays from neutrons captured by either H or Gd. The fourth set combines all of the reactions and enhancements. Preliminary calculations and physical measurements of the doses that the cells will receive In these rotators have been made.

  3. High power accelerator-based boron neutron capture with a liquid lithium target and new applications to treatment of infectious diseases.

    Science.gov (United States)

    Halfon, S; Paul, M; Steinberg, D; Nagler, A; Arenshtam, A; Kijel, D; Polacheck, I; Srebnik, M

    2009-07-01

    A new conceptual design for an accelerator-based boron neutron capture therapy (ABNCT) facility based on the high-current low-energy proton beam driven by the linear accelerator at SARAF (Soreq Applied Research Accelerator Facility) incident on a windowless forced-flow liquid-lithium target, is described. The liquid-lithium target, currently in construction at Soreq NRC, will produce a neutron field suitable for the BNCT treatment of deep-seated tumor tissues, through the reaction (7)Li(p,n)(7)Be. The liquid-lithium target is designed to overcome the major problem of solid lithium targets, namely to sustain and dissipate the power deposited by the high-intensity proton beam. Together with diseases conventionally targeted by BNCT, we propose to study the application of our setup to a novel approach in treatment of diseases associated with bacterial infections and biofilms, e.g. inflammations on implants and prosthetic devices, cystic fibrosis, infectious kidney stones. Feasibility experiments evaluating the boron neutron capture effectiveness on bacteria annihilation are taking place at the Soreq nuclear reactor.

  4. High power accelerator-based boron neutron capture with a liquid lithium target and new applications to treatment of infectious diseases

    Energy Technology Data Exchange (ETDEWEB)

    Halfon, S. [Soreq NRC, Yavne 81800 (Israel); Racah Institute of Physics, Hebrew University, Jerusalem 91904 (Israel)], E-mail: halfon@phys.huji.ac.il; Paul, M. [Racah Institute of Physics, Hebrew University, Jerusalem 91904 (Israel); Steinberg, D. [Biofilm Laboratory, Institute of Dental Sciences, Faculty of Dentistry, Hebrew University-Hadassah (Israel); Nagler, A.; Arenshtam, A.; Kijel, D. [Soreq NRC, Yavne 81800 (Israel); Polacheck, I. [Clinical Microbiology and Infectious Diseases, Hadassah-Hebrew University Medical Center (Israel); Srebnik, M. [Department of Medicinal Chemistry and Natural Products, School of Pharmacy, Hebrew University, Jerusalem 91120 (Israel)

    2009-07-15

    A new conceptual design for an accelerator-based boron neutron capture therapy (ABNCT) facility based on the high-current low-energy proton beam driven by the linear accelerator at SARAF (Soreq Applied Research Accelerator Facility) incident on a windowless forced-flow liquid-lithium target, is described. The liquid-lithium target, currently in construction at Soreq NRC, will produce a neutron field suitable for the BNCT treatment of deep-seated tumor tissues, through the reaction {sup 7}Li(p,n){sup 7}Be. The liquid-lithium target is designed to overcome the major problem of solid lithium targets, namely to sustain and dissipate the power deposited by the high-intensity proton beam. Together with diseases conventionally targeted by BNCT, we propose to study the application of our setup to a novel approach in treatment of diseases associated with bacterial infections and biofilms, e.g. inflammations on implants and prosthetic devices, cystic fibrosis, infectious kidney stones. Feasibility experiments evaluating the boron neutron capture effectiveness on bacteria annihilation are taking place at the Soreq nuclear reactor.

  5. Accelerator-based epithermal neutron beam design for neutron capture therapy.

    Science.gov (United States)

    Yanch, J C; Zhou, X L; Shefer, R E; Klinkowstein, R E

    1992-01-01

    Recent interest in the production of epithermal neutrons for use in boron neutron capture therapy (BNCT) has promoted an investigation into the feasibility of generating such neutrons with a high current proton accelerator. Energetic protons (2.5 MeV) on a 7Li target produce a spectrum of neutrons with maximum energy of roughly 800 keV. A number of combinations of D2O moderator, lead reflector, 6Li thermal neutron filtration, and D2O/6Li shielding will result in a useful epithermal flux of 1.6 x 10(8) n/s at the patient position. The neutron beam is capable of delivering 3000 RBE-cGy to a tumor at a depth of 7.5 cm in a total treatment time of 60-93 min (depending on RBE values used and based on a 24-cm diameter x 19-cm length D2O moderator). Treatment of deeper tumors with therapeutic advantage would also be possible. Maximum advantage depths (RBE weighted) of 8.2-9.2 (again depending on RBE values and precise moderator configuration) are obtained in a right-circular cylindrical phantom composed of brain-equivalent material with an advantage ratio of 4.7-6.3. A tandem cascade accelerator (TCA), designed and constructed at Science Research Laboratory (SRL) in Somerville MA, can provide the required proton beam parameters for BNCT of deep-seated tumors. An optimized configuration of materials required to shift the accelerator neutron spectrum down to therapeutically useful energies has been designed using Monte Carlo simulation in the Whitaker College Biomedical Imaging and Computation Laboratory at MIT. Actual construction of the moderator/reflector assembly is currently underway.

  6. NCTPlan application for neutron capture therapy dosimetric planning at MEPhI nuclear research reactor.

    Science.gov (United States)

    Elyutina, A S; Kiger, W S; Portnov, A A

    2011-12-01

    The results of modeling of two therapeutic beams HEC-1 and HEC-4 at the NRNU "MEPhI" research nuclear reactor exploitable for preclinical treatments are reported. The exact models of the beams are constructed as an input to the NCTPlan code used for planning Neutron Capture Therapy (NCT) procedure. The computations are purposed to improve the accuracy of prediction of a dose absorbed in tissue with the account of all components of radiation.

  7. Evaluation of absorbed effective dose and treatment conditions for a brain tumor outside of the head phantom center in treatment by Boron Neutron Capture Therapy Using Monte Carlo Simulation

    Directory of Open Access Journals (Sweden)

    Samira Mirzaiee

    2016-04-01

    (including 252Cf source, moderator, refelector and neutron and photon filters was simulated. A spherical-shaped tumor was considered outside of the phantom center. The head phantom consists of three parts of the skin, skull and brain. The simulation was done by the MCNPX 2.6.0 computational code. In this simulation, the tumor with a radius of 1.5 cm at a depth of 2 cm inside the brain was considered. Results: Tumor treatment was investigated with different boron concentrations in the head phantom. The maximum dose is approximately 0.055 Sv/hr, and is related to the conditions that Boron is not absorbed in healthy tissue. The absorbed dose amount of the epithermal neutrons, under the conditions that Boron is not absorbed in healthy tissue, at the entrance of the skull and in brain tissue extremily drops, and gradually decreases. Conclusion: The calculations showed when a patient receives radiation about 5 minutes, the received dose equals approximately 4.6 mSv.Under these treatment conditions, the whole body equivalent dose  does not exceed 5 mSv per year.

  8. Proteomic analysis of cellular response induced by boron neutron capture reaction in human squamous cell carcinoma SAS cells.

    Science.gov (United States)

    Sato, Akira; Itoh, Tasuku; Imamichi, Shoji; Kikuhara, Sota; Fujimori, Hiroaki; Hirai, Takahisa; Saito, Soichiro; Sakurai, Yoshinori; Tanaka, Hiroki; Nakamura, Hiroyuki; Suzuki, Minoru; Murakami, Yasufumi; Baiseitov, Diaz; Berikkhanova, Kulzhan; Zhumadilov, Zhaxybay; Imahori, Yoshio; Itami, Jun; Ono, Koji; Masunaga, Shinichiro; Masutani, Mitsuko

    2015-12-01

    To understand the mechanism of cell death induced by boron neutron capture reaction (BNCR), we performed proteome analyses of human squamous tumor SAS cells after BNCR. Cells were irradiated with thermal neutron beam at KUR after incubation under boronophenylalanine (BPA)(+) and BPA(-) conditions. BNCR mainly induced typical apoptosis in SAS cells 24h post-irradiation. Proteomic analysis in SAS cells suggested that proteins functioning in endoplasmic reticulum, DNA repair, and RNA processing showed dynamic changes at early phase after BNCR and could be involved in the regulation of cellular response to BNCR. We found that the BNCR induces fragments of endoplasmic reticulum-localized lymphoid-restricted protein (LRMP). The fragmentation of LRMP was also observed in the rat tumor graft model 20 hours after BNCT treatment carried out at the National Nuclear Center of the Republic of Kazakhstan. These data suggest that dynamic changes of LRMP could be involved during cellular response to BNCR.

  9. Application of neutron capture autoradiography to Boron Delivery seeking techniques for selective accumulation of boron compounds to tumor with intra-arterial administration of boron entrapped water-in-oil-in-water emulsion

    Energy Technology Data Exchange (ETDEWEB)

    Mikado, S. [Physical Science Laboratories, College of Industrial Technology, Nihon University, Chiba (Japan)], E-mail: mikado@cit.nihon-u.ac.jp; Yanagie, H. [Department of Nuclear Engineering and Management, University of Tokyo, Tokyo (Japan); Cooperative Unit of Medicine and Engineering, University of Tokyo Hospital, Tokyo (Japan); Yasuda, N. [Fundamental Technology Center, National Institute of Radiological Sciences, Chiba (Japan); Higashi, S.; Ikushima, I. [Miyakonojyo Metropolitan Hospital, Miyazaki (Japan); Mizumachi, R.; Murata, Y. [Department of Pharmacology, Kumamoto Institute Branch, Mitsubishi Chemical Safety Institute Ltd., Kumamoto (Japan); Morishita, Y. [Department of Human and Molecular Pathology, University of Tokyo, Tokyo (Japan); Nishimura, R. [Faculty of Agriculture, Laboratory of Veterinary Surgery, University of Tokyo (Japan); Shinohara, A. [Department of Humanities, The Graduate School of Seisen University, Tokyo (Japan); Ogura, K. [Physical Science Laboratories, College of Industrial Technology, Nihon University, Chiba (Japan); Sugiyama, H. [Cooperative Unit of Medicine and Engineering, University of Tokyo Hospital, Tokyo (Japan); Iikura, H.; Ando, H. [Japan Atomic Energy Agency, Ibaraki (Japan); Ishimoto, M. [Department of Nuclear Professional School, University of Tokyo (Japan); Takamoto, S. [Cooperative Unit of Medicine and Engineering, University of Tokyo Hospital, Tokyo (Japan); Department of Cardiac Surgery, University of Tokyo Hospital, Tokyo (Japan); Eriguchi, M. [Cooperative Unit of Medicine and Engineering, University of Tokyo Hospital, Tokyo (Japan); Department of Microbiology, Syowa University School of Pharmaceutical Sciences, Tokyo (Japan); Takahashi, H. [Department of Nuclear Engineering and Management, University of Tokyo, Tokyo (Japan); Cooperative Unit of Medicine and Engineering, University of Tokyo Hospital, Tokyo (Japan); Kimura, M. [Department of Physics, Toho University, Chiba (Japan)

    2009-06-21

    It is necessary to accumulate the {sup 10}B atoms selectively to the tumor cells for effective Boron Neutron Capture Therapy (BNCT). In order to achieve an accurate measurement of {sup 10}B accumulations in the biological samples, we employed a technique of neutron capture autoradiography (NCAR) of sliced samples of tumor tissues using CR-39 plastic track detectors. The CR-39 track detectors attached with the biological samples were exposed to thermal neutrons in the thermal column of the JRR3 of Japan Atomic Energy Agency (JAEA). We obtained quantitative NCAR images of the samples for VX-2 tumor in rabbit liver after injection of {sup 10}BSH entrapped water-in-oil-in-water (WOW) emulsion by intra-arterial injection via proper hepatic artery. The {sup 10}B accumulations and distributions in VX-2 tumor and normal liver of rabbit were investigated by means of alpha-track density measurements. In this study, we showed the selective accumulation of {sup 10}B atoms in the VX-2 tumor by intra-arterial injection of {sup 10}B entrapped WOW emulsion until 3 days after injection by using digitized NCAR images (i.e. alpha-track mapping)

  10. A microdosimetric study of {sup 10}B(n,{alpha}){sup 7}Li and {sup 157}Gd(n,{gamma}) reactions for neutron capture therapy

    Energy Technology Data Exchange (ETDEWEB)

    Wang, C.K.C.; Sutton, M.; Evans, T.M. [Georgia Inst. of Tech., Atlanta, GA (United States); Laster, B.H. [Brookhaven National Lab., Upton, NY (United States). Medical Dept.

    1999-01-01

    This paper presents the microdosimetric analysis for the most interesting cell survival experiment recently performed at the Brookhaven National Laboratory (BNL). In this experiment, the cells were first treated with a gadolinium (Gd) labeled tumor-seeking boronated porphyrin (Gd-BOPP) or with BOPP alone, and then irradiated with thermal neutrons. The resulting cell-survival curves indicate that the {sup 157}Gd(n,{gamma}) reactions are very effective in cell killing. The death of a cell treated with Gd-BOPP was attributed to either the {sup 10}B(n,{alpha}){sup 7}Li reactions or the {sup 157}Gd(n,{gamma}) reactions (or both). However, the quantitative relationship between the two types of reaction and the cell-survival fraction was not clear. This paper presents the microdosimetric analysis for the BNL experiment based on the measured experimental parameters, and the results clearly suggest a quantitative relationship between the two types of reaction and the cell survival fraction. The results also suggest new research in gadolinium neutron capture therapy (GdNCT) which may lead to a more practical modality than the boron neutron capture therapy (BNCT) for treating cancers.

  11. Assessment of Proton Microbeam Analysis of 11B for Quantitative Microdistribution Analysis of Boronated Neutron Capture Agent Analogs in Biological Tissues

    Energy Technology Data Exchange (ETDEWEB)

    Bench, G; Grant, P G; Ueda, D L; Autry-Conwell, S A; Hou, Y; Boggan, J E

    2002-12-04

    Purpose: To assess the {sup 11}B(p, {alpha}){sup 8}Be* nuclear reaction for quantitatively mapping the in-vivo sub-cellular distribution of boron within gliosarcoma tumors treated with boronated neutron capture therapy agent (NCTA) analogs. Materials and Methods: Intracranial tumors were produced in Fisher 344 rats using a 9L gliosarcoma model. Fourteen days later, the majority of rats were treated with f-boronophenylalanine and sacrificed 30 or 180 minutes after intravenous injection. Freeze dried tumor cryosections were imaged using the {sup 11}B(p, {alpha}){sup 8}Be* nuclear reaction and proton microbeams obtained from the nuclear microprobe at Lawrence Livermore National Laboratory. Results/Discussion: With{sup 11}B(p, {alpha}){sup 8}Be* analysis, {sup 11}B distributions within cells can be quantitatively imaged with spatial resolutions down to 1.5 {micro}m, minimum detection limits of 0.8 mg/kg and acquisition times of several hours. These capabilities offer advantages over alpha track autoradiography, electron energy loss spectroscopy and secondary ion mass spectrometry (SIMS) for 'B quantitation in tissues. However, the spatial resolution, multi-isotope capability and analysis times achieved with SIMS are superior to those achieved with {sup 11}B(p, {alpha}){sup 8}Be* analysis. Conclusions: When accuracy in quantitation is crucial, the assessing the microdistribution of {sup 11}B. {sup 11}B(p, {alpha}){sup 8}Be* reaction is well suited for Otherwise, SIMS may well be better suited to image the microdistribution of boron associated with NCTAs in biological tissues.

  12. Fission reactor neutron sources for neutron capture therapy--a critical review.

    Science.gov (United States)

    Harling, Otto K; Riley, Kent J

    2003-01-01

    The status of fission reactor-based neutron beams for neutron capture therapy (NCT) is reviewed critically. Epithermal neutron beams, which are favored for treatment of deep-seated tumors, have been constructed or are under construction at a number of reactors worldwide. Some of the most recently constructed epithermal neutron beams approach the theoretical optimum for beam purity. Of these higher quality beams, at least one is suitable for use in high through-put routine therapy. It is concluded that reactor-based epithermal neutron beams with near optimum characteristics are currently available and more can be constructed at existing reactors. Suitable reactors include relatively low power reactors using the core directly as a source of neutrons or a fission converter if core neutrons are difficult to access. Thermal neutron beams for NCT studies with small animals or for shallow tumor treatments, with near optimum properties have been available at reactors for many years. Additional high quality thermal beams can also be constructed at existing reactors or at new, small reactors. Furthermore, it should be possible to design and construct new low power reactors specifically for NCT, which meet all requirements for routine therapy and which are based on proven and highly safe reactor technology.

  13. Alanine and TLD coupled detectors for fast neutron dose measurements in neutron capture therapy (NCT).

    Science.gov (United States)

    Cecilia, A; Baccaro, S; Cemmi, A; Colli, V; Gambarini, G; Rosi, G; Scolari, L

    2004-01-01

    A method was investigated to measure gamma and fast neutron doses in phantoms exposed to an epithermal neutron beam designed for neutron capture therapy (NCT). The gamma dose component was measured by TLD-300 [CaF2:Tm] and the fast neutron dose, mainly due to elastic scattering with hydrogen nuclei, was measured by alanine dosemeters [CH3CH(NH2)COOH]. The gamma and fast neutron doses deposited in alanine dosemeters are very near to those released in tissue, because of the alanine tissue equivalence. Couples of TLD-300 and alanine dosemeters were irradiated in phantoms positioned in the epithermal column of the Tapiro reactor (ENEA-Casaccia RC). The dosemeter response depends on the linear energy transfer (LET) of radiation, hence the precision and reliability of the fast neutron dose values obtained with the proposed method have been investigated. Results showed that the combination of alanine and TLD detectors is a promising method to separate gamma dose and fast neutron dose in NCT.

  14. A fundamental study on hyper-thermal neutrons for neutron capture therapy.

    Science.gov (United States)

    Sakurai, Y; Kobayashi, T; Kanda, K

    1994-12-01

    The utilization of hyper-thermal neutrons, which have an energy spectrum with a Maxwellian distribution at a higher temperature than room temperature (300 K), was studied in order to improve the thermal neutron flux distribution at depth in a living body for neutron capture therapy. Simulation calculations were carried out using a Monte Carlo code 'MCNP-V3' in order to investigate the characteristics of hyper-thermal neutrons, i.e. (i) depth dependence of the neutron energy spectrum, and (ii) depth distribution of the reaction rate in a water phantom for materials with 1/v neutron absorption. It is confirmed that hyper-thermal neutron irradiation can improve the thermal neutron flux distribution in the deeper areas in a living body compared with thermal neutron irradiation. When hyper-thermal neutrons with a 3000 K Maxwellian distribution are incident on a body, the reaction rates of 1/v materials such as 14N, 10B etc are about twice that observed for incident thermal neutrons at 300 K, at a depth of 5 cm. The limit of the treatable depth for tumours having 30 ppm 10B is expected to be about 1.5 cm greater by utilizing hyper-thermal neutrons at 3000 K compared with the incidence of thermal neutrons at 300 K.

  15. DNA double-strand break induction in Ku80-deficient CHO cells following Boron Neutron Capture Reaction

    Directory of Open Access Journals (Sweden)

    Masunaga Shinichiro

    2011-09-01

    Full Text Available Abstract Background Boron neutron capture reaction (BNCR is based on irradiation of tumors after accumulation of boron compound. 10B captures neutrons and produces an alpha (4He particle and a recoiled lithium nucleus (7Li. These particles have the characteristics of high linear energy transfer (LET radiation and have marked biological effects. The purpose of this study is to verify that BNCR will increase cell killing and slow disappearance of repair protein-related foci to a greater extent in DNA repair-deficient cells than in wild-type cells. Methods Chinese hamster ovary (CHO-K1 cells and a DNA double-strand break (DSB repair deficient mutant derivative, xrs-5 (Ku80 deficient CHO mutant cells, were irradiated by thermal neutrons. The quantity of DNA-DSBs following BNCR was evaluated by measuring the phosphorylation of histone protein H2AX (gamma-H2AX and 53BP1 foci using immunofluorescence intensity. Results Two hours after neutron irradiation, the number of gamma-H2AX and 53BP1 foci in the CHO-K1 cells was decreased to 36.5-42.8% of the levels seen 30 min after irradiation. In contrast, two hours after irradiation, foci levels in the xrs-5 cells were 58.4-69.5% of those observed 30 min after irradiation. The number of gamma-H2AX foci in xrs-5 cells at 60-120 min after BNCT correlated with the cell killing effect of BNCR. However, in CHO-K1 cells, the RBE (relative biological effectiveness estimated by the number of foci following BNCR was increased depending on the repair time and was not always correlated with the RBE of cytotoxicity. Conclusion Mutant xrs-5 cells show extreme sensitivity to ionizing radiation, because xrs-5 cells lack functional Ku-protein. Our results suggest that the DNA-DSBs induced by BNCR were not well repaired in the Ku80 deficient cells. The RBE following BNCR of radio-sensitive mutant cells was not increased but was lower than that of radio-resistant cells. These results suggest that gamma-ray resistant cells have

  16. Thick beryllium target as an epithermal neutron source for neutron capture therapy.

    Science.gov (United States)

    Wang, C K; Moore, B R

    1994-10-01

    Accelerator-based intense epithermal neutron sources for Neutron Capture Therapy (NCT) have been considered as an alternative to nuclear reactors. Lithium (Li) has generally received the widest attention for this application, since the threshold energy is low and neutron yield is high. Because of the poor thermal and chemical properties of Li and the need for heat removal in the target, the design of Li targets has been quite difficult. Beryllium (Be) has been thought of as an alternative target because of its good thermal and chemical properties and reasonable neutron yield. However, in order to have a neutron yield comparable to that of a thick Li target bombarded with 2.5 MeV protons, the proton energy required for a thick Be target must be approaching 4 MeV. Consequently, the neutrons emitted are more energetic. In addition, a significant amount of high-energy gamma rays, which is undesirable, will occur when Be is bombarded with low-energy protons. Regardless of the more energetic neutrons and additional gamma rays, in this paper it is shown that it is possible to develop a high-quality and high-intensity epithermal neutron beam based on a thick Be target for NCT treatment. For a fixed proton current, the optimal Be-target-based beam (with 4-MeV protons) can produce a neutron beam, with both quality and intensity slightly better than those produced by the optimal Li-target-based beam (with 2.5-MeV protons). The single-session NCT treatment time for the optimal Be-target-based beam is estimated to be 88 min for a proton current of 50 mA.(ABSTRACT TRUNCATED AT 250 WORDS)

  17. A theoretical model for the production of Ac-225 for cancer therapy by neutron capture transmutation of Ra-226.

    Science.gov (United States)

    Melville, G; Melville, P

    2013-02-01

    Radium needles that were once implanted into tumours as a cancer treatment are now obsolete and constitute a radioactive waste problem, as their half-life is 1600 years. We are investigating the reduction of radium by transmutation by bombarding Ra-226 with high-energy neutrons from a neutron source to produce Ra-225 and hence Ac-225, which can be used as a generator to produce Bi-213 for use in 'Targeted Alpha Therapy' for cancer. This paper examines the possibility of producing Ac-225 by neutron capture using a theoretical model in which neutron energy is convoluted with the corresponding neutron cross sections of Ra-226. The total integrated yield can then be obtained. This study shows that an intense beam of high-energy neutrons could initiate neutron capture on Ra-226 to produce Ra-225 and hence practical amounts of Ac-225 and a useful reduction of Ra-226.

  18. 硼中子俘获疗法对胶质瘤干细胞增殖和细胞周期的影响%Effect of boron neutron capture therapy on cell proliferation and cell cycle arrest in glioma stem cells

    Institute of Scientific and Technical Information of China (English)

    孙婷; 钱兴龙; 李炎炎; 张紫竹; 李斌; 陈桂林; 韦永新; 谢学顺; 周幽心

    2014-01-01

    Objective To study the effect and mechanism of boron neutron capture therapy (BNCT) on cell cycle procession in human glioma stem cells (GSCs) in vitro,and to analyze the difference of sensitivity for BNCT on GSCs and glioma cells.Methods Firstly,uptake of boronophenylalarine (BPA) on human GSCs SU2 and glioma cells SHG-44 was detected.Then the cells enriched boron-10 (10B) were irradiated by In-Hospital Neutron Irradiator (IHNI-1).The radiation sensitivity was measured using clonogenic survival assay.The proliferation was examined by MTT assay.The cell cycle procession was determined using flow cytometry.The protein expression of cyclin B1,CDK1 and P21[WAF1] were detected by Western blot.Results 10B concentration of SU2 and SHG-44 cells arrived at (1.76 ±0.28) and (2.50 ±0.12) μg/107cells at 24 h in 5 mMBPA.After radiation by IHNI-1,the survival fraction and viability of cells enriched 10B were decreased significantly (P < 0.05 orP < 0.01),compared with those of 10B-free.The BNCT sensitivity of SU2 cells was lower than that of SHG-44 cells (P < 0.05).The proportion of G2/M phase of SU2 and SHG-44 cells was increased after BNCT compared with that of 10B-free(P < 0.05).The protein levels of cyclin B1 and CDK1 were decreased(P < 0.01),and that of P21[WAF1] was increased(P < 0.01).Conclusions The BNCT sensitivity of GSCs was lower than that of glioma cells.BNCT could inhibite cell regeneration and proliferation and make G2/M to be blocked by inhibition of cell cycle protein formation.%目的 研究硼中子俘获疗法(BNCT)对体外培养人胶质瘤干细胞(GSCs)周期进程的影响及机制,比较GSCs和胶质瘤细胞株SHG-44对BNCT敏感性的差异.方法 首先检测人GSCsSU2和人胶质瘤细胞株SHG-44吸收含硼化合物二羟基苯丙氨酸硼(BPA)的情况,然后采用医院中子照射器(IHNI-1)对含硼(10B)细胞进行照射,克隆存活实验检测细胞的放射敏感性,MTT法检测细胞增殖率,流式细胞

  19. Reference dosimetry calculations for neutron capture therapy with comparison of analytical and voxel models.

    Science.gov (United States)

    Goorley, J T; Kiger, W S; Zamenhof, R G

    2002-02-01

    As clinical trials of Neutron Capture Therapy (NCT) are initiated in the U.S. and other countries, new treatment planning codes are being developed to calculate detailed dose distributions in patient-specific models. The thorough evaluation and comparison of treatment planning codes is a critical step toward the eventual standardization of dosimetry, which, in turn, is an essential element for the rational comparison of clinical results from different institutions. In this paper we report development of a reference suite of computational test problems for NCT dosimetry and discuss common issues encountered in these calculations to facilitate quantitative evaluations and comparisons of NCT treatment planning codes. Specifically, detailed depth-kerma rate curves were calculated using the Monte Carlo radiation transport code MCNP4B for four different representations of the modified Snyder head phantom, an analytic, multishell, ellipsoidal model, and voxel representations of this model with cubic voxel sizes of 16, 8, and 4 mm. Monoenergetic and monodirectional beams of 0.0253 eV, 1, 2, 10, 100, and 1000 keV neutrons, and 0.2, 0.5, 1, 2, 5, and 10 MeV photons were individually simulated to calculate kerma rates to a statistical uncertainty of neutron beam with a broad neutron spectrum, similar to epithermal beams currently used or proposed for NCT clinical trials, was computed for all models. The thermal neutron, fast neutron, and photon kerma rates calculated with the 4 and 8 mm voxel models were within 2% and 4%, respectively, of those calculated for the analytical model. The 16 mm voxel model produced unacceptably large discrepancies for all dose components. The effects from different kerma data sets and tissue compositions were evaluated. Updating the kerma data from ICRU 46 to ICRU 63 data produced less than 2% difference in kerma rate profiles. The depth-dose profile data, Monte Carlo code input, kerma factors, and model construction files are available

  20. Boron neutron capture irradiation: setting up a clinical programme in Nice; Irradiation par capture de neutrons: mise en place d`un programme clinique a Nice

    Energy Technology Data Exchange (ETDEWEB)

    Pignol, J.P.; Chauvel, P.; Courdi, A.; Iborra-Brassart, N.; Frenay, M.; Herault, J.; Bensadoun, R.J.; Milano, G.; Demard, F. [Centre de Lutte Contre le Cancer Antoine Lacassagne, 06 - Nice (France); Paquis, P.; Lonjon, M.; Lebrun-Frenay, C.; Grellier, P.; Chatel, M. [Hopital Pasteur, 06 - Nice (France); Nepveu, F.; Patau, J.P. [Toulouse-3 Univ., 31 (France); Breteau, N. [Hopital de la Source, 45 - Orleans (France)

    1996-12-31

    Neutron capture irradiation aims to selectively destroy tumor tumor cell using {sup 10}B(n,{alpha}){sup 7}Li nuclear reactions produced within themselves. Following the capture reaction, an {alpha} particle and a, {sup 7}Li ion are emitted. Carrying an energy of 2.79 MeV, they destroy all molecular structures along their path close to 10 {mu}m. These captures, used exclusively with a `slow` neutron irradiation, provide a neutron capture therapy (BNCT). If they are used in addition to a fast neutron beam irradiation, they provide a neutron capture potentiation (NCP). The Centre Antoine-Lacassagne in Nice is actively involved in the European Demonstration project for BNCT of grade IV glioblastomas (GBM) after surgical excision and BSH administration. Taking into account the preliminary results obtained in Japan, work on an `epithermal` neutron target compatible with various cyclotron beams is in progress to facilitate further developments of this technique. For NCP, thermalized neutron yield has been measured in phantoms irradiated in the fast neutron beam of the biomedical cyclotron in Nice. A thermal peak appears after 5 cm depth in the tissues, delayed after the fast neutron peak at 1.8 cm depth. Thus, a physical overdosage of 10 % may be obtained if 100 ppm of {sup 10}B are assumed in the tissues. Our results using CAL 58 GBM cell line demonstrate a dose modification factor (DMF) of 1.19 when 100 ppm of boric acid are added to the growth medium. Thus for the particles, issued from neutron capture, a biological efficiency at least twice that of fast neutrons can be derived. These results, compared with historical data on fast neutron irradiation of glioblastoma, suggest that a therapeutic window may be obtained for GBM. (author). 26 refs.

  1. A coupled deterministic/stochastic method for computing neutron capture therapy dose rates

    Science.gov (United States)

    Hubbard, Thomas Richard

    Neutron capture therapy (NCT) is an experimental method of treating brain tumors and other cancers by: (1) injecting or infusing the patient with a tumor-seeking, neutron target-labeled drug; and (2) irradiating the patient in an intense epithermal neutron fluence. The nuclear reaction between the neutrons and the target nuclei (e.g. sp{10}B(n,alpha)sp7Lirbrack releases energy in the form of high-LET (i.e. energy deposited within the range of a cell diameter) reaction particles which selectively kill the tumor cell. The efficacy of NCT is partly dependent on the delivery of maximum thermal neutron fluence to the tumor and the minimization of radiation dose to healthy tissue. Since the filtered neutron source (e.g. research reactor) usually provides a broad energy spectrum of highly-penetrating neutron and gamma-photon radiation, detailed transport calculations are necessary in order to plan treatments that use optimal treatment facility configurations and patient positioning. Current computational methods for NCT use either discrete ordinates calculation or, more often, Monte Carlo simulation to predict neutron fluences in the vicinity of the tumor. These methods do not, however, accurately calculate the transport of radiation throughout the entire facility or the deposition of dose in all the various parts of the body due to shortcomings of using either method alone. A computational method, specifically designed for NCT problems, has been adapted from the MASH methodology and couples a forward discrete ordinates (Ssb{n}) calculation with an adjoint Monte Carlo run to predict the dose at any point within the patient. The transport from the source through the filter/collimator is performed with a forward DORT run, and this is then coupled to adjoint MORSE results at a selected coupling parallelepiped which surrounds human phantom. Another routine was written to allow the user to generate the MORSE models at various angles and positions within the treatment room. The

  2. Promising cancer treatment modality: the University of California Davis/McClellan Nuclear Radiation Center neutron capture therapy program

    Science.gov (United States)

    Autry-Conwell, Susan A.; Boggan, James E.; Edwards, Benjamin F.; Hou, Yongjin; Vincente, Maria-Graca; Liu, Hungyuan; Richards, Wade J.

    2000-12-01

    Neutron capture therapy (NCT) is a promising new binary therapeutic modality for the treatment of localized tumors. It is accomplished by injection and localization within the tumor of a neutron capture agent (NCA) that alone, is non- toxic. Whenthe tumor is then exposed to neutrons, a relatively non-toxic form of radiation, crytotoxic products are produced that directly or indirectly cause tumor cell death, and yet preserves normal surrounding tissue not contain the NCA. The UC Davis NCT program is currently working to develop and test new compounds or NCA in vitro and in vivo. Many groups worldwide are also working to develop the next generation NCA, but less than five facilities internationally are currently capable to treating clinical brain tumor patients by NCT and only two US facilities, MIT and Brookhaven National Laboratory. In addition to compound development, the UC Davis NCT program is preparing the UC Davis McClellan Nuclear Radiation Center's 2 megawatt TRIGA reactor for NCT clinical trials which would make it the only such facility on the West Coast.

  3. Computational characterization and experimental validation of the thermal neutron source for neutron capture therapy research at the University of Missouri

    Energy Technology Data Exchange (ETDEWEB)

    Broekman, J. D. [University of Missouri, Research Reactor Center, 1513 Research Park Drive, Columbia, MO 65211-3400 (United States); Nigg, D. W. [Idaho National Laboratory, PO Box 1625, Idaho Falls, ID 83415 (United States); Hawthorne, M. F. [University of Missouri, International Institute of Nano and Molecular Medicine, 1514 Research Park Dr., Columbia, MO 65211-3450 (United States)

    2013-07-01

    Parameter studies, design calculations and neutronic performance measurements have been completed for a new thermal neutron beamline constructed for neutron capture therapy cell and small-animal radiobiology studies at the University of Missouri Research Reactor. The beamline features the use of single-crystal silicon and bismuth sections for neutron filtering and for reduction of incident gamma radiation. The computational models used for the final beam design and performance evaluation are based on coupled discrete-ordinates and Monte Carlo techniques that permit detailed modeling of the neutron transmission properties of the filtering crystals with very few approximations. Validation protocols based on neutron activation spectrometry measurements and rigorous least-square adjustment techniques show that the beam produces a neutron spectrum that has the anticipated level of thermal neutron flux and a somewhat higher than expected, but radio-biologically insignificant, epithermal neutron flux component. (authors)

  4. Self-shielding effects in neutron spectra measurements for neutron capture therapy by means of activation foils.

    Science.gov (United States)

    Pytel, Krzysztof; Józefowicz, Krystyna; Pytel, Beatrycze; Koziel, Alina

    2004-01-01

    The design and optimisation of a neutron beam for neutron capture therapy (NCT) is accompanied by the neutron spectra measurements at the target position. The method of activation detectors was applied for the neutron spectra measurements. Epithermal neutron energy region imposes the resonance structure of activation cross sections resulting in strong self-shielding effects. The neutron self-shielding correction factor was calculated using a simple analytical model of a single absorption event. Such a procedure has been applied to individual cross sections from pointwise ENDF/B-VI library and new corrected activation cross sections were introduced to a spectra unfolding algorithm. The method has been verified experimentally both for isotropic and for parallel neutron beams. Two sets of diluted and non-diluted activation foils covered with cadmium were irradiated in the neutron field. The comparison of activation rates of diluted and non-diluted foils has demonstrated the correctness of the applied self-shielding model.

  5. Neutron Capture Nucleosynthesis

    CERN Document Server

    Kiss, Miklos

    2016-01-01

    Heavy elements (beyond iron) are formed in neutron capture nucleosynthesis processes. We have proposed a simple unified model to investigate the neutron capture nucleosynthesis in arbitrary neutron density environment. We have also investigated what neutron density is required to reproduce the measured abundance of nuclei assuming equilibrium processes. We found both of these that the medium neutron density has a particularly important role at neutron capture nucleosynthesis. About these results most of the nuclei can formed at medium neutron capture density environment e.g. in some kind of AGB stars. Besides these observations our model is capable to use educational purpose.

  6. The requirements and development of neutron beams for neutron capture therapy of brain cancer.

    Science.gov (United States)

    Moss, R L; Aizawa, O; Beynon, D; Brugger, R; Constantine, G; Harling, O; Liu, H B; Watkins, P

    1997-05-01

    One of the two overriding conditions for successful BNCT is that there must be a sufficient number of thermal neutrons delivered to each of the boronated cells in the tumour bed (target volume). Despite the poor experience with BNCT in the USA some 40 years ago, the continued apparent success of BNCT in Japan since 1968, lead indirectly to the re-start of clinical trials on BNCT in 1994 at both Brookhaven and MIT. Similar trials will start soon at Petten in Europe. At other centres worldwide, many neutron beam designs are being proposed with either thermal or epithermal neutrons, emanating predominantly from nuclear research reactors. It is apparent that whilst the success of BNCT depends on a suitable neutron beam, there is a diversity in available designs, as well as each proposed type of neutron source, with consequently different characteristics of the emergent neutron beam. The paper presents the historical development of neutron beams used for BNCT, addresses the requirements on the types of beams, describes some of the existing designs and other proposals elsewhere and lastly, considers the broader requirements in designing NCT facilities. The focus of the paper is on treatment of brain cancer, neutron beam requirements for other types of cancer may vary.

  7. Experimental verification of improved depth-dose distribution using hyper-thermal neutron incidence in neutron capture therapy

    Science.gov (United States)

    Sakurai, Yoshinori; Kobayashi, Tooru

    2001-01-01

    We have proposed the utilization of `hyper-thermal neutrons' for neutron capture therapy (NCT) from the viewpoint of the improvement in the dose distribution in a human body. In order to verify the improved depth-dose distribution due to hyper-thermal neutron incidence, two experiments were carried out using a test-type hyper-thermal neutron generator at a thermal neutron irradiation field in Kyoto University Reactor (KUR), which is actually utilized for NCT clinical irradiation. From the free-in-air experiment for the spectrum-shift characteristics, it was confirmed that the hyper-thermal neutrons of approximately 860 K at maximum could be obtained by the generator. From the phantom experiment, the improvement effect and the controllability for the depth-dose distribution were confirmed. For example, it was found that the relative neutron depth-dose distribution was about 1 cm improved with the 860 K hyper-thermal neutron incidence, compared to the normal thermal neutron incidence.

  8. Spectrum evaluation at the filter-modified neutron irradiation field for neutron capture therapy in Kyoto University Research Reactor

    Science.gov (United States)

    Sakurai, Yoshinori; Kobayashi, Tooru

    2004-10-01

    The Heavy Water Neutron Irradiation Facility of the Kyoto University Research Reactor (KUR-HWNIF) was updated in March 1996, mainly to improve the facility for neutron capture therapy (NCT). In this facility, neutron beams with various energy spectra, from almost pure thermal to epithermal, are available. The evaluation of the neutron energy spectra by multi-activation-foil method was performed as a series of the facility characterization. The spectra at the normal irradiation position were evaluated for the combinations of heavy-water thickness of the spectrum shifter and the open-close condition of the cadmium and boral filters. The initial spectra were made mainly using a two-dimensional transport code, and the final spectra were obtained using an adjusting code. For the verification of the evaluated spectra, simulation calculations using a phantom were performed on the assumption of NCT-clinical-irradiation conditions. It resulted that the calculated data for the depth neutron-flux distributions were in good agreement with the experimental ones.

  9. Experimental verification of improved depth-dose distribution using hyper-thermal neutron incidence in neutron capture therapy.

    Science.gov (United States)

    Sakurai, Y; Kobayashi, T

    2001-01-01

    We have proposed the utilization of 'hyper-thermal neutrons' for neutron capture therapy (NCT) from the viewpoint of the improvement in the dose distribution in a human body. In order to verify the improved depth-dose distribution due to hyper-thermal neutron incidence, two experiments were carried out using a test-type hyper-thermal neutron generator at a thermal neutron irradiation field in Kyoto University Reactor (KUR), which is actually utilized for NCT clinical irradiation. From the free-in-air experiment for the spectrum-shift characteristics, it was confirmed that the hyper-thermal neutrons of approximately 860 K at maximum could be obtained by the generator. From the phantom experiment, the improvement effect and the controllability for the depth-dose distribution were confirmed. For example, it was found that the relative neutron depth-dose distribution was about 1 cm improved with the 860 K hyper-thermal neutron incidence, compared to the normal thermal neutron incidence.

  10. Monte Carlo methods of neutron beam design for neutron capture therapy at the MIT Research Reactor (MITR-II).

    Science.gov (United States)

    Clement, S D; Choi, J R; Zamenhof, R G; Yanch, J C; Harling, O K

    1990-01-01

    Monte Carlo methods of coupled neutron/photon transport are being used in the design of filtered beams for Neutron Capture Therapy (NCT). This method of beam analysis provides segregation of each individual dose component, and thereby facilitates beam optimization. The Monte Carlo method is discussed in some detail in relation to NCT epithermal beam design. Ideal neutron beams (i.e., plane-wave monoenergetic neutron beams with no primary gamma-ray contamination) have been modeled both for comparison and to establish target conditions for a practical NCT epithermal beam design. Detailed models of the 5 MWt Massachusetts Institute of Technology Research Reactor (MITR-II) together with a polyethylene head phantom have been used to characterize approximately 100 beam filter and moderator configurations. Using the Monte Carlo methodology of beam design and benchmarking/calibrating our computations with measurements, has resulted in an epithermal beam design which is useful for therapy of deep-seated brain tumors. This beam is predicted to be capable of delivering a dose of 2000 RBE-cGy (cJ/kg) to a therapeutic advantage depth of 5.7 cm in polyethylene assuming 30 micrograms/g 10B in tumor with a ten-to-one tumor-to-blood ratio, and a beam diameter of 18.4 cm. The advantage ratio (AR) is predicted to be 2.2 with a total irradiation time of approximately 80 minutes. Further optimization work on the MITR-II epithermal beams is expected to improve the available beams.

  11. Radiosensitivity of pimonidazole-unlabelled intratumour quiescent cell population to γ-rays, accelerated carbon ion beams and boron neutron capture reaction

    Science.gov (United States)

    Masunaga, S; Sakurai, Y; Tanaka, H; Hirayama, R; Matsumoto, Y; Uzawa, A; Suzuki, M; Kondo, N; Narabayashi, M; Maruhashi, A; Ono, K

    2013-01-01

    Objective To detect the radiosensitivity of intratumour quiescent (Q) cells unlabelled with pimonidazole to accelerated carbon ion beams and the boron neutron capture reaction (BNCR). Methods EL4 tumour-bearing C57BL/J mice received 5-bromo-29-deoxyuridine (BrdU) continuously to label all intratumour proliferating (P) cells. After the administration of pimonidazole, tumours were irradiated with c-rays, accelerated carbon ion beams or reactor neutron beams with the prior administration of a 10B-carrier. Responses of intratumour Q and total (P+Q) cell populations were assessed based on frequencies of micronucleation and apoptosis using immunofluorescence staining for BrdU. The response of pimonidazole-unlabelled tumour cells was assessed by means of apoptosis frequency using immunofluorescence staining for pimonidazole. Results Following c-ray irradiation, the pimonidazole-unlabelled tumour cell fraction showed significantly enhanced radiosensitivity compared with the whole tumour cell fraction, more remarkably in the Q than total cell populations. However, a significantly greater decrease in radiosensitivity in the pimonidazole-unlabelled cell fraction, evaluated using a delayed assay or a decrease in radiation dose rate, was more clearly observed among the Q than total cells. These changes in radiosensitivity were suppressed following carbon ion beam and neutron beam-only irradiaton. In the BNCR, the use of a 10B-carrier, especially L-para-boronophenylalanine-10B, enhanced the sensitivity of the pimonidazole-unlabelled cells more clearly in the Q than total cells. Conclusion The radiosensitivity of the pimonidazole-unlabelled cell fraction depends on the quality of radiation delivered and characteristics of the 10B-carrier used in the BNCR. Advances in knowledge The pimonidazole-unlabelled subfraction of Q tumour cells may be a critical target in tumour control. PMID:23255546

  12. Measurements of neutron distribution in neutrons-gamma-rays mixed field using imaging plate for neutron capture therapy.

    Science.gov (United States)

    Tanaka, Kenichi; Endo, Satoru; Hoshi, Masaharu

    2010-01-01

    The imaging plate (IP) technique is tried to be used as a handy method to measure the spatial neutron distribution via the (157)Gd(n,gamma)(158)Gd reaction for neutron capture therapy (NCT). For this purpose, IP is set in a water phantom and irradiated in a mixed field of neutrons and gamma-rays. The Hiroshima University Radiobiological Research Accelerator is utilized for this experiment. The neutrons are moderated with 20-cm-thick D(2)O to obtain suitable neutron field for NCT. The signal for IP doped with Gd as a neutron-response enhancer is subtracted with its contribution by gamma-rays, which was estimated using IP without Gd. The gamma-ray response of Gd-doped IP to non-Gd IP is set at 1.34, the value measured for (60)Co gamma-rays, in estimating the gamma-ray contribution to Gd-doped IP signal. Then measured distribution of the (157)Gd(n,gamma)(158)Gd reaction rate agrees within 10% with the calculated value based on the method that has already been validated for its reproducibility of Au activation. However, the evaluated distribution of the (157)Gd(n,gamma)(158)Gd reaction rate is so sensitive to gamma-ray energy, e.g. the discrepancy of the (157)Gd(n,gamma)(158)Gd reaction rate between measurement and calculation becomes 30% for the photon energy change from 33keV to 1.253MeV.

  13. Quantitative analysis of proton boron fusion therapy (PBFT) in various conditions

    Energy Technology Data Exchange (ETDEWEB)

    Jung, Joo-Young; Yoon, Do-Kun; Suh, Tae Suk [College of Medicine, Catholic University of Korea, Seoul (Korea, Republic of)

    2015-05-15

    From the theoretical point of view, the PBFT has some strong advantages over currently existing radiotherapy methods. First, boron-based tumor targeting is required prior to performing the treatments such as boron-neutron capture therapy (BNCT). Tumor targeting should be performed before the BNCT by injecting the boronate compound. If boron is not taken up by the normal tissue, the normal tissue can be spared the irradiation by alpha particles. When boron uptake occurs in the target region, selective therapy is possible by neutron capture reaction of labeled boron particles in the target region. Likewise, when boron is distributed in the tumor region for the PBFT, the proposed method can represent a more critical discriminative therapy than either the BNCT or conventional particle therapy. In the conventional proton therapy, in order to deliver a dose to a tumor, the proton beam energy has to be adjusted along the tumor region (e.g., shape and depth). The proton therapy aims at delivering the maximal dose to the tumor by using protons only. In this study, the effectiveness of the PBFT with respect to several physical parameters was evaluated quantitatively by using Monte Carlo simulations. We confirmed that the PBFT can be used to perform critical discriminative therapy. Also, the results of our studies can be used for constructing the PFBT dose database that can be utilized in treatment planning systems (TPSs)

  14. Preclinical studies of neutron capture therapy effectiveness in the treatment of malignant tumours, at the nuclear reactor hvr-sm InP as of RUz Preclinical studies of neutron capture therapy effectiveness in the treatment of malignant tumours, at the nuclear reactor hvr-sm InP as of RUz

    OpenAIRE

    KHODJAEVA NAZIMA KHAYRULLAEVNA; NAVRUZOV SARIMBEK NAVRUZOVICH; KAHHOROV JAMAL NEMATOVICH; KULABDULLAEV GAYRAT ASATOVICH; КIM ANDREY ALEKSEEVICH

    2016-01-01

    Developed for treatment of radio resistant malignant tumors the Gadolinium neutron capture therapy (GdNCT) is based on the nuclear capture and reactions that occur when 155Gd and 157Gd, which are non-radioactive constituents of natural elemental gadolinium, are irradiated by thermal neutrons with low energy, In this article, results of scientific researches on development GdNCT in Uzbekistan are presented. The beam of epithermal neutrons with characteristics satisfying the all requirements of...

  15. Microanalysis system of ppm-order 10B concentrations in tissue for neutron capture therapy by prompt gamma-ray spectrometry

    Science.gov (United States)

    Kobayashi, Tooru; Kanda, Keiji

    1983-01-01

    For neutron capture therapy, a new technique for measuring 10B concentrations of ppm order in tissue has been developed by using 10B(n, α) 7Li ∗ prompt gamma-ray spectrometry. The measuring system consists of a Ge(Li) detector and a 6LiF tile neutron shield attached to the neutron guide tube of the Kyoto University Reactor (KUR) with very low background gamma-rays. The 10B concentrations of unknown samples were determined in comparison with gamma-ray data obtained from known samples. The detection limit of the system is 0.1-0.5 ppm 10B concentration. In the practical use of the system for neutron capture therapy, 10B concentrations of 10 ppm, which is ordinarily pre-injected into the tumor, can be measured in less than 30 s with 10% accuracy by using 1 g samples. Moreover, the system has the advantage that pre-treatment of the sample is not required. As a neutron monitor in a homogeneous sample, gamma-rays emitted from H(n, γ)D reactions are used. Therefore, neutron irradiation conditions of this system, i.e. fluence rate, energy spectrum, and distribution in the sample do not affect the analyzing results, and the quantity and dimensions of the sample are also not restricted.

  16. Relative biological effectiveness and tolerance dose of fission neutrons in canine skin for a potential combination of neutron capture therapy and fast-neutron therapy.

    Science.gov (United States)

    Kadosawa, Tsuyoshi; Ohashi, Fumihito; Nishimura, Ryohei; Sasaki, Nobuo; Saito, Isao; Wakabayashi, Hiroaki; Takeuchi, Akira

    2003-10-01

    To investigate the potential efficacy of fission neutrons from a fast-neutron reactor for the treatment of radioresistant tumors, the relative biological effectiveness (RBE) and tolerance dose of fission neutrons in canine skin were determined. The forelimbs of 34 healthy mongrel dogs received a single dose of fission neutrons (5.6, 6.8, 8.2, 9.6 or 11 Gy) or 137Cs gamma rays (10, 15, 20, 25 or 30 Gy). Based on observations of radiodermatitis for each radiation, the single-fraction RBE of fission neutrons in the sixth month was calculated as approximately 3. The tolerance doses of fission neutrons and gamma rays, defined as the highest doses giving no moist desquamation on the irradiated skin in the recovery phase, were estimated as 7.6 Gy and 20 Gy, respectively. The tolerance dose of 7.6 Gy of fission neutrons included 5.0 Gy of fast neutrons possessing high anti-tumor effects and 1.4 x 10(12) n/cm2 of thermal neutrons, which could be applicable to neutron capture therapy (NCT). The combination of fast-neutron therapy and NCT using a fast-neutron reactor might be useful for the treatment of radioresistant tumors.

  17. Power Burst Facility/Boron Neutron Capture Therapy Program for cancer treatment

    Energy Technology Data Exchange (ETDEWEB)

    Ackermann, A.L. (ed.); Dorn, R.V. III.

    1990-09-01

    This monthly bulletin describes activities in the following project areas during this reporting period: supporting technology development, large animal model studies, neutron source and facility preparation, administration and common support, and PBF operations. (FI)

  18. Microdosimetry of neutron field for boron neutron capture therapy at Kyoto university reactor.

    Science.gov (United States)

    Endo, S; Onizuka, Y; Ishikawa, M; Takada, M; Sakurai, Y; Kobayashi, T; Tanaka, K; Hoshi, M; Shizuma, K

    2004-01-01

    Microdosimetric single event spectrum in a human body simulated by an acrylic phantom has been measured for the clinical BNCT field at the Kyoto University Reactor (KUR). The recoil particles resulting from the initial reaction and subsequent interactions, namely protons, electrons, alpha particles and carbon nuclei are identified in the microdosimetric spectrum. The relative contributions to the neutron dose from proton, alpha particles and carbon are estimated to be about 0.9, 0.07 and 0.3, respectively, four depths between 5 and 41 mm. We estimate that the dose averaged lineal energy, yD decreased with depth from 64 to 46 keV microm(-1). Relative biological effectiveness (RBE) of this neutron field using a response function for the microdosimetric spectrum was estimated to decrease from 3.6 to 2.9 with increasing depth.

  19. Boron neutron capture therapy for newly diagnosed glioblastoma multiforme: An assessment of clinical potential

    Energy Technology Data Exchange (ETDEWEB)

    Hopewell, J.W., E-mail: john.hopewell@gtc.ox.ac.uk [Green Templeton College and Particle Therapy Cancer Research Institute, University of Oxford, Oxford (United Kingdom); Gorlia, T. [Data Center, EORTC, Brussels (Belgium); Pellettieri, L. [Hammercap Medical AB, Stockholm (Sweden)] [Department of Neurosurgery, Goeteborg University, Goeteborg (Sweden); Giusti, V. [Hammercap Medical AB, Stockholm (Sweden)] [Department of Mechanical, Nuclear and Production Engineering, University of Pisa, Pisa (Italy); H-Stenstam, B. [Nykoeping Hospital, County of Sormland (Sweden); Skoeld, K. [Hammercap Medical AB, Stockholm (Sweden)

    2011-12-15

    The purpose of this analysis was to assess the potential of BNCT, with L-boronophenylalanine (L-BPA), as first line radiotherapy for glioblastoma multiforme (GBM). The survival of patients with newly diagnosed GBM from a phase II BNCT study was compared with those from the two arms of a phase III study with conventional radiotherapy (RT) vs. RT plus concomitant and adjuvant medication with temozolomide (TMZ). A small subgroup, for which the methylation status of the O{sup 6}-methylguanine-DNA methyltransferase (MGMT) DNA-repair gene was known, was also considered. The results indicated that the use of BNCT with BPA should be explored in a stratified randomized phase II trial in which patients with the unmethylated MGMT DNA-repair gene are offered BNCT vs. RT plus TMZ.

  20. Boron neutron capture therapy for recurrent oral cancer and metastasis of cervical lymph node

    Energy Technology Data Exchange (ETDEWEB)

    Kimura, Y. [Department of Dentistry and Oral Surgery, Division of Medicine for Function and Morphology of Sensory Organs, Osaka Medical College, 2-7 Daigaku-machi Takatsuki City, Osaka (Japan)], E-mail: ora018@poh.osaka-med.ac.jp; Ariyoshi, Y.; Shimahara, M. [Department of Dentistry and Oral Surgery, Division of Medicine for Function and Morphology of Sensory Organs, Osaka Medical College, 2-7 Daigaku-machi Takatsuki City, Osaka (Japan); Miyatake, S.; Kawabata, S. [Department of Neurosurgery, Division of Surgery, Osaka Medical College, 2-7 Daigaku-machi Takatsuki City, Osaka (Japan); Ono, K.; Suzuki, M. [Particle Radiation Oncology Research Center, Kyoto University, Kumatori-cho, Sennan-gun, Osaka (Japan); Maruhashi, A. [Medical Physics, Department of Radiation Life Sciences, Research Reactor Institute, Kyoto University, Kumatori-cho, Sennan-gun, Osaka (Japan)

    2009-07-15

    We treated 6 patients with recurrent oral cancer and metastasis to the cervical lymph nodes after conventional treatments in 5 and non-conventional in 1 using BNCT, and herein report our results. The clinical response in our patients ranged from CR to PD. In 5 cases, spontaneous pain decreased immediately after BNCT. Three of the 6 are alive at the time of writing and we found that BNCT contributed to QOL improvement in all.

  1. Development of a Tandem-Electrostatic-Quadrupole facility for Accelerator-Based Boron Neutron Capture Therapy

    Energy Technology Data Exchange (ETDEWEB)

    Kreiner, A.J., E-mail: kreiner@tandar.cnea.gov.ar [Gerencia de Investigacion y Aplicaciones, Comision Nacional de Energia Atomica, Av. Gral Paz 1499, 1650 San Martin, Buenos Aires (Argentina)] [Escuela de Ciencia y Tecnologia, Universidad Nacional de San Martin (Argentina)] [CONICET, Buenos Aires (Argentina); Castell, W. [Gerencia de Investigacion y Aplicaciones, Comision Nacional de Energia Atomica, Av. Gral Paz 1499, 1650 San Martin, Buenos Aires (Argentina); Di Paolo, H. [Gerencia de Investigacion y Aplicaciones, Comision Nacional de Energia Atomica, Av. Gral Paz 1499, 1650 San Martin, Buenos Aires (Argentina)] [Escuela de Ciencia y Tecnologia, Universidad Nacional de San Martin (Argentina); Baldo, M. [Gerencia de Investigacion y Aplicaciones, Comision Nacional de Energia Atomica, Av. Gral Paz 1499, 1650 San Martin, Buenos Aires (Argentina); Bergueiro, J. [Gerencia de Investigacion y Aplicaciones, Comision Nacional de Energia Atomica, Av. Gral Paz 1499, 1650 San Martin, Buenos Aires (Argentina)] [CONICET, Buenos Aires (Argentina)

    2011-12-15

    We describe the present status of an ongoing project to develop a Tandem-ElectroStatic-Quadrupole (TESQ) accelerator facility for Accelerator-Based (AB)-BNCT. The project final goal is a machine capable of delivering 30 mA of 2.4 MeV protons to be used in conjunction with a neutron production target based on the {sup 7}Li(p,n){sup 7}Be reaction. The machine currently being constructed is a folded TESQ with a high-voltage terminal at 0.6 MV. We report here on the progress achieved in a number of different areas.

  2. Power Burst Facility/Boron Neutron Capture Therapy Program for cancer treatment

    Energy Technology Data Exchange (ETDEWEB)

    Ackermann, A.L. (ed.)

    1990-10-01

    This bulletin discusses activities during this reporting period in the areas of: supporting technology development; large animal model studies; melanoma project; human studies; stability, pharmacology, and toxicology of drugs; and PBF technical support. (FL)

  3. Correlation of clinical outcome to the estimated radiation dose from Boron Neutron Capture Therapy (BNCT)

    Energy Technology Data Exchange (ETDEWEB)

    Chadha, M. [Beth Israel Medical Center, NY (United States). Dept. of Radiation Oncology; Coderre, J.A.; Chanana, A.D. [Brookhaven National Lab., Upton, NY (United States)] [and others

    1996-12-31

    A phase I/II trial delivering a single fraction of BNCT using p-Boronophenylalanine-Fructose and epithermal neutrons at the the Brookhaven Medical Research Reactor was initiated in September 1994. The primary endpiont of the study was to evaluate the feasibility and safety of a given BNCT dose. The clinical outcome of the disease was a secondary endpoint of the study. The objective of this paper is to evaluate the correlation of the clinical outcome of patients to the estimated radiation dose from BNCT.

  4. Neutron capture reactions at DANCE

    Science.gov (United States)

    Bredeweg, T. A.

    2008-05-01

    The Detector for Advanced Neutron Capture Experiments (DANCE) is a 4π BaF2 array consisting of 160 active detector elements. The primary purpose of the array is to perform neutron capture cross section measurements on small (>~100 μg) and/or radioactive (DANCE we have performed neutron capture cross section measurements on a wide array of medium to heavy mass nuclides. Measurements to date include neutron capture cross sections on 241,243Am, neutron capture and neutron-induced fission cross sections and capture-to-fission ratio (α = σγ/σf) for 235U using a new fission-tagging detector as well as neutron capture cross sections for several astrophysics branch-point nuclei. Results from several of these measurements will be presented along with a discussion of additional physics information that can be extracted from the DANCE data.

  5. Controllability of depth dose distribution for neutron capture therapy at the Heavy Water Neutron Irradiation Facility of Kyoto University Research Reactor.

    Science.gov (United States)

    Sakurai, Yoshinori; Kobayashi, Tooru

    2002-10-01

    The updating construction of the Heavy Water Neutron Irradiation Facility of the Kyoto University Research Reactor has been performed from November 1995 to March 1996 mainly for the improvement in neutron capture therapy. On the performance, the neutron irradiation modes with the variable energy spectra from almost pure thermal to epi-thermal neutrons became available by the control of the heavy-water thickness in the spectrum shifter and by the open-and-close of the cadmium and boral thermal neutron filters. The depth distributions of thermal, epi-thermal and fast neutron fluxes were measured by activation method using gold and indium, and the depth distributions of gamma-ray absorbed dose rate were measured using thermo-luminescent dosimeter of beryllium oxide for the several irradiation modes. From these measured data, the controllability of the depth dose distribution using the spectrum shifter and the thermal neutron filters was confirmed.

  6. Synthesis and characterization of gadolinium nanostructured materials with potential applications in magnetic resonance imaging, neutron-capture therapy and targeted drug delivery

    Energy Technology Data Exchange (ETDEWEB)

    Stefanakis, Dimitrios; Ghanotakis, Demetrios F., E-mail: ghanotakis@chemistry.uoc.g [University of Crete, Department of Chemistry (Greece)

    2010-05-15

    Two Gadolinium nanostructured materials, Gd{sub 2}(OH){sub 5}NO{sub 3} nanoparticles and Gd(OH){sub 3} nanorods, were synthesized and extensively characterized by various techniques. In addition to the potential use of Gd{sub 2}(OH){sub 5}NO{sub 3} in magnetic resonance imaging (MRI) and Neutron-capture therapy (NCT) application, it could also be used in targeted drug delivery. An antibiotic (nalidixic acid), two amino acids (aspartic and glutamic acid), a fatty acid and a surfactant (SDS) were intercalated in the nanoparticles. The surface of the nanoparticles was modified with folic acid in order to be capable of targeted delivery to folate receptor expressing sites, such as tumor human cells.

  7. Dose distributions in a human head phantom for neutron capture therapy using moderated neutrons from the 2.5 MeV proton-7Li reaction or from fission of 235U

    Science.gov (United States)

    Tanaka, Kenichi; Kobayashi, Tooru; Sakurai, Yoshinori; Nakagawa, Yoshinobu; Endo, Satoru; Hoshi, Masaharu

    2001-10-01

    The feasibility of neutron capture therapy (NCT) using an accelerator-based neutron source of the 7Li(p,n) reaction produced by 2.5 MeV protons was investigated by comparing the neutron beam tailored by both the Hiroshima University radiological research accelerator (HIRRAC) and the heavy water neutron irradiation facility in the Kyoto University reactor (KUR-HWNIF) from the viewpoint of the contamination dose ratios of the fast neutrons and the gamma rays. These contamination ratios to the boron dose were estimated in a water phantom of 20 cm diameter and 20 cm length to simulate a human head, with experiments by the same techniques for NCT in KUR-HWNIF and/or the simulation calculations by the Monte Carlo N-particle transport code system version 4B (MCNP-4B). It was found that the 7Li(p,n) neutrons produced by 2.5 MeV protons combined with 20, 25 or 30 cm thick D2O moderators of 20 cm diameter could make irradiation fields for NCT with depth-dose characteristics similar to those from the epithermal neutron beam at the KUR-HWNIF.

  8. Biodistribution of BPA and BSH after single, repeated and simultaneous administrations for neutron-capture therapy of cancer

    Energy Technology Data Exchange (ETDEWEB)

    Ichikawa, H. [Faculty of Pharmaceutical Sciences and Cooperative Research Center of Life Sciences, Kobe Gakuin University, 1-1-3 Minatojima, Chuo-ku, Kobe 650-8586 (Japan)], E-mail: ichikawa@pharm.kobegakuin.ac.jp; Taniguchi, E. [Faculty of Pharmaceutical Sciences and Cooperative Research Center of Life Sciences, Kobe Gakuin University, 1-1-3 Minatojima, Chuo-ku, Kobe 650-8586 (Japan); Fujimoto, T. [Department of Orthopaedic Surgery, Hyogo Cancer Center, Akashi 673-0021 (Japan); Fukumori, Y. [Faculty of Pharmaceutical Sciences and Cooperative Research Center of Life Sciences, Kobe Gakuin University, 1-1-3 Minatojima, Chuo-ku, Kobe 650-8586 (Japan)

    2009-07-15

    The effect of administration mode of L-BPA and BSH on the biodistribution in the melanoma-bearing hamsters was investigated. In single intravenous (i.v.) administration, BSH (100 mg BSH/kg) showed no significant retention of {sup 10}B in all the tissues, including tumors, while long-term retention of {sup 10}B in the tumor, muscle and brain was observed with L-BPA (500 mg BPA/kg). The dose escalation of L-BPA and the simultaneous single administration of L-BPA and BSH were not so effective at increasing boron accumulation in tumor after bolus i.v. injection. The boron concentration in tumor was 41 {mu}g B/g after single bolus i.v. injection even at the dose of 1000 mg BPA/kg. In contrast, two sequential bolus i.v. injections of L-BPA with the dose of 500 mg BPA/kg each was found to be effective at increasing {sup 10}B accumulation in the tumor; the maximum {sup 10}B concentration in the tumor reached 52 {mu}g B/g at 3 h after the second i.v. injection.

  9. The medical-irradiation characteristics for neutron capture therapy at the Heavy Water Neutron Irradiation Facility of Kyoto University Research Reactor.

    Science.gov (United States)

    Sakurai, Yoshinori; Kobayashi, Tooru

    2002-10-01

    At the Heavy Water Neutron Irradiation Facility of the Kyoto University Research Reactor, the mix irradiation of thermal and epi-thermal neutrons, and the solo irradiation of epi-thermal neutrons are available additionally to the thermal neutron irradiation, and then the neutron capture therapy (NCT) at this facility became more flexible, after the update in 1996. The estimation of the depth dose distributions in NCT clinical irradiation, were performed for the standard irradiation modes of thermal, mixed and epi-thermal neutrons, from the both sides of experiment and calculation. On the assumption that the 10B concentration in tumor part was 40 ppm and the ratio of tumor to normal tissue was 3.5, the advantage depth were estimated to 5.4, 6.0, and 8.0, for the respective standard irradiation modes. It was confirmed that the various irradiation conditions can be selected according to the target-volume conditions, such as size, depth, etc. Besides, in the viewpoint of the radiation shielding for patient, it was confirmed that the whole-body exposure is effectively reduced by the new clinical collimators, compared with the old one.

  10. Application of Cycloaddition Reactions to the Syntheses of Novel Boron Compounds

    OpenAIRE

    Maguire, John A.; Hosmane, Narayan S; Yinghuai Zhu; Xiao Siwei

    2010-01-01

    This review covers the application of cycloaddition reactions in forming the boron-containing compounds such as symmetric star-shaped boron-enriched dendritic molecules, nano-structured boron materials and aromatic boronic esters. The resulting boron compounds are potentially important reagents for both materials science and medical applications such as in boron neutron capture therapy (BNCT) in cancer treatment and as drug delivery agents and synthetic intermediates for carbon-carbon cross-c...

  11. Neutron capture nuclei-containing carbon nanoparticles for destruction of cancer cells.

    Science.gov (United States)

    Hwang, Kuo Chu; Lai, Po Dong; Chiang, Chi-Shiun; Wang, Pei-Jen; Yuan, Chiun-Jye

    2010-11-01

    HeLa cells were incubated with neutron capture nuclei (boron-10 and gadolinium)-containing carbon nanoparticles, followed by irradiation of slow thermal neutron beam. Under a neutron flux of 6 x 10(11) n/cm(2) (or 10 min irradiation at a neutron flux of 1 x 10(9) n/cm(2) s), the percentages of acute cell death at 8 h after irradiation are 52, 55, and 28% for HeLa cells fed with BCo@CNPs, GdCo@CNPs, and Co@CNPs, respectively. The proliferation capability of the survived HeLa cells was also found to be significantly suppressed. At 48 h after neutron irradiation, the cell viability further decreases to 35 +/- 5% as compared to the control set receiving the same amount of neutron irradiation dose but in the absence of carbon nanoparticles. This work demonstrates "proof-of-concept" examples of neutron capture therapy using (10)B-, (157)Gd-, and (59)Co-containing carbon nanoparticles for effective destruction of cancer cells. It will also be reported the preparation and surface functionalization of boron or gadolinium doped core-shell cobalt/carbon nanoparticles (BCo@CNPs, GdCo@CNPs and Co@CNPs) using a modified DC pulsed arc discharge method, and their characterization by various spectroscopic measurements, including TEM, XRD, SQUID, FT-IR, etc. Tumor cell targeting ability was introduced by surface modification of these carbon nanoparticles with folate moieties.

  12. Synovectomy by Neutron capture; Sinovectomia por captura de neutrones

    Energy Technology Data Exchange (ETDEWEB)

    Vega C, H.R.; Torres M, C. [Centro Regional de Estudios Nucleares, Universidad Autonoma de Zacatecas, C. Cipres 10, Fracc. La Penuela, 98000 Zacatecas (Mexico)

    1998-12-31

    The Synovectomy by Neutron capture has as purpose the treatment of the rheumatoid arthritis, illness which at present does not have a definitive curing. This therapy requires a neutron source for irradiating the articulation affected. The energy spectra and the intensity of these neutrons are fundamental since these neutrons induce nuclear reactions of capture with Boron-10 inside the articulation and the freely energy of these reactions is transferred at the productive tissue of synovial liquid, annihilating it. In this work it is presented the neutron spectra results obtained with moderator packings of spherical geometry which contains in its center a Pu{sup 239} Be source. The calculations were realized through Monte Carlo method. The moderators assayed were light water, heavy water base and the both combination of them. The spectra obtained, the average energy, the neutron total number by neutron emitted by source, the thermal neutron percentage and the dose equivalent allow us to suggest that the moderator packing more adequate is what has a light water thickness 0.5 cm (radius 2 cm) and 24.5 cm heavy water (radius 26.5 cm). (Author)

  13. Complexion of Boric Acid with 2-Deoxy-D-glucose (DG) as a novel boron carrier for BNCT

    OpenAIRE

    Akan, Zafer; Demiroglu, Hasan; Avcibasi, Ugur; Oto, Gokhan; Ozdemir, Hulya; Deniz, Sabahattin; Basak, Ali Sadi

    2014-01-01

    Objective: Boron neutron capture therapy (BNCT) is an intensive research area for cancer researchers. Especially the side effects and inabilities of conventional therapies in some cases, directs researchers to find out a new cancer therapy methods such as BNCT. One of three important problem of BNCT is targeting of boron to tumor tissue. Borono Phenyl Alanine (BPA) and Borono Sodium Borocaptate (BSH) are already using in clinical studies as boron carriers. New boron carriers are searching fo...

  14. Gamma/neutron dose evaluation using Fricke gel and alanine gel dosimeters to be applied in boron neutron capture therapy.

    Science.gov (United States)

    Mangueira, T F; Silva, C F; Coelho, P R P; Campos, L L

    2010-01-01

    Gel dosimetry has been studied mainly for medical applications. The radiation induced ferric ions concentration can be measured by different techniques to be related with the absorbed dose. Aiming to assess gamma/thermal neutrons dose from research reactors, Fricke gel and alanine gel solutions produced at IPEN using 300 bloom gelatin were mixed with Na(2)B(4)O(7) salt, and the mixtures were irradiated at the beam hole #3 of the IEA-R1 research reactor, (BH#3) adapted to BNCT studies, and the dose-response was evaluated using spectrophotometry technique.

  15. Dose Determination using alanine detectors in a Mixed Neutron and Gamma Field for Boron Neutron Capture Therapy of Liver Malignancies

    DEFF Research Database (Denmark)

    Schmitz, T.; Blaickner, M.; Ziegner, M.

    2011-01-01

    be suitable for measurements in mixed neutron and gamma fields. Materials and Methods Two experiments have been carried out in the thermal column of the TRIGA Mark II reactor at the University of Mainz. Alanine dosimeters have been irradiated in a phantom and in liver tissue. Results For the interpretation......, in combination with flux measurements and Monte Carlo calculations with FLUKA, suggest that it is possible to establish a system for monitoring the dose in a mixed neutron and gamma field for BNCT and other applications in radiotherapy....

  16. The status of Tsukuba BNCT trial: BPA-based boron neutron capture therapy combined with X-ray irradiation

    Energy Technology Data Exchange (ETDEWEB)

    Yamamoto, T., E-mail: tetsu_tsukuba@yahoo.co.jp [Department of Neurosurgery, Graduate School of Comprehensive Human Science, University of Tsukuba, Tennodai 1-1-1, Tsukuba (Japan)] [Department of Radiation Oncology, Graduate School of Comprehensive Human Science, University of Tsukuba, Tennodai 1-1-1, Tsukuba (Japan); Nakai, K. [Department of Neurosurgery, Graduate School of Comprehensive Human Science, University of Tsukuba, Tennodai 1-1-1, Tsukuba (Japan); Nariai, T. [Department of Neurosurgery, Tokyo Medical and Dental University, Yushima 1-5-45, Bunkyo-ku, Tokyo (Japan); Kumada, H.; Okumura, T.; Mizumoto, M.; Tsuboi, K. [Department of Radiation Oncology, Graduate School of Comprehensive Human Science, University of Tsukuba, Tennodai 1-1-1, Tsukuba (Japan); Zaboronok, A.; Ishikawa, E.; Aiyama, H.; Endo, K.; Takada, T.; Yoshida, F.; Shibata, Y.; Matsumura, A. [Department of Neurosurgery, Graduate School of Comprehensive Human Science, University of Tsukuba, Tennodai 1-1-1, Tsukuba (Japan)

    2011-12-15

    The phase II trial has been prepared to assess the effectiveness of BPA (250 mg/kg)-based NCT combined with X-ray irradiation and temozolomide (75 mg/m{sup 2}) for the treatment of newly diagnosed GBM. BPA uptake is determined by {sup 18}F-BPA-PET and/or {sup 11}C-MET-PET, and a tumor with the lesion to normal ratio of 2 or more is indicated for BNCT. The maximum normal brain point dose prescribed was limited to 13.0 Gy or less. Primary end point is overall survival.

  17. Accelerator tube construction and characterization for a tandem-electrostatic-quadrupole for accelerator-based boron neutron capture therapy

    Energy Technology Data Exchange (ETDEWEB)

    Cartelli, D.; Thatar Vento, V. [Gerencia de Investigacion y Aplicaciones, Comision Nacional de Energia Atomica (Argentina)] [CONICET, Av Rivadavia 1917 (1033), Buenos Aires (Argentina); Castell, W. [Gerencia de Investigacion y Aplicaciones, Comision Nacional de Energia Atomica (Argentina); Di Paolo, H. [Gerencia de Investigacion y Aplicaciones, Comision Nacional de Energia Atomica (Argentina)] [Escuela de Ciencia y Tecnologia, Universidad Nacional de San Martin (Argentina); Kesque, J.M. [Gerencia de Investigacion y Aplicaciones, Comision Nacional de Energia Atomica (Argentina); Bergueiro, J. [Gerencia de Investigacion y Aplicaciones, Comision Nacional de Energia Atomica (Argentina)] [CONICET, Av Rivadavia 1917 (1033), Buenos Aires (Argentina); Valda, A.A. [Gerencia de Investigacion y Aplicaciones, Comision Nacional de Energia Atomica (Argentina)] [Escuela de Ciencia y Tecnologia, Universidad Nacional de San Martin (Argentina)

    2011-12-15

    The accelerator tubes are essential components of the accelerator. Their function is to transport and accelerate a very intense proton or deuteron beam through the machine, from the ion source to the neutron production target, without significant losses. In this contribution, we discuss materials selected for the tube construction, the procedures used for their assembly and the testing performed to meet the stringent requirements to which it is subjected.

  18. Optimum design of a moderator system based on dose calculation for an accelerator driven Boron Neutron Capture Therapy.

    Science.gov (United States)

    Inoue, R; Hiraga, F; Kiyanagi, Y

    2014-06-01

    An accelerator based BNCT has been desired because of its therapeutic convenience. However, optimal design of a neutron moderator system is still one of the issues. Therefore, detailed studies on materials consisting of the moderator system are necessary to obtain the optimal condition. In this study, the epithermal neutron flux and the RBE dose have been calculated as the indicators to look for optimal materials for the filter and the moderator. As a result, it was found that a combination of MgF2 moderator with Fe filter gave best performance, and the moderator system gave a dose ratio greater than 3 and an epithermal neutron flux over 1.0×10(9)cm(-2)s(-1).

  19. Boron-Based Drug Design.

    Science.gov (United States)

    Ban, Hyun Seung; Nakamura, Hiroyuki

    2015-06-01

    The use of the element boron, which is not generally observed in a living body, possesses a high potential for the discovery of new biological activity in pharmaceutical drug design. In this account, we describe our recent developments in boron-based drug design, including boronic acid containing protein tyrosine kinase inhibitors, proteasome inhibitors, and tubulin polymerization inhibitors, and ortho-carborane-containing proteasome activators, hypoxia-inducible factor 1 inhibitors, and topoisomerase inhibitors. Furthermore, we applied a closo-dodecaborate as a water-soluble moiety as well as a boron-10 source for the design of boron carriers in boron neutron capture therapy, such as boronated porphyrins and boron lipids for a liposomal boron delivery system.

  20. Neutron capture cross section of Am241

    Science.gov (United States)

    Jandel, M.; Bredeweg, T. A.; Bond, E. M.; Chadwick, M. B.; Clement, R. R.; Couture, A.; O'Donnell, J. M.; Haight, R. C.; Kawano, T.; Reifarth, R.; Rundberg, R. S.; Ullmann, J. L.; Vieira, D. J.; Wilhelmy, J. B.; Wouters, J. M.; Agvaanluvsan, U.; Parker, W. E.; Wu, C. Y.; Becker, J. A.

    2008-09-01

    The neutron capture cross section of Am241 for incident neutrons from 0.02 eV to 320 keV has been measured with the detector for advanced neutron capture experiments (DANCE) at the Los Alamos Neutron Science Center. The thermal neutron capture cross section was determined to be 665±33 b. Our result is in good agreement with other recent measurements. Resonance parameters for Enwell with the measured data, and the extracted averaged resonance parameters in the unresolved resonance region are consistent with those for the resolved resonances.

  1. Radiation quality evaluation in heavy water field using tissue equivalent-proportional counter with wall containing boron

    Energy Technology Data Exchange (ETDEWEB)

    Onizuka, Y. [Kyushu Univ., Faculty of Medicine, Fukuoka (Japan); Endo, S.; Ishikawa, M. [Hiroshima Univ., Research Inst. for Radiation Biology and Medicine, Hiroshima (JP)] [and others

    2003-01-01

    A heavy water installation at the Kyoto University Reactor (KUR) is used for the boron neutron capture therapy. The contributions of boron neutron capture reaction to the dose are required for the evaluation of the boron neutron capture therapy in relation to the biological effectiveness. The radiation therapy fields are measured by a technique of micro-dosimetry. Three types of tissue equivalent-proportional counter are used for measurement of the radiation therapy fields; a LET counter with wall containing boron for thermal neutrons, a LET counter with wall containing no boron for epithermal neutrons, and a helical wire proportional counter with carbon wall for gamma rays. Irradiations of the counters are carried out in the neutron capture therapy fields with two modes, a thermal neutron mode and an epithermal neutron mode. An acrylic plate is used for human body phantom. Each energy spectrum in the counters is measured at depth 6.7 mm in the phantom by multi-channel analyzer. The energy spectra in three types of the counters show that most of neutron energy transfers to the effects of {sup 4}He(1.49 MeV) and {sup 7}Li(0.85 MeV) following to thermal neutron capture reactions of {sup 10}B in the wall. (M. Suetake)

  2. Application of cycloaddition reactions to the syntheses of novel boron compounds.

    Science.gov (United States)

    Zhu, Yinghuai; Siwei, Xiao; Maguire, John A; Hosmane, Narayan S

    2010-12-21

    This review covers the application of cycloaddition reactions in forming the boron-containing compounds such as symmetric star-shaped boron-enriched dendritic molecules, nano-structured boron materials and aromatic boronic esters. The resulting boron compounds are potentially important reagents for both materials science and medical applications such as in boron neutron capture therapy (BNCT) in cancer treatment and as drug delivery agents and synthetic intermediates for carbon-carbon cross-coupling reactions. In addition, the use of boron cage compounds in a number of cycloaddition reactions to synthesize unique aromatic species will be reviewed briefly.

  3. Application of Cycloaddition Reactions to the Syntheses of Novel Boron Compounds

    Directory of Open Access Journals (Sweden)

    John A. Maguire

    2010-12-01

    Full Text Available This review covers the application of cycloaddition reactions in forming the boron-containing compounds such as symmetric star-shaped boron-enriched dendritic molecules, nano-structured boron materials and aromatic boronic esters. The resulting boron compounds are potentially important reagents for both materials science and medical applications such as in boron neutron capture therapy (BNCT in cancer treatment and as drug delivery agents and synthetic intermediates for carbon-carbon cross-coupling reactions. In addition, the use of boron cage compounds in a number of cycloaddition reactions to synthesize unique aromatic species will be reviewed briefly.

  4. Solid state microdosimetry in hadron therapy.

    Science.gov (United States)

    Rosenfeld, A B; Bradley, P D; Cornelius, I; Allen, B J; Zaider, M; Maughan, R L; Yanch, J C; Coderre, J; Flanz, J B; Kobayashi, T

    2002-01-01

    A report of recent developments in silicon microdosimetry is presented. SOI based microdosemeters have shown promise as a viable alternative to traditional tissue-equivalent proportional counters. The application of these silicon microdosemeters to such radiation therapy modalities as boron neutron capture therapy (BNCT), boron neutron capture synovectomy (BNCS), proton therapy (PT), and fast neutron therapy (FNT) has been performed. Several shortcomings of the current silicon microdosemeter were identified and will be taken into account in the design of a second-generation device.

  5. Boron concentration measurement system for the Czech BNCT project

    Science.gov (United States)

    Honzátko, J.; Tomandl, I.

    2000-07-01

    In the framework of the Czech Boron Neutron Capture Therapy (BNCT) project a Prompt Gamma Ray Analysis (PGRA) facility for the determination of the boron concentration in biological samples was built at light-water reactor at Řež. The facility utilizes the beam of thermal neutrons from a neutron guide. The pure beam of thermal neutrons and background conditions enables the determination of 1 ppm with the reasonable statistical error 5% within 15 minutes.

  6. Capturing the Future: Direct and Indirect Probes of Neutron Capture

    Energy Technology Data Exchange (ETDEWEB)

    Couture, Aaron Joseph [Los Alamos National Lab. (LANL), Los Alamos, NM (United States)

    2016-08-31

    This report documents aspects of direct and indirect neutron capture. The importance of neutron capture rates and methods to determine them are presented. The following conclusions are drawn: direct neutron capture measurements remain a backbone of experimental study; work is being done to take increased advantage of indirect methods for neutron capture; both instrumentation and facilities are making new measurements possible; more work is needed on the nuclear theory side to understand what is needed furthest from stability.

  7. Subcellular boron and fluorine distributions with SIMS ion microscopy in BNCT and cancer research

    Energy Technology Data Exchange (ETDEWEB)

    Subhash Chandra

    2008-05-30

    The development of a secondary ion mass spectrometry (SIMS) based technique of Ion Microscopy in boron neutron capture therapy (BNCT) was the main goal of this project, so that one can study the subcellular location of boron-10 atoms and their partitioning between the normal and cancerous tissue. This information is fundamental for the screening of boronated drugs appropriate for neutron capture therapy of cancer. Our studies at Cornell concentrated mainly on studies of glioblastoma multiforme (GBM). The early years of the grant were dedicated to the development of cryogenic methods and correlative microscopic approaches so that a reliable subcellular analysis of boron-10 atoms can be made with SIMS. In later years SIMS was applied to animal models and human tissues of GBM for studying the efficacy of potential boronated agents in BNCT. Under this grant the SIMS program at Cornell attained a new level of excellence and collaborative SIMS studies were published with leading BNCT researchers in the U.S.

  8. Neutron capture cross sections from Surrogate measurements

    Directory of Open Access Journals (Sweden)

    Scielzo N.D.

    2010-03-01

    Full Text Available The prospects for determining cross sections for compound-nuclear neutron-capture reactions from Surrogate measurements are investigated. Calculations as well as experimental results are presented that test the Weisskopf-Ewing approximation, which is employed in most analyses of Surrogate data. It is concluded that, in general, one has to go beyond this approximation in order to obtain (n,γ cross sections of sufficient accuracy for most astrophysical and nuclear-energy applications.

  9. Neutron capture therapy beam design at Harwell.

    Science.gov (United States)

    Constantine, G

    1990-01-01

    At Harwell, we have progressed from designing, building, and using small-diameter beams of epithermal neutrons for radiobiology studies to designing a radiotherapy facility for the 25-MW research reactor DIDO. The program is well into the survey phase, where the main emphasis is on tailoring the neutron spectrum. The incorporation of titanium and vanadium in an aluminium spectrum shaper in the D2O reflector has been shown to yield a significant reduction in the mean energy of neutrons incident on the patient by suppression of streaming through the cross-section window in aluminium at 25 keV.

  10. Neutron Capture Cross Section of 239Pu

    Science.gov (United States)

    Mosby, S.; Arnold, C.; Bredeweg, T. A.; Couture, A.; Jandel, M.; O'Donnell, J. M.; Rusev, G.; Ullmann, J. L.; Chyzh, A.; Henderson, R.; Kwan, E.; Wu, C. Y.

    2014-09-01

    The 239Pu(n,γ) cross section has been measured over the energy range 10 eV - 10 keV using the Detector for Advanced Neutron Capture Experiments (DANCE) as part of a campaign to produce precision (n,γ) measurements on 239Pu in the keV region. Fission coincidences were measured with a PPAC and used to characterize the prompt fission γ-ray spectrum in this region. The resulting spectra will be used to better characterize the fission component of another experiment with a thicker target to extend the (n,γ) cross section measurement well into the keV region.

  11. Neutron capture measurements on {sup 171}Tm

    Energy Technology Data Exchange (ETDEWEB)

    Reifarth, R. E-mail: www.reifarth@lanl.gov; Haight, R.; Heil, M.; Fowler, M.M.; Kaeppeler, F.; Miller, G.G.; Rundberg, R.S.; Ullmann, J.L.; Wilhelmy, J.B

    2003-05-05

    A first proof of principal experiment of measuring neutron capture cross sections of radioactive isotopes was performed on {sup 171}Tm which has a half life of 1.92 years. This isotope was chosen for its ease of production and its radiation properties. The experiment was done at an 8 meter irradiation station at LANSCE using the pulse height weighting technique. A complemental activation measurement at FZK as well as a theoretical estimation indicated a significant background component above 1 keV neutron energy during the experiment at LANSCE.

  12. Neutron capture cross section of $^{93}$Zr

    CERN Multimedia

    We propose to measure the neutron capture cross section of the radioactive isotope $^{93}$Zr. This project aims at the substantial improvement of existing results for applications in nuclear astrophysics and emerging nuclear technologies. In particular, the superior quality of the data that can be obtained at n_TOF will allow on one side a better characterization of s-process nucleosynthesis and on the other side a more accurate material balance in systems for transmutation of nuclear waste, given that this radioactive isotope is widely present in fission products.

  13. Halo Effect on Direct Neutron Capture Process

    Institute of Scientific and Technical Information of China (English)

    刘祖华; 周宏余

    2004-01-01

    We calculate the capture cross sections of the 10Be(n,γ) 11 Be reaction by means of the asymptotic normalization coefficient method and demonstrate the halo effects on the capture cross sections for the direct radiative neutron capture where a p-, s- or d-wave neutron is captured into an s-orbit or p-orbit in 11 Be by emitting an E1 γ-ray,respectively. The result shows that the enormous enhancement of the capture cross section is just due to the large overlap of the incident neutron wave with the extended tail of the halo, which is clearly illustrated by the reduced transition amplitude function.

  14. Measurement of thermal neutron capture cross section

    CERN Document Server

    Huang Xiao Long; LuHanLin; Yu Wei Xiang; Zhao Wen Rong

    2001-01-01

    The thermal neutron capture cross sections of sup 7 sup 1 Ga(n, gamma) sup 7 sup 2 Ga, sup 9 sup 4 Zr(n, gamma) sup 9 sup 5 Zr and sup 1 sup 9 sup 1 Ir(n, gamma) sup 1 sup 9 sup 2 Ir sup m sup 1 sup + sup g sup , sup m sup 2 reactions were measured by using activation method and compared with other measured data. Meanwhile the half-life of sup 7 sup 2 Ga was also measured. The samples were irradiated with the neutron in the thermal column of heavy water reactor of China Institute of Atomic Energy. The activities of the reaction products were measured by well-calibrated Ge(Li) detector

  15. Non-Statistical Effects in Neutron Capture

    Science.gov (United States)

    Koehler, P. E.; Bredeweg, T. A.; Guber, K. H.; Harvey, J. A.; O'Donnell, J. M.; Reifarth, R.; Rundberg, R. S.; Ullmann, J. L.; Vieira, D. J.; Wiarda, D.; Wouters, J. M.

    2009-01-01

    There have been many reports of non-statistical effects in neutron-capture measurements. However, reports of deviations of reduced-neutron-width (Γn0) distributions from the expected Porter-Thomas (PT) shape largely have been ignored. Most of these deviations have been reported for odd-A nuclides. Because reliable spin (J) assignments have been absent for most resonances for such nuclides, it is possible that reported deviations from PT might be due to incorrect J assignments. We recently developed a new method for measuring spins of neutron resonances by using the DANCE detector at the Los Alamos Neutron Science Center (LANSCE). Measurements made with a 147Sm sample allowed us to determine spins of almost all known resonances below 1 keV. Furthermore, analysis of these data revealed that the Γn0 distribution was in good agreement with PT for resonances below 350 eV, but in disagreement with PT for resonances between 350 and 700 eV. Our previous (n,α) measurements had revealed that the α strength function also changes abruptly at this energy. There currently is no known explanation for these two non-statistical effects. Recently, we have developed another new method for determining the spins of neutron resonances. To implement this technique required a small change (to record pulse-height information for coincidence events) to a much simpler apparatus: A pair of C6D6 γ-ray detectors which we have employed for many years to measure neutron-capture cross sections at the Oak Ridge Electron Linear Accelerator (ORELA). Measurements with a 95Mo sample revealed that not only does the method work very well for determining spins, but it also makes possible parity assignments. Taken together, these new techniques at LANSCE and ORELA could be very useful for further elucidation of non-statistical effects.

  16. Rapid neutron capture process in supernovae and chemical element formation

    NARCIS (Netherlands)

    Baruah, Rulee; Duorah, Kalpana; Duorah, H. L.

    2009-01-01

    The rapid neutron capture process (r-process) is one of the major nucleosynthesis processes responsible for the synthesis of heavy nuclei beyond iron. Isotopes beyond Fe are most exclusively formed in neutron capture processes and more heavier ones are produced by the r-process. Approximately half o

  17. Neutron Capture Experiments Using the DANCE Array at Los Alamos

    Science.gov (United States)

    Dashdorj, D.; Mitchell, G. E.; Baramsai, B.; Chyzh, A.; Walker, C.; Agvaanluvsan, U.; Becker, J. A.; Parker, W.; Sleaford, B.; Wu, C. Y.; Bredeweg, T. A.; Couture, A.; Haight, R. C.; Jandel, M.; Rundberg, R. S.; Ullmann, J. L.; Vieira, D. J.; Wouters, J. M.; Krtička, M.; Bečvář, F.

    2009-03-01

    The Detector for Advanced Neutron Capture Experiments (DANCE) is designed for neutron capture measurements on very small and/or radioactive targets. The DANCE array of 160 BaF2 scintillation detectors is located at the Lujan Center at the Los Alamos Neutron Science Center (LANSCE). Accurate measurements of neutron capture data are important for many current applications as well as for basic understanding of neutron capture. The gamma rays following neutron capture reactions have been studied by the time-of-flight technique using the DANCE array. The high granularity of the array allows measurements of the gamma-ray multiplicity. The gamma-ray multiplicities and energy spectra for different multiplicities can be measured and analyzed for spin and parity determination of the resolved resonances.

  18. Neutron-capture therapy of human cancer: in vitro results on the preparation of boron-labeled antibodies to carcinoembryonic antigen.

    OpenAIRE

    Mizusawa, E; Dahlman, H L; Bennett, S. J.; Goldenberg, D M; Hawthorne, M F

    1982-01-01

    Two samples of 2-phenyl-1,2-dicarba-closo-[1-3H]dodecaborane(12) were prepared by treating 1-lithio-2-phenyl-1,2-dicarba-closo-dodecaborane(12) with 3H2O (0.1 and 5.0 Ci/ml, respectively). These tritiated phenylcarborane samples were subsequently converted to corresponding samples of p-[1,2-dicarba-closo-[1-3H]dodecaboran(12)-2-yl]benzenediazonium ion ([3H]DBD) suitable for azo-coupling reactions. Reaction of the two tritiated diazonium ion samples with 2-napthol resulted in the formation of ...

  19. Characteristics and application of spherical-type activation detectors in neutron spectrum measurements at a boron neutron capture therapy (BNCT) facility

    Energy Technology Data Exchange (ETDEWEB)

    Lin, Heng-Xiao; Chen, Wei-Lin [Institute of Nuclear Engineering and Science, National Tsing Hua University, Hsinchu 300, Taiwan, ROC (China); Liu, Yuan-Hao [Neuboron Medtech Ltd., Nanjing, Jiangsu Province 21112 (China); Sheu, Rong-Jiun, E-mail: rjsheu@mx.nthu.edu.tw [Institute of Nuclear Engineering and Science, National Tsing Hua University, Hsinchu 300, Taiwan, ROC (China); Department of Engineering and System Science, National Tsing Hua University, Hsinchu 300, Taiwan, ROC (China)

    2016-03-01

    A set of spherical-type activation detectors was developed aiming to provide better determination of the neutron spectrum at the Tsing Hua Open-pool Reactor (THOR) BNCT facility. An activation foil embedded in a specially designed spherical holder exhibits three advantages: (1) minimizing the effect of neutron angular dependence, (2) creating response functions with broadened coverage of neutron energies by introducing additional moderators or absorbers to the central activation foil, and (3) reducing irradiation time because of improved detection efficiencies to epithermal neutron beam. This paper presents the design concept and the calculated response functions of new detectors. Theoretical and experimental demonstrations of the performance of the detectors are provided through comparisons of the unfolded neutron spectra determined using this method and conventional multiple-foil activation techniques.

  20. Neutron radiation therapy: application of advanced technology to the treatment of cancer

    CERN Document Server

    Maughan, R L; Kota, C; Burmeister, J; Porter, A T; Forman, J D; Blosser, H G; Blosser, E; Blosser, G

    1999-01-01

    The design and construction of a unique superconducting cyclotron for use in fast neutron radiation therapy is described. The clinical results obtained in the treatment of adenocarcinoma of the prostate with this accelerator are presented. Future use of the boron neutron capture reaction as a means of enhancing fast neutron therapy in the treatment of patients with brain tumors (glioblastoma multiforme) is also discussed.

  1. Non-Statistical Effects in Neutron Capture

    CERN Document Server

    Köhler, P E; Guber, K H; Harvey, J A; ODonnell, J M; Reifarth, R; Rundberg, R S; Ullmann, J L; Vieira, D J; Wiarda, D; Wouters, J M

    2008-01-01

    There have been many reports of non-statistical effects in neutron-capture measurements. However, reports of deviations of reduced-neutron-width distributions from the expected Porter-Thomas (PT) shape largely have been ignored. Most of these deviations have been reported for odd-A nuclides. Because reliable spin (J) assignments have been absent for most resonances for such nuclides, it is possible that reported deviations from PT might be due to incorrect J assignments. We recently developed a new method for measuring spins of neutron resonances by using the DANCE detector at LANSCE. Measurements made with a 147Sm sample allowed us to determine spins of almost all known resonances below 1 keV. Furthermore, analysis of these data revealed that the reduced-neutron-width distribution was in good agreement with PT for resonances below 350 eV, but in disagreement with PT for resonances between 350 and 700 eV. Our previous (n,alpha) measurements had revealed that the alpha strength function also changes abruptly a...

  2. Synthesis of boron nitride nanotubes and their applications

    OpenAIRE

    Saban Kalay; Zehra Yilmaz; Ozlem Sen; Melis Emanet; Emine Kazanc; Mustafa Çulha

    2015-01-01

    Boron nitride nanotubes (BNNTs) have been increasingly investigated for use in a wide range of applications due to their unique physicochemical properties including high hydrophobicity, heat and electrical insulation, resistance to oxidation, and hydrogen storage capacity. They are also valued for their possible medical and biomedical applications including drug delivery, use in biomaterials, and neutron capture therapy. In this review, BNNT synthesis methods and the surface modification stra...

  3. Neutron Capture Experiments on Unstable Nuclei

    Energy Technology Data Exchange (ETDEWEB)

    Jon M. Schwantes; Ralf Sudowe; Heino Nitsche; Darleane C. Hoffman

    2003-12-16

    A primary objective of this project is to study neutron capture cross sections for various stable and unstable isotopes that will contribute to the Science Based Stockpile Stewardship (SBSS) program by providing improved data for modeling and interpretation of nuclear device performance. The information obtained will also be important in astrophysical modeling of nucleosynthesis. During this reporting period, the emphasis has been on preparing a radioactive target of {sup 155}Eu (half-life = 4.7 years), and several stable targets, including isotopically separated {sup 154}Sm, {sup 151}Eu, and {sup 153}Eu. Measurements of their neutron capture cross sections will be conducted in collaboration with researchers at the Los Alamos Neutron Science Center (LANSCE) facility using the Detector for Advanced Neutron Capture Experiments (DANCE). A suitable backing material (beryllium) for the targets has been selected after careful calculations of its contribution to the background of the measurements. In addition, a high voltage plating procedure has been developed and optimized. Stable targets of {sup 151}Eu and {sup 153}Eu and a target of natural Eu ({approx}50% {sup 151}Eu and {approx}50% {sup 153}Eu) have each been plated to a mass thickness of >1 mg/cm{sup 2} and delivered to the DANCE collaboration at Los Alamos National Laboratory (LANL). Natural Eu targets will be tested first to confirm that the target dimensions and backing are appropriate prior to performing measurements on the extremely valuable targets of separated isotopes. In order to prepare a target of the radioactive {sup 155}Eu, it must first be separated from the {sup 154}Sm target material that was irradiated in a very high neutron flux of 1.5x1015 neutrons/cm{sup 2}/s for 50 days. The reaction is {sup 154}Sm (n,f){sup 155}Sm (half-life = 22 minutes) {sup 155}Eu. Considerable progress has been made in developing a suitable high-yield and high-purity separation method for separating Eu from targets

  4. Heterogeneous Neutron Capture Record of the Norton County Enstatite Achondrite

    Science.gov (United States)

    Hidaka, H.; Yoneda, S.

    2012-09-01

    Large and heterogeneous isotopic variations of Sm and Gd due to neutron capture reactions caused by cosmic-ray irradiation were found in chemical and mineral separates from the Norton County meteorite.

  5. Thermal neutron capture cross sections of tellurium isotopes

    Energy Technology Data Exchange (ETDEWEB)

    Tomandl, I.; Honzatko, J.; von Egidy, T.; Wirth, H.-F.; Belgya, T.; Lakatos, M.; Szentmiklosi, L.; Revay, Zs.; Molnar, G.L.; Firestone, R.B.; Bondarenko, V.

    2004-03-01

    New values for thermal neutron capture cross sections of the tellurium isotopes 122Te, 124Te, 125Te, 126Te, 128Te, and 130Te are reported. These values are based on a combination of newly determined partial g-ray cross sections obtained from experiments on targets contained natural Te and gamma intensities per capture of individual Te isotopes. Isomeric ratios for the thermal neutron capture on the even tellurium isotopes are also given.

  6. Neutronic effects on tungsten-186 double neutron capture

    Science.gov (United States)

    Garland, Marc Alan

    Rhenium-188, a daughter product of tungsten-188, is an isotope of great interest in therapeutic nuclear medicine, being used in dozens of laboratory and clinical investigations worldwide. Applications include various cancer therapy strategies, treatment of rheumatoid arthritis, prevention of restenosis following coronary artery angioplasty, and palliation of bone pain associated with cancer metastases. With its half-life of 17 hours, 2.12 MeV (maximum) beta-particle emission, chemical similarity to technetium-99m (the most widely used diagnostic radioisotope), and its availability in a convenient tungsten-188/rhenium-188 generator system, rhenium-188 is a superb candidate for a broad range of applications. Production of 188W is typically via double neutron capture by 186W in a high flux nuclear reactor, predominantly the High Flux Isotope Reactor at the Oak Ridge National Laboratory in Tennessee. Experience at HFIR has shown that production yields (measured in Ci of 188W produced per g of 186W target) decrease considerably as target size increases. While the phenomenon of neutron resonance self-shielding would be expected to produce such an effect, temperature effects on neutron flux distribution and neutron capture rates may also be involved. Experimental investigations of these phenomena have not been previously performed. The work presented in this thesis evaluates the factors that contribute to the decrease in 188W yield from both theoretical and experimental standpoints. Neutron self-shielding and temperature effects were characterized to develop a strategy for target design that would optimize production yield, an important factor in minimizing health care costs. It was determined that decrease in yield due to neutron self-shielding can be attributed to depletion of epithermal neutrons at resonant energies, most significantly within the initial 0.4 mm depth of the target. The results from these studies further show that 188W yield in the interior of the

  7. The investigation of physical conditions of boron uptake region in proton boron fusion therapy (PBFT)

    Science.gov (United States)

    Jung, Joo-Young; Yoon, Do-Kun; Lee, Heui Chang; Lu, Bo; Suh, Tae Suk

    2016-09-01

    We conducted a quantitative study to identify the effectiveness of proton boron fusion therapy (PBFT). Four simulation scenarios were designed to investigate the escalation in total dose with the proton boron reaction using a Monte Carlo n-particle extended (MCNPX 2.6.0) simulation. The peak integrated dose was obtained for three different physical conditions (i.e., boron uptake region (BUR) thickness, BUR location, and boron concentration) with differing proton beam energy (60-90 MeV). We found that the peak integrated dose was increased by up to 96.62% compared to the pristine proton Bragg-peak. For the synergetic effect to take place with 60-70 MeV proton beam, the BUR had to be at least 0.3 cm thick while spanning the Bragg-peak. Similarly to the thickness, the BUR location needed to be within 0.3 cm from the Bragg-peak when the thickness was maintained at 0.9 cm. An effective proton boron reaction required the boron concentration to be equal to or greater than 14.4 mg/g. These results demonstrate the impact of various physical and beam conditions of the PBFT, which are critical environmental factors for the treatment planning. We envision that this study will advance our understanding of the PBFT, which can be an invaluable treatment method for maximizing the potential of proton therapy.

  8. The investigation of physical conditions of boron uptake region in proton boron fusion therapy (PBFT

    Directory of Open Access Journals (Sweden)

    Joo-Young Jung

    2016-09-01

    Full Text Available We conducted a quantitative study to identify the effectiveness of proton boron fusion therapy (PBFT. Four simulation scenarios were designed to investigate the escalation in total dose with the proton boron reaction using a Monte Carlo n-particle extended (MCNPX 2.6.0 simulation. The peak integrated dose was obtained for three different physical conditions (i.e., boron uptake region (BUR thickness, BUR location, and boron concentration with differing proton beam energy (60–90 MeV. We found that the peak integrated dose was increased by up to 96.62% compared to the pristine proton Bragg-peak. For the synergetic effect to take place with 60–70 MeV proton beam, the BUR had to be at least 0.3 cm thick while spanning the Bragg-peak. Similarly to the thickness, the BUR location needed to be within 0.3 cm from the Bragg-peak when the thickness was maintained at 0.9 cm. An effective proton boron reaction required the boron concentration to be equal to or greater than 14.4 mg/g. These results demonstrate the impact of various physical and beam conditions of the PBFT, which are critical environmental factors for the treatment planning. We envision that this study will advance our understanding of the PBFT, which can be an invaluable treatment method for maximizing the potential of proton therapy.

  9. Thermal-neutron capture for A=26-35

    Energy Technology Data Exchange (ETDEWEB)

    Chunmei, Z.; Firestone, R.B.

    2001-06-01

    The prompt gamma-ray data of thermal- neutron captures fornuclear mass number A=26-35 had been evaluated and published in "ATOMICDATA AND NUCLEAR DATA TABLES, 26, 511 (1981)". Since that time themanyexperimental data of the thermal-neutron captures have been measuredand published. The update of the evaluated prompt gamma-ray data is verynecessary for use in PGAA of high-resolution analytical prompt gamma-rayspectroscopy. Besides, the evaluation is also very needed in theEvaluated Nuclear Structure Data File, ENSDF, because there are no promptgamma-ray data in ENSDF. The levels, prompt gamma-rays and decay schemesof thermal-neutron captures for nuclides (26Mg, 27Al, 28Si, 29Si, 30Si,31P, 32S, 33S, 34S, and 35Cl) with nuclear mass number A=26-35 have beenevaluated on the basis of all experimental data. The normalizationfactors, from which absolute prompt gamma-ray intensity can be obtained,and necessary comments are given in the text. The ENSDF format has beenadopted in this evaluation. The physical check (intensity balance andenergy balance) of evaluated thermal-neutron capture data has been done.The evaluated data have been put into Evaluated Nuclear Structure DataFile, ENSDF. This evaluation may be considered as an update of the promptgamma-ray from thermal-neutron capture data tables as published in"ATOMIC DATA AND NUCLEAR DATA TABLES, 26, 511 (1981)".

  10. Thermal-neutron capture for A=36-44

    Energy Technology Data Exchange (ETDEWEB)

    Chunmei, Z.; Firestone, R.B.

    2003-01-01

    The prompt gamma-ray data of thermal- neutron captures fornuclear mass number A=26-35 had been evaluated and published in "ATOMICDATA AND NUCLEAR DATA TABLES, 26, 511 (1981)". Since that time the manyexperimental data of the thermal-neutron captures have been measured andpublished. The update of the evaluated prompt gamma-ray data is verynecessary for use in PGAA of high-resolution analytical prompt gamma-rayspectroscopy. Besides, the evaluation is also very needed in theEvaluated Nuclear Structure Data File, ENSDF, because there are no promptgamma-ray data in ENSDF. The levels, prompt gamma-rays and decay schemesof thermal-neutron captures fornuclides (26Mg, 27Al, 28Si, 29Si, 30Si,31P, 32S, 33S, 34S, and 35Cl) with nuclear mass number A=26-35 have beenevaluated on the basis of all experimental data. The normalizationfactors, from which absolute prompt gamma-ray intensity can be obtained,and necessary comments are given in the text. The ENSDF format has beenadopted in this evaluation. The physical check (intensity balance andenergy balance) of evaluated thermal-neutron capture data has been done.The evaluated data have been put into Evaluated Nuclear Structure DataFile, ENSDF. This evaluation may be considered as an update of the promptgamma-ray from thermal-neutron capture data tables as published in"ATOMIC DATA AND NUCLEAR DATA TABLES, 26, 511 (1981)".

  11. Neutron Capture Cross Sections of 236U and 234U

    Science.gov (United States)

    Rundberg, R. S.; Bredeweg, T. A.; Bond, E. M.; Haight, R. C.; Hunt, L. F.; Kronenberg, A.; O'Donnell, J. M.; Schwantes, J. M.; Ullmann, J. L.; Vieira, D. J.; Wilhelmy, J. B.; Wouters, J. M.

    2006-03-01

    Accurate neutron capture cross sections of the actinide elements at neutron energies up to 1 MeV are needed to better interpret archived nuclear test data, for post-detonation nuclear attribution, and the Advanced Fuel Cycle Initiative. The Detector for Advance Neutron Capture Experiments, DANCE, has unique capabilities that allow the differentiation of capture gamma rays from fission gamma rays and background gamma rays from scattered neutrons captured by barium isotopes in the barium fluoride scintillators. The DANCE array has a high granularity, 160 scintillators, high efficiency, and nearly 4-π solid angle. Through the use of cuts in cluster multiplicity and calorimetric energy the capture gamma-rays are differentiated from other sources of gamma rays. The preliminary results for the capture cross sections of 236U are in agreement with the ENDF/B-VI evaluation. The preliminary results for 234U lower are than ENDF/B-VI evaluation and are closer to older evaluations.

  12. Detecting energy dependent neutron capture distributions in a liquid scintillator

    Energy Technology Data Exchange (ETDEWEB)

    Balmer, Matthew J.I., E-mail: m.balmer@lancaster.ac.uk [Department of Engineering, Lancaster University, LA1 4YR (United Kingdom); Gamage, Kelum A.A. [Department of Engineering, Lancaster University, LA1 4YR (United Kingdom); Taylor, Graeme C. [Neutron Metrology Group, National Physical Laboratory, Teddington, TW11 0LW (United Kingdom)

    2015-03-11

    A novel technique is being developed to estimate the effective dose of a neutron field based on the distribution of neutron captures in a scintillator. Using Monte Carlo techniques, a number of monoenergetic neutron source energies and locations were modelled and their neutron capture response was recorded. Using back propagation Artificial Neural Networks (ANN) the energy and incident direction of the neutron field was predicted from the distribution of neutron captures within a {sup 6}Li-loaded liquid scintillator. Using this proposed technique, the effective dose of {sup 252}Cf, {sup 241}AmBe and {sup 241}AmLi neutron fields was estimated to within 30% for four perpendicular angles in the horizontal plane. Initial theoretical investigations show that this technique holds some promise for real-time estimation of the effective dose of a neutron field.

  13. Detector for advanced neutron capture experiments at LANSCE

    Energy Technology Data Exchange (ETDEWEB)

    Ullmann, J. L. (John L.); Reifarth, R. (Rene); Haight, Robert C.; Hunt, L. F. (Lloyd F.); O' Donnell, J. M.; Bredeweg, T. A. (Todd A); Wilhelmy, J. B. (Jerry B.); Fowler, Malcolm M.; Vieira, D. J. (David J.); Wouters, J. M. (Jan Marc); Strottman, D.; Kaeppeler, F. (Franz K.); Heil, M.; Chamberlin, E. P. (Edwin P.)

    2002-01-01

    The Detector for Advanced Neutron Capture Experiments (DANCE) is a 159-element 4x barium fluoride array designed to study neutron capture on small quantities, 1 mg or less, of radioactive nuclides. It is being built on a 20 m neutron flight path which views the 'upper tier' water moderator at the Manuel J. Lujan Jr. Neutron Scattering Center at the Los Alamos Neutron Science Center. The detector design is based on Monte Carlo calculations which have suggested ways to minimize backgrounds due to neutron scattering events. A data acquisition system based on fast transient digitizers is bcing implemented

  14. Enhancing the Detector for Advanced Neutron Capture Experiments

    Directory of Open Access Journals (Sweden)

    Couture A.

    2015-01-01

    Full Text Available The Detector for Advanced Neutron Capture Experiments (DANCE has been used for extensive studies of neutron capture, gamma decay, photon strength functions, and prompt and delayed fission-gamma emission. Despite these successes, the potential measurements have been limited by the data acquisition hardware. We report on a major upgrade of the DANCE data acquisition that simultaneously enables strait-forward coupling to auxiliary detectors, including high-resolution high-purity germanium detectors and neutron tagging array. The upgrade will enhance the time domain accessible for time-of-flight neutron measurements as well as improve the resolution in the DANCE barium fluoride crystals for photons.

  15. Study of thermal neutron capture by /sup 32/S

    Energy Technology Data Exchange (ETDEWEB)

    Taichang, G.; Zongren, S.; Xiantang, Z.; Guohua, L.; Dazhao, D.

    1985-01-15

    The thermal neutron capture by /sup 32/S has been studied using a 140 cm/sup 3/ Ge(Li) detector at the thermal column of the heavy water moderated reactor at Institute of Atomic Energy. The thermal neutron flux at sample is 2 x 10/sup 6/n/cm/sup 2/-sec and the cadmium ratio (for gold) is 200.

  16. Neutron-capture nucleosynthesis in the first stars

    Energy Technology Data Exchange (ETDEWEB)

    Roederer, Ian U. [Department of Astronomy, University of Michigan, 500 Church Street, Ann Arbor, MI 48109 (United States); Preston, George W.; Thompson, Ian B.; Shectman, Stephen A. [Carnegie Observatories, 813 Santa Barbara Street, Pasadena, CA 91101 (United States); Sneden, Christopher, E-mail: iur@umich.edu [Department of Astronomy, University of Texas at Austin, 1 University Station C1400, Austin, TX 78712 (United States)

    2014-04-01

    Recent studies suggest that metal-poor stars enhanced in carbon but containing low levels of neutron-capture elements may have been among the first to incorporate the nucleosynthesis products of the first generation of stars. We have observed 16 stars with enhanced carbon or nitrogen using the MIKE Spectrograph on the Magellan Telescopes at Las Campanas Observatory and the Tull Spectrograph on the Smith Telescope at McDonald Observatory. We present radial velocities, stellar parameters, and detailed abundance patterns for these stars. Strontium, yttrium, zirconium, barium, europium, ytterbium, and other heavy elements are detected. In four stars, these heavy elements appear to have originated in some form of r-process nucleosynthesis. In one star, a partial s-process origin is possible. The origin of the heavy elements in the rest of the sample cannot be determined unambiguously. The presence of elements heavier than the iron group offers further evidence that zero-metallicity rapidly rotating massive stars and pair instability supernovae did not contribute substantial amounts of neutron-capture elements to the regions where the stars in our sample formed. If the carbon- or nitrogen-enhanced metal-poor stars with low levels of neutron-capture elements were enriched by products of zero-metallicity supernovae only, then the presence of these heavy elements indicates that at least one form of neutron-capture reaction operated in some of the first stars.

  17. Shape Isomer in 236U Populated by Thermal Neutron Capture

    DEFF Research Database (Denmark)

    Andersen, Verner; Christensen, Carl Jørgen; Borggreen, J.

    1976-01-01

    The 116 ns shape isomer in 236U was populated by thermal neutron capture. Conversion electrons and X-rays were detected simultaneously in delayed coincidence with fission. The ratio of delayed to prompt fission was measured with the result, σIIf/σf = (1.0±0.2) × 10−5. A branching of the isomeric...

  18. A γ-ray telescope for on-line measurements of low boron concentrations in a head phantom for BNCT

    Science.gov (United States)

    Verbakel, W. F. A. R.; Stecher-Rasmussen, F.

    1997-02-01

    In Boron Neutron Capture Therapy the 10B(n, α)7 Li reaction is used to create a tumour-destructing field of high Linear Energy Transfer (LET) particles. The therapy requires a high boron concentration in the tumour and a low boron concentration in the healthy tissue. The boron neutron capture reaction is accompanied by the emission of a photon of energy 478 keV. It is investigated whether measuring of these photons can serve as a tool to determine the boron concentration during therapy in the tumour as well as in the healthy tissue. Such a measurement is complicated by the presence of a large background photon field. To study the feasibility, an experimental configuration has been designed at a test facility of the Low-Flux Reactor (LFR). The LFR provides an epithermal neutron beam for irradiation of a head phantom which simulates a human head with a tumour. This paper shows that the reconstruction of the position and the size of the tumour as well as the ratio of the boron concentrations appeared to be possible. In a second stage it is shown that these measurements can be expanded to experiments with the therapy neutron beam of the High-Flux Reactor (HFR).

  19. Functionalization and cellular uptake of boron carbide nanoparticles

    DEFF Research Database (Denmark)

    Mortensen, M. W.; Björkdahl, O.; Sørensen, P. G.;

    2006-01-01

    In this paper we present surface modification strategies of boron carbide nanoparticles, which allow for bioconjugation of the transacting transcriptional activator (TAT) peptide and fluorescent dyes. Coated nanoparticles can be translocated into murine EL4 thymoma cells and B16 F10 malignant...... melanoma cells in amounts as high as 0.3 wt. % and 1 wt. %, respectively. Neutron irradiation of a test system consisting of untreated B16 cells mixed with B16 cells loaded with boron carbide nanoparticles were found to inhibit the proliferative capacity of untreated cells, showing that cells loaded...... with boron-containing nanoparticles can hinder the growth of neighboring cells upon neutron irradiation. This could provide the first step toward a T cell-guided boron neutron capture therapy....

  20. Progress on the europium neutron capture study using DANCE

    Science.gov (United States)

    Agvaanluvsan, U.; Becker, J. A.; Macri, R. A.; Parker, W.; Wilk, P.; Wu, C. Y.; Bredeweg, T. A.; Esch, E.; Haight, R. C.; O'Donnell, J. M.; Reifarth, R.; Rundberg, R. S.; Schwantes, J. M.; Ullmann, J. L.; Vieira, D. J.; Wilhelmy, J. B.; Wouters, J. M.; Mitchell, G. E.; Sheets, S.; Bečvář, F.; Krtička, M.

    2007-08-01

    The accurate measurement of neutron capture cross sections of the Eu isotopes is important for many reasons including nuclear astrophysics and nuclear diagnostics. Neutron capture excitation functions of 151,153Eu targets were measured recently using a 4π γ-ray calorimeter array DANCE located at the Los Alamos Neutron Science Center for En = 0.1-100 keV. The progress on the data analysis efforts is given in the present paper. The γ-ray multiplicity distributions for the Eu targets and Be backing are significantly different. The γ-ray multiplicity distribution is found to be the same for different neutron energies for both 151Eu and 153Eu. The statistical simulation to model the γ-ray decay cascade is summarized.

  1. Progress on the Europium Neutron-Capture Study using DANCE

    Energy Technology Data Exchange (ETDEWEB)

    Agvaanluvsan, U; Becker, J A; Macri, R A; Parker, W; Wilk, P; Wu, C Y; Bredeweg, T A; Esch, E; Haight, R C; O' Donnell, J M; Reifarth, R; Rundberg, R S; Schwantes, J M; Ullmann, J L; Vieira, D J; Wilhelmy, J B; Wouters, J M; Mitchell, G E; Sheets, S A; Becvar, F; Krticka, M

    2006-09-05

    The accurate measurement of neutron-capture cross sections of the Eu isotopes is important for many reasons including nuclear astrophysics and nuclear diagnostics. Neutron capture excitation functions of {sup 151,153}Eu targets were measured recently using a 4{pi} {gamma}-ray calorimeter array DANCE located at the Los Alamos Neutron Science Center for E{sub n} = 0.1-100 keV. The progress on the data analysis efforts is given in the present paper. The {gamma}-ray multiplicity distributions for the Eu targets and Be backing are significantly different. The {gamma}-ray multiplicity distribution is found to be the same for different neutron energies for both {sup 151}Eu and {sup 153}Eu. The statistical simulation to model the {gamma}-ray decay cascade is summarized.

  2. Progress on the europium neutron capture study using DANCE

    Energy Technology Data Exchange (ETDEWEB)

    Agvaanluvsan, U. [Lawrence Livermore National Laboratory, 7000 East Avenue, P.O. Box 808, L-414, Livermore, CA 94551 (United States)]. E-mail: agvaanluvsan1@llnl.gov; Becker, J.A. [Lawrence Livermore National Laboratory, 7000 East Avenue, P.O. Box 808, L-414, Livermore, CA 94551 (United States); Macri, R.A. [Lawrence Livermore National Laboratory, 7000 East Avenue, P.O. Box 808, L-414, Livermore, CA 94551 (United States); Parker, W. [Lawrence Livermore National Laboratory, 7000 East Avenue, P.O. Box 808, L-414, Livermore, CA 94551 (United States); Wilk, P. [Lawrence Livermore National Laboratory, 7000 East Avenue, P.O. Box 808, L-414, Livermore, CA 94551 (United States); Wu, C.Y. [Lawrence Livermore National Laboratory, 7000 East Avenue, P.O. Box 808, L-414, Livermore, CA 94551 (United States); Bredeweg, T.A.; Esch, E.; Haight, R.C.; O' Donnell, J.M.; Reifarth, R.; Rundberg, R.S.; Schwantes, J.M.; Ullmann, J.L.; Vieira, D.J.; Wilhelmy, J.B.; Wouters, J.M. [Los Alamos National Laboratory, Los Alamos, NM 87545 (United States); Mitchell, G.E.; Sheets, S. [North Carolina State University, Raleigh, NC 27695 (United States)]|[Triangle Universities Nuclear Laboratory, Durham, NC 27708 (United States); Becvar, F.; Krticka, M. [Charles University in Prague, CZ 180 00 Prague 8 (Czech Republic)

    2007-08-15

    The accurate measurement of neutron capture cross sections of the Eu isotopes is important for many reasons including nuclear astrophysics and nuclear diagnostics. Neutron capture excitation functions of {sup 151,153}Eu targets were measured recently using a 4{pi} {gamma}-ray calorimeter array DANCE located at the Los Alamos Neutron Science Center for E {sub n} = 0.1-100 keV. The progress on the data analysis efforts is given in the present paper. The {gamma}-ray multiplicity distributions for the Eu targets and Be backing are significantly different. The {gamma}-ray multiplicity distribution is found to be the same for different neutron energies for both {sup 151}Eu and {sup 153}Eu. The statistical simulation to model the {gamma}-ray decay cascade is summarized.

  3. Measurement of internal conversion electrons from Gd neutron capture

    Energy Technology Data Exchange (ETDEWEB)

    Kandlakunta, P. [Nuclear Engineering Program, Department of Mechanical and Aerospace Engineering, The Ohio State University, Columbus, OH 43210 (United States); Cao, L.R., E-mail: cao.152@osu.edu [Nuclear Engineering Program, Department of Mechanical and Aerospace Engineering, The Ohio State University, Columbus, OH 43210 (United States); Mulligan, P. [Nuclear Engineering Program, Department of Mechanical and Aerospace Engineering, The Ohio State University, Columbus, OH 43210 (United States)

    2013-03-21

    Gadolinium (Gd) is a suitable material for neutron conversion because of its superior neutron absorption cross-section. However, the principal secondary particles that generate electron-hole pairs in a semiconductor detector after Gd neutron capture are low-energy internal conversion (IC) electrons. We measured the IC electron spectrum due to Gd neutron capture by using a thermal neutron beam and a digitizer-based multidetector spectroscopy. We also discussed the effective use of the IC electrons in the context of a twin-detector design and the associated gamma-ray rejection issues. Extensive simulations of the spectra of IC electrons and gamma rays agreed well with the experimental results; both types of results support the feasibility of the proposed n–γ separation method.

  4. Neutron capture reactions on Lu isotopes at DANCE

    Directory of Open Access Journals (Sweden)

    Wouters J.M.

    2010-03-01

    Full Text Available The DANCE (Detector for Advanced Neutron Capture Experiments array located at the Los Alamos national laboratory has been used to obtain the neutron capture cross sections for the 175Lu and 176Lu isotopes with neutron energies from thermal up to 100 keV. Both isotopes are of current interest for the nucleosynthesis s-process in astrophysics and for applications as in reactor physics or in nuclear medicine. Three targets were used to perform these measurements. One was natLu foil and the other two were isotope-enriched targets of 175Lu and 176Lu. The cross sections are obtained for now through a precise neutron flux determination and a normalization at the thermal neutron cross section value. A comparison with the recent experimental data and the evaluated data of ENDF/B-VII.0 will be presented. In addition, resonances parameters and spin assignments for some resonances will be featured.

  5. Thermal-neutron capture gamma rays from natural calcium

    NARCIS (Netherlands)

    Gruppelaar, H.; Spilling, P.

    1967-01-01

    Gamma rays from thermal-neutron capture in natural Ca and enriched 40Ca were investigated with a 5 cm3 Ge(Li) detector. Many low-energy γ-lines have been found. More than 90% of the γ-rays result from capture in 40Ca and about 5% from capture in 44Ca. From the data a decay scheme of 41Ca and a parti

  6. Thermal Neutron Capture onto the Stable Tungsten Isotopes

    Directory of Open Access Journals (Sweden)

    Nichols A.

    2012-02-01

    Full Text Available Thermal neutron-capture measurements of the stable tungsten isotopes have been carried out using the guided thermal-neutron beam at the Budapest Reactor. Prompt singles spectra were collected and analyzed using the HYPERMET γ-ray analysis software package for the compound tungsten systems 183W, 184W, and 187W, prepared from isotopically-enriched samples of 182W, 183W, and 186W, respectively. These new data provide both confirmation and new insights into the decay schemes and structure of the tungsten isotopes reported in the Evaluated Gamma-ray Activation File based upon previous elemental analysis. The experimental data have also been compared to Monte Carlo simulations of γ-ray emission following the thermal neutron-capture process using the statistical-decay code DICEBOX. Together, the experimental cross sections and modeledfeeding contribution from the quasi continuum, have been used to determine the total radiative thermal neutron-capture cross sections for the tungsten isotopes and provide improved decay-scheme information for the structural- and neutron-data libraries.

  7. Neutron capture strategy and technique developments for GNEP

    Energy Technology Data Exchange (ETDEWEB)

    Couture, Aaron Joseph [Los Alamos National Laboratory

    2008-01-01

    The initial three years of neutron capture measurements have been very successful in providing data for the Advanced Fuel Cycle Initiative/Global Nuclear Energy Partnership (AFCI/GNEP) program. Now that the most straightforward measurements have been completed, additional technical challenges face future measurements. In particular, techniques are needed to perform measurements that exhibit at least one of three major problems -- large fission:capture ratios, large capture:capture ratios, and high intrinsic activity samples. This paper will set forward a plan for attacking these technical challenges and moving forward with future measurements.

  8. New aspects of the neutron capture in light nuclei

    Energy Technology Data Exchange (ETDEWEB)

    Mengoni, A. [Institute of Physical and Chemical Research, Wako, Saitama (Japan)

    1997-03-01

    Several neutron capture cross sections of light nuclei (A {<=} 40) for neutron energies up to the MeV region have been recently calculated. Examples are (target nuclei): {sup 12}C, {sup 13}C, {sup 16}O and {sup 10}Be. The results of these calculations will be shown together with a comparison with the most recent experimental data. In the case of n + {sup 10}Be case, the cross section of the inverse process (Coulomb dissociation of {sup 11}Be) is considered and compared with the measurement. A discussion on the relevant nuclear structure information required for the evaluation of nuclear data of light nuclei is given. (author)

  9. Astrophysically Relevant Neutron Capture near the Border of Stability

    CERN Document Server

    Mohr, P J; Beer, H

    1996-01-01

    The neutron capture cross section on $^{26}$Mg was measured in the astrophysically relevant energy region from 25 keV to 220 keV. The experimental results agree well with a calculation using the Direct Capture (DC) model together with systematic folding potentials. This experiment confirms for the $^{26}$Mg(n,$\\gamma$)$^{27}$Mg reaction that the DC process is at least comparable to the Compound--Nucleus (CN) process. The reliability of DC calculations is discussed, and we present some ideas for future experiments which could reduce the theoretical uncertainties of DC calculations.

  10. Synthesis of boron nitride nanotubes and their applications

    Directory of Open Access Journals (Sweden)

    Saban Kalay

    2015-01-01

    Full Text Available Boron nitride nanotubes (BNNTs have been increasingly investigated for use in a wide range of applications due to their unique physicochemical properties including high hydrophobicity, heat and electrical insulation, resistance to oxidation, and hydrogen storage capacity. They are also valued for their possible medical and biomedical applications including drug delivery, use in biomaterials, and neutron capture therapy. In this review, BNNT synthesis methods and the surface modification strategies are first discussed, and then their toxicity and application studies are summarized. Finally, a perspective for the future use of these novel materials is discussed.

  11. Neutron capture nucleosynthesis during core helium burning in massive stars

    Energy Technology Data Exchange (ETDEWEB)

    Prantzos, N.; Arnould, M.; Arcoragi, J.P.

    1987-04-01

    Neutron-capture nucleosynthesis during core He burning in massive (ZAMS mass = 50-100 solar mass) mass-losing stars, which are identified with Wolf-Rayet stars, is studied in the framework of recent stellar models based on the Roxburgh criterion for convection and on the latest nuclear data available. The nucleosynthesis is followed with the aid of a full nuclear reaction network incorporating up-to-date Maxwellian-averaged neutron-capture cross sections and new density- and temperature-dependent beta-decay rates. Numerical techniques are developed in order to integrate efficiently the set of coupled differential equations of the network. The resulting stellar core and surface abundances are presented, as well as the composition of the stellar winds ejected during the WC phase. Consideration is given to the implications of these results for the composition of OB associations and of the solar system, for the isotopic anomalies in meteorites and in the galactic cosmic rays, as well as for nuclear gamma-ray line astronomy. 114 references.

  12. Neutron Capture Cross Sections for the Weak s Process

    CERN Document Server

    Heil, M; Kaeppeler, F; Gallino, R; Pignatari, M; Uberseder, E

    2009-01-01

    In past decades a lot of progress has been made towards understanding the main s-process component that takes place in thermally pulsing Asymptotic Giant Branch (AGB) stars. During this process about half of the heavy elements, mainly between 90=8Msolar) and is much less understood. A better characterization of the weak s component would help disentangle the various contributions to element production in this region. For this purpose, a series of measurements of neutron-capture cross sections have been performed on medium-mass nuclei at the 3.7-MV Van de Graaff accelerator at FZK using the activation method. Also, neutron captures on abundant light elements with A<56 play an important role for s-process nucleosynthesis, since they act as neutron poisons and affect the stellar neutron balance. New results are presented for the (n,g) cross sections of 41K and 45Sc, and revisions are reported for a number of cross sections based on improved spectroscopic information.

  13. Radiative neutron capture: Hauser Feshbach vs. statistical resonances

    Science.gov (United States)

    Rochman, D.; Goriely, S.; Koning, A. J.; Ferroukhi, H.

    2017-01-01

    The radiative neutron capture rates for isotopes of astrophysical interest are commonly calculated on the basis of the statistical Hauser Feshbach (HF) reaction model, leading to smooth and monotonically varying temperature-dependent Maxwellian-averaged cross sections (MACS). The HF approximation is known to be valid if the number of resonances in the compound system is relatively high. However, such a condition is hardly fulfilled for keV neutrons captured on light or exotic neutron-rich nuclei. For this reason, a different procedure is proposed here, based on the generation of statistical resonances. This novel technique, called the "High Fidelity Resonance" (HFR) method is shown to provide similar results as the HF approach for nuclei with a high level density but to deviate and be more realistic than HF predictions for light and neutron-rich nuclei or at relatively low sub-keV energies. The MACS derived with the HFR method are systematically compared with the traditional HF calculations for some 3300 neutron-rich nuclei and shown to give rise to significantly larger predictions with respect to the HF approach at energies of astrophysical relevance. For this reason, the HF approach should not be applied to light or neutron-rich nuclei. The Doppler broadening of the generated resonances is also studied and found to have a negligible impact on the calculated MACS.

  14. Neutron resonance parameters of dysprosium isotopes using neutron capture yields

    Energy Technology Data Exchange (ETDEWEB)

    Shin, S. G.; Kye, Y. U.; Cho, M. H. [POSTECH, Pohang (Korea, Republic of); Namkung, W. [Pohang Accelerator Laboratory, Pohang (Korea, Republic of); Kim, G. N. [Kyungpook National University, Daegu (Korea, Republic of); Lee, M. W.; Kang, Y. R. [Dongnam Inst. Of Radiological and Medical Science, Busan (Korea, Republic of)

    2015-10-15

    Dysprosium is used in the field of nuclear reactor system because it has a very large thermal neutron absorption cross-section. The dysprosium alloyed with special stainless steels is attractive for control in nuclear reactor because of the ability to absorb neutrons readily without swelling or contracting over time and its high melting point. Dysprosium is also one of fission products from the thermal fission of {sup 234}U, {sup 233}U, and {sup 239}Pu. The fission products are accumulated in the reactor core by the burn-up of the nuclear fuel and the poison effect is increased. Therefore, it is required to understand how Dysprosium as both a poison and an absorbing material in the control rod has an effect on the neutron population in a nuclear reactor system over all energy regions. Neutron Capture experiments on Dy isotopes were performed at the electron linear accelerator (LINAC) facility of the Rensselear Polytechnic Institute (RPI) in the neutron energy region from 10 eV to 1 keV. Resonance parameters were extracted by fitting the neutron capture data using the SAMMY multilevel R-matrix Bayesian code.

  15. Production of Molybdenum-99 using Neutron Capture Methods

    Energy Technology Data Exchange (ETDEWEB)

    Toth, James J; Greenwood, Lawrence R; Soderquist, Chuck Z; Wittman, Richard S; Pierson, Bruce D; Burns, Kimberly A; Lavender, Curt A; Painter, Chad L; Love, Edward F; Wall, Donald E

    2011-01-01

    Pacific Northwest National Laboratory (PNNL), operated by Battelle, has identified a reference process for the production of molybdenum-99 (99Mo) for use in a chromatographic generator to separate the daughter product, technetium-99m (99mTc). The reference process uses the neutron capture reaction of natural or enriched molybdenum oxide via the reaction 98Mo(n,γ)99Mo. The irradiated molybdenum is dissolved in an alkaline solution, whereby the molybdenum, dissolved as the molybdate anion, is loaded on a proprietary ion exchange material in the chromatographic generator. The approach of this investigation is to provide a systematic collection of technologies to make the neutron capture method for Mo-99 production economically viable. This approach would result in the development of a technetium Tc99m generator and a new type of target. The target is comprised of molybdenum, either natural or enriched, and is tailored to the design of currently operating U.S. research reactors. The systematic collection of technologies requires evaluation of new metallurgical methods to produce the target, evaluation of target geometries tailored to research reactors, and chemical methods to dissolve the irradiated target materials for use in a chromatographic generator. A Technical specification for testing the target and neutron capture method in a research reactor is also required. This report includes identification of research and demonstration activities needed to enable deployment of neutron capture production method, including irradiations of prototypic targets, chemical processing of irradiated targets, and loading and extraction tests of Mo99 and Tc99m on the sorbent material in a prototypic generator design. The prototypical generator design is based on the proprietary method and systems for isotope product generation. The proprietary methods and systems described in this report are clearly delineated with footnotes. Ultimately, the Tc-99m generator solution provided by

  16. Neutron Capture Reactions on Fe and Ni Isotopes for the Astrophysical s-process

    CERN Document Server

    Lederer, C; Massimi, C; Žugec, P; Barbagallo, M; Colonna, N; Domingo-Pardo, C; Guerrero, C; Gunsing, F; Käppeler, F; Tain, J L; Altstadt, S; Andrzejewski, J; Audouin, L; Bécares, V; Bečvář, F; Belloni, F; Berthoumieux, E; Billowes, J; Boccone, V; Bosnar, D; Brugger, M; Calviani, M; Calviño, F; Cano-Ott, D; Carrapiço, C; Cerutti, F; Chiaveri, E; Chin, M; Cortés, G; Cortés-Giraldo, M A; Diakaki, M; Duran, I; Dressler, R; Dzysiuk, N; Eleftheriadis, C; Ferrari, A; Fraval, K; Ganesan, S; García, A R; Gómez-Hornillos, M B; Gonçalves, I F; González-Romero, E; Griesmayer, E; Gurusamy, P; Jenkins, D G; Jericha, E; Kadi, Y; Karadimos, D; Kivel, N; Koehler, P; Kokkoris, M; Korschinek, G; Krtička, M; Kroll, J; Langer, C; Leeb, H; Leong, L S; Losito, R; Manousos, A; Marganiec, J; Martínez, T; Mastinu, P F; Mastromarco, M; Meaze, M; Mendoza, E; Mengoni, A; Milazzo, P M; Mingrone, F; Mirea, M; Mondelaers, W; Paradela, C; Pavlik, A; Perkowski, J; Pignatari, M; Plompen, A; Praena, J; Quesada, J M; Rauscher, T; Reifarth, R; Riego, A; Roman, F; Rubbia, C; Sarmento, R; Schillebeeckx, P; Schmidt, S; Schumann, D; Tagliente, G; Tarrío, D; Tassan-Got, L; Tsinganis, A; Valenta, S; Vannini, G; Variale, V; Vaz, P; Ventura, A; Versaci, R; Vermeulen, M J; Vlachoudis, V; Vlastou, R; Wallner, A; Ware, T; Weigand, M; Weiß, C; Wright, T J

    2014-01-01

    Neutron capture cross sections in the keV neutron energy region are the key nuclear physics input to study the astrophysical slow neutron capture process. In the past years, a series of neutron capture cross section measurements has been performed at the neutron time-of-flight facility n\\_TOF at CERN focussing on the Fe/Ni mass region. Recent results and future developments in the neutron time-of-flight technique are discussed.

  17. Accelerator Based Neutron Beams for Neutron Capture Therapy

    Energy Technology Data Exchange (ETDEWEB)

    Yanch, Jacquelyn C.

    2003-04-11

    The DOE-funded accelerator BNCT program at the Massachusetts Institute of Technology has resulted in the only operating accelerator-based epithermal neutron beam facility capable of generating significant dose rates in the world. With five separate beamlines and two different epithermal neutron beam assemblies installed, we are currently capable of treating patients with rheumatoid arthritis in less than 15 minutes (knee joints) or 4 minutes (finger joints) or irradiating patients with shallow brain tumors to a healthy tissue dose of 12.6 Gy in 3.6 hours. The accelerator, designed by Newton scientific Incorporated, is located in dedicated laboratory space that MIT renovated specifically for this project. The Laboratory for Accelerator Beam Applications consists of an accelerator room, a control room, a shielded radiation vault, and additional laboratory space nearby. In addition to the design, construction and characterization of the tandem electrostatic accelerator, this program also resulted in other significant accomplishments. Assemblies for generating epithermal neutron beams were designed, constructed and experimentally evaluated using mixed-field dosimetry techniques. Strategies for target construction and target cooling were implemented and tested. We demonstrated that the method of submerged jet impingement using water as the coolant is capable of handling power densities of up to 6 x 10(sup 7) W/m(sup 2) with heat transfer coefficients of 10(sup 6)W/m(sup 2)-K. Experiments with the liquid metal gallium demonstrated its superiority compared with water with little effect on the neutronic properties of the epithermal beam. Monoenergetic proton beams generated using the accelerator were used to evaluate proton RBE as a function of LET and demonstrated a maximum RBE at approximately 30-40 keV/um, a finding consistent with results published by other researchers. We also developed an experimental approach to biological intercomparison of epithermal beams and compared the RBE characteristics of the MIT Reactor M67 clinical beam, The Brookhaven Medical Research Reactor clinical beam (both of which were used in Phase I/II clinical trials of BNCT) and the MIT LABA BNCS beam. Additional research initiated under this program involved an investigation of the potential of BNCT for the prevention of restenosis and the development of accelerator-based fast neutron brachytherapy. A total of 10 student research theses (2 Undergraduate, 4 Masters, and 4 Doctoral) were completed as part of this research program.

  18. Application of proton boron fusion reaction to radiation therapy: A Monte Carlo simulation study

    Science.gov (United States)

    Yoon, Do-Kun; Jung, Joo-Young; Suh, Tae Suk

    2014-12-01

    Three alpha particles are emitted from the point of reaction between a proton and boron. The alpha particles are effective in inducing the death of a tumor cell. After boron is accumulated in the tumor region, the emitted from outside the body proton can react with the boron in the tumor region. An increase of the proton's maximum dose level is caused by the boron and only the tumor cell is damaged more critically. In addition, a prompt gamma ray is emitted from the proton boron reaction point. Here, we show that the effectiveness of the proton boron fusion therapy was verified using Monte Carlo simulations. We found that a dramatic increase by more than half of the proton's maximum dose level was induced by the boron in the tumor region. This increase occurred only when the proton's maximum dose point was located within the boron uptake region. In addition, the 719 keV prompt gamma ray peak produced by the proton boron fusion reaction was positively detected. This therapy method features the advantages such as the application of Bragg-peak to the therapy, the accurate targeting of tumor, improved therapy effects, and the monitoring of the therapy region during treatment.

  19. Neutron Capture Reactions on lu Isotopes at Dance

    Science.gov (United States)

    Roig, O.; Meot, V.; Daugas, J.-M.; Morel, P.; Jandel, M.; Vieira, D. J.; Bond, E. M.; Bredeweg, T. A.; Couture, A. J.; Haight, R. C.; Keksis, A. L.; Rundberg, R. S.; Ullmann, J. L.; Wouters, J. M.

    2013-03-01

    The DANCE1 (Detector for Advanced Neutron Capture Experiments) array at LANSCE spallation neutron source in Los Alamos has been used to obtain the neutron radiative capture cross sections for 175Lu and 176Lu with neutron energies from thermal up to 100 keV. Both isotopes are of current interest for the nucleosynthesis s-process.2,3 Three targets were used to perform these measurements. One was natural Lu foil of 31 mg/cm2 and the other two were isotope-enriched targets of 175Lu and 176Lu. Firstly, the cross sections were obtained by normalizing yield to a well-known cross section at the thermal neutron energy. Now, we want to obtain absolute cross sections of radiative capture through a precise neutron flux determination, an accurate target mass measurement and an efficiency determination of the DANCE array.

  20. Scissors Mode of 162Dy Studied from Resonance Neutron Capture

    Directory of Open Access Journals (Sweden)

    Baramsai B.

    2015-01-01

    Full Text Available Multi-step cascade γ-ray spectra from the neutron capture at isolated resonances of 161Dy nucleus were measured at the LANSCE/DANCE time-of-flight facility in Los Alamos National Laboratory. The objectives of this experiment were to confirm and possibly extend the spin assignment of s-wave neutron resonances and get new information on photon strength functions with emphasis on the role of the M1 scissors mode vibration. The preliminary results show that the scissors mode plays a significant role in all transitions between accessible states of the studied nucleus. The photon strength functions describing well our data are compared to results from 3He-induced reactions, (n,γ experiments on Gd isotopes, and (γ,γ’ reactions.

  1. Scissors mode of Gd nuclei studied from resonance neutron capture

    Science.gov (United States)

    Kroll, J.; Baramsai, B.; Becker, J. A.; Bečvár, F.; Bredeweg, T. A.; Couture, A.; Chyzh, A.; Dashdorj, D.; Haight, R. C.; Heil, M.; Jandel, M.; Käppeler, F.; Krtička, M.; Mitchell, G. E.; O'Donnell, J. M.; Parker, W.; Reifarth, R.; Rundberg, R. S.; Ullmann, J. L.; Valenta, S.; Vieira, D. J.; Walker, C. L.; Wilhelmy, J. B.; Wouters, J. M.; Wu, C. Y.

    2012-10-01

    Spectra of γ rays following the neutron capture at isolated resonances of stable Gd nuclei weremeasured. The objectives were to get new information on photon strength of 153,155-159Gd with emphasis on the role of the M1 scissors-mode vibration. An analysis of the data obtained clearly indicates that the scissors mode is coupled not only to the ground state, but also to all excited levels of the nuclei studied. The specificity of our approach ensures unbiasedness in estimating the sumed scissors-mode strength ΣB(M1)↑, even for odd product nuclei, for which conventional nuclear resonance fluorescence measurements yield only limited information. Our analysis indicates that for these nuclei the sum ΣB(M1)↑ increases with A and for 157,159Gd it is significantly higher compared to 156,158Gd.

  2. Neutron capture measurements on unstable nuclei at LANSCE

    Energy Technology Data Exchange (ETDEWEB)

    Ullmann, J.L.; Haight, R.C. [LANSCE-3, Los Alamos National Laboratory, Los Alamos, New Mexico 87545 (United States); Fowler, M.M.; Miller, G.G.; Rundberg, R.S.; Wilhelmy, J.B. [CST-11, Los Alamos National Laboratory, Los Alamos, New Mexico 87545 (United States)

    1999-06-01

    Although neutron capture by stable isotopes has been extensively measured, there are very few measurements on unstable isotopes. The intense neutron flux at the Manual Lujan Jr. Neutron Scattering Center at LANSCE enables us to measure capture on targets with masses of about 1 mg over the energy range from 1 eV to 100 keV. These measurements are important not only for understanding the basic physics, but also for calculations of stellar nucleosynthesis and Science-Based Stockpile Stewardship. Preliminary measurements on {sup 169}Tm and {sup 171}Tm have been made with deuterated benzene detectors. A new detector array at the Lujan center and a new radioactive isotope separator will combine to give Los Alamos a unique capability for making these measurements. {copyright} {ital 1999 American Institute of Physics.}

  3. Scissors Mode of 162Dy Studied from Resonance Neutron Capture

    Science.gov (United States)

    Baramsai, B.; Bečvář, F.; Bredeweg, T. A.; Haight, R. C.; Jandel, M.; Kroll, J.; Krtička, M.; Mitchell, G. E.; O'Donnell, J. M.; Rundberg, R. S.; Ullmann, J. L.; Valenta, S.; Wilhelmy, J. B.

    2015-05-01

    Multi-step cascade γ-ray spectra from the neutron capture at isolated resonances of 161Dy nucleus were measured at the LANSCE/DANCE time-of-flight facility in Los Alamos National Laboratory. The objectives of this experiment were to confirm and possibly extend the spin assignment of s-wave neutron resonances and get new information on photon strength functions with emphasis on the role of the M1 scissors mode vibration. The preliminary results show that the scissors mode plays a significant role in all transitions between accessible states of the studied nucleus. The photon strength functions describing well our data are compared to results from 3He-induced reactions, (n,γ) experiments on Gd isotopes, and (γ,γ') reactions.

  4. Study of thermal neutron capture in /sup 32/S

    Energy Technology Data Exchange (ETDEWEB)

    GUO Taichang; SHI Zongren; ZENG Xiantang; LI Guohua; DING Dazhao

    1985-10-01

    The ..gamma..-ray spectrum of the /sup 32/S (n, ..gamma..) reaction at thermal neutron energy is measured by using a Ge(Li) detector. Among 86 ..gamma.. rays identified, 23 are recognized as primary ..gamma.. transitions. The excitation energies of 25 levels and the decay branching ratios are deduced. Three possible levels at 7505.0, 4473.1, and 2884.6 keV were not reported previously. The neutron separation energy of S is determined to be 8641.7 +- 0.6 keV. The thermal neutron capture cross section of /sup 32/S is determined to be 529 +- 26 mb by summing the transition intensities to the ground state of /sup 33/S and comparing with the well-known Au (n, ..gamma..) cross section. The partial capture cross sections of seven primary E1 transitions are calculated by the formula of the Lane-Lynn direct capture theory, and compared with measured values.

  5. Stellar neutron capture rates and the s process

    Directory of Open Access Journals (Sweden)

    Käppeler F.

    2012-02-01

    Full Text Available Neutron reactions are responsible for the formation of the elements heavier than iron. The corresponding scenarios relate to helium burning in Red Giant stars (s process and to supernova explosions (r and p processes. The s process, which operates in or near the valley of β-stability, has produced about half of the elemental abundances between Fe and Bi. Accurate (n, γ cross sections are the essential input for s process studies, because they determine the abundances produced by that process. Following a brief summary of the neutron capture processes, the focus will be set on the s process in massive stars, where the role of reliable cross section information is particularly important. Eventually, the intriguing aspects of the origin of 60Fe will be addressed. Attempts to determine the stellar cross section of that isotope are pushing experimental possibilities to their limits and present a pertinent challenge for future facilities.

  6. Neutron Capture Measurements on Unstable Nuclei at LANSCE

    Energy Technology Data Exchange (ETDEWEB)

    Ullmann, J.; Haight, R.; Wilhelmy, J.; Fowler, M.; Rundberg, R.; Miller, G.

    1998-11-04

    Although neutron capture by stable isotopes has been extensively measured, there are very few measurements on unstable isotopes. The intense neutron flux at the Manual Lujan Jr. Neutron Scattering Center at LANSCE enables us to measure capture on targets with masses of about 1 mg over the energy range from 1 eV to 100 keV. These measurements are important not only for understanding the basic physics, but also for calculations of stellar nucleosynthesis and Science-Based Stockpile Stewardship. Preliminary measurements on {sup 169}Tm and {sup 171}Tm have been made with deuterated benzene detectors. A new detector array at the Lujan center and a new radioactive isotope separator will combine to give Los Alamos a unique capability for making these measurements.

  7. Levels of 186Re populated in thermal neutron capture reaction

    Directory of Open Access Journals (Sweden)

    Bērzinš J.

    2015-01-01

    Full Text Available Levels of 186Re have been studied in the thermal neutron capture reaction with an enriched 185Re target. Evaluation of spectrum measured with GAMS5 allowed to obtain energies and intensities of more than 500 γ-lines assigned to 186Re. Most of the obtained transitions have been placed in the model-independent level scheme of the doubly odd 186Re nucleus, taking into account the available data of earlier experiments as well as the results of recent 187Re(p, d186Re reaction measurements. Structure of the 186Re low-lying levels has been analysed in terms of the particle-plus-rotor coupling model.

  8. Preparation of radioactive rare earth targets for neutron capture study

    Energy Technology Data Exchange (ETDEWEB)

    Miller, G. G. (Geoffrey G.); Rogers, P. S. Z. (Pamela S. Z.); Palmer, P. D. (Phillip D.); Dry, D. E. (Donald E.); Rundberg, R. S. (Robert S.); Fowler, Malcolm M.; Wilhelmy, J. B. (Jerry B.)

    2002-01-01

    The understanding of thc details of nucleosynthesis in stars remains a great challenge. Though the basic mechanisms governing the processes have been known since the pioneering work of Burbidge, Burbidge, Fowler and Hoyle (l), we are now evolving into a condition where we can ask more specific questions. Of particular interest are the dynamics of the s ('slow') process. In this process the general condition is one in which sequential neutron captures occur at time scales long compared with the beta decay half lives of the capturing nuclides. The nucleosynthesis period for C or Ne burning stellar shells is believed to be in the year to few year time frame (2). This means that radionuclides with similar half lives to this burning period serve as 'branch point' nuclides. That is, there will be a competition between a capture to the next heavier isotope and a beta decay to the element of nexl higher atomic number. By understanding the abundances of these competing reactions we can learn about the dynamics of the nucleosynthesis process in the stellar medium. Crucial to this understanding is that we have a knowledge of the underlying neutron reaction cross sections on these unstable nuclides in the relevant stellar energy regions (neutrons of 0.1-100 KeV). Tm (1.9 years) and ls'Sm (90 ycws) have decay properties that permit their handling in an open fume hood. These Iwo were therefore selected to be the first radionuclides for neutron capture study in what will be an ongoing effort.

  9. Rapid Neutron Capture Process in Supernovae and Chemical Element Formation

    Indian Academy of Sciences (India)

    Rulee Baruah; Kalpana Duorah; H. L. Duorah

    2009-09-01

    The rapid neutron capture process (r-process) is one of the major nucleosynthesis processes responsible for the synthesis of heavy nuclei beyond iron. Isotopes beyond Fe are most exclusively formed in neutron capture processes and more heavier ones are produced by the r-process. Approximately half of the heavy elements with mass number ≻ 70 and all of the actinides in the solar system are believed to have been produced in the r-process. We have studied the r-process in supernovae for the production of heavy elements beyond = 40 with the newest mass values available. The supernova envelopes at a temperature ≻ 109 K and neutron density of 1024 cm-3 are considered to be one of the most potential sites for the r-process. The primary goal of the r-process calculations is to fit the global abundance curve for solar system r-process isotopes by varying time dependent parameters such as temperature and neutron density. This method aims at comparing the calculated abundances of the stable isotopes with observation.We have studied the r-process path corresponding to temperatures ranging from 1.0 × 109 K to 3.0 × 109 K and neutron density ranging from 1020 cm-3 to 1030 cm-3. With temperature and density conditions of 3.0 × 109 K and 1020 cm-3 a nucleus of mass 273 was theoretically found corresponding to atomic number 115. The elements obtained along the r-process path are compared with the observed data at all the above temperature and density range.

  10. Determination of boron concentration in blood and tissue samples from patients with liver metastases of colorectal carcinoma using Prompt Gamma Ray Activation Analysis (PGAA)

    Energy Technology Data Exchange (ETDEWEB)

    Schmitz, T., E-mail: schmito@uni-mainz.d [Institute for Nuclear Chemistry, University of Mainz, Fritz-Strassmann-Weg 2, D-55128 Mainz (Germany); Appelman, K., E-mail: k.appelman@hetnet.n [Institute for Energy, Joint Research Centre of the European Commission, Petten (Netherlands); Kudejova, P., E-mail: petra.kudejova@frm2.tum.d [Forschungs-Neutronenquelle Heinz Maier-Leibnitz (FRM II), Technische Universitaet Muenchen, D-85748 Garching (Germany); Schuetz, C., E-mail: schuetc@uni-mainz.d [Institute for Nuclear Chemistry, University of Mainz, Fritz-Strassmann-Weg 2, D-55128 Mainz (Germany); Kratz, J.V., E-mail: jvkratz@uni-mainz.d [Institute for Nuclear Chemistry, University of Mainz, Fritz-Strassmann-Weg 2, D-55128 Mainz (Germany); Moss, R., E-mail: raymond.moss@ec.europa.e [Institute for Energy, Joint Research Centre of the European Commission, Petten (Netherlands); Otto, G., E-mail: gerd.otto@unimedizin-mainz.d [Department of Hepatobiliary, Pancreatic and Transplantation Surgery, University of Mainz, Langenbeckstr. 1, D-55131 Mainz (Germany); Hampel, G., E-mail: gabriele.hampel@uni-mainz.d [Institute for Nuclear Chemistry, University of Mainz, Fritz-Strassmann-Weg 2, D-55128 Mainz (Germany)

    2011-07-15

    As part of the studies on Boron Neutron Capture Therapy at the University of Mainz, Germany, a clinical trial has been started in which, four patients suffering from liver metastases of colorectal carcinoma have been enrolled. Specimens of blood and healthy tissue samples taken from the patients were measured at the PGAA facilities at the HFR in Petten, The Netherlands, and at the FRM II in Munich, Germany. From the measured boron concentrations, pharmacokinetic curves and blood-to-tissue concentration ratios were produced.

  11. Boron

    Science.gov (United States)

    ... an eye wash. Boron was used as a food preservative between 1870 and 1920, and during World Wars ... chemical symbol), B (symbole chimique), Borate, Borate de Sodium, Borates, Bore, Boric Acid, Boric Anhydride, Boric Tartrate, ...

  12. Boron concentration measurement in biological tissues by charged particle spectrometry.

    Science.gov (United States)

    Bortolussi, S; Altieri, S

    2013-11-01

    Measurement of boron concentration in biological tissues is a fundamental aspect of boron neutron capture therapy, because the outcome of the therapy depends on the distribution of boron at a cellular level, besides on its overall concentration. This work describes a measurement technique based on the spectroscopy of the charged particles emitted in the reaction (10)B(n,α)(7)Li induced by thermal neutrons, allowing for a quantitative determination of the boron concentration in the different components that may be simultaneously present in a tissue sample, such as healthy cells, tumor cells and necrotic cells. Thin sections of tissue containing (10)B are cut at low temperatures and irradiated under vacuum in a thermal neutron field. The charged particles arising from the sample during the irradiation are collected by a thin silicon detector, and their spectrum is used to determine boron concentration through relatively easy calculations. The advantages and disadvantages of this technique are here described, and validation of the method using tissue standards with known boron concentrations is presented.

  13. Improved Actinide Neutron Capture Cross Sections Using Accelerator Mass Spectrometry

    Science.gov (United States)

    Bauder, W.; Pardo, R. C.; Kondev, F. G.; Kondrashev, S.; Nair, C.; Nusair, O.; Palchan, T.; Scott, R.; Seweryniak, D.; Vondrasek, R.; Collon, P.; Paul, M.; Youinou, G.; Salvatores, M.; Palmotti, G.; Berg, J.; Maddock, T.; Imel, G.

    2014-09-01

    The MANTRA (Measurement of Actinide Neutron TRAnsmutations) project will improve energy-integrated neutron capture cross section data across the actinide region. These data are incorporated into nuclear reactor models and are an important piece in understanding Generation IV reactor designs. We will infer the capture cross sections by measuring isotopic ratios from actinide samples, irradiated in the Advanced Test Reactor at INL, with Accelerator Mass Spectrometry (AMS) at ATLAS (ANL). The superior sensitivity of AMS allows us to extract multiple cross sections from a single sample. In order to analyze the large number of samples needed for MANTRA and to meet the goal of extracting multiple cross sections per sample, we have made a number of modifications to the AMS setup at ATLAS. In particular, we are developing a technique to inject solid material into the ECR with laser ablation. With laser ablation, we can better control material injection and potentially increase efficiency in the ECR, thus creating less contamination in the source and reducing cross talk. I will present work on the laser ablation system and preliminary results from our AMS measurements. The MANTRA (Measurement of Actinide Neutron TRAnsmutations) project will improve energy-integrated neutron capture cross section data across the actinide region. These data are incorporated into nuclear reactor models and are an important piece in understanding Generation IV reactor designs. We will infer the capture cross sections by measuring isotopic ratios from actinide samples, irradiated in the Advanced Test Reactor at INL, with Accelerator Mass Spectrometry (AMS) at ATLAS (ANL). The superior sensitivity of AMS allows us to extract multiple cross sections from a single sample. In order to analyze the large number of samples needed for MANTRA and to meet the goal of extracting multiple cross sections per sample, we have made a number of modifications to the AMS setup at ATLAS. In particular, we are

  14. Neutron capture and (n,2n) measurements on 241Am

    Energy Technology Data Exchange (ETDEWEB)

    Vieira, D; Jandel, M; Bredeweg, T; Bond, E; Clement, R; Couture, A; Haight, R; O' Donnell, J; Reifarth, R; Ullmann, J; Wilhelmy, J; Wouters, J; Tonchev, A; Hutcheson, A; Angell, C; Crowell, A; Fallin, B; Hammond, S; Howell, C; Karowowski, H; Kelley, J; Pedroni, R; Tornow, W; Macri, R; Agvaanluvsan, U; Becker, J; Dashdorj, D; Stoyer, M; Wu, C

    2007-07-18

    We report on a set of neutron-induced reaction measurements on {sup 241}Am which are important for nuclear forensics and advanced nuclear reactor design. Neutron capture measurements have been performed on the DANCE detector array at the Los Alamos Neutron Scattering CEnter (LANSCE). In general, good agreement is found with the most recent data evaluations up to an incident neutron energy of {approx} 300 keV where background limits the measurement. Using mono-energetic neutrons produced in the {sup 2}H(d,n){sup 3}He reaction at Triangle University Nuclear Laboratory (TUNL), we have measured the {sup 241}Am(n,2n) excitation function from threshold (6.7 MeV) to 14.5 MeV using the activation method. Good agreement is found with previous measurements, with the exception of the three data points reported by Perdikakis et al. around 11 MeV, where we obtain a much lower cross section that is more consistent with theoretical estimates.

  15. Gamma spectrum following neutron capture in {sup 167}Er

    Energy Technology Data Exchange (ETDEWEB)

    Visser, D.; Khoo, T.L.; Lister, C.J. [and others

    1995-08-01

    Statistical decay from a highly excited state samples all the lower-lying states and, hence, provides a sensitive measure of the level density. Pairing has a major impact on the level density, e.g. creating a pair gap between the 0- and 2-quasiparticle configurations. Hence the shape of the statistical spectrum contains information on pairing, and can be used to provide information on the reduction of pairing with thermal excitation energy. For this reason, we measured the complete spectrum of {gamma}rays following thermal neutron capture in {sup 167}Er. The experiment was performed at the Brookhaven reactor using Compton-suppressed Ge detectors from TESSA. The spectrum, which was corrected for detector response and efficiency, reveals primary (first-step, high-energy) transitions up to nearly 8 MeV, secondary (last-step, lower-energy) transitions, as we as a continuous statistical component. Effort was expanded to identify all lines from contaminant sources and an upper limit of 5% was tentatively set for their contributions. The spectral shape of the statistical spectrum will be compared with theoretical spectra obtained from a calculation of pairing which accounts for a stepwise reduction of the pair correlations as the number of quasiparticles increases. The primary lines which decay directly to the near-yrast states will also be used to deduce the level densities.

  16. Neutron capture effects and pre-atmospheric sizes of meteoroids

    Institute of Scientific and Technical Information of China (English)

    WANG Daode; LIN Yangting

    2003-01-01

    Excesses of 80Kr and 82Kr, produced by secondary neutron capture effects of 79Br and 81Br, were observed in meteorites. Epithermal neutron flux, Jn (30-300 eV), and fast neutron flux, Jn( > 5 MeV), were determined according to reactions of 79Br(n, γβ80Kr, 81Br(n, γβ82Kr, and 24Mg(n, α)21Ne, respectively. Cosmogenic noble gases of several ordinary chondrites fell in China indicate a positive relationship between Jn (30-300 eV)/Jn ( > 5 MeV) ratio and Jn (30-300 eV). This suggests large pre-atmospheric sizes of the meteorites, and a considerable fraction of the secondary neutrons were slowed down to epithermal energy. According to its relationship with Jn (30-300 eV)/Jn ( > 5 MeV) ratio, the pre-atmospheric minimum radii and masses of several Chinese chondrites were estimated as below: Zhaodong: 60 cm, 3200 kg; Laochengzhen: 23 cm, 490 kg; Suizhou: 31 cm, 450 kg; Xi Ujimgin: 22 cm, 160 kg; Dongtai: 21 cm, 140 kg.

  17. Study of thermal neutron capture on /sup 32/S

    Energy Technology Data Exchange (ETDEWEB)

    Guo Taichang; Shi Zongren; Zeng Xiantang; Li Guohua; Ding Dazhao

    1985-02-01

    The ..gamma..-ray spectrum of the /sup 32/S (n,..gamma..) reaction at thermal energy measured by using a Ge(Li) detector. Among 86 ..gamma.. rays identified 23 ones are recognized as primary ..gamma..-transitions. The excitation energies of 25 levels and the decay branch ratios are deduced. Three possible levels of 7505.0, 4473.1, and 2884.6 keV were not reported previously. The neutron separation energy of /sup 33/S is determined to be 8641.7 +- 0.6 keV. The thermal neutron capture cross section of /sup 32/S is determined to be 529 +- 26 mb by summing the transition intensities to the ground state of /sup 33/S and comparing with the well known Au (n,..gamma..) cross sections. The partial capture cross section of seven primary E1 transitions are calculated by the formula of the Lane-Lynn direct capture theory and compared with measured values.

  18. Neutron-Capture Nucleosynthesis in the First Stars

    CERN Document Server

    Roederer, Ian U; Thompson, Ian B; Shectman, Stephen A; Sneden, Chris

    2014-01-01

    Recent studies suggest that metal-poor stars enhanced in carbon but containing low levels of neutron-capture elements may have been among the first to incorporate the nucleosynthesis products of the first generation of stars. We have observed 16 stars with enhanced carbon or nitrogen using the MIKE Spectrograph on the Magellan Telescopes at Las Campanas Observatory and the Tull Spectrograph on the Smith Telescope at McDonald Observatory. We present radial velocities, stellar parameters, and detailed abundance patterns for these stars. Strontium, yttrium, zirconium, barium, europium, ytterbium, and other heavy elements are detected. In four stars, these heavy elements appear to have originated in some form of r-process nucleosynthesis. In one star, a partial s-process origin is possible. The origin of the heavy elements in the rest of the sample cannot be determined unambiguously. The presence of elements heavier than the iron group offers further evidence that zero-metallicity rapidly-rotating massive stars a...

  19. First platinum moderated positron beam based on neutron capture

    CERN Document Server

    Hugenschmidt, C; Repper, R; Schreckenbach, K; Sperr, P; Triftshaeuser, W

    2002-01-01

    A positron beam based on absorption of high energy prompt gamma-rays from thermal neutron capture in sup 1 sup 1 sup 3 Cd was installed at a neutron guide of the high flux reactor at the ILL in Grenoble. Measurements were performed for various source geometries, dependent on converter mass, moderator surface and extraction voltages. The results lead to an optimised design of the in-pile positron source which will be implemented at the Munich research reactor FRM-II. The positron source consists of platinum foils acting as gamma-e sup + e sup - -converter and positron moderator. Due to the negative positron work function moderation in heated platinum leads to emission of monoenergetic positrons. The positron work function of polycrystalline platinum was determined to 1.95(5) eV. After acceleration to several keV by four electrical lenses the beam was magnetically guided in a solenoid field of 7.5 mT leading to a NaI-detector in order to detect the 511 keV gamma-radiation of the annihilating positrons. The posi...

  20. New measurement of neutron capture resonances of 209Bi

    CERN Document Server

    Domingo-Pardo, C; Abbondanno, U; Aerts, G; Alvarez-Pol, H; Alvarez-Velarde, F; Andriamonje, Samuel A; Andrzejewski, J; Assimakopoulos, Panayiotis; Audouin, L; Badurek, G; Baumann, P; Becvar, F; Berthoumieux, E; Calviño, F; Cano-Ott, D; Capote, R; Carrillode Albornoz, A; Cennini, P; Chepel, V; Chiaveri, Enrico; Colonna, N; Cortés, G; Couture, A; Cox, J; Dahlfors, M; David, S; Dillman, I; Dolfini, R; Dridi, W; Durán, I; Eleftheriadis, C; Embid-Segura, M; Ferrant, L; Ferrari, A; Ferreira-Marques, R; Fitzpatrick, L; Frais-Kölbl, H; Fujii, K; Furman, W; Gallino, R; Gonçalves, I; Gonzalez-Romero, E; Goverdovski, A; Gramegna, F; Griesmayer, E; Guerrero, C; Gunsing, F; Haas, B; Haight, R; Heil, M; Herrera-Martínez, A; Igashira, M; Isaev, S; Jericha, E; Kadi, Y; Kappeler, F; Karamanis, D; Karadimos, D; Kerveno, M; Ketlerov, V; Köhler, P; Konovalov, V; Kossionides, E; Krticka, M; Lamboudis, C; Leeb, H; Lindote, A; Lopes, I; Lozano, M; Lukic, S; Marganiec, J; Marques, L; Marrone, S; Mastinu, P; Mengoni, A; Milazzo, P M; Moreau, C; Mosconi, M; Neves, F; Oberhummer, Heinz; Oshima, M; O'Brien, S; Pancin, J; Papachristodoulou, C; Papadopoulos, C; Paradela, C; Patronis, N; Pavlik, A; Pavlopoulos, P; Perrot, L; Plag, R; Plompen, A; Plukis, A; Poch, A; Pretel, C; Quesada, J; Rauscher, T; Reifarth, R; Rosetti, M; Rubbia, Carlo; Rudolf, G; Rullhusen, P; Salgado, J; Sarchiapone, L; Savvidis, I; Stéphan, C; Tagliente, G; Taín, J L; Tassan-Got, L; Tavora, L; Terlizzi, R; Vannini, G; Vaz, P; Ventura, A; Villamarín, D; Vincente, M C; Vlachoudis, V; Vlastou, R; Voss, F; Walter, S; Wendler, H; Wiescher, M; Wisshak, K

    2006-01-01

    The neutron capture cross section of Bi209 has been measured at the CERN n TOF facility by employing the pulse-height-weighting technique. Improvements over previous measurements are mainly because of an optimized detection system, which led to a practically negligible neutron sensitivity. Additional experimental sources of systematic error, such as the electronic threshold in the detectors, summing of gamma-rays, internal electron conversion, and the isomeric state in bismuth, have been taken into account. Gamma-ray absorption effects inside the sample have been corrected by employing a nonpolynomial weighting function. Because Bi209 is the last stable isotope in the reaction path of the stellar s-process, the Maxwellian averaged capture cross section is important for the recycling of the reaction flow by alpha-decays. In the relevant stellar range of thermal energies between kT=5 and 8 keV our new capture rate is about 16% higher than the presently accepted value used for nucleosynthesis calculations. At th...

  1. Boron Hazards to Fish, Wildlife, and Invertebrates: A Synoptic Review

    Science.gov (United States)

    Eisler, R.

    1990-01-01

    Ecological and toxicological aspects of boron (B) in the environment are reviewed, with emphasis on natural resources. Subtopics covered include environmental chemistry, background concentrations, effects, and current recommendations for the protection of living resources. Boron is not now considered essential in mammalian nutrition, although low dietary levels protect against fluorosis and bone demineralization. Excessive consumption (i.e., >1,000 mg B/kg diet, >15 mg B/kg body weight daily, >1.0 mg B/L drinking water, or >210 mg B/kg body weight in a single dose) adversely affects growth, survival, or reproduction in sensitive mammals. Boron and its compounds are potent teratogens when applied directly to the mammalian embryo, but there is no evidence of mutagenicity or carcinogenicity. Boron`s unique affinity for cancerous tissues has been exploited in neutron capture radiation therapy of malignant human brain tumors. Current boron criteria recommended for the protection of sensitive species include aquatic life, <5.0 mg B/L in livestock drinking waters, <30 mg B/kg in waterfowl diets, and <100 mg B/kg in livestock diets.

  2. 用于硼中子俘获治疗的加速器超热中子源靶的设计%The design of accelerator-based epithermal neutron source target used in boron neutron capture therapy

    Institute of Scientific and Technical Information of China (English)

    张静; 包尚联

    2002-01-01

    提出适合硼中子俘获治疗加速器Li(P,n)Be反应中子源的一个金属锂靶的设计,并对中子产额进行了计算.用Monte Carlo的方法研究了中子在水中的慢化和反射层对中子能谱的影响.结果表明,在这种几何结构下Li(p,n)7Be反应产生的中子经过5cm的水层慢化后可作为硼中子俘获治疗的超热中子源.

  3. Neutron capture cross section and capture gamma-ray spectra of 89Y

    Directory of Open Access Journals (Sweden)

    Katabuchi Tatsuya

    2016-01-01

    Full Text Available The neutron capture cross section of 89Y was measured by the time-of-flight method in an energy range from 15 to 100 keV. A pulse-height weighting technique was applied to derive the capture yield. The absolute cross section was determined based on the standard reaciotn 197 Au(n, γ198 Au reaction. The neutron capture γ-ray spectrum was derived by unfolding the pulse-height spectrum with detector response functions.

  4. Submicron-sized boron carbide particles encapsulated in turbostratic graphite prepared by laser fragmentation in liquid medium.

    Science.gov (United States)

    Ishikawa, Yoshie; Sasaki, Takeshi; Koshizaki, Naoto

    2010-08-01

    Submicron-sized B4C spherical particles were obtained by laser fragmentation of large B4C particles dispersed in ethyl acetate. The irradiated surface of large B4C raw particles was heated and melted by laser energy absorption. B4C droplets were then cooled down, and finally B4C spherical particles were obtained. Moreover, each B4C particle obtained was encapsulated in a graphitic layer that is useful for medical functionalization of particles. Thus, obtained B4C particles encapsulated in graphitic layer may have potential uses in boron neutron capture therapy.

  5. Multidimensional potential of boron-containing molecules in functional materials

    Indian Academy of Sciences (India)

    Wolfgang Kaim; Narayan S Hosmane

    2010-01-01

    Boron-containing molecular systems have received much attention under theoretical aspects and from the side of synthetic organic chemistry. However, their potential for further applications such as optically interesting effects such as Non-Linear Optics (NLO), medical uses for Boron Neutron Capture Therapy (BNCT), or magnetism has been recognised only fairly recently. Molecular systems containing boron offer particular mechanisms to accommodate unpaired electrons which may result in stable radicals as spin-bearing materials. Among such materials are organoboron compounds in which the prototypical electron deficient (10B, 11B) boron vs. carbon centers can accept and help to delocalise added electrons in a 2-dimensionally conjugated system. Alternatively, oligoboron clusters B$_{n}$X$_{n}^{k}$ and the related carboranes or metallacarboranes are capable of adding or losing single electrons to form paramagnetic clusters with 3-dimensionally delocalised spin, according to combined experimental studies and quantum chemical calculations. The unique nuclear properties of 10B are of therapeutic value if their selective transport via appended carbon nanotubes, boron nanotubes, or magnetic nanoparticles can be effected.

  6. Neutron capture measurements on 62Ni, 63Ni and 197Au and their relevance for stellar nucleosynthesis

    CERN Document Server

    Lederer, Claudia

    Neutron capture reactions in stars are responsible for forming about 99% of the elemental abundances heavier than Fe. Two processes contribute about equally to the overall abundance pattern: the slow neutron capture process (s process) where neutron densities are small and therefore radioactive decay is generally faster than subsequent neutron capture on radionuclides, and the rapid neutron capture process (r process) which takes place in environments of high neutron densities, driving the reaction path towards the neutron rich side. The key nuclear physics input for s process studies are stellar neutron capture cross sections, called MACS (Maxwellian-averaged cross section). In the course of this work, dierent reactions relevant to s process nucleosynthesis have been studied. To improve and check existing information, neutron capture cross sections of most stable Fe and Ni isotopes were measured via the time-of-flight technique at the n TOF facility at CERN. This campaign was triggered by a work of Sneden et...

  7. Neutron capture and neutron-induced fission experiments on americium isotopes with DANCE

    Science.gov (United States)

    Jandel, M.; Bredeweg, T. A.; Stoyer, M. A.; Wu, C. Y.; Fowler, M. M.; Becker, J. A.; Bond, E. M.; Couture, A.; Haight, R. C.; Haslett, R. J.; Henderson, R. A.; Keksis, A. L.; O'Donnell, J. M.; Rundberg, R. S.; Ullmann, J. L.; Vieira, D. J.; Wilhelmy, J. B.; Wouters, J. M.

    2009-01-01

    Neutron capture cross section data on Am isotopes were measured using the Detector for Advanced Neutron Capture Experiments (DANCE) at Los Alamos National Laboratory. The neutron capture cross section was determined for 241Am for neutron energies between thermal and 320 keV. Preliminary results were also obtained for 243Am for neutron energies between 10 eV and 250 keV. The results on concurrent neutron-induced fission and neutron-capture measurements on 242mAm will be presented where the fission events were actively triggered during the experiments. In these experiments, a Parallel-Plate Avalanche Counter (PPAC) detector that surrounds the target located in the center of the DANCE array was used as a fission-tagging detector to separate (n,γ) events from (n,f) events. The first direct observation of neutron capture on 242mAm in the resonance region in between 2 and 9 eV of the neutron energy was obtained.

  8. Measurement of gamma-ray production from thermal neutron capture on gadolinium for neutrino experiments

    Science.gov (United States)

    Yano, Takatomi

    2017-02-01

    Recently, several scientific applications of gadolinium are found in neutrino physics experiments. Gadolinium-157 is the nucleus, which has the largest thermal neutron capture cross-section among all stable nuclei. Gadolinium-155 also has the large cross-section. These neutron capture reactions provide the gamma-ray cascade with the total energy of about 8 MeV. This reaction is applied for several neutrino experiments, e.g. reactor neutrino experiments and Gd doped large water Cherenkov detector experiments, to recognize inverse-beta-decay reaction. A good Gd(n,γ) simulation model is needed to evaluate the detection efficiency of the neutron capture reaction, i.e. the efficiency of IBD detection. In this presentation, we will report the development and study status of a Gd(n,γ) calculation model and comparison with our experimental data taken at ANNRI/MLF beam line, J-PARC.

  9. New measurement of $\\theta_{13}$ via neutron capture on hydrogen at Daya Bay

    CERN Document Server

    An, F P; Band, H R; Bishai, M; Blyth, S; Cao, D; Cao, G F; Cao, J; Cen, W R; Chan, Y L; Chang, J F; Chang, L C; Chang, Y; Chen, H S; Chen, Q Y; Chen, S M; Chen, Y X; Chen, Y; Cheng, J H; Cheng, J -H; Cheng, J; Cheng, Y P; Cheng, Z K; Cherwinka, J J; Chu, M C; Chukanov, A; Cummings, J P; de Arcos, J; Deng, Z Y; Ding, X F; Ding, Y Y; Diwan, M V; Dolgareva, M; Dove, J; Dwyer, D A; Edwards, W R; Gill, R; Gonchar, M; Gong, G H; Gong, H; Grassi, M; Gu, W Q; Guan, M Y; Guo, L; Guo, R P; Guo, X H; Guo, Z; Hackenburg, R W; Han, R; Hans, S; He, M; Heeger, K M; Heng, Y K; Higuera, A; Hor, Y K; Hsiung, Y B; Hu, B Z; Hu, T; Hu, W; Huang, E C; Huang, H X; Huang, X T; Huber, P; Huo, W; Hussain, G; Jaffe, D E; Jaffke, P; Jen, K L; Jetter, S; Ji, X P; Ji, X L; Jiao, J B; Johnson, R A; Joshi, J; Kang, L; Kettell, S H; Kohn, S; Kramer, M; Kwan, K K; Kwok, M W; Kwok, T; Langford, T J; Lau, K; Lebanowski, L; Lee, J; Lee, J H C; Lei, R T; Leitner, R; Leung, J K C; Li, C; Li, D J; Li, F; Li, G S; Li, Q J; Li, S; Li, S C; Li, W D; Li, X N; Li, Y F; Li, Z B; Liang, H; Lin, C J; Lin, G L; Lin, S; Lin, S K; Lin, Y -C; Ling, J J; Link, J M; Littenberg, L; Littlejohn, B R; Liu, D W; Liu, J J; Liu, J L; Liu, J C; Loh, C W; Lu, C; Lu, H Q; Lu, J S; Luk, K B; Lv, Z; Ma, Q M; Ma, X Y; Ma, X B; Ma, Y Q; Malyshkin, Y; Caicedo, D A Martinez; McDonald, K T; McKeown, R D; Mitchell, I; Mooney, M; Nakajima, Y; Napolitano, J; Naumov, D; Naumova, E; Ngai, H Y; Ning, Z; Ochoa-Ricoux, J P; Olshevskiy, A; Pan, H -R; Park, J; Patton, S; Pec, V; Peng, J C; Pinsky, L; Pun, C S J; Qi, F Z; Qi, M; Qian, X; Raper, N; Ren, J; Rosero, R; Roskovec, B; Ruan, X C; Steiner, H; Sun, G X; Sun, J L; Tang, W; Taychenachev, D; Konstantin, T; Tsang, K V; Tull, C E; Viaux, N; Viren, B; Vorobel, V; Wang, C H; Wang, M; Wang, N Y; Wang, R G; Wang, W; Wang, W W; Wang, X; Wang, Y F; Wang, Z; Wang, Z M; Wei, H Y; Wen, L J; Whisnant, K; White, C G; Whitehead, L; Wise, T; Wong, H L H; Wong, S C F; Worcester, E; Wu, C -H; Wu, Q; Xia, D M; Xia, J K; Xing, Z Z; Xu, J Y; Xu, J L; Xu, J; Xu, Y; Xue, T; Yan, J; Yang, C G; Yang, H; Yang, L; Yang, M S; Yang, M T; Ye, M; Ye, Z; Yeh, M; Young, B L; Yu, G Y; Yu, Z Y; Zhan, L; Zhang, C; Zhang, H H; Zhang, J W; Zhang, Q M; Zhang, X T; Zhang, Y M; Zhang, Y X; Zhang, Z J; Zhang, Z Y; Zhang, Z P; Zhao, J; Zhao, Q W; Zhao, Y F; Zhao, Y B; Zhong, W L; Zhou, L; Zhou, N; Zhuang, H L; Zou, J H

    2016-01-01

    This article reports an improved independent measurement of neutrino mixing angle $\\theta_{13}$ at the Daya Bay Reactor Neutrino Experiment. Electron antineutrinos were identified by inverse $\\beta$-decays with the emitted neutron captured by hydrogen, yielding a data-set with principally distinct uncertainties from that with neutrons captured by gadolinium. With the final two of eight antineutrino detectors installed, this study used 621 days of data including the previously reported 217-day data set with six detectors. The dominant statistical uncertainty was reduced by 49%. Intensive studies of the cosmogenic muon-induced $^9$Li and fast neutron backgrounds and the neutron-capture energy selection efficiency, resulted in a reduction of the systematic uncertainty by 26%. The deficit in the detected number of antineutrinos at the far detectors relative to the expected number based on the near detectors yielded $\\sin^22\\theta_{13} = 0.071 \\pm 0.011$ in the three-neutrino-oscillation framework. The combination...

  10. Abundances of neutron-capture elements in G 24-25

    DEFF Research Database (Denmark)

    Liu, S.; Nissen, Poul Erik; Schuster, W. J.

    2012-01-01

    Aims. The differences between the neutron-capture element abundances of halo stars are important to our understanding of the nucleosynthesis of elements heavier than the iron group. We present a detailed abundance analysis of carbon and twelve neutron-capture elements from Sr up to Pb...... overabundances of carbon and heavy s-process elements and mild overabundances of Eu and light s-process elements. This abundance distribution is consistent with that of a typical CH giant. The abundance pattern can be explained by mass transfer from a former asymptotic giant branch component, which is now...

  11. Continuum quasiparticle random phase approximation for astrophysical direct neutron capture reaction of neutron-rich nuclei

    OpenAIRE

    Matsuo, Masayuki

    2014-01-01

    We formulate a many-body theory to calculate the cross section of direct radiative neutron capture reaction by means of the Hartree-Fock-Bogoliubov mean-field model and the continuum quasiparticle random phase approximation (QRPA). A focus is put on very neutron-rich nuclei and low-energy neutron kinetic energy in the range of O(1 keV) - O(1 MeV), relevant for the rapid neutron-capture process of nucleosynthesis. We begin with the photo-absorption cross section and the E1 strength function, t...

  12. Complementary incorporation of boron compounds with different cellular targets in melanoma

    Energy Technology Data Exchange (ETDEWEB)

    Morre, D.E. [University of Sydney, Dept. of Pharmacy, Sydney, NSW (Australia); Setiawan, Y.; Allen, B.J. [St George Cancer Care Centre, Kogarah, NSW (Australia)

    1996-12-31

    Full text. The heterogeneity of malignant tumours is well known, and post-surgical control may only be achieved by the application of a number of adjuvant therapies. In boron neutron capture therapy (BNCT), a similar effect could be achieved by utilising boron compounds with quite different uptake and incorporation mechanisms. While tumour growth delay or control can be induced by BNCT in animal models, long term control in human patients may be much more difficult. Thus we have carried out experiments with two boron compounds which exhibit quite different pharmacokinetics and interact with cancer cells by quite different mechanisms. The compounds studied were p-boronophenylalanine (BPA) and boronated low density lipoprotein (B-LDL). Non-specific boron compounds such as n-alkyl carboranes can be delivered to melanoma tumour cells when incorporated in reconstituted LDL. Biodistribution studies were performed with BALB/c mice bearing subcutaneous Harding-Passey melanoma xenografts. The mice were pretreated with a high fat diet and hydrocortisone to down regulate the non-autonomous LDL receptors. A tumour to blood boron concentration ratio of 5:1 was achieved 18 hours after administration of B-LDL. The same compound administered in a non-specific arachis oil vehicle failed to demonstrate selective uptake in the tumour. Neutron capture therapy using B-LDL as the boron delivery vehicle produced a growth delay effect on the tumours which was equivalent to that found when BPA was administered as the fructose complex to develop a similar boron concentration in the tumour. This is indicative that the boron microdistribution across different types of tumour cells achieved by B-LDL has a similar effect to that achieved by BPA in the tumour model, even though the uptake mechanisms for BPA and B-LDL are different. BPA uptake is thought to be dependent on the amino acid transport mechanism, whereas receptor density determines LDL incorporation. Thus the combined administration

  13. Measurements and simulations of boron carbide as degrader material for proton therapy

    Science.gov (United States)

    Gerbershagen, Alexander; Baumgarten, Christian; Kiselev, Daniela; van der Meer, Robert; Risters, Yannic; Schippers, Marco

    2016-07-01

    We report on test measurements using boron carbide (B4C) as degrader material in comparison with the conventional graphite, which is currently used in many proton therapy degraders. Boron carbide is a material of lower average atomic weight and higher density than graphite. Calculations predict that, compared to graphite, the use of boron carbide results in a lower emittance behind the degrader due to the shorter degrader length. Downstream of the acceptance defining collimation system we expect a higher beam transmission, especially at low beam energies. This is of great interest in proton therapy applications as it allows either a reduction of the beam intensity extracted from the cyclotron leading to lower activation or a reduction of the treatment time. This paper summarizes the results of simulations and experiments carried out at the PROSCAN facility at the Paul Scherrer Institute1. The simulations predict an increase in the transmitted beam current after the collimation system of approx. 30.5% for beam degradation from 250 to 84 MeV for a boron carbide degrader compared to graphite. The experiment carried out with a boron carbide block reducing the energy to 84 MeV yielded a transmission improvement of 37% compared with the graphite degrader set to that energy.

  14. Measurements and simulations of boron carbide as degrader material for proton therapy.

    Science.gov (United States)

    Gerbershagen, Alexander; Baumgarten, Christian; Kiselev, Daniela; van der Meer, Robert; Risters, Yannic; Schippers, Marco

    2016-07-21

    We report on test measurements using boron carbide (B4C) as degrader material in comparison with the conventional graphite, which is currently used in many proton therapy degraders. Boron carbide is a material of lower average atomic weight and higher density than graphite. Calculations predict that, compared to graphite, the use of boron carbide results in a lower emittance behind the degrader due to the shorter degrader length. Downstream of the acceptance defining collimation system we expect a higher beam transmission, especially at low beam energies. This is of great interest in proton therapy applications as it allows either a reduction of the beam intensity extracted from the cyclotron leading to lower activation or a reduction of the treatment time. This paper summarizes the results of simulations and experiments carried out at the PROSCAN facility at the Paul Scherrer Institute(1). The simulations predict an increase in the transmitted beam current after the collimation system of approx. 30.5% for beam degradation from 250 to 84 MeV for a boron carbide degrader compared to graphite. The experiment carried out with a boron carbide block reducing the energy to 84 MeV yielded a transmission improvement of 37% compared with the graphite degrader set to that energy.

  15. DANCEing with the Stars: Measuring Neutron Capture on Unstable Isotopes with DANCE

    Science.gov (United States)

    Couture, A.; Agvaanluvsan, U.; Baker, J. D.; Bayarbadrahk, B.; Becker, J. A.; Bond, E.; Bredeweg, T. A.; Chyzh, A.; Dashdorj, D.; Fowler, M.; Haight, R. C.; Jandel, M.; Keksis, A. L.; O'Donnell, J. M.; Reifarth, R.; Rundberg, R.; Ullmann, J. L.; Vieira, D. J.; Wouters, J. M.

    2009-03-01

    Isotopes heavier than iron are known to be produced in stars through neutron capture processes. Two major processes, the slow (s) and rapid (r) processes are each responsible for 50% of the abundances of the heavy isotopes. The neutron capture cross sections of the isotopes on the s process path reveal information about the expected abundances of the elements as well as stellar conditions and dynamics. Until recently, measurements on unstable isotopes, which are most important for determining stellar temperatures and reaction flow, have not been experimentally feasible. The Detector for Advance Neutron Capture Experiments (DANCE) located at the Los Alamos Neutron Science Center (LANSCE) was designed to perform time-of-flight neutron capture measurements on unstable isotopes for nuclear astrophysics, stockpile stewardship, and reactor development. DANCE is a 4-π BaF2 scintillator array which can perform measurements on sub-milligram samples of isotopes with half-lives as short as a few hundred days. These cross sections are critical for advancing our understanding of the production of the heavy isotopes.

  16. Thermal-neutron capture gamma rays from natural magnesium and enriched 25Mg

    NARCIS (Netherlands)

    Spilling, P.; Gruppelaar, H.; Kamp, A.M.F. op den

    1967-01-01

    Gamma rays from neutron capture in natural magnesium and in enriched 25Mg have been studied with Ge(Li) detectors. Altogether 101 γ-rays have been observed. Most of these γ-rays could be fitted into the level schemes of 25Mg, 26Mg and 27Mg. If it is assumed that the capture cross section for natura

  17. Slow neutron capture nucleosynthesis in the progenitor of SN 1987A

    Energy Technology Data Exchange (ETDEWEB)

    Prantzos, N.; Arnould, M.; Casse, M.

    1988-08-01

    The Ba overabundance detected in the SN 1987A ejecta (Williams, 1987; Danziger et al., 1988) is intepreted in terms of slow-neutron-capture nucleosynthesis during core He burning in the (presumed) progenitor Sk-69 deg 202. The results of nucleosynthesis computations are reported, and their relevance to the observations is discussed. 24 references.

  18. Astrophysical neutron capture rates in s- and r-process nucleosynthesis

    CERN Document Server

    Beer, H; Oberhummer, Heinz; Rauscher, T; Mutti, P; Corvi, F; Sedyshev, P V; Popov, Yu P; Popov, Yu.P.

    1997-01-01

    Astrophysical neutron capture rates of light and heavy nuclei have been measured and calculated. For the measurements the activation technique was applied at the 3.75 MV Karlsruhe Van de Graaff accelerator, and at the Geel electron linear accelerator (GELINA) the time-of-flight (TOF) method was used. The calculations were performed using direct and compound nuclear capture models.

  19. New Neutron-Capture Measurements in 23 Open Clusters. I. The R-Process

    CERN Document Server

    Overbeek, Jamie C; Jacobson, Heather R

    2016-01-01

    Neutron-capture elements, those with Z > 35, are the least well-understood in terms of nucleosynthesis and formation environments. The rapid neutron-capture, or r-process, elements are formed in the environments and/or remnants of massive stars, while the slow neutron-capture, or s-process, elements are primarily formed in low-mass AGB stars. These elements can provide much information about Galactic star formation and enrichment, but observational data is limited. We have assembled a sample of 68 stars in 23 open clusters that we use to probe abundance trends for six neutron-capture elements (Eu, Gd, Dy, Mo, Pr, and Nd) with cluster age and location in the disk of the Galaxy. In order to keep our analysis as homogenous as possible, we use an automated synthesis fitting program, which also enables us to measure multiple (3-10) lines for each element. We find that the pure r-process elements (Eu, Gd, and Dy) have positive trends with increasing cluster age, while the mixed r- and s- process elements (Mo, Pr, a...

  20. Astrophysical radiative neutron capture on 10B taking into account resonance at 475 keV

    CERN Document Server

    Dubovichenko, Sergey

    2013-01-01

    The possibility of the description of the available experimental data for cross sections of the neutron capture reaction on 10B at thermal and astrophysical energies, taking into account the resonance at 475 keV, was considered within the framework of the modified potential cluster model with forbidden states and accounting for the resonance behavior of the scattering phase shifts.

  1. Model-Independent Calculation of Radiative Neutron Capture on Lithium-7

    NARCIS (Netherlands)

    Rupak, Gautam; Higa, Renato

    2011-01-01

    The radiative neutron capture on lithium-7 is calculated model independently using a low-energy halo effective field theory. The cross section is expressed in terms of scattering parameters directly related to the S-matrix elements. It depends on the poorly known p-wave effective range parameter r(1

  2. Neutron-Capture Kr-80 and Ar-36 in the Martian Atmosphere and Regolith

    Science.gov (United States)

    Rao, M. N.; Bogard, D. D.; Nyquist, L.; McKay, D. S.; Masarik, J.

    2001-01-01

    We calculate that approximately 10% of martian atmospheric Kr-80 formed by neutron capture on Mars in approx. 0.5 Ga. The regolith contains even larger amounts of n-capture Kr-80 and Ar-36, which may provide clues to the evolution of the martian regolith and atmosphere. Additional information is contained in the original extended abstract.

  3. Spectromicroscopy of boron in human glioblastomas following administration of Na2B12H11SH

    Science.gov (United States)

    Gilbert, B.; Perfetti, L.; Fauchoux, O.; Redondo, J.; Baudat, P.-A.; Andres, R.; Neumann, M.; Steen, S.; Gabel, D.; Mercanti, Delio; Ciotti, M. Teresa; Perfetti, P.; Margaritondo, G.; de Stasio, Gelsomina

    2000-07-01

    Boron neutron capture therapy (BNCT) is an experimental, binary treatment for brain cancer which requires as the first step that tumor tissue is targeted with a boron-10 containing compound. Subsequent exposure to a thermal neutron flux results in destructive, short range nuclear reaction within 10 μm of the boron compound. The success of the therapy requires than the BNCT agents be well localized in tumor, rather than healthy tissue. The MEPHISTO spectromicroscope, which performs microchemical analysis by x-ray absorption near edge structure (XANES) spectroscopy from microscopic areas, has been used to study the distribution of trace quantities of boron in human brain cancer tissues surgically removed from patients first administered with the compound Na2B12H11SH (BSH). The interpretation of XANES spectra is complicated by interference from physiologically present sulfur and phosphorus, which contribute structure in the same energy range as boron. We addressed this problem with the present extensive set of spectra from S, B, and P in relevant compounds. We demonstrate that a linear combination of sulfate, phosphate and BSH XANES can be used to reproduce the spectra acquired on boron-treated human brain tumor tissues. We analyzed human glioblastoma tissue from two patients administered and one not administered with BSH. As well as weak signals attributed to BSH, x-ray absorption spectra acquired from tissue samples detected boron in a reduced chemical state with respect to boron in BSH. This chemical state was characterized by a sharp absorption peak at 188.3 eV. Complementary studies on BSH reference samples were not able to reproduce this chemical state of boron, indicating that it is not an artifact produced during sample preparation or x-ray exposure. These data demonstrate that the chemical state of BSH may be altered by in vivo metabolism.

  4. Prompt gamma-ray emission for future imaging applications in proton-boron fusion therapy

    Science.gov (United States)

    Petringa, G.; Cirrone, G. A. P.; Caliri, C.; Cuttone, G.; Giuffrida, L.; La Rosa, G.; Manna, R.; Manti, L.; Marchese, V.; Marchetta, C.; Margarone, D.; Milluzzo, G.; Picciotto, A.; Romano, F.; Romano, F. P.; Russo, A. D.; Russo, G.; Santonocito, D.; Scuderi, V.

    2017-03-01

    Recently, an approach exploiting the proton therapy biological enhancement by using Boron atoms injected inside a tumor, has been proposed [1-3]. Here, the 11B(p,α)2α nuclear fusion reaction channel, where three alpha particles are produced with an average energy around 4 MeV, is considered [4]. These alphas are able to penetrate the cells nucleus and strongly damage their DNA. In addition, gamma prompts emitted by the proton Boron nuclear reactions can be used for on-line proton beam imaging purposes. In this work an experimental study of the gamma prompt emissions from the proton Boron nuclear reactions has been carried out with the main aim to understand and quantify the most probable emission for future clinical applications.

  5. Boron-based Drug Design for Cancer Therapy

    Institute of Scientific and Technical Information of China (English)

    H.Nakamura; R.Horikoshi; T.Usui; H.S.Ban

    2007-01-01

    1 Results Selective inhibition of protein tyrosine kinases is gaining importance as an effective therapeutic approach for the treatment of a wide range of human cancers.The epidermal growth factor receptor (EGFR) protein tyrosine kinase is one of the important kinases that play a fundamental role in cell growth signal pathways.We focused on the 4-anilinoquinazoline framework,which is observed in both compounds as a common structure.A boron atom has a vacant orbital and interconverts with ease between th...

  6. Measurement of Neutron Capture Cross Section of 62Ni in the keV-Region

    Science.gov (United States)

    Alpizar-Vicente, A. M.; Bredeweg, T. A.; Esch, E.-I.; Greife, U.; Haight, R. C.; Hatarik, R.; O'Donnell, J. M.; Reifarth, R.; Rundberg, R. S.; Ullmann, J. L.; Vieira, D. J.; Wilhelmy, J. B.; Wouters, J. M.

    2006-03-01

    The neutron capture cross section of 62Ni, relative to gold as a standard, was determined in the energy range from 250 eV to 100 keV. This energy range covers the region between 5 keV to 20 keV, which is not available in ENDF. Capture events are detected with the 160-fold 4π BaF2 Detector for Advanced Neutron Capture Experiments (DANCE) at the Los Alamos Neutron Science Center. One of the challenges was to process the high count rate of 4 MHz, which required an optimization of the data acquisition software. The neutron energy was determined by the time-of-flight technique using a flight path of 20.25 m. The sample mass of the 96% enriched 62Ni target was 210 mg and it was mounted in a 1.5 μm thick Mylar foil.

  7. Validating (d,pγ as a Surrogate for Neutron Capture

    Directory of Open Access Journals (Sweden)

    Ratkiewicz A.

    2015-01-01

    Full Text Available The r-process is responsible for creating roughly half of the elements heavier than iron. It has recently become understood that the rates at which neutron capture reactions proceed at late times in the r-process may dramatically affect the final abundance pattern. However, direct measurements of neutron capture reaction rates on exotic nuclei are exceptionally difficult, necessitating the development of indirect approaches such as the surrogate technique. The (d,pγ reaction at low energies was identified as a promising surrogate for the (n,γ reaction, as both reactions share many characteristics. We report on a program to validate (d,pγ as a surrogate for (n,γ using 95Mo as a target. The experimental campaign includes direct measurements of the γ-ray intensities from the decay of excited states populated in the 95Mo(n,γ and 95Mo(d,pγ reactions.

  8. The Open Cluster Chemical Abundances and Mapping (OCCAM) Survey: Optical Extension for Neutron Capture Elements

    Science.gov (United States)

    Melendez, Matthew; O'Connell, Julia; Frinchaboy, Peter M.; Donor, John; Cunha, Katia M. L.; Shetrone, Matthew D.; Majewski, Steven R.; Zasowski, Gail; Pinsonneault, Marc H.; Roman-Lopes, Alexandre; Stassun, Keivan G.; APOGEE Team

    2017-01-01

    The Open Cluster Chemical Abundance & Mapping (OCCAM) survey is a systematic survey of Galactic open clusters using data primarily from the SDSS-III/APOGEE-1 survey. However, neutron capture elements are very limited in the IR region covered by APOGEE. In an effort to fully study detailed Galactic chemical evolution, we are conducting a high resolution (R~60,000) spectroscopic abundance analysis of neutron capture elements for OCCAM clusters in the optical regime to complement the APOGEE results. As part of this effort, we present Ba II, La II, Ce II and Eu II results for a few open clusters without previous abundance measurements using data obtained at McDonald Observatory with the 2.1m Otto Struve telescope and Sandiford Echelle Spectrograph.This work is supported by an NSF AAG grant AST-1311835.

  9. Validating (d,pγ) as a surrogate for neutron capture

    Energy Technology Data Exchange (ETDEWEB)

    Ratkiewicz, A. [Rutgers Univ., New Brunswick, NJ (United States); Cizewski, J. A. [Rutgers Univ., New Brunswick, NJ (United States); Pain, S. D. [Oak Ridge National Lab. (ORNL), Oak Ridge, TN (United States); Adekola, A. S. [Rutgers Univ., New Brunswick, NJ (United States); Burke, J. T. [Lawrence Livermore National Lab. (LLNL), Livermore, CA (United States); Casperson, R. J. [Lawrence Livermore National Lab. (LLNL), Livermore, CA (United States); Fotiadis, Nikolaos [Los Alamos National Lab. (LANL), Los Alamos, NM (United States); McCleskey, M. [Texas A & M Univ., College Station, TX (United States); Burcher, S. [Rutgers Univ., New Brunswick, NJ (United States); Shand, C. M [Rutgers Univ., New Brunswick, NJ (United States); Austin, R. A. E. [Saint Mary' s Univ., Halifax (Canada); Baugher, T. [Rutgers Univ., New Brunswick, NJ (United States); Carpenter, M. P. [Argonne National Lab. (ANL), Argonne, IL (United States); Devlin, Matthew James [Los Alamos National Lab. (LANL), Los Alamos, NM (United States); Escher, J. E. [Lawrence Livermore National Lab. (LLNL), Livermore, CA (United States); Hardy, S. [Rutgers Univ., New Brunswick, NJ (United States); Hatarik, R. [Lawrence Livermore National Lab. (LLNL), Livermore, CA (United States); Howard, M. E. [Rutgers Univ., New Brunswick, NJ (United States); Hughes, R. O. [Univ. of Richmond, VA (United States); Jones, K. L. [Univ. of Tennessee, Knoxville, TN (United States); Kozub, R. L. [Tennessee Technological Univ., Cookeville, TN (United States); Lister, C. J. [Univ. of Massachusetts, Lowell, MA (United States); Manning, B. [Rutgers Univ., New Brunswick, NJ (United States); O' Donnell, John M. [Los Alamos National Lab. (LANL), Los Alamos, NM (United States); Peters, W. A. [oak ridge associated Univ., TN (United States); Ross, T. J. [Univ. of Richmond, VA (United States); Scielzo, N. D. [Lawrence Livermore National Lab. (LLNL), Livermore, CA (United States); Seweryniak, D. [Argonne National Lab. (ANL), Argonne, IL (United States); Zhu, S. [Argonne National Lab. (ANL), Argonne, IL (United States)

    2015-02-13

    The r-process is responsible for creating roughly half of the elements heavier than iron. It has recently become understood that the rates at which neutron capture reactions proceed at late times in the r-process may dramatically affect the final abundance pattern. However, direct measurements of neutron capture reaction rates on exotic nuclei are exceptionally difficult, necessitating the development of indirect approaches such as the surrogate technique. The (d,pγ) reaction at low energies was identified as a promising surrogate for the (n,γ) reaction, as both reactions share many characteristics. We report on a program to validate (d,pγ) as a surrogate for (n,γ) using 95Mo as a target. The experimental campaign includes direct measurements of the γ-ray intensities from the decay of excited states populated in the 95Mo(n,γ) and 95Mo(d,pγ) reactions.

  10. Two-step γ cascades following thermal neutron capture in Gd,157155

    Science.gov (United States)

    Valenta, S.; Bečvář, F.; Kroll, J.; Krtička, M.; Tomandl, I.

    2015-12-01

    Spectra of two-step γ cascades following neutron capture in Gd,157155 are measured using the two-Ge-detector facility installed at the thermal neutron beam of the research reactor LVR-15 at Řež. The main objective of this experiment is to obtain new information on photon strength functions, with the emphasis on the role of M 1 scissors-mode vibration. An analysis of accumulated γ -ray spectra, made within the statistical model, leads to the conclusion that the scissors mode significantly affects γ decay of all states of studied nuclei. Experimental data are compared to photon strength functions deduced from other experiments. Agreement of our results with those obtained from DANCE measurement of γ spectra following resonance neutron capture is obtained.

  11. Investigation of the Statistical Properties of Stable Eu Nuclei using Neutron-Capture Reactions

    Energy Technology Data Exchange (ETDEWEB)

    Agvaanluvsan, U; Alpizar-Vicente, A; Becker, J A; Becvar, F; Bredeweg, T A; Clement, R; Esch, E; Folden, III, C M; Hatarik, R; Haight, R C; Hoffman, D C; Krticka, M; Macri, R A; Mitchell, G E; Nitsche, H; O' Donnell, J M; Parker, W; Reifarth, R; Rundberg, R S; Schwantes, J M; Sheets, S A; Ullmann, J L; Vieira, D J; Wilhelmy, J B; Wilk, P; Wouters, J M; Wu, C Y

    2005-10-04

    Neutron capture for incident neutron energies <1eV up to 100 keV has been measured for {sup 151,153}Eu targets. The highly efficient DANCE (Detector for Advanced Neutron Capture Experiments) array coupled with the intense neutron beam at Los Alamos Neutron Science Center is used for the experiment. Stable Eu isotopes mass separated and electroplated on Be backings were used. Properties of well-resolved, strong resonances in two Eu nuclei are examined. The parameters for most of these resonances are known. Detailed multiplicity information for each resonance is obtained employing the high granularity of the DANCE array. The radiative decay cascades corresponding to each resonance are obtained in the experiment. The measurements are compared to simulation of these cascades which calculated with various models for the radiative strength function. Comparison between the experimental data and simulation provides an opportunity to investigate the average quantities.

  12. Validating (d,p gamma) as a Surrogate for Neutron Capture

    Energy Technology Data Exchange (ETDEWEB)

    Ratkiewicz, A. [Rutgers University; Cizewski, J. A. [Rutgers University; Pain, S. [Oak Ridge National Laboratory (ORNL); Adekola, A. S. [Rutgers University; Burke, J. T. [Lawrence Livermore National Laboratory (LLNL); Casperson, R.J. [Lawrence Livermore National Laboratory (LLNL); Fotiades, N. [Los Alamos National Laboratory (LANL); McCleskey, M. [Texas A& M University; Burcher, S. [Rutgers University; Shand, C. M. [Rutgers Univ./Univ. of Surrey, UK; Austin, R. A. E. [Saint Mary’s University, Halifa, Canada; Baugher, T. [Rutgers University; Carpenter, M. P. [Argonne National Laboratory (ANL); Devlin, M. [Los Alamos National Laboratory (LANL); Escher, J. E. [Lawrence Livermore National Laboratory (LLNL); Hardy, S. [Rutgers Univ./Univ. of Surrey, UK; Hatarik, R. [Lawrence Livermore National Laboratory (LLNL); Howard, M. [Rutgers University; Hughes, R. [University of Richmond, VA; Jones, K. L. [University of Tennessee, Knoxville (UTK); Kozub, R. L. [Tennessee Technological University (TTU); Lister, C. J. [University of Massachusetts, Lowell; Manning, B. [Rutgers University; O' Donnell, J. M. [Los Alamos National Laboratory (LANL); Peters, W. A. [Oak Ridge Associated Universities (ORAU); Ross, T.J. [University of Richmond, VA; Scielzo, N.D. [Lawrence Livermore National Laboratory (LLNL); Seweryniak, D. [Argonne National Laboratory (ANL); Zhu, S. [Argonne National Laboratory (ANL)

    2015-01-01

    The r-process is responsible for creating roughly half of the elements heavier than iron. It has recently become understood that the rates at which neutron capture reactions proceed at late times in the rprocess may dramatically affect the final abundance pattern. However, direct measurements of neutron capture reaction rates on exotic nuclei are exceptionally difficult, necessitating the development of indirect approaches such as the surrogate technique. The (d,py) reaction at low energies was identified as a promising surrogate for the (n,y) reaction, as both reactions share many characteristics. We report on a program to validate (d,py) as a surrogate for (n,y) using 95Mo as a target. The experimental campaign includes direct measurements of the y-ray intensities from the decay of excited states populated in the 95Mo(n,y) and 95Mo(d,py) reactions.

  13. Neutron Transfer Reactions: Surrogates for Neutron Capture for Basic and Applied Nuclear Science

    Science.gov (United States)

    Cizewski, J. A.; Jones, K. L.; Kozub, R. L.; Pain, S. D.; Peters, W. A.; Adekola, A.; Allen, J.; Bardayan, D. W.; Becker, J. A.; Blackmon, J. C.; Chae, K. Y.; Chipps, K. A.; Erikson, L.; Gaddis, A.; Harlin, C.; Hatarik, R.; Howard, J.; Jandel, M.; Johnson, M. S.; Kapler, R.; Krolas, W.; Liang, F.; Livesay, R. J.; Ma, Z.; Matei, C.; Matthews, C.; Moazen, B.; Nesaraja, C. D.; O'Malley, P.; Patterson, N.; Paulauskas, S. V.; Pelham, T.; Pittman, S. T.; Radford, D.; Rogers, J.; Schmitt, K.; Shapira, D.; Shriner, J. F.; Sissom, D. J.; Smith, M. S.; Swan, T.; Thomas, J. S.; Vieira, D. J.; Wilhelmy, J. B.; Wilson, G. L.

    2009-03-01

    Neutron capture reactions on unstable nuclei are important for both basic and applied nuclear science. A program has been developed at the Holifield Radioactive Ion Beam Facility at Oak Ridge National Laboratory to study single-neutron transfer (d,p) reactions with rare isotope beams to provide information on neutron-induced reactions on unstable nuclei. Results from (d,p) studies on 130,132Sn, 134Te and 75As are discussed.

  14. Neutron transfer reactions: Surrogates for neutron capture for basic and applied nuclear science

    Energy Technology Data Exchange (ETDEWEB)

    Cizewski, J. A. [Rutgers University; Jones, K. L. [University of Tennessee; Kozub, R. L. [Tennessee Technological University; Pain, Steven D [ORNL; Peters, W. A. [Rutgers University; Adekola, Aderemi S [ORNL; Allen, J. [Rutgers University; Bardayan, Daniel W [ORNL; Becker, J. [Lawrence Livermore National Laboratory (LLNL); Blackmon, Jeff C [ORNL; Chae, K. Y. [University of Tennessee; Chipps, K. [Colorado School of Mines, Golden; Erikson, Luke [Colorado School of Mines, Golden; Gaddis, A. L. [Furman University; Harlin, Christopher W [ORNL; Hatarik, Robert [Rutgers University; Howard, Joshua A [ORNL; Jandel, M. [Los Alamos National Laboratory (LANL); Johnson, Micah [ORNL; Kapler, R. [University of Tennessee; Krolas, W. [University of Warsaw; Liang, J Felix [ORNL; Livesay, Jake [ORNL; Ma, Zhanwen [ORNL; Matei, Catalin [Oak Ridge Associated Universities (ORAU); Matthews, C. [Rutgers University; Moazen, Brian [University of Tennessee; Nesaraja, Caroline D [ORNL; O' Malley, Patrick [Rutgers University; Patterson, N. P. [University of Surrey, UK; Paulauskas, Stanley [University of Tennessee; Pelham, T. [University of Surrey, UK; Pittman, S. T. [University of Tennessee, Knoxville (UTK); Radford, David C [ORNL; Rogers, J. [Tennessee Technological University; Schmitt, Kyle [University of Tennessee; Shapira, Dan [ORNL; ShrinerJr., J. F. [Tennessee Technological University; Sissom, D. J. [Tennessee Technological University; Smith, Michael Scott [ORNL; Swan, T. P. [University of Surrey, UK; Thomas, J. S. [Rutgers University; Vieira, D. J. [Los Alamos National Laboratory (LANL); Wilhelmy, J. B. [Los Alamos National Laboratory (LANL); Wilson, Gemma L [ORNL

    2009-04-01

    Neutron capture reactions on unstable nuclei are important for both basic and applied nuclear science. A program has been developed at the Holifield Radioactive Ion Beam Facility at Oak Ridge National Laboratory to study single-neutron transfer (d,p) reactions with rare isotope beams to provide information on neutron-induced reactions on unstable nuclei. Results from (d,p) studies on {sup 130,132}Sn, {sup 134}Te and {sup 75}As are discussed.

  15. Neutron capture measurement on {sup 173}Lu at LANSCE with DANCE detector

    Energy Technology Data Exchange (ETDEWEB)

    Theroine, C.; Ebran, A.; Meot, V.; Roig, O. [CEA DAM DIF, F-91297 Arpajon (France); Bond, E. M.; Bredeweg, T. A.; Couture, A.; Haight, R. C.; Jandel, M.; Nortier, F. M.; O' Donnell, J. M.; Rundberg, R. S.; Taylor, W. A.; Ullmann, J. L.; Viera, D. J.; Wilhelmy, J. B.; Wouters, J. M. [Los Alamos National Laboratory, Los Alamos, New Mexico 87545 (United States)

    2013-06-10

    The (n,{gamma}) cross section on the unstable {sup 173}Lu(t{sub 1/2} = 1.37y) has been measured from thermal energy up to 200 eV at Los Alamos Neutron Science Center (LANSCE) with The Detector for Advanced Neutron Capture Experiements (DANCE). The main aim of this study is to validate and optimize reaction models for unstable nucleus. A preliminary capture yield will be presented in this paper.

  16. Neutron capture measurement on 173Lu at LANSCE with DANCE detector

    Science.gov (United States)

    Theroine, C.; Ebran, A.; Méot, V.; Roig, O.; Bond, E. M.; Bredeweg, T. A.; Couture, A.; Haight, R. C.; Jandel, M.; Nortier, F. M.; O'Donnell, J. M.; Rundberg, R. S.; Taylor, W. A.; Ullmann, J. L.; Viera, D. J.; Wilhelmy, J. B.; Wouters, J. M.

    2013-06-01

    The (n,γ) cross section on the unstable 173Lu(t1/2 = 1.37y) has been measured from thermal energy up to 200 eV at Los Alamos Neutron Science Center (LANSCE) with The Detector for Advanced Neutron Capture Experiements (DANCE). The main aim of this study is to validate and optimize reaction models for unstable nucleus. A preliminary capture yield will be presented in this paper.

  17. A fast Monte Carlo program for pulsed-neutron capture-gamma tools

    Energy Technology Data Exchange (ETDEWEB)

    Hovgaard, J.

    1992-02-01

    A fast model for the pulsed-neutron capture-gamma tool has been developed. It is believed that the program produce valid results even though some approximation have been introduced. A correct {gamma} photon transport simulation, which is under preparation, has for instance not yet been included. Simulations performed so far has shown that the model, with respect to computing time and accuracy, fully lives up to expectations with respect to computing time and accuracy. (au).

  18. A fast Monte Carlo program for pulsed-neutron capture-gamma tools

    Energy Technology Data Exchange (ETDEWEB)

    Hovgaard, J.

    1992-02-01

    A fast model for the pulsed-neutron capture-gamma tool has been developed. It is believed that the program produce valid results even though some approximation have been introduced. A correct [gamma] photon transport simulation, which is under preparation, has for instance not yet been included. Simulations performed so far has shown that the model, with respect to computing time and accuracy, fully lives up to expectations with respect to computing time and accuracy. (au).

  19. Neutron-capture experiment on 77Se with EXILL at ILL Grenoble

    Directory of Open Access Journals (Sweden)

    Lorenz Ch.

    2015-01-01

    Full Text Available The neutron capture reaction at 77Se has been studied with cold neutrons in the course of the EXILL campaign at the high-flux reactor of the Institut Laue-Langevin Grenoble. A simulation of the detector array with Geant4 has been accomplished and evaluated. The detector response has been deduced and measured spectra were unfolded, which have been compared with simulations using γDex to determine strength functions.

  20. Analytical solutions for the slow neutron capture process of heavy element nucleosynthesis

    Institute of Scientific and Technical Information of China (English)

    Wu Kai-Su

    2009-01-01

    In this paper,the network equation for the slow neutron capture process (s-process) of heavy element nucleosynthesis is investigated. Dividing the s-process network reaction chains into two standard forms and using the technique of matrix decomposition,a group of analytical solutions for the network equation are obtained. With the analytical solutions,a calculation for heavy element abundance of the solar system is carried out and the results are in good agreement with the astrophysical measurements.

  1. Analytical sensitivities and energies of thermal-neutron-capture gamma rays

    Science.gov (United States)

    Duffey, D.; El-Kady, A.; Senftle, F.E.

    1970-01-01

    A table of the analytical sensitivities of the principal lines in the thermal-neutron-capture gamma ray spectrum has been compiled for most of the elements. In addition a second table of the full-energy, single-escape, and double-escape peaks has been compiled according to energy for all significant lines above 3 MeV. Lines that contrast well with adjacent lines are noted as prominent. The tables are useful for spectral interpretation and calibration. ?? 1970.

  2. Analytical sensitivities and energies of thermal neutron capture gamma rays II

    Science.gov (United States)

    Senftle, F.E.; Moore, H.D.; Leep, D.B.; El-Kady, A.; Duffey, D.

    1971-01-01

    A table of the analytical sensitivities of the principal lines in the thermal neutron capture gamma-ray spectrum from 0 to 3 MeV has been compiled for most of the elements. A tabulation of the full-energy, single-escape, and double-escape peaks has also been made according to energy. The tables are useful for spectral interpretation and calibration. ?? 1971.

  3. Neutron-capture experiment on 77Se with EXILL at ILL Grenoble

    Science.gov (United States)

    Lorenz, Ch.; John, R.; Massarczyk, R.; Schwengner, R.; Blanc, A.; de France, G.; Jentschel, M.; Köster, U.; Mutti, P.; Simpson, G.; Soldner, T.; Urban, W.; Valenta, S.; Belgya, T.

    2015-05-01

    The neutron capture reaction at 77Se has been studied with cold neutrons in the course of the EXILL campaign at the high-flux reactor of the Institut Laue-Langevin Grenoble. A simulation of the detector array with Geant4 has been accomplished and evaluated. The detector response has been deduced and measured spectra were unfolded, which have been compared with simulations using γDex to determine strength functions.

  4. Revision and extensions of neutron capture cross-sections in the European activation file EAF-3

    Energy Technology Data Exchange (ETDEWEB)

    Kopecky, J.; Delfini, M.G.; Kamp, H.A.J. van der; Nierop, D.

    1992-07-01

    This report contains an extensive description of the work performed to compile, extend and revise the neutron capture data subfile of the European Activation File (EAF-3). The starter was the EAF-1 data file from 1989. The present version, EAF/NG-3, contains (n, [gamma]) excitation functions for all nuclides (729 targets) with half-lives exceeding 1/2 day in the mass range from H-1 to Cm-248. (author). 35 refs.; 9 figs.; 7 tabs.

  5. Intermediate structure in the /sup 238/U neutron capture cross section

    Energy Technology Data Exchange (ETDEWEB)

    Perez, R.B.; de Saussure, G.

    1975-10-01

    Recent measurements of the /sup 238/U neutron capture cross section show large fluctuations in the unresolved resonance region. To test whether or not the observed long-range fluctuation of the neutron capture represent departures from the compound nuclear model, the Wald-Wolfowitz runs and correlation tests were applied to the /sup 238/U neutron capture data obtained at ORELA. The Wald-Wolfowitz runs test deals with the statistic, R, which is the number of unbroken sequences of data points above or below a given reference line. This statistic is to be compared with the expected value of runs E(R) +- sigma(R) arising from randomly distributed data. In the correlation test we have computed the first serial correlation coefficient of the data as well as its expected value and variance for a set of random data. In both tests one computes the probability, P, for the given statistical entity to depart from its expected value by more than epsilon standard deviations. Both tests confirm the presence of intermediate structure between 5 and 100 keV. The range of the structure far exceeds the width of the experimental resolution and level widths. 3 tables, 2 figures. (auth)

  6. Determination of the Neutron-Capture Rate of 17C for the R-process Nucleosynthesis

    CERN Document Server

    Heine, M; Wu, M -R; Adachi, T; Aksyutina, Y; Alcantara, J; Altstadt, S; Alvarez-Pol, H; Ashwood, N; Aumann, T; Avdeichikov, V; Barr, M; Beceiro-Novo, S; Bemmerer, D; Benlliure, J; Bertulani, C A; Boretzky, K; Borge, M J G; Burgunder, G; Caamano, M; Caesar, C; Casarejos, E; Catford, W; Cederkäll, J; Chakraborty, S; Chartier, M; Chulkov, L V; Cortina-Gil, D; Crespo, R; Pramanik, U Datta; Fernandez, P Diaz; Dillmann, I; Elekes, Z; Enders, J; Ershova, O; Estrade, A; Farinon, F; Fraile, L M; Freer, M; Freudenberger, M; Fynbo, H O U; Galaviz, D; Geissel, H; Gernhäuser, R; Göbel, K; Golubev, P; Diaz, D Gonzalez; Hagdahl, J; Heftrich, T; Heil, M; Heinz, A; Henriques, A; Holl, M; Ickert, G; Ignatov, A; Jakobsson, B; Johansson, H T; Jonson, B; Kalantar-Nayestanaki, N; Kanungo, R; Kelic-Heil, A; Knöbel, R; Kröll, T; Krücken, R; Kurcewicz, J; Kurz, N; Labiche, M; Langer, C; Bleis, T Le; Lemmon, R; Lepyoshkina, O; Lindberg, S; Machado, J; Marganiec, J; Martínez-Pinedo, G; Maroussov, V; Mostazo, M; Movsesyan, A; Najafi, A; Neff, T; Nilsson, T; Nociforo, C; Panin, V; Paschalis, S; Perea, A; Petri, M; Pietri, S; Plag, R; Prochazka, A; Rahaman, A; Rastrepina, G; Reifarth, R; Ribeiro, G; Ricciardi, M V; Rigollet, C; Riisager, K; Röder, M; Rossi, D; del Rio, J Sanchez; Savran, D; Scheit, H; Simon, H; Sorlin, O; Stoica, V; Streicher, B; Taylor, J T; Tengblad, O; Terashima, S; Thies, R; Togano, Y; Uberseder, E; Van de Walle, J; Velho, P; Volkov, V; Wagner, A; Wamers, F; Weick, H; Weigand, M; Wheldon, C; Wilson, G; Wimmer, C; Winfield, J S; Woods, P; Yakorev, D; Zhukov, M V; Zilges, A; Zuber, K

    2016-01-01

    With the R$^{3}$B-LAND setup at GSI we have measured exclusive relative-energy spectra of the Coulomb dissociation of $^{18}$C at a projectile energy around 425~AMeV on a lead target, which are needed to determine the radiative neutron-capture cross sections of $^{17}$C into the ground state of $^{18}$C. Those data have been used to constrain theoretical calculations for transitions populating excited states in $^{18}$C. This allowed to derive the astrophysical cross section $\\sigma^{*}_{\\mathrm{n}\\gamma}$ accounting for the thermal population of $^{17}$C target states in astrophysical scenarios. The experimentally verified capture rate is significantly lower than those of previously obtained Hauser-Feshbach estimations at temperatures $T_{9}\\leq{}1$~GK. Network simulations with updated neutron-capture rates and hydrodynamics according to the neutrino-driven wind model as well as the neutron-star merger scenario reveal no pronounced influence of neutron capture of $^{17}$C on the production of second- and thi...

  7. Diversity of abundance patterns of neutron-capture elements in very metal-poor stars

    Science.gov (United States)

    Aoki, Misa; Aoki, Wako; Ishimaru, Yuhri; Wanajo, Shinya

    2014-05-01

    Observations of Very Metal-Poor stars indicate that there are at least two sites to r-process; "weak r-process" and "main r-process". A question is whether these two are well separated or there exists a variation in the r-process. We present the results of abundance analysis of neutron-capture elements in the two Very Metal-Poor stars HD107752 and HD110184 in the Milky Way halo observed with the Subaru Telescope HDS. The abundance patterns show overabundace at light n-capture elements (e.g. Sr, Y), inferring the element yielding of weak r-process, while heavy neutron-capture elements (e.g. Ba, Eu) are deficient; however, the overabundance of light ones is not as significant as that previously found in stars representing the weak r-process (e.g. HD122563; Honda et al. 2006). Our study show diversity in the abundance patterns from light to heavy neutron-capture elements in VMP stars, suggesting a variation in r-process, which may depend on electron fraction of environment.

  8. Diversity of abundance patterns of neutron-capture elements in very metal-poor stars

    Energy Technology Data Exchange (ETDEWEB)

    Aoki, Misa; Ishimaru, Yuhri [International Christian University 10-2, Osawa, Mitaka, Tokyo 181-0015 (Japan); Aoki, Wako; Wanajo, Shinya [National Astronomical Observatory of Japan (NAOJ) 2-21-1, Osawa, Mitaka, Tokyo 181-8588 (Japan)

    2014-05-02

    Observations of Very Metal-Poor stars indicate that there are at least two sites to r-process; “weak r-process” and “main r-process”. A question is whether these two are well separated or there exists a variation in the r-process. We present the results of abundance analysis of neutron-capture elements in the two Very Metal-Poor stars HD107752 and HD110184 in the Milky Way halo observed with the Subaru Telescope HDS. The abundance patterns show overabundace at light n-capture elements (e.g. Sr, Y), inferring the element yielding of weak r-process, while heavy neutron-capture elements (e.g. Ba, Eu) are deficient; however, the overabundance of light ones is not as significant as that previously found in stars representing the weak r-process (e.g. HD122563; Honda et al. 2006). Our study show diversity in the abundance patterns from light to heavy neutron-capture elements in VMP stars, suggesting a variation in r-process, which may depend on electron fraction of environment.

  9. Neutron Capture Cross Section Measurement on 91Zr at J-PARC/MLF/ANNRI

    Directory of Open Access Journals (Sweden)

    Hori Jun-ichi

    2015-01-01

    Full Text Available The neutron capture cross section measurement on 91Zr was performed at neutron TOF beam line ANNRI installed at J-PARC/MLF. Prompt capture gamma rays from the sample were detected with an array of large Ge detectors at a distance of 21.5 m from the spallation neutron source by the time-of-fligh (TOF method. The neutron capture gamma-ray pulse-height spectra from the 182-eV p-wave resonance and the 292-eV s-wave resonance were obtained by gating on the TOF regions, respectively. Though the decay patterns of primary transitions from the capture state were quite different between resonances, the prominent characteristics common to both resonances was the very strong ground-state transition from the 935-keV state. Therefore, a ground-state transition method was applied to obtain the capture yield, so that the background components due to impurities were successfully eliminated. The preliminary result of the neutron capture cross section for 91Zr up to 5 keV is presented.

  10. New measurement of θ13 via neutron capture on hydrogen at Daya Bay

    Science.gov (United States)

    An, F. P.; Balantekin, A. B.; Band, H. R.; Bishai, M.; Blyth, S.; Cao, D.; Cao, G. F.; Cao, J.; Cen, W. R.; Chan, Y. L.; Chang, J. F.; Chang, L. C.; Chang, Y.; Chen, H. S.; Chen, Q. Y.; Chen, S. M.; Chen, Y. X.; Chen, Y.; Cheng, J. H.; Cheng, J.-H.; Cheng, J.; Cheng, Y. P.; Cheng, Z. K.; Cherwinka, J. J.; Chu, M. C.; Chukanov, A.; Cummings, J. P.; de Arcos, J.; Deng, Z. Y.; Ding, X. F.; Ding, Y. Y.; Diwan, M. V.; Dolgareva, M.; Dove, J.; Dwyer, D. A.; Edwards, W. R.; Gill, R.; Gonchar, M.; Gong, G. H.; Gong, H.; Grassi, M.; Gu, W. Q.; Guan, M. Y.; Guo, L.; Guo, R. P.; Guo, X. H.; Guo, Z.; Hackenburg, R. W.; Han, R.; Hans, S.; He, M.; Heeger, K. M.; Heng, Y. K.; Higuera, A.; Hor, Y. K.; Hsiung, Y. B.; Hu, B. Z.; Hu, T.; Hu, W.; Huang, E. C.; Huang, H. X.; Huang, X. T.; Huber, P.; Huo, W.; Hussain, G.; Jaffe, D. E.; Jaffke, P.; Jen, K. L.; Jetter, S.; Ji, X. P.; Ji, X. L.; Jiao, J. B.; Johnson, R. A.; Joshi, J.; Kang, L.; Kettell, S. H.; Kohn, S.; Kramer, M.; Kwan, K. K.; Kwok, M. W.; Kwok, T.; Langford, T. J.; Lau, K.; Lebanowski, L.; Lee, J.; Lee, J. H. C.; Lei, R. T.; Leitner, R.; Leung, J. K. C.; Li, C.; Li, D. J.; Li, F.; Li, G. S.; Li, Q. J.; Li, S.; Li, S. C.; Li, W. D.; Li, X. N.; Li, Y. F.; Li, Z. B.; Liang, H.; Lin, C. J.; Lin, G. L.; Lin, S.; Lin, S. K.; Lin, Y.-C.; Ling, J. J.; Link, J. M.; Littenberg, L.; Littlejohn, B. R.; Liu, D. W.; Liu, J. J.; Liu, J. L.; Liu, J. C.; Loh, C. W.; Lu, C.; Lu, H. Q.; Lu, J. S.; Luk, K. B.; Lv, Z.; Ma, Q. M.; Ma, X. Y.; Ma, X. B.; Ma, Y. Q.; Malyshkin, Y.; Martinez Caicedo, D. A.; McDonald, K. T.; McKeown, R. D.; Mitchell, I.; Mooney, M.; Nakajima, Y.; Napolitano, J.; Naumov, D.; Naumova, E.; Ngai, H. Y.; Ning, Z.; Ochoa-Ricoux, J. P.; Olshevskiy, A.; Pan, H.-R.; Park, J.; Patton, S.; Pec, V.; Peng, J. C.; Pinsky, L.; Pun, C. S. J.; Qi, F. Z.; Qi, M.; Qian, X.; Raper, N.; Ren, J.; Rosero, R.; Roskovec, B.; Ruan, X. C.; Steiner, H.; Sun, G. X.; Sun, J. L.; Tang, W.; Taychenachev, D.; Konstantin, T.; Tsang, K. V.; Tull, C. E.; Viaux, N.; Viren, B.; Vorobel, V.; Wang, C. H.; Wang, M.; Wang, N. Y.; Wang, R. G.; Wang, W.; Wang, W. W.; Wang, X.; Wang, Y. F.; Wang, Z.; Wang, Z.; Wang, Z. M.; Wei, H. Y.; Wen, L. J.; Whisnant, K.; White, C. G.; Whitehead, L.; Wise, T.; Wong, H. L. H.; Wong, S. C. F.; Worcester, E.; Wu, C.-H.; Wu, Q.; Xia, D. M.; Xia, J. K.; Xing, Z. Z.; Xu, J. Y.; Xu, J. L.; Xu, J.; Xu, Y.; Xue, T.; Yan, J.; Yang, C. G.; Yang, H.; Yang, L.; Yang, M. S.; Yang, M. T.; Ye, M.; Ye, Z.; Yeh, M.; Young, B. L.; Yu, G. Y.; Yu, Z. Y.; Zhan, L.; Zhang, C.; Zhang, H. H.; Zhang, J. W.; Zhang, Q. M.; Zhang, X. T.; Zhang, Y. M.; Zhang, Y. X.; Zhang, Y. M.; Zhang, Z. J.; Zhang, Z. Y.; Zhang, Z. P.; Zhao, J.; Zhao, Q. W.; Zhao, Y. F.; Zhao, Y. B.; Zhong, W. L.; Zhou, L.; Zhou, N.; Zhuang, H. L.; Zou, J. H.; Daya Bay Collaboration

    2016-04-01

    This article reports an improved independent measurement of neutrino mixing angle θ13 at the Daya Bay Reactor Neutrino Experiment. Electron antineutrinos were identified by inverse β -decays with the emitted neutron captured by hydrogen, yielding a data set with principally distinct uncertainties from that with neutrons captured by gadolinium. With the final two of eight antineutrino detectors installed, this study used 621 days of data including the previously reported 217-day data set with six detectors. The dominant statistical uncertainty was reduced by 49%. Intensive studies of the cosmogenic muon-induced 9Li and fast neutron backgrounds and the neutron-capture energy selection efficiency, resulted in a reduction of the systematic uncertainty by 26%. The deficit in the detected number of antineutrinos at the far detectors relative to the expected number based on the near detectors yielded sin22 θ13=0.071 ±0.011 in the three-neutrino-oscillation framework. The combination of this result with the gadolinium-capture result is also reported.

  11. FY07 LDRD Final Report Neutron Capture Cross-Section Measurements at DANCE

    Energy Technology Data Exchange (ETDEWEB)

    Parker, W; Agvaanluvsan, U; Wilk, P; Becker, J; Wang, T

    2008-02-08

    We have measured neutron capture cross sections intended to address defense science problems including mix and the Quantification of Margins and Uncertainties (QMU), and provide details about statistical decay of excited nuclei. A major part of this project included developing the ability to produce radioactive targets. The cross-section measurements were made using the white neutron source at the Los Alamos Neutron Science Center, the detector array called DANCE (The Detector for Advanced Neutron Capture Experiments) and targets important for astrophysics and stockpile stewardship. DANCE is at the leading edge of neutron capture physics and represents a major leap forward in capability. The detector array was recently built with LDRD money. Our measurements are a significant part of the early results from the new experimental DANCE facility. Neutron capture reactions are important for basic nuclear science, including astrophysics and the statistics of the {gamma}-ray cascades, and for applied science, including stockpile science and technology. We were most interested in neutron capture with neutron energies in the range between 1 eV and a few hundred keV, with targets important to basic science, and the s-process in particular. Of particular interest were neutron capture cross-section measurements of rare isotopes, especially radioactive isotopes. A strong collaboration between universities and Los Alamos due to the Academic Alliance was in place at the start of our project. Our project gave Livermore leverage in focusing on Livermore interests. The Lawrence Livermore Laboratory did not have a resident expert in cross-section measurements; this project allowed us to develop this expertise. For many radionuclides, the cross sections for destruction, especially (n,{gamma}), are not well known, and there is no adequate model that describes neutron capture. The modeling problem is significant because, at low energies where capture reactions are important, the neutron

  12. The thermal neutron capture cross section of the radioactive isotope $^{60}$Fe

    CERN Document Server

    Heftrich, T; Dressler, R; Eberhardt, K; Endres, A; Glorius, J; Göbel, K; Hampel, G; Heftrich, M; Käppeler, F; Lederer, C; Mikorski, M; Plag, R; Reifarth, R; Stieghorst, C; Schmidt, S; Schumann, D; Slavkovská, Z; Sonnabend, K; Wallner, A; Weigand, M; Wiehl, N; Zauner, S

    2015-01-01

    50% of the heavy element abundances are produced via slow neutron capture reactions in different stellar scenarios. The underlying nucleosynthesis models need the input of neutron capture cross sections. One of the fundamental signatures for active nucleosynthesis in our galaxy is the observation of long-lived radioactive isotopes, such as $^{60}$Fe with a half-life of $2.60\\times10^6$ yr. To reproduce this $\\gamma$-activity in the universe, the nucleosynthesis of $^{60}$Fe has to be understood reliably. A $^{60}$Fe sample produced at the Paul-Scherrer-Institut was activated with thermal and epithermal neutrons at the research reactor at the Johannes Gutenberg-Universit\\"at Mainz. The thermal neutron capture cross section has been measured for the first time to $\\sigma_{\\text{th}}=0.226 \\ (^{+0.044}_{-0.049})$ b. An upper limit of $\\sigma_{\\text{RI}} < 0.50$ b could be determined for the resonance integral. An extrapolation towards the astrophysicaly interesting energy regime between $kT$=10 keV and 100 ke...

  13. The intermediate neutron-capture process and carbon-enhanced metal-poor stars

    CERN Document Server

    Hampel, Melanie; Lugaro, Maria; Meyer, Bradley S

    2016-01-01

    Carbon-enhanced metal-poor (CEMP) stars in the Galactic Halo display enrichments in heavy elements associated with either the s (slow) or the r (rapid) neutron-capture process (e.g., barium and europium respectively), and in some cases they display evidence of both. The abundance patterns of these CEMP-s/r stars, which show both Ba and Eu enrichment, are particularly puzzling since the s and the r processes require neutron densities that are more than ten orders of magnitude apart, and hence are thought to occur in very different stellar sites with very different physical conditions. We investigate whether the abundance patterns of CEMP-s/r stars can arise from the nucleosynthesis of the intermediate neutron-capture process (the i process), which is characterised by neutron densities between those of the s and the r processes. Using nuclear network calculations, we study neutron capture nucleosynthesis at different constant neutron densities n ranging from $10^7$ to $10^{15}$ cm$^{-3}$. With respect to the cl...

  14. First tomographic image of neutron capture rate in a BNCT facility

    Energy Technology Data Exchange (ETDEWEB)

    Minsky, D.M., E-mail: minsky@tandar.cnea.gov.ar [Gerencia de Investigacion y Aplicaciones, CAC, CNEA, Av. Gral. Paz 1499 (B1650KNA), San Martin, Prov. Bs. As. (Argentina)] [Escuela de Ciencia y Tecnologia, , UNSAM, M. de Irigoyen 3100 (1650), San Martin, Prov. Bs. As. (Argentina)] [Conicet, Av. Rivadavia 1917 (C1033AAJ), Buenos Aires (Argentina); Valda, A.A. [Gerencia de Investigacion y Aplicaciones, CAC, CNEA, Av. Gral. Paz 1499 (B1650KNA), San Martin, Prov. Bs. As. (Argentina)] [Escuela de Ciencia y Tecnologia, , UNSAM, M. de Irigoyen 3100 (1650), San Martin, Prov. Bs. As. (Argentina); Kreiner, A.J. [Gerencia de Investigacion y Aplicaciones, CAC, CNEA, Av. Gral. Paz 1499 (B1650KNA), San Martin, Prov. Bs. As. (Argentina)] [Escuela de Ciencia y Tecnologia, , UNSAM, M. de Irigoyen 3100 (1650), San Martin, Prov. Bs. As. (Argentina)] [Conicet, Av. Rivadavia 1917 (C1033AAJ), Buenos Aires (Argentina); Green, S.; Wojnecki, C. [School of Physics and Astronomy, University of Birmingham, B15 2 TT (United Kingdom)] [Department of Medical Physics, University Hospital Birmingham, Birmingham B15 2TH (United Kingdom); Ghani, Z. [Department of Medical Physics, University Hospital Birmingham, Birmingham B15 2TH (United Kingdom)

    2011-12-15

    This work discusses the development of online dosimetry of the boron dose via Single Photon Emission Computed Tomography (SPECT) during a BNCT treatment irradiation. Such a system will allow the online computation of boron dose maps without the large current uncertainties in the assessment of the boron concentration in different tissues. The first tomographic boron dose image with a SPECT prototype is shown.

  15. The Radiative Strength Function Using the Neutron-Capture Reaction on 151,153Eu

    Science.gov (United States)

    Agvaanluvsan, U.; Alpizar-Vicente, A.; Becker, J. A.; Bečvář, F.; Bredeweg, T. A.; Clement, R.; Esch, E.; Folden, C. M.; Hatarik, R.; Haight, R. C.; Hoffman, D. C.; Krtička, M.; Macri, R. A.; Mitchell, G. E.; Nitsche, H.; O'Donnell, J. M.; Parker, W.; Reifarth, R.; Rundberg, R. S.; Schwantes, J. M.; Sheets, S. A.; Ullmann, J. L.; Vieira, D. J.; Wilhelmy, J. B.; Wilk, P.; Wouters, J. M.; Wu, C. Y.

    2006-03-01

    Radiative strength functions in 152,154Eu nuclei for γ-ray energies below 6 MeV have been investigated. Neutron capture for incident neutron energies <1eV up to 100 keV has been measured for 151,153Eu targets. Properties of γ decay of neutron resonances in 152,154Eu nuclei are examined. The results of measurements are compared to outcome of simulation of γ cascades based on various models for the radiative strength function. Comparison between experimental data and simulation suggests existence of the low-energy resonance in these two nuclei.

  16. GEANT simulations of neutron capture experiments with a 4p BaF2 detector

    CERN Document Server

    Heil, M; Kaeppeler, F; Wisshak, K; Voss, F; Ullmann, J L; Haight, R C; Seabury, E H; Wilhelmy, J B; Rundberg, R S; Fowler, M M

    2004-01-01

    The goal of this research project is to give quantitative information useful for the design of a g-ray detector to investigate neutron capture (n, g) reactions on radioactive nuclei at the Manuel Lujan Jr. Neutron Scattering Center (MLNSC) moderated neutron source at LANSCE. Data for neutron energies from thermal up to approximately 500 keV are desired. The radioactive nuclei can have half-lives as short as a few months. With the sample sizes foreseen, typically 1 mg, the radioactive decay rate can exceed tens of Curies (Ci).

  17. The Radiative Strength Function Using the Neutron-Capture Reaction on 151,153Eu

    Energy Technology Data Exchange (ETDEWEB)

    Agvaanluvsan, U; Alpizar-Vicente, A; Becker, J A; Becvar, F; Bredeweg, T A; Clement, R; Esch, E; Folden, C M; Hatarik, R; Haight, R C; Hoffman, D C; Krticka, M; Macri, R A; Mitchell, G E; Nitsche, H; O' Donnell, J M; Parker, W; Reifarth, R; Rundberg, R S; Schwantes, J M; Sheets, S A; Ullmann, J L; Vieira, D J; Wilhelmy, J B; Wilk, P; Wouters, J M; Wu, C Y

    2005-10-04

    Radiative strength functions in {sup 152,154}Eu nuclei for {gamma}-ray energies below 6 MeV have been investigated. Neutron capture for incident neutron energies <1eV up to 100 keV has been measured for {sup 151,153}Eu targets. Properties of resonances in these two nuclei are examined. The measurements are compared to simulation of cascades performed with various models for the radiative strength function. Comparison between experimental data and simulation suggests an existence of the low-energy resonance in these two nuclei.

  18. Neutron capture cross section of $^{25}$Mg and its astrophysical implications

    CERN Multimedia

    We propose to measure the neutron capture cross section of the stable $^{25}$Mg isotope. This experiment aims at the improvement of existing results for nuclear astrophysics.The measurement will be carried out under similar conditions as for the Mgexperiment that was completed at n_TOF during 2003. A metal $^{25}$Mg-enriched sample will be used in the proposed experiment instead of a MgO powder sample, which was used in the previous measurement and prevented us to minimize the uncertainty of the measured cross section. This experiment will be part of an ongoing study for a comprehensive discussion of the s-process abundances in massive stars.

  19. Measurements of keV-neutron capture {gamma} rays of fission products. 3

    Energy Technology Data Exchange (ETDEWEB)

    Igashira, Masayuki [Tokyo Inst. of Tech. (Japan). Research Lab. for Nuclear Reactors

    1997-03-01

    {gamma} rays from the keV-neutron capture reactions by {sup 143,145}Nd and {sup 153}Eu have been measured in a neutron energy region of 10 to 80 keV, using a large anti-Compton NaI(Tl) {gamma}-ray spectrometer and the {sup 7}Li(p,n){sup 7}Be pulsed neutron source with a 3-MV Pelletron accelerator. The preliminary results for the capture cross sections and {gamma}-ray spectra of those nuclei are presented and discussed. (author)

  20. Measurements of fast—neutron capture cross sections for 159Tb and 169Tm

    Institute of Scientific and Technical Information of China (English)

    ChenJin-Xiang; ShiZhao-Min; 等

    1998-01-01

    The neutron capture cross sections for 159Tb and 169Tm relative to the 197Au (n,γ)198Au reaction are measured at neutron energies of 0.57,1.10 and 1.60 MeV by using the activation method.The activities of the products are measured with a high resolution HPGe detector gamma-ray spectrometer.The errors of the present work are 5-6% for Tb,6-7% for Tm.The recommended data in energy region of 0.4-3.0MeV are given as compared with other data published previously.

  1. Levels of 188Re nucleus populated in thermal neutron capture reaction

    Science.gov (United States)

    Běrziņš, J.; Krasta, T.; Simonova, L.; Balodis, M.; Bondarenko, V.; Jentschel, M.; Urban, W.; Tomandl, I.

    2016-03-01

    Levels of 188Re populated in thermal neutron capture reaction with enriched 187Re targets have been studied. Single γ-ray spectrum of 188Re, measured with the high-resolution crystal diffraction spectrometer GAMS5, as well as γγ-coincidence experiments performed with high efficiency Ge detectors, allowed to develop model-independent level scheme of the doubly-odd 188Re nucleus up to ˜ 1.5 MeV excitation energy. Analysis of the established 188Re level scheme in terms of the quasiparticle-plus-rotor model indicates coexistence of axially-deformed and triaxial structures in the energy range above 400 keV.

  2. Neutron capture cross-section of fission products in the European activation file EAF-3

    Energy Technology Data Exchange (ETDEWEB)

    Kopecky, J.; Delfini, M.G.; Kamp, H.A.J. van der; Gruppelaar, H.; Nierop, D. (Netherlands Energy Research Foundation (ECN), Petten (Netherlands))

    1992-05-01

    This paper contains a description of the work performed to extend and revise the neutron capture data in the European Activation File (EAF-3) with emphasis on nuclides in the fission-product mass range. The starter was the EAF-1 data file from 1989. The present version, EAF/NG-3, contains (n,[gamma]) excitation functions for all nuclides (729 targets) with half-lives exceeding 1/2 day in the mass range from H-1 to Cm-248. The data file is equipped with a preliminary uncertainty file, that will be improved in the near future. (author). 19 refs.; 5 figs.; 3 tabs.

  3. Gd@C82 metallofullerenes for neutron capture therapy—fullerene solubilization by poly(ethylene glycol-block-poly(2-(N, N-diethylaminoethyl methacrylate and resultant efficacy in vitro

    Directory of Open Access Journals (Sweden)

    Yukichi Horiguchi, Shinpei Kudo and Yukio Nagasaki

    2011-01-01

    Full Text Available Poly(ethylene glycol-block-poly(2-(N,N-diethylaminoethyl methacrylate (PEG-b-PAMA was found to solubilize fullerenes such as C60, and this technique was applied to metallofullerenes. Gd@C82 was easily dissolved in water in the presence of PEG-b-PAMA without any covalent derivatization, forming a transparent complex about 20–30 nm in diameter. Low cytotoxicity was confirmed in vitro. Neutron irradiation of cultured cells (colon-26 adenocarcinoma with Gd@C82-PEG-b-PAMA-complexed nanoparticles showed effective cytotoxicity, indicating the effective emission of gamma rays and internal conversion electrons produced from the neutron capture reaction of Gd. This result suggests a potentially valuable approach to gadolinium-based neutron capture therapy.

  4. Neutron Capture Elements in s-Process-Rich, Very Metal-Poor Stars

    CERN Document Server

    Aoki, W; Norris, J E; Beers, T C; Ando, H; Iwamoto, N; Kajino, T; Mathews, G J; Fujimoto, M; Aoki, Wako; Ryan, Sean G.; Norris, John E.; Beers, Timothy C.; Ando, Hiroyasu; Iwamoto, Nobuyuki; Kajino, Toshitaka; Mathews, Grant J.; Fujimoto, Masayuki

    2001-01-01

    We report abundance estimates for neutron-capture elements, including lead (Pb), and nucleosynthesis models for their origin, in two carbon-rich, very metal-poor stars, LP625-44 and LP706-7. These stars are subgiants whose surface abundances are likely to have been strongly affected by mass transfer from companion AGB stars that have since evolved to white dwarfs. The detections of Pb, which forms the final abundance peak of the s-process, enable a comparison of the abundance patterns from Sr (Z=38) to Pb (Z=82) with predictions of AGB models. The derived chemical compositions provide strong constraints on the AGB stellar models, as well as on s-process nucleosynthesis at low metallicity. The present paper reports details of the abundance analysis for 16 neutron-capture elements in LP 625-44, including the effects of hyperfine splitting and isotope shifts of spectral lines for some elements. A Pb abundance is also derived for LP706-7 by a re-analysis of a previously observed spectrum. We investigate the chara...

  5. Detector-Response Correction of Two-Dimensional γ-Ray Spectra from Neutron Capture

    Directory of Open Access Journals (Sweden)

    Rusev G.

    2015-01-01

    Full Text Available The neutron-capture reaction produces a large variety of γ-ray cascades with different γ-ray multiplicities. A measured spectral distribution of these cascades for each γ-ray multiplicity is of importance to applications and studies of γ-ray statistical properties. The DANCE array, a 4π ball of 160 BaF2 detectors, is an ideal tool for measurement of neutron-capture γ-rays. The high granularity of DANCE enables measurements of high-multiplicity γ-ray cascades. The measured two-dimensional spectra (γ-ray energy, γ-ray multiplicity have to be corrected for the DANCE detector response in order to compare them with predictions of the statistical model or use them in applications. The detector-response correction problem becomes more difficult for a 4π detection system than for a single detector. A trial and error approach and an iterative decomposition of γ-ray multiplets, have been successfully applied to the detector-response correction. Applications of the decomposition methods are discussed for two-dimensional γ-ray spectra measured at DANCE from γ-ray sources and from the 10B(n, γ and 113Cd(n, γ reactions.

  6. Chemical enrichment mechanisms in Omega Centauri: clues from neutron-capture elements

    CERN Document Server

    D'Orazi, Valentina; Pancino, Elena; Bragaglia, Angela; Carretta, Eugenio; Lucatello, Sara; Sneden, Chris

    2011-01-01

    In the complex picture of multiple stellar populations in globular clusters (GCs), a special role is played by NGC 5139 Omega Centauri. At variance with the majority of GCs, Omega Cen exhibits significant star-to-star variations in metallicity and in relative neutron-capture element abundance ratios with respect to Fe, along with split evolutionary sequences as revealed from colour-magnitude diagrams. Combining information from photometry and spectroscopy, several studies suggested that an age spread of several Gyr has to be invoked to explain (at least partially) some of the observed features. However, a comprehensive understanding of the formation, evolution and chemical enrichment processes is still not at hand. Relatively metal-rich Omega cen stars display neutron-capture abundance distributions dominated by contributions from the s-process, but it is not clear what roles have been played by the so-called main and weak s-process components in generating these abundances. To gain better insight into this q...

  7. Neutron capture cross section of $^{90}$Zr Bottleneck in the s-process reaction flow

    CERN Document Server

    Tagliente, G; Milazzo, P M; Moreau, C; Aerts, G; Abbondanno, U; Alvarez, H; Alvarez-Velarde, F; Andriamonje, Samuel A; Andrzejewski, J; Assimakopoulos, Panayiotis; Audouin, L; Badurek, G; Baumann, P; Bečvář, F; Berthoumieux, E; Bisterzo, S; Calviño, F; Calviani, M; Cano-Ott, D; Capote, R; Carrapiço, C; Cennini, P; Chepel, V; Chiaveri, Enrico; Colonna, N; Cortés, G; Couture, A; Cox, J; Dahlfors, M; David, S; Dillman, I; Domingo-Pardo, C; Dridi, W; Durán, I; Eleftheriadis, C; Embid-Segura, M; Ferrant, L; Ferrari, A; Ferreira-Marques, R; Furman, W; Gallino, R; Gonçalves, I; Gonzalez-Romero, E; Gramegna, F; Guerrero, C; Gunsing, F; Haas, B; Haight, R; Heil, M; Herrera-Martínez, A; Igashira, M; Jericha, E; Käppeler, F; Kadi, Y; Karadimos, D; Karamanis, D; Kerveno, M; Köhler, P; Kossionides, E; Krtička, M; Lamboudis, C; Leeb, H; Lindote, A; Lopes, I; Lozano, M; Lukic, S; Marganiec, J; Marrone, S; Martínez, T; Massimi, C; Mastinu, P; Mengoni, A; Mosconi, M; Neves, F; Oberhummer, Heinz; O'Brien, S; Pancin, J; Papachristodoulou, C; Papadopoulos, C; Paradela, C; Patronis, N; Pavlik, A; Pavlopoulos, P; Perrot, L; Pigni, M T; Plag, R; Plompen, A; Plukis, A; Poch, A; Praena, J; Pretel, C; Quesada, J; Rauscher, T; Reifarth, R; Rubbia, Carlo; Rudolf, G; Rullhusen, P; Salgado, J; Santos, J; Sarchiapone, L; Savvidis, I; Stéphan, C; Taín, J L; Tassan-Got, L; Tavora, L; Terlizzi, R; Vannini, G; Vaz, P; Ventura, A; Villamarín, D; Vincente, M, C; Vlachoudis, V; Vlastou, R; Voss, F; Walter, S; Wendler, H; Wiescher, M; Wisshak, K

    2008-01-01

    The neutron capture cross sections of the Zr isotopes have important implications in nuclear astrophysics and for reactor design. The small cross section of the neutron magic nucleus 90Zr, which accounts for more than 50% of natural zirconium represents one of the key isotopes for the stellar s-process, because it acts as a bottleneck in the neutron capture chain between the Fe seed and the heavier isotopes. The same element, Zr, also is an important component of the structural materials used in traditional and advanced nuclear reactors. The (n,γ) cross section has been measured at CERN, using the n_TOF spallation neutron source. In total, 45 resonances could be resolved in the neutron energy range below 70 keV, 10 being observed for the first time thanks to the high resolution and low backgrounds at n_TOF. On average, the Γγ widths obtained in resonance analyses with the R-matrix code SAMMY were 15% smaller than reported previously. By these results, the accuracy of the Maxwellian averaged cross section f...

  8. Investigation of 186Re via radiative thermal-neutron capture on 185Re

    Science.gov (United States)

    Matters, D. A.; Lerch, A. G.; Hurst, A. M.; Szentmiklósi, L.; Carroll, J. J.; Detwiler, B.; Révay, Zs.; McClory, J. W.; McHale, S. R.; Firestone, R. B.; Sleaford, B. W.; Krtička, M.; Belgya, T.

    2016-05-01

    Partial γ -ray production cross sections and the total radiative thermal-neutron capture cross section for the 185Re(n ,γ ) 186Re reaction were measured using the Prompt Gamma Activation Analysis facility at the Budapest Research Reactor with an enriched 185Re target. The 186Re cross sections were standardized using well-known 35Cl(n ,γ )36Cl cross sections from irradiation of a stoichiometric natReCl3 target. The resulting cross sections for transitions feeding the 186Re ground state from low-lying levels below a cutoff energy of Ec=746 keV were combined with a modeled probability of ground-state feeding from levels above Ec to arrive at a total cross section of σ0=111 (6 ) b for radiative thermal-neutron capture on 185Re. A comparison of modeled discrete-level populations with measured transition intensities led to proposed revisions for seven tentative spin-parity assignments in the adopted level scheme for 186Re. Additionally, 102 primary γ rays were measured, including 50 previously unknown. A neutron-separation energy of Sn=6179.59 (5 ) keV was determined from a global least-squares fit of the measured γ -ray energies to the known 186Re decay scheme. The total capture cross section and separation energy results are comparable to earlier measurements of these values.

  9. Study of Neutron-Capture Element Abundances in Metal-Poor Stars

    CERN Document Server

    Li, Hongjie; Liang, Shuai; Cui, Wenyuan; Zhang, Bo

    2013-01-01

    This work describes a study of elemental abundances for 30 metal-poor stars whose chemical abundances provide excellent information for setting constraints on models of neutron-capture processes. Based on the abundances of main r- and weak r-process stars, the abundance patterns of main r-process and weak r-process are obtained. The two r-process component coefficients are defined to determine the relative contributions from individual neutron-capture process to abundances of metal-poor stars. Based on the component coefficients, we find that metal-poor stars BD+4 2621 and HD 4306 are also weak r-process stars, which means that the abundance pattern produced by weak r-process is stable. All metal-poor star abundances contain the contributions of both main r-process and weak r-process. The elements produced by weak r-process have increased along with Fe over the polluted history. Most of the metal-poor star abundances do not follow the pattern observed in solar system, but there is a small fraction that do. Fo...

  10. Stellar neutron capture cross sections of 41K and 45Sc

    Science.gov (United States)

    Heil, M.; Plag, R.; Uberseder, E.; Bisterzo, S.; Käppeler, F.; Mengoni, A.; Pignatari, M.

    2016-05-01

    The neutron capture cross sections of light nuclei (A important for s -process scenarios since they act as neutron poisons. We report on measurements of the neutron capture cross sections of 41K and 45Sc, which were performed at the Karlsruhe 3.7 MV Van de Graaff accelerator via the activation method in a quasistellar neutron spectrum corresponding to a thermal energy of k T =25 keV. Systematic effects were controlled by repeated irradiations, resulting in overall uncertainties of less than 3%. The measured spectrum-averaged data have been used to normalize the energy-dependent (n ,γ ) cross sections from the main data libraries JEFF-3.2, JENDL-4.0, and ENDF/B-VII.1, and a set of Maxwellian averaged cross sections was calculated for improving the s -process nucleosynthesis yields in AGB stars and in massive stars. At k T =30 keV, the new Maxwellian averaged cross sections of 41K and 45Sc are 19.2 ±0.6 mb and 61.3 ±1.8 mb, respectively. Both values are 20% lower than previously recommended. The effect of neutron poisons is discussed for nuclei with A <56 in general and for the investigated isotopes in particular.

  11. The neutron capture cross section of the ${s}$-process branch point isotope $^{63}$Ni

    CERN Multimedia

    Neutron capture nucleosynthesis in massive stars plays an important role in Galactic chemical evolution as well as for the analysis of abundance patterns in very old metal-poor halo stars. The so-called weak ${s}$-process component, which is responsible for most of the ${s}$ abundances between Fe and Sr, turned out to be very sensitive to the stellar neutron capture cross sections in this mass region and, in particular, of isotopes near the seed distribution around Fe. In this context, the unstable isotope $^{63}$Ni is of particular interest because it represents the first branching point in the reaction path of the ${s}$-process. We propose to measure this cross section at n_TOF from thermal energies up to 500 keV, covering the entire range of astrophysical interest. These data are needed to replace uncertain theoretical predicitons by first experimental information to understand the consequences of the $^{63}$Ni branching for the abundance pattern of the subsequent isotopes, especially for $^{63}$Cu and $^{...

  12. Development of local radiation therapy

    Energy Technology Data Exchange (ETDEWEB)

    Lee, Seung Hoon; Lim, Sang Moo; Choi, Chang Woon; Chai, Jong Su; Kim, Eun Hee; Kim, Mi Sook; Yoo, Seong Yul; Cho, Chul Koo; Lee, Yong Sik; Lee, Hyun Moo

    1999-04-01

    The major limitations of radiation therapy for cancer are the low effectiveness of low LET and inevitable normal tissue damage. Boron Neutron Capture Therapy (BNCT) is a form of potent radiation therapy using Boron-10 having a high propensityof capturing theraml neutrons from nuclear reactor and reacting with a prompt nuclear reaction. Photodynamic therapy is a similiar treatment of modality to BNCT using tumor-seeking photosenistizer and LASER beam. If Boron-10 and photosensitizers are introduced selectively into tumor cells, it is theoretically possible to destroy the tumor and to spare the surrounding normal tissue. Therefore, BNCT and PDT will be new potent treatment modalities in the next century. In this project, we performed PDT in the patients with bladder cancers, oropharyngeal cancer, and skin cancers. Also we developed I-BPA, new porphyrin compounds, methods for estimation of radiobiological effect of neutron beam, and superficial animal brain tumor model. Furthermore, we prepared preclinical procedures for clinical application of BNCT, such as the macro- and microscopic dosimetry, obtaining thermal neutron flux from device used for fast neutron production in KCCH have been performed.

  13. Abundances of neutron-capture elements in the Hot Extreme-Helium Stars V1920 Cygni and HD 124448

    CERN Document Server

    Pandey, G; Rao, N K; Jeffery, C S; Pandey, Gajendra; Lambert, David L.

    2004-01-01

    Analysis of HST STIS ultraviolet spectra of two hot extreme helium stars (EHes): V1920 Cyg and HD 124448 provide the first measurements of abundances of neutron-capture elements for EHes. Although the two stars have similar abundances for elements up through the iron-group, they differ strikingly in their abundances of heavier elements: V1920 Cyg is enriched by a factor of 30 in light neutron-capture elements (Y/Fe, Zr/Fe) relative to HD 124448. These differences in abundances of neutron-capture elements among EHes mirrors that exhibited by the RCrB stars, and is evidence supporting the view that there is an evolutionary connection between these two groups of hydrogen-deficient stars. Also, the abundances of Y and Zr in V1920 Cyg provide evidence that at least one EHe star went through a s-process synthesis episode in its earlier evolution.

  14. Neutron capture cross sections of $^{70,72,73,74,76}$ Ge at n_TOF EAR-1

    CERN Multimedia

    We propose to measure the (n;$\\gamma$ ) cross sections of the isotopes $^{70;72;73;74;76}$Ge. Neutron induced reactions on Ge are of importance for the astrophysical slow neutron capture process, which is responsible for forming about half of the overall elemental abundances heavier than Fe. The neutron capture cross section on Ge affects the abundances produced in this process for a number of heavier isotopes up to a mass number of A = 90. Additionally, neutron capture on Ge is of interest for low background experiments involving Ge detectors. Experimental cross section data presently available for Ge (n;$\\gamma$ ) are scarce and cover only a fraction of the neutron energy range of interest. (n;$\\gamma$ ) cross sections will be measured in the full energy range from 25 meV to about 200 keV at n TOF EAR-1.

  15. Neutron capture surrogate reaction on 75As in inverse kinematics using (d,pγ)

    Science.gov (United States)

    Peters, W. A.; Cizewski, J. A.; Hatarik, R.; O'Malley, P. D.; Jones, K. L.; Schmitt, K.; Moazen, B. H.; Chae, K. Y.; Pittman, S. T.; Kozub, R. L.; Vieira, D.; Jandel, M.; Wilhelmy, J. B.; Matei, C.; Escher, J.; Bardayan, D. W.; Pain, S. D.; Smith, M. S.

    2010-03-01

    The 75As(d,pγ) reaction in inverse kinematics as a surrogate for neutron capture was performed at Oak Ridge National Laboratory using a deuterated plastic target. The intensity of the 165 keV γ-ray from 76As in coincidence with ejected protons, from exciting 76As above the neutron separation energy populating a compound state, was measured. A tight geometry of four segmented germanium clover γ-ray detectors together with eight ORRUBA-type silicon-strip charged-particle detectors was used to optimize geometric acceptance. The preliminary analysis of the 75As experiment, and the efficacy and future plans of the (d,pγ) surrogate campaign in inverse kinematics, are discussed.

  16. Neutron Capture Surrogate Reaction on 75As in Inverse Kinematics Using (d,p(gamma))

    Energy Technology Data Exchange (ETDEWEB)

    Peters, W A; Cizewski, J A; Hatarik, R; O?Malley, P D; Jones, K L; Schmitt, K; Moazen, B H; Chae, K Y; Pittman, S T; Kozub, R L; Vieira, D; Jandel, M; Wilhelmy, J B; Matei, C; Escher, J; Bardayan, D W; Pain, S D; Smith, M S

    2009-11-09

    The {sup 75}As(d,p{gamma}) reaction in inverse kinematics as a surrogate for neutron capture was performed at Oak Ridge National Laboratory using a deuterated plastic target. The intensity of the 165 keV {gamma}-ray from {sup 76}As in coincidence with ejected protons, from exciting {sup 76}As above the neutron separation energy populating a compound state, was measured. A tight geometry of four segmented germanium clover {gamma}-ray detectors together with eight ORRUBA-type silicon-strip charged-particle detectors was used to optimize geometric acceptance. The preliminary analysis of the {sup 75}As experiment, and the efficacy and future plans of the (d,p{gamma}) surrogate campaign in inverse kinematics, are discussed.

  17. Neutron capture surrogate reaction on 75As in inverse kinematics using (d,p )

    Energy Technology Data Exchange (ETDEWEB)

    Peters, W. A. [Rutgers University; Cizewski, J. A. [Rutgers University; Hatarik, Robert [Rutgers University; O' Malley, Patrick [Rutgers University; Jones, K. L. [University of Tennessee; Schmitt, Kyle [University of Tennessee; Moazen, Brian [University of Tennessee; Chae, K. Y. [University of Tennessee; Pittman, S. T. [University of Tennessee, Knoxville (UTK); Kozub, R. L. [Tennessee Technological University; Vieira, D. J. [Los Alamos National Laboratory (LANL); Jandel, M. [Los Alamos National Laboratory (LANL); Wilhelmy, J. B. [Los Alamos National Laboratory (LANL); Matei, Catalin [Oak Ridge Associated Universities (ORAU); Escher, J. [Lawrence Livermore National Laboratory (LLNL); Bardayan, Daniel W [ORNL; Pain, Steven D [ORNL; Smith, Michael Scott [ORNL

    2010-01-01

    The 75As(d,p ) reaction in inverse kinematics as a surrogate for neutron capture was performed at Oak Ridge National Laboratory using a deuterated plastic target. The intensity of the 165 keV -ray from 76As in coincidence with ejected protons, from exciting 76As above the neutron separation energy populating a compound state, was measured. A tight geometry of four segmented germanium clover -ray detectors together with eight ORRUBA-type silicon-strip charged-particle detectors were used to optimize geometric acceptance. The preliminary analysis of the 75As experiment and the ecacy and future plans of the (d,p ) surrogate campaign in inverse kinematics are discussed.

  18. /sup 74/Ge: Transitions and levels excited in thermal-neutron capture

    Energy Technology Data Exchange (ETDEWEB)

    Hofmeyr, C.; Franklyn, C.; Barreau, G.; Boerner, H.; Brissot, R.; Faust, H.; Schreckenbach, K.

    1985-01-15

    Gamma-ray transitions due to thermal-neutron capture in /sup 73/Ge were measured at ILL, Grenoble, using the curved-crystal spectrometers GAMS 1, 2 and 3, a pair spectrometer and a Ge(Li) spectrometer. Some 750 transitions were identified, of which 450 were placed in a level and decay scheme with the aid of an interactive program. Selected energy regions were scanned with the internal-conversion electron spectrometer BILL, yielding 18 transitions corresponding to delta-rays and sixteen unmatched candidates. The levels up to 4 MeV are presented together with the degree of corroboration obtained from published (p, t) and (t, p) results and ..beta..-decay data.

  19. Neutron capture surrogate reaction on 75As in inverse kinematics using (d,pγ

    Directory of Open Access Journals (Sweden)

    Smith M.S.

    2010-03-01

    Full Text Available The 75As(d,pγ reaction in inverse kinematics as a surrogate for neutron capture was performed at Oak Ridge National Laboratory using a deuterated plastic target. The intensity of the 165 keV γ-ray from 76As in coincidence with ejected protons, from exciting 76As above the neutron separation energy populating a compound state, was measured. A tight geometry of four segmented germanium clover γ-ray detectors together with eight ORRUBA-type silicon-strip charged-particle detectors was used to optimize geometric acceptance. The preliminary analysis of the 75As experiment, and the eïňČcacy and future plans of the (d,pγ surrogate campaign in inverse kinematics, are discussed.

  20. Neutron-capture experiment on {sup 78}Se with EXOGAM at ILL Grenoble

    Energy Technology Data Exchange (ETDEWEB)

    John, Robert; Massarczyk, Ralph; Schwengner, Ronald [Helmholtz-Zentrum Dresden-Rossendorf e.V., Dresden (Germany); Blanc, Aurelien; Jentschel, Michael; Koester, Ulli; Mutti, Paolo; Urban, Waldemar [Institut Max von Laue - Paul Langevin, 38 - Grenoble (France); Belgya, Tamas [IKI Budapest (Hungary); Valenta, Stanislav [Karlova Univ., Prague (Czech Republic)

    2013-07-01

    We present first results of a neutron-capture study of {sup 78}Se. The experiment was carried out with cold neutrons at the reactor of the Institut Laue-Langevin (ILL) at Grenoble. Gamma rays following the {sup 77}Se(n, γ) reaction were measured with eight EXOGAM clover detectors, one clover detector taken from the Lohengrin setup and six GASP detectors. This setup enabled the measurement of two- and three-fold γ-ray coincidences as well as of angular correlations of the γ rays with high efficiency. The aim of the analysis is to gain detailed information about the deexcitation patterns of the capture state and lower-lying excited states. These may be used as a test for statistical simulations of γ-ray cascades and their inputs, such as γ-ray strength functions and level densities.

  1. Resonance neutron capture in {sup 60}Ni below 450 keV

    Energy Technology Data Exchange (ETDEWEB)

    Corvi, F.; Fioni, G. E-mail: gfioni@cea.fr; Gunsing, F.; Mutti, P.; Zanini, L

    2002-01-28

    High-resolution neutron capture cross-section measurements on {sup 60}Ni have been performed at the Geel Linear Accelerator in the energy range from 1 to 450 keV. An experimentally determined weighting function, obtained by a total energy detection set-up, has been applied to the measured capture spectra. The parameters of 275 resonances have been determined in a recent reanalysis using the FANAC R-matrix shape fitting code. Accurate values of the maxwellian-averaged capture cross section for stellar temperatures ranging from kT=5 to 100 keV, corresponding to different scenarios of s-process stellar nucleosynthesis, have been calculated. The distributions of partial radiative widths for s- and p-wave resonances have been derived. A correlation of 0.64 between capture and reduced neutron widths is compatible with the presence of nonstatistical effects in the capture of {sup 60}Ni.

  2. Resonance neutron capture in sup 6 sup 0 Ni below 450 keV

    CERN Document Server

    Corvi, F; Gunsing, F; Mutti, P; Zanini, L

    2002-01-01

    High-resolution neutron capture cross-section measurements on sup 6 sup 0 Ni have been performed at the Geel Linear Accelerator in the energy range from 1 to 450 keV. An experimentally determined weighting function, obtained by a total energy detection set-up, has been applied to the measured capture spectra. The parameters of 275 resonances have been determined in a recent reanalysis using the FANAC R-matrix shape fitting code. Accurate values of the maxwellian-averaged capture cross section for stellar temperatures ranging from kT=5 to 100 keV, corresponding to different scenarios of s-process stellar nucleosynthesis, have been calculated. The distributions of partial radiative widths for s- and p-wave resonances have been derived. A correlation of 0.64 between capture and reduced neutron widths is compatible with the presence of nonstatistical effects in the capture of sup 6 sup 0 Ni.

  3. Independent Measurement of Theta13 via Neutron Capture on Hydrogen at Daya Bay

    CERN Document Server

    An, F P; Band, H R; Beriguete, W; Bishai, M; Blyth, S; Butorov, I; Cao, G F; Cao, J; Chan, Y L; Chang, J F; Chang, L C; Chang, Y; Chasman, C; Chen, H; Chen, Q Y; Chen, S M; Chen, X; Chen, Y X; Chen, Y; Cheng, Y P; Cherwinka, J J; Chu, M C; Cummings, J P; de Arcos, J; Deng, Z Y; Ding, Y Y; Diwan, M V; Draeger, E; Du, X F; Dwyer, D A; Edwards, W R; Ely, S R; Fu, J Y; Ge, L Q; Gill, R; Gonchar, M; Gong, G H; Gong, H; Gornushkin, Y A; Gu, W Q; Guan, M Y; Guo, X H; Hackenburg, R W; Han, G H; Hans, S; He, M; Heeger, K M; Heng, Y K; Hinrichs, P; Hor, Y K; Hsiung, Y B; Hu, B Z; Hu, L M; Hu, L J; Hu, T; Hu, W; Huang, E; Huang, H; Huang, X T; Huber, P; Hussain, G; Isvan, Z; Jaffe, D E; Jaffke, P; Jen, K L; Jetter, S; Ji, X P; Ji, X L; Jiang, H J; Jiao, J B; Johnson, R A; Kang, L; Kettell, S H; Kramer, M; Kwan, K K; Kwok, M W; Kwok, T; Lai, W C; Lau, K; Lebanowski, L; Lee, J; Lei, R T; Leitner, R; Leung, A; Leung, J K C; Lewis, C A; Li, D J; Li, F; Li, G S; Li, Q J; Li, W D; Li, X N; Li, X Q; Li, Y F; Li, Z B; Liang, H; Lin, C J; Lin, G L; Lin, P Y; Lin, S K; Lin, Y C; Ling, J J; Link, J M; Littenberg, L; Littlejohn, B R; Liu, D W; Liu, H; Liu, J L; Liu, J C; Liu, S S; Liu, Y B; Lu, C; Lu, H Q; Luk, K -B; Ma, Q M; Ma, X Y; Ma, X B; Ma, Y Q; McDonald, K T; McFarlane, M C; McKeown, R D; Meng, Y; Mitchell, I; Kebwaro, J Monari; Nakajima, Y; Napolitano, J; Naumov, D; Naumova, E; Nemchenok, I; Ngai, H Y; Ning, Z; Ochoa-Ricoux, J P; Olshevski, A; Patton, S; Pec, V; Peng, J C; Piilonen, L E; Pinsky, L; Pun, C S J; Qi, F Z; Qi, M; Qian, X; Raper, N; Ren, B; Ren, J; Rosero, R; Roskovec, B; Ruan, X C; Shao, B B; Steiner, H; Sun, G X; Sun, J L; Y,; Tam, H; Tang, X; Themann, H; Tsang, K V; Tsang, R H M; Tull, C E; Tung, Y C; Viren, B; Vorobel, V; Wang, C H; Wang, L S; Wang, L Y; Wang, M; Wang, N Y; Wang, R G; Wang, W; Wang, W W; Wang, X; Wang, Y F; Wang, Z; Wang, Z M; Webber, D M; Wei, H Y; Wei, Y D; Wen, L J; Whisnant, K; White, C G; Whitehead, L; Wise, T; Wong, H L H; Wong, S C F; Worcester, E; Wu, Q; Xia, D M; Xia, J K; Xia, X; Xing, Z Z; Xu, J Y; Xu, J L; Xu, J; Xu, Y; Xue, T; Yan, J; Yang, C C; Yang, L; Yang, M S; Yang, M T; Ye, M; Yeh, M; Yeh, Y S; Young, B L; Yu, G Y; Yu, J Y; Yu, Z Y; Zang, S L; Zeng, B; Zhan, L; Zhang, C; Zhang, F H; Zhang, J W; Zhang, Q M; Zhang, Q; Zhang, S H; Zhang, Y C; Zhang, Y M; Zhang, Y H; Zhang, Y X; Zhang, Z J; Zhang, Z Y; Zhang, Z P; Zhao, J; Zhao, Q W; Zhao, Y; Zhao, Y B; Zheng, L; Zhong, W L; Zhou, L; Zhou, Z Y; Zhuang, H L; Zou, J H

    2014-01-01

    A new measurement of the $\\theta_{13}$ mixing angle has been obtained at the Daya Bay Reactor Neutrino Experiment via the detection of inverse beta decays tagged by neutron capture on hydrogen. The antineutrino events for hydrogen capture are distinct from those for gadolinium capture with largely different systematic uncertainties, allowing a determination independent of the gadolinium-capture result and an improvement on the precision of $\\theta_{13}$ measurement. With a 217-day antineutrino data set obtained with six antineutrino detectors and from six 2.9 GW$_{th}$ reactors, the rate deficit observed at the far hall is interpreted as $\\sin^22\\theta_{13}=0.083\\pm0.018$ in the three-flavor oscillation model. When combined with the gadolinium-capture result from Daya Bay, we obtain $\\sin^22\\theta_{13}=0.089\\pm0.008$ as the final result for the six-antineutrino-detector configuration of the Daya Bay experiment.

  4. First Measurement of \\theta_13 from Delayed Neutron Capture on Hydrogen in the Double Chooz Experiment

    CERN Document Server

    Abe, Y; Anjos, J C dos; Barriere, J C; Bergevin, M; Bernstein, A; Bezerra, T J C; Bezrukhov, L; Blucher, E; Bowden, N S; Buck, C; Busenitz, J; Cabrera, A; Caden, E; Camilleri, L; Carr, R; Cerrada, M; Chang, P -J; Chimenti, P; Classen, T; Collin, A P; Conover, E; Conrad, J M; Crespo-Anadón, J I; Crum, K; Cucoanes, A; Damon, E; Dawson, J V; Dazeley, S; Dietrich, D; Djurcic, Z; Dracos, M; Durand, V; Ebert, J; Efremenko, Y; Elnimr, M; Erickson, A; Etenko, A; Fallot, M; Fechner, M; von Feilitzsch, F; Felde, J; Fernandes, S M; Fischer, V; Franco, D; Franke, A J; Franke, M; Furuta, H; Gama, R; Gil-Botella, I; Giot, L; Göger-Neff, M; Gonzalez, L F G; Goodenough, L; Goodman, M C; Goon, J TM; Greiner, D; Haag, N; Habib, S; Hagner, C; Hara, T; Hartmann, F X; Haser, J; Hatzikoutelis, A; Hayakawa, T; Hofmann, M; Horton-Smith, G A; Hourlier, A; Ishitsuka, M; Jochum, J; Jollet, C; Jones, C L; Kaether, F; Kalousis, L N; Kamyshkov, Y; Kaplan, D M; Kawasaki, T; Keefer, G; Kemp, E; de Kerret, H; Konno, T; Kryn, D; Kuze, M; Lachenmaier, T; Lane, C E; Langbrandtner, C; Lasserre, T; Letourneau, A; Lhuillier, D; Lima, H P; Lindner, M; López-Castaño, J M; LoSecco, J M; Lubsandorzhiev, B K; Lucht, S; McKee, D; Maeda, J; Maesano, C N; Mariani, C; Maricic, J; Martino, J; Matsubara, T; Mention, G; Meregaglia, A; Meyer, M; Miletic, T; Milincic, R; Miyata, H; Mueller, Th A; Nagasaka, Y; Nakajima, K; Novella, P; Obolensky, M; Oberauer, L; Onillon, A; Osborn, A; Ostrovskiy, I; Palomares, C; Pepe, I M; Perasso, S; Perrin, P; Pfahler, P; Porta, A; Potzel, W; Pronost, G; Reichenbacher, J; Reinhold, B; Remoto, A; Röhling, M; Roncin, R; Roth, S; Rybolt, B; Sakamoto, Y; Santorelli, R; Sato, F; Schönert, S; Schoppmann, S; Schwetz, T; Shaevitz, M H; Shimojima, S; Shrestha, D; Sida, J-L; Sinev, V; Skorokhvatov, M; Smith, E; Spitz, J; Stahl, A; Stancu, I; Stokes, L F F; Strait, M; Stüken, A; Suekane, F; Sukhotin, S; Sumiyoshi, T; Sun, Y; Svoboda, R; Terao, K; Tonazzo, A; Toups, M; Thi, H H Trinh; Valdiviesso, G; Veyssiere, C; Wagner, S; Watanabe, H; White, B; Wiebusch, C; Winslow, L; Worcester, M; Wurm, M; Yermia, F; Zimmer, V

    2013-01-01

    The Double Chooz experiment has determined the value of the neutrino oscillation parameter $\\theta_{13}$ from an analysis of inverse beta decay interactions with neutron capture on hydrogen. This analysis uses a three times larger fiducial volume than the standard Double Chooz assessment, which is restricted to a region doped with gadolinium (Gd), yielding an exposure of 113.1 GW-ton-years. The data sample used in this analysis is distinct from that of the Gd analysis, and the systematic uncertainties are also largely independent, with some exceptions, such as the reactor neutrino flux prediction. A combined rate- and energy-dependent fit finds $\\sin^2 2\\theta_{13}=0.097\\pm 0.034(stat.) \\pm 0.034 (syst.)$, excluding the no-oscillation hypothesis at 2.0 \\sigma. This result is consistent with previous measurements of $\\sin^2 2\\theta_{13}$.

  5. Experimental neutron capture data of 58Ni from the CERN n_TOF facility

    Directory of Open Access Journals (Sweden)

    Žugec P.

    2015-01-01

    Full Text Available The neutron capture cross section of 58Ni was measured at the neutron time of flight facility n_TOF at CERN, from 27 meV to 400 keV neutron energy. Special care has been taken to identify all the possible sources of background, with the so-called neutron background obtained for the first time using high-precision GEANT4 simulations. The energy range up to 122 keV was treated as the resolved resonance region, where 51 resonances were identified and analyzed by a multilevel R-matrix code SAMMY. Above 122 keV the code SESH was used in analyzing the unresolved resonance region of the capture yield. Maxwellian averaged cross sections were calculated in the temperature range of kT = 5 – 100 keV, and their astrophysical implications were investigated.

  6. Improved Neutron Capture Cross Section Measurements with the n_TOF Total Absorption Calorimeter

    CERN Document Server

    Mendoza, E; Perkowski, J; Andriamonje, S; Carrapico, C; Moinul, M; Vannini, G; Quesada, J M; Harrisopulos, S; Milazzo, P M; Berthier, B; Lozano, M; Krticka, M; Domingo-Pardo, C; Nolte, R; Chiaveri, E; Saarmento, H; Jericha, E; Ferrari, A; Massimi, C; Giubrone, G; Avrigeanu, V; Martinez, T; Guerrero, C; Andrzejewski, J; Karadimos, D; Mengoni, A; Ganesan, S; Vlachoudis, V; Becares, V; Cortes, G; Variale, V; Losito, H; Calvino, F; Kappeler, F; Gunsing, F; Gramegna, F; Colonna, N; Marrone, S; Pavlik, A; Berthoumieux, E; Paradela, C; Mastinu, P F; Vaz, P; Tassan-Got, L; Kadi, Y; Tarrio, D; Cano-Ott, D; Brugger, M; Wallner, A; Audouin, L; Fernandez-Ordonez, M; Becvar, F; Goncalves, I F; Cerutti, F; Ventura, A; Mosconi, M; Tagliente, G; Duran, I; Casado, A; Ioannides, K; Weiss, C; Mirea, M; Gomez-Hornillos, M B; Vlastou, R; Calviani, M; Lederer, C; Gonzalez-Romero, E; Marganiec, J; Vidriales, J J; Lebbos, E; Leeb, H; Heil, M; Dillmann, I; Tain, J L; Belloni, F

    2011-01-01

    The n\\_TOF collaboration operates a Total Absorption Calorimeter (TAC) {[}1] for measuring neutron capture cross-sections of low-mass and/or radioactive samples. The results obtained with the TAC have led to a substantial improvement of the capture cross sections of (237)Np and (240)Pu {[}2]. The experience acquired during the first measurements has allowed us to optimize the performance of the TAC and to improve the capture signal to background ratio, thus opening the way to more complex and demanding measurements on rare radioactive materials. The new design has been reached by a series of detailed Monte Carlo simulations of complete experiments and dedicated test measurements. The new capture setup will be presented and the main achievements highlighted.

  7. Neutron capture on (94)Zr: Resonance parameters and Maxwellian-averaged cross sections

    CERN Document Server

    Tagliente, G; Fujii, K; Abbondanno, U; Aerts, G; Alvarez, H; Alvarez-Velarde, F; Andriamonje, S; Andrzejewski, J; Audouin, L; Badurek, G; Baumann, P; Becvar, F; Belloni, F; Berthoumieux, E; Bisterzo, S; Calvino, F; Calviani, M; Cano-Ott, D; Capote, R; Carrapico, C; Cennini, P; Chepel, V; Chiaveri, E; Colonna, N; Cortes, G; Couture, A; Cox, J; Dahlfors, M; David, S; Dillmann, I; Domingo-Pardo, C; Dridi, W; Duran, I; Eleftheriadis, C; Embid-Segura, M; Ferrari, A; Ferreira-Marques, R; Furman, W; Gallino, R; Goncalves, I; Gonzalez-Romero, E; Gramegna, F; Guerrero, C; Gunsing, F; Haas, B; Haight, R; Heil, M; Herrera-Martinez, A; Jericha, E; Kappeler, F; Kadi, Y; Karadimos, D; Karamanis, D; Kerveno, M; Kossionides, E; Krticka, M; Lamboudis, C; Leeb, H; Lindote, A; Lopes, I; Lozano, M; Lukic, S; Marganiec, J; Marrone, S; Martinez, T; Massimi, C; Mastinu, P; Mengoni, A; Moreau, C; Mosconi, M; Neves, F; Oberhummer, H; O'Brien, S; Pancin, J; Papachristodoulou, C; Papadopoulos, C; Paradela, C; Patronis, N; Pavlik, A; Pavlopoulos, P; Perrot, L; Pigni, M.T; Plag, R; Plompen, A; Plukis, A; Poch, A; Praena, J; Pretel, C; Quesada, J; Rauscher, T; Reifarth, R; Rosetti, M; Rubbia, C; Rudolf, G; Rullhusen, P; Salgado, J; Santos, C; Sarchiapone, L; Savvidis, I; Stephan, C; Tain, J.L; Tassan-Got, L; Tavora, L; Terlizzi, R; Vannini, G; Vaz, P; Ventura, A; Villamarin, D; Vincente, M.C; Vlachoudis, V; Vlastou, R; Voss, F; Walter, S; Wiescher, M; Wisshak, K

    2011-01-01

    The neutron capture cross sections of the Zr isotopes play an important role in nucleosynthesis studies. The s-process reaction flow between the Fe seed and the heavier isotopes passes through the neutron magic nucleus (90)Zr and through (91,92,93,94)Zr, but only part of the flow extends to (96)Zr because of the branching point at (95)Zr. Apart from their effect on the s-process flow, the comparably small isotopic (n, gamma) cross sections make Zr also an interesting structural material for nuclear reactors. The (94)Zr (n, gamma) cross section has been measured with high resolution at the spallation neutron source n_TOF at CERN and resonance parameters are reported up to 60 keV neutron energy.

  8. Subaru/HDS study of CH stars: elemental abundances for stellar neutron-capture process studies

    Science.gov (United States)

    Goswami, Aruna; Aoki, Wako; Karinkuzhi, Drisya

    2016-01-01

    A comprehensive abundance analysis providing rare insight into the chemical history of lead stars is still lacking. We present results from high-resolution (R ˜ 50 000) spectral analyses of three CH stars, HD 26, HD 198269 and HD 224959, and, a carbon star with a dusty envelope, HD 100764. Previous studies on these objects are limited by both resolution and wavelength regions and the results differ significantly from each other. We have undertaken to reanalyse the chemical composition of these objects based on high-resolution Subaru spectra covering the wavelength regions 4020-6775 Å. Considering local thermodynamic equilibrium and using model atmospheres, we have derived the stellar parameters, the effective temperatures Teff, surface gravities log g, and metallicities [Fe/H] for these objects. The derived parameters for HD 26, HD 100764, HD 198269 and HD 224959 are (5000, 1.6, -1.13), (4750, 2.0 -0.86), (4500, 1.5, -2.06) and (5050, 2.1, -2.44), respectively. The stars are found to exhibit large enhancements of heavy elements relative to iron in conformity to previous studies. Large enhancement of Pb with respect to iron is also confirmed. Updates on the elemental abundances for several s-process elements (Y, Zr, La, Ce, Nd, Sm and Pb) along with the first-time estimates of abundances for a number of other heavy elements (Sr, Ba, Pr, Eu, Er and W) are reported. Our analysis suggests that neutron-capture elements in HD 26 primarily originate in the s-process while the major contributions to the abundances of neutron-capture elements in the more metal-poor objects HD 224959 and HD 198269 are from the r-process, possibly from materials that are pre-enriched with products of the r-process.

  9. Open Cluster Neutron Capture Element Abundances and Milky Way Disk Evolution

    Science.gov (United States)

    Jacobson, Heather R.; Friel, E. D.

    2012-01-01

    Open clusters, whose ages and distances can be precisely determined, are useful probes of the chemical evolution of the Milky Way disk. The sample sizes of clusters subject to homogeneous analysis of high resolution spectra have grown in recent years, and increased attention has turned to measuring the abundances of neutron capture elements. The relative abundances of r-process elements (e.g., europium) to s-process elements (e.g., barium, lanthanum and zirconium) in cluster stars reveal the relative contributions of Type II supernovae and low-mass AGB stars to the chemical evolution of the galactic disk. A recent study of cluster s-process element abundances has revealed a surprising trend of increasing s-process element abundance ([s/Fe]) with decreasing cluster age, at odds with current s-process yield predictions (D'Orazi et al. 2009, Maiorca et al. 2011). We have undertaken an analysis of Zr, Ba, La, and Eu abundances in 17 open clusters based on high resolution optical spectra. The sample spans 700 Myr to 10 Gyr in age and Rgc 7-22 kpc in galactocentric distance, allowing for the exploration of neutron capture [x/Fe] ratios as a function of age and location in the disk. Preliminary results confirm the trend of enhanced [s/Fe] with decreasing cluster age found by other studies, though with a weaker correlation. Here we present the latest results of this analysis, including newly-determined abundances for the r-process element Eu for an expanded cluster sample that includes outer disk objects. This research is supported by a National Science Foundation Astronomy and Astrophysics Postdoctoral Fellowship to HRJ under award AST-0901919.

  10. Exploring new labelling strategies for boronated compounds: towards fast development and efficient assessment of BNCT drug candidates

    OpenAIRE

    Gona, Kiran Babu

    2015-01-01

    208 p. La terapia por captura de neutrones (BNCT o Boron Neutron Capture Therapy), fue descrita por primera vez por Locher en 1936 y es una modalidad terapéutica binaria para el tratamiento del cáncer que se basa en la captura de neutrones térmicos por medio de átomos de 10B, previamente acumulados en las células tumorales. La captura del neutrón térmico resulta en la formación de un núcleo de 11B, que fisiona para generar dos iones altamente energéticos: 4He2+ y 7Li3+. El daño y la poster...

  11. Hadron Therapy in Latin America

    Science.gov (United States)

    Kreiner, A. J.; Bergueiro, J.; Burlon, A. A.; Di Paolo, H.; Castell, W.; Thatar Vento, V.; Levinas, P.; Cartelli, D.; Kesque, J. M.; Valda, A. A.; Ilardo, J. C.; Baldo, M.; Erhardt, J.; Debray, M. E.; Somacal, H. R.; Minsky, D. M.; Estrada, L.; Hazarabedian, A.; Johann, F.; Suarez Sandin, J. C.; Igarzabal, M.; Huck, H.; Repetto, M.; Obligado, M.; Lell, J.; Padulo, J.; Herrera, M.; Gonzalez, S. R.; Capoulat, M. E.; Davidson, J.; Davidson, M.

    2010-08-01

    The use of proton and heavy ion beams for radiotherapy is a well established cancer treatment modality in the first world, which is becoming increasingly widespread, due to its clear advantages over conventional photon-based treatments. This strategy is suitable when the tumor is spatially well localized. Also the use of neutrons has tradition. Here Boron Neutron Capture Therapy (BNCT) stands out, though on a much smaller scale, being a promising alternative for tumors which are diffuse and infiltrating. On this sector, so far only nuclear reactors have been used as neutron sources. In this paper we briefly describe the situation in Latin America and in particular we discuss the present status of an ongoing project to develop a folded Tandem-ElectroStatic-Quadrupole (TESQ) accelerator for Accelerator-Based (AB)-Boron Neutron Capture Therapy (BNCT) at the Atomic Energy Commission of Argentina. The project goal is a machine capable of delivering 30 mA of 2.4 MeV protons to be used in conjunction with a neutron production target based on the 7Li(p,n)7Be reaction. These are the specifications needed to produce sufficiently intense and clean epithermal neutron beams to perform BNCT for deep-seated tumors in less than an hour. The machine being currently designed and constructed is a folded TESQ with a terminal at 0.6 MV as a smaller scale prototype. Since the concept is modular the same structure will be used for the 1.2 MV final accelerator.

  12. Implementing in vasion neutron capture therapy (INCT) using capillary neutron optical systems (CNOS) assessment

    Science.gov (United States)

    Borisov, G. I.; Kumakhov, M. A.; Kondratenko, R. I.; Spryshkova, R. A.

    2005-07-01

    During LNCT the exposed object represents a practically ideal trap for neutrons In this instance, the number of neutrons that entered the object through the inlet hole is equal to the number of nuclear reactions of their absorption. Using this model and nuclear data about all considered nuclides for a biological tissue, the following INCT characteristics were theoretically calculated with regard to introduction of dosage-forming preparations based on different concentrations of lOB, l57Gd and 235U nuclides: - effective masses irradiated by thermal neutrons, - energies absorbed in the object for one thermal neutron entered, - partial content of basic dosage-forming reactions, - partial content of absorbed dosage of thermal neutrons from basic dosage-forming reactions, - quantity of thermal neutrons needed to create a total absorbed dosage of 5 Gr within the focal spot area of 0,28 cm2, - number of nuclear reactions with dosage-forming nuclides of preparations per one cell based on the cell volume of 7x7x7 m. It follows from the data obtained that dosage-forming nuclide 10B is not only the optimal but also the only one suitable for INCT. Using the obtained outcome, one can assess parameters of capillary neutron optical systems (CNOS) that are pre-requisite to implement INCT at particular experimental channels (EC) of research nuclear reactors.

  13. Shielding design and dose assessment for accelerator based neutron capture therapy.

    Science.gov (United States)

    Howard, W B; Yanch, J C

    1995-05-01

    Preparations are ongoing to test the viability and usefulness of an accelerator source of epithermal neutrons for ultimate use in a clinical environment. This feasibility study is to be conducted in a shielded room located on the Massachusetts Institute of Technology campus and will not involve patient irradiations. The accelerator production of neutrons is based on the 7Li(p, n)7Be reaction, and a maximum proton beam current of 4 mA at an energy of 2.5 MeV is anticipated. The resultant 3.58 x 10(12) neutrons s-1 have a maximum energy of 800 keV and will be substantially moderated. This paper describes the Monte Carlo methods used to estimate the neutron and photon dose rates in a variety of locations in the vicinity of the accelerator, as well as the shielding configuration required when the device is run at maximum current. Results indicate that the highest absorbed dose rate to which any individual will be exposed is 3 microSv h-1 (0.3 mrem h-1). The highest possible yearly dose is 0.2 microSv (2 x 10(-2) mrem) to the general public or 0.9 mSv (90 mrem) to a radiation worker in close proximity to the accelerator facility. The shielding necessary to achieve these dose levels is also discussed.

  14. Optimization of an accelerator-based epithermal neutron source for neutron capture therapy

    Energy Technology Data Exchange (ETDEWEB)

    Kononov, O.E.; Kononov, V.N.; Bokhovko, M.V.; Korobeynikov, V.V.; Soloviev, A.N.; Chu, W.T.

    2004-02-20

    A modeling investigation was performed to choose moderator material and size for creating optimal epithermal neutron beams for BNCT based on a proton accelerator and the 7Li(p,n)7Be reaction as a neutrons source. An optimal configuration is suggested for the beam shaping assembly made from polytetrafluoroethylene and magnesium fluorine. Results of calculation were experimentally tested and are in good agreement with measurements.

  15. Evaluation of an iron-filtered epithermal neutron beam for neutron-capture therapy.

    Science.gov (United States)

    Musolino, S V; McGinley, P H; Greenwood, R C; Kliauga, P; Fairchild, R G

    1991-01-01

    An epithermal neutron filter using iron, aluminum, and sulfur was evaluated to determine if the therapeutic performance could be improved with respect to aluminum-sulfur-based filters. An empirically optimized filter was developed that delivered a 93% pure beam of 24-keV epithermal neutrons. It was expected that a thick filter using iron with a density thickness greater than 200 g/cm2 would eliminate the excess gamma contamination found in Al-S filters. This research showed that prompt gamma production from neutron interactions in iron was the dominant dose component. Dosimetric parameters of the beam were determined from the measurement of absorbed dose in air, thermal neutron flux in a head phantom, neutron and gamma spectroscopy, and microdosimetry.

  16. 铀氢锆堆中子源辐照含硼C6胶质瘤细胞的生物学效应研究%Biological effects of boron-absorbed C6 glioma cells irradiated by UHZr reactor neutron source

    Institute of Scientific and Technical Information of China (English)

    江新标; 赵英; 曹锐锋; 肖艳; 陈伟; 屠荆; 章翔

    2005-01-01

    利用蒙卡程序MCNP/4B(Monte Carlo N-particle transportcode/4B)设计了C6细胞辐照实验的铀氢锆堆中子源.建立了细胞培养、孵育、L-BPA(L-boron phenylalanine)给药、细胞内宏观硼浓度测定及辐照实验方法,观察了BNCT(Boron neutron capture therapy)辐照实验对体外C6胶质瘤细胞的放射生物学效应,研究了C6细胞BNCT辐照效应与照射剂量之间的关系.试验结果表明,在同等吸收剂量下,BNCT对C6细胞的杀伤作用远远大于γ射线.

  17. Using (d,pγ) as a Surrogate for Neutron Capture with ^75As

    Science.gov (United States)

    Peters, W. A.; Cizewski, J. A.; Hatarik, R.; O'Malley, P.; Viei